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Abstract
The cost of adverse drug reactions to society in the form of deaths, chronic illness, foetal malfor-
mation, and many other effects is quite significant. For example, in the United States of America,
adverse reactions to prescribed drugs is around the fourth leading cause of death. The reporting
of adverse drug reactions is spontaneous and voluntary in Australia.
Many methods that have been used for the analysis of adverse drug reaction data, mostly using
a statistical approach as a basis for clinical analysis in drug safety surveillance decision support.
This thesis examines new approaches that may be used in the analysis of drug safety data. These
methods differ significantly from the statistical methods in that they utilize covariability meth-
ods of association to define drug-reaction relationships. Covariability algorithms were developed
in collaboration with Musa Mammadov to discover drugs associated with adverse reactions and
possible drug-drug interactions. This method uses the system organ class (SOC) classification in
the Australian Adverse Drug Reaction Advisory Committee (ADRAC) data to stratify reactions.
The text categorization algorithm BoosTexter was found to work with the same drug safety data
and its performance and modus operandi was compared to our algorithms. These alternative meth-
ods were compared to a standard disproportionality analysis methods for signal detection in drug
safety data including the Bayesean mulit-item gamma Poisson shrinker (MGPS), which was found
to have a problem with similar reaction terms in a report and innocent by-stander drugs.
A classification of drug terms was made using the anatomical-therapeutic-chemical classification
(ATC) codes. This reduced the number of drug variables from 5081 drug terms to 14 main drug
classes. The ATC classification is structured into a hierarchy of five levels. Exploitation of the
ATC hierarchy allows the drug safety data to be stratified in such a way as to make them accessible
to powerful existing tools. A data mining method that uses association rules, which groups them
on the basis of content, was used as a basis for applying the ATC and SOC ontologies to ADRAC
data. This allows different views of these associations (even very rare ones). A signal detection
method was developed using these association rules, which also incorporates critical reaction terms.
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Introduction
In what manner we ought to bear sickness: For we ought to have these two principles
in readiness: that except the will nothing is good or bad; and that we ought not to lead
events, but to follow. Epitectus A.D. c. 50–120 Book III, chapter 10 [131].
0.1 Background
The twentieth century opened with only one widely available modern medicine: acetysalicilic
acid (aspirin). In the 1940s the first antibiotic, the first mass produced antimalarial, and the
first antitubercular were introduced. The 1950s and 1960s saw the rapid introduction of oral
contraceptives, medicines for diabetes, and then medicines for mental illness, many infectious
diseases, cardiovascular diseases, and cancer. By the 1970s effective medicines – though not always
ideal – existed for nearly every major illness. In 1975 the World Health Assembly introduced
the concepts of “essential drugs” and “national drug policy”, and they quickly became part of
the global public health vocabulary. The number of people estimated to have access to essential
medicines grew from about 2.1 billion in 1977 to 3.8 billion in the late 1990s. This has had great
benefit, but unsafe and wasteful drug use persists: 25–75% of antibiotics prescriptions in teaching
hospitals are inappropriate, half of the world’s 15 billion injections per year are unsafe, and 50% of
patients worldwide fail to take medicines correctly [420]. Along with this increased use of medicines
comes the possibility of undesirable side affects.
The aim of this thesis is to evaluate techniques that can be applied to the analysis of drug safety
data, based on the data supplied by the Australian Adverse Drug Reaction Advisory Committee
(ADRAC) in order to detect possible new side effects of these drugs. The collection of drug
safety data was motivated particularly after the introduction of the drug thalidomide in 1956
and the subsequent publication by McBride in 1961 regarding the injurious effects of the drug on
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2babies [345, 532, 543]. Thalidomide was a hypnotic drug, which if taken by women during early
pregnancy increased the risk of congenital malformation of the limbs of the child. It was the effects
of thalidomide that gave rise to national pharmacovigilance centers in Western countries in the
early 1960s [532]. The occurrence of phocomelia in association with thalidomide highlighted the
necessity to detect possible but as yet unknown effects of marketed drugs at an early stage [528].
The principle concern of pharmacovigilance is the detection of adverse events (AEs) that are
novel by virtue of their clinical nature, and/or severity as early as possible in the post-approval
period with minimum patient exposure [206, 489]. This study of the safety of marketed drugs
under the practical conditions of clinical usage in large communities involves a paradox, which is
explained in detail by Mann [335]. Briefly it concerns the fact that, since the thalidomide disaster,
there have been dozens of licensed medicines withdrawn from the market. Three problems arise
from this situation: (i) the small number of patients contributing pre-marketing safety trials and
the rarity of ADRs even serious ones [133], (ii) the difference between pre- and post-marketing
patients, (iii) doctors may be slow or ineffective in detecting and reporting ADRs.
Historically, the most commonly employed strategies to detect ADEs have involved rule-based
criteria that incorporate frequency thresholds and/or the clinical nature of the events under review
[37, 44]. Australia’s pharmacovigilance agency is the Adverse Drug Reactions Advisory Committee
(ADRAC) established in 1969, which is part of the Therapeutic Goods Administration (TGA).
The TGA is a division of the Commonwealth Department of Health and Aged Care located in
Canberra. The TGA has the statutory responsibility under a 1989 Act of Parliament for the pre-
market registration of all therapeutic drugs, medications and medical devices, and for their post
market vigilance. A computerized repository of ADRAC data was introduced in 1972. The TGA,
like the World Health Organization (WHO) [574, 575], is particularly interested in data on serious
and unexpected reactions that have not previously been noticed [375, 376, 377].
The problem with detecting adverse reactions from drugs is that they may not show up until
long after the drugs have been widely prescribed. Part of the problem is that these events are rare.
Another difficulty is that the reporting system for adverse drug reactions (ADRs) is voluntary
[71, 97, 213, 270, 409]. Spontaneous reporting is of value for serious reactions, but a limitation
is under reporting, even for fatal adverse events [515]. It has been estimated that only 15% of
fatal episodes of thromboembolism in women taking combined oral contraceptives [240], and 11%
of fatal blood dyscrasias associated with phenylbutazone or oxyphenbutazone [239], were reported
3by doctors or coroners. All the cases of ADRs studied by O’Brien [377] had not been reported to
ADRAC.
Adverse drug events can be the result of a confluence of factors that may not be encountered in
clinical trials because they occur so infrequently [409]. It is thus important to collect and analyze
data on factors that enhance a patient’s potential to react adversely to a drug. The problem of
ADRs is a serious one. In the United States of America, ADR is the fourth to the sixth leading
cause of death, despite ADRs being under reported [71, 218, 348], and many studies show that
they account for 2–6% of all hospital admissions [410]. The ability of a hospital’s (ADR) database
to identify common and repeated patterns of preventable ADEs has been analyzed. Categorization
by type of error and outcome suggested that three high-priority preventable ADEs accounted for
50% of all reports: (i) overdoses of anti-coagulants or insufficient monitoring and adjustments were
associated with hemorrhagic events, (ii) overdosing or failure to adjust for drug-drug interactions of
opiate agonists was associated with somnolence (see Section 12.7) and respiratory depression, and
(iii) inappropriate dosing or insufficient monitoring of insulins was associated with hypoglycemia
[565].
Some of the problems associated with drug testing trials are: (i) the sample size is usually
2000 to 3000 patients for any given drug; (ii) pediatric, geriatric and patients with complicated
medical histories are often excluded from trials; (iii) although most adverse reactions occur soon
after starting the drug, adverse reactions with long latencies of onset may be more difficult to
recognize [71, 134, 344]. Furthermore, clinical trials employ numerous inclusion and exclusion
criteria that promote homogenous data sets amenable to statistical analysis but do not reflect real-
life clinical permutations and combinations of demographics, comorbid illnesses, and concomitant
medications, and their limited duration precludes detection of ADRs with prolonged latency [202].
Rare, serious reactions, although striking (and may be disastrous for a particular patient), have
little impact on an individual’s risk, whereas more common reactions, even with much lower fatality
rates, are more likely to lead to adverse outcomes for patients [264]. There is also a need for better
reporting [138, 223, 252, 270], so that drug safety ‘signals’ (previously undocumented reactions
associated with the drug) can be detected earlier [106, 134, 223]. However, Hauben and Reich
[210] believe this is an inappropriate use of the word. Indeed there are several serious fundamental
problems with the current postmarketing surveillance system to detect serious adverse drug events,
to determine their incidence rates and to act in a timely manner [151, 522]. To further compound
4the issue, statistical techniques have traditionally been under used in spontaneous systems used
for postmarketing surveillance of ADRs. It must be pointed out that the purpose of postmarketing
surveillance is justified by the fact that, at the time of regulatory authorization, the safety profile
of the pharmaceutic agent in question is incomplete [202].
This type of data requires several reports to generate a signal because of the many factors
that can influence whether an adverse reaction occurs in an individual. Some examples of such
factors are the following. Environmental such as air pollution or water contamination. Lifestyle
variables such as diet, alcohol consumption, or smoking. Interactions such as drug-drug or drug-
alcohol interactions. Medical conditions such as liver or renal function. Route of administration,
which has been demonstrated, for example, miconazole and warfarin with the potentiation of the
anticoagulation effect [367] (also see Sections 2.1.3 and 2.1.4). In some cases other factors make it
very difficult to prove an association between a drug and a reaction, for example, congestive heart
failure and itraconazole, because in this case, usually patients are very sick and taking many other
medications [8]. One approach to elucidating contributing factors to the development of ADRs is
pharmacogenetics, which investigates the role of different genes which may enhance an individual’s
susceptibility or resistance to producing an adverse reaction to a drug [348, 406, 432, 490, 566].
In a review of a specific type of ADR, the association of erythromycin and infantile hyper-
trophic pyloric stenosis (IHPS) – a gastrointestinal condition, Hauben provides a case study, which
illustrates many issues involved in the study of ADRs [208], and an earlier case of unusual reactions
that may have been associated with HIV infection [207].
0.2 The Inadequacy of Current Postmarketing Surveillance
. . . Rulers, statesmen, nations, are wont to be emphatically commended to the teach-
ing, which experience offers in history. But what experience and history teach is this
— that peoples and governments never have learned anything from history, or acted
on principles deduced from it. (Was die Erfahrung aber und die Geschichte lehnen, ist
dieses, das Vo¨lker und Regierungen niemals etwas as der Geschichte gelernt.) Hegel
[214], p. 155.
Despite the resolve to improve pharmacovigilance to avoid another disaster like that of thalido-
mide, in August of 2004 another drug Vioxx (rofecoxib) was withdrawn from the market in what
5has been described as the biggest adverse drug event disaster in history [28, 110, 153, 514]. For
more background on this see Section 2.3. In Section 2.1.1 the inadequacy of the current signal
detection methods will be outlined to show that there is an urgent need for improved methods.
In addition to this, the regulatory organizations that use such methods require upgrading. For
example, I understand (anecdotally) that the recently enhanced system at the TGA still has many
problems and that the Food and Drug Administration (FDA) of the United States of America
needs an Information Technology upgrade as a matter of urgency [118]. For a fuller discussion of
the roˆle of the FDA see Slater [475]. It must also be noted that, although the safety of patients
depends not only on drug licensing by regulatory bodies and their post-marketing drug safety
surveillance, pharmacovigilance; it is also important that the same post-marketing information
needed to confirm ADE signals is also needed to refute such signals to protect patients’ ability to
benefit from needed medicines that may be under suspicion due to spurious signals [335]. Also, as
outlined in Section 2.1.3, there will be increased possibility of tailoring prescriptions to individuals.
As described in Section 2.1.1, the non-Bayesian or frequentist forms of disproportionality anal-
ysis used for ADR signal detection are too sensitive, in the case of the disproportionality methods,
or too insensitive, in the case of the Bayesian methods.
Although the focus of my thesis is on the analysis of drug safety data, the overall system they
are intended to serve cannot be ignored. Furthermore, the lack of success of methods currently
used for adverse event signalling indicates that it is worthwhile looking for inspiration from diverse
fields that address related problems. For example, detecting rare events of significance, revealing
patterns and relationships of interest in large, sparse collections of data, managing combinatorial
complexity and missing information. It will also be stressed the importance crucial relevant domain
knowledge for methods developed for the analysis of real world data. Such problems that are well
understood in a given discipline may offer valuable insights or be directly or indirectly applicable to
ADR data processing to facilitate the development of surveillance processes. With this in view the
next chapter diverse literature that has direct relevance to the current project or may be worthy
of future investigation by others to refine and evaluate methods currently being developed.
60.3 Research Questions
Drug safety tools, which can be referred to as disproportionality analysis signal detection meth-
ods, attempt to overcome the poor quality of this type of spontaneous reporting data (such as,
incomplete information, lack of adequate control data, poor structure, and variable terminology).
They search the database for disproportionally high associations or dependencies between vari-
ables, usually drug and reaction, compared to reports for that event in the entire database. They
differ in their precise model of expectedness, but to various degrees they use the generality of all
drugs and reactions in the database as a control [202, 299]. The problem in general with the dis-
proportionality approach is that it is essentially two-dimensional (see Section 2.1.1). The purpose
of this thesis is to show why there is a need for both better signal detection methods and better
structuring of these data.
1. Using the ADRAC drug safety data, can methods be developed or applied that avoid, (i) the
hypersensitivity of the disproportionality methods, and (ii) the insensitivity of the Bayesian
methods?
2. Can drug ontologies as well as reaction ontologies be used to structure data to facilitate
application and development of analytic methods to improve their clinical relevance?
3. Do these drug ontologies and reaction ontologies simplify the data to make them accessible to
more methodologies?
4. Can weighting critical reaction terms enhance ADR signal detection?
5. Can methods be developed for the detection of drug-drug interactions and/or syndromes?
0.4 Contribution
My contribution to the field of pharmacovigilance decision support is to apply a drug ontology to
Australian drug safety data and show how this can be used to greatly improve methods used in
this field. I have investigated novel application of a text categorization method to drug safety data,
and compared it to covariability methods specifically designed to avoid problems encountered by
disproportionality methods. I have shown how the drug ontology enables association rules data
mining methods to utilize drug safety data effectively. I have helped develop a prototype method
7for adverse event signalling using association rules and critical reaction terms to sensitize it to more
serious events. I have been able to compare my results using the Australian data on a standard
Bayesian method for drug safety signal detection.
Chapter 1
Theoretic connections and
Philosophic reflections for Adverse
Drug Event Monitoring Systems
The problem of ADRs is a serious one. In the United States of America, ADR is between the fourth
to the sixth leading cause of death [2, 71, 218, 287, 348], despite ADRs being under reported (the
true total of ADRs is unknown). Pre-market trials have a limited capability for determining the
safety of drugs for release to the pharmaceutical market. Post-marketing surveillance needs better
drug safety signal generating methods. Rapid development of automated techniques for the analy-
sis of large amounts of data, which has occurred over the last fifteen years should provide a useful
resource to use and develop tools to apply to the ADR question. Furthermore, theories with an
even longer history may provide a source of useful knowledge to pharmacovigilance field.
A little Learning is a dang’rous Thing;
Drink deep, or taste not the Pierian Spring;
There shallow Draughts intoxicate the Brain,
And drinking largely sobers us again. Alexander Pope, An Essay on Criticism [411].
1.1 Introduction
Adverse drug reactions involve many concepts and issues: physical, social, and behavioral, and
phenomena, such as events. The management of drug safety includes many participants: drug
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9consumers, medical practitioners, pharmacists, drug manufactures and distributers, safety regu-
latory authorities, and governments. The literature on the field of drug reactions alone is vast.
There are many other fields that impinge on drug safety, and some of those fields, such as, rare
events, decision support, data mining, machine learning, and ontology each have a vast literature
in their respective discipline. Nevertheless, an awareness of theory and practice of these various
fields provides a rich source for research and development to enhance drug safety methodology.
For example, possibly there are lessons to be learned that can be applied to drug safety, from areas
such as nuclear reactor safety, where the scale of the possible events is potentially so great.1 In
this field, models of risk and rare event prediction that hopefully have no precedent. Regarding
the surveillance of drugs recently authorized for prescription, there are risks of serious events be-
cause of the constraints to premarket testing. In view of the fact that automated methods used
to support postmarket surveillance are not sufficiently effective, lessons from disparate fields that
have developed their own ways of dealing with risk management and rare event prediction, need
to be incorporated into drug safety methodology.
To highlight the risks encountered in premarket testing, there is a very recent report in the UK,
where all six drug trail volunteers who took an anti-inflammatory drug, which maniplulates the
immune system, were hospitalized suffering multiple organ failure. Two were in critical condition
and the remainder were in a serious condition [192, 398]. “Such an extreme reaction among so
many trial participants is extremely rare. . . . However, at least one similar drug has already
shown side effects in human trials. Skin rashes and gut reactions have been seen during tests of a
drug called anti-CTLA4 antibody.” [398]
1.1.1 Philosophic Scope
Science has managed to discover a great deal about the world and how it works, but
it is a thoroughly human enterprise, messy, fallible, and fumbling; rather than using a
uniquely rational method unavailable to other inquirers, it is continuous with the most
ordinary of empirical inquiry. Suan Haack Defending Science—within reason Preface p. 9
[190].
I must stress that the very nature of drug safety data, and its context in the field of medicine,
1For example the, Chernobyl, and Three Mile Island events, which were serious enough, but were potentially far
more extreme.
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incomplete and inexact – see Section 1.5. This means that any approach based purely on exact
sciences, such as statistical (even Baysean) and Aristotelean (binary) logic, is doomed to be un-
satisfactory – see Sections 1.3, 1.6 and 1.7. I explore many candidates that may help to broaden
this scope, including ones from the exact sciences, and focus on some specific interesting ones.
1.1.2 Overview
This review, because of the vastness of the literature of many of the disciplines, covers only examples
of theory and practice. After visiting the field of risk and rare events in a variety of settings, data
mining is examined with particular emphasis on the burgeoning field of text categorization, which,
because of many general similarities between the problem of assigning a block of text into categories
of subjects described in the text, and the problem of attributing adverse drug events (ADE) to
other information relevant to that event. It was text categorization software that was found capable
of using the same drug safety data and producing comparable results to algorithms described in
this thesis that were specifically designed to address problems inherent in these data. I have given
some theory on fuzzy logic, which has been much used for processing medical data. The next area
to be covered is that of ontology and how its employment can better structure data in order to
make it more widely accessible to many powerful and well established methodologies. This review
concludes on the adverse drug reaction literature, which is vast in its own right and, because it is
the main focus of this thesis, a separate chapter (Chapter 2) will be devoted to it.
1.2 Probability and Events
W. A. Thompson in his book Applied Probability [517] defines an event as the potential outcome
of a probability experiment. In our present case, we may consider adverse drug reactions (ADRs)
to be the outcome of a probability experiment.
Some events are simple or indivisible or elementary and others are compound; elementary events
can be connected by words “and”, “or”, “not”.
Two properties of events are defined: (i) they are exhaustive – when an experiment is performed,
one or more of the elementary events always occurs; (ii) they are mutually exclusive – that is it is
impossible for two elementary events to occur in a particular performance of an experiment.
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The compound event which contains all outcomes of the experiment is called the certain event
S and its compliment notS is called the impossible event φ, which acts like zero in the number
system of arithmetic.
Axiom 1 The probability of all events must be non-negative. P (E) ≥ 0 ∀ E.
Axiom 2 The probability of a certain event is one. P (E|E) = 1 ∀ E.
Axiom 3 If A1, A2, . . . are pairwise mutually exclusive events (finite or denumerable in number),
then P (A1 +A2 + . . . ) = P (A1) + P (A2) + . . .
A set function P (C), is defined for class A of sets closed under countable set operations,2 and
satisfying Axioms 1, 2, and 3, is called a probability measure; in a sense, such functions measure
likelihoods with which the sets occur [517].
Thompson (pp. 39–46) [519] has developed a probability calculus for rare events using a method
for synthesizing compound events. This is done specifically for nuclear reactor failure. In this
context, basic failure parameters need to be determined from failure records of similar equipment.
This study of ‘equipment’ includes human error, which is well understood in this field.
1.2.1 Risk
In a review of assessing risks and the determination of rare event probabilities was conducted by
Sampson and Smith [446]. Somewhat later DeWoody et al. developed a method for assessing the
risk for a rare event based on the following scenario. There exists a large population with unknown
percentage p of defects. A sample of size N is drawn from the population and, in the sample, 0
defects are drawn. Given these data, we want to determine the probability that no more than n
defects will be found in another random3 sample of N drawn from the population. Estimates on
the range of p and n are calculated from a derived joint distribution which depends on p, n and N .
Asymptotic risk results based on an infinite sample were then developed. They show that these
results are applicable even with relatively small sample spaces. Prentice discusses risk connected to
genetic susceptibility to medical conditions [230] and the limitations of non-parametric maximum
likelihood estimation of the bivariate survivor function [413].
2A class is closed under an operation if performing the operation on members of the class does not yield things
outside the class. The motivation for requiring that A be closed under countable set operations is that we wish to
discuss events having structure of this complexity; for example, A = A1+A2+ . . . and B =
⋂∞
i=1Bi where Aj and
Bi are events. The closure of A then insures that P (A) and P (B) are defined.
3It is interesting to note that randomness is just a hypothesis. As pointed out by Zellinger [596], an individual
measurement result remains objectively random because of the finiteness of information.
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A quantitative definition of risk is suggested by Kaplan and Garrick [261] in terms of the idea
of a “set of triplets”. The definition is extended to include uncertainty and completeness, and the
use of Bayes’ theorem is described in this connection. Using this definition these authors discuss
the notions of “relative risk”, “relativity of risk”, and “acceptability of risk”. Predicting the size
of low-probability, high-consequence natural disasters, industrial and pollutant releases is often
difficult due to limitations in the availability of data on rare events and future circumstances.
Englehardt [130] proposed a two Bayesian probability distribution for inferring future incident-
size probabilities from limited indirect, and subjective information. The distributions are derived
from Pareto distributions that were shown to fit data on different incident types and were justified
theoretically. The derived distributions incorporated both inherent variability and uncertainty due
to information limitations. Information requirements for incident-size prediction using the methods
were low, particularly when the population distribution had a thick tail. Use of the distributions
to predict oil-spill consequences was demonstrated. Warn et al. [549] applied Bayesian methods
to compare absolute and relative risk scales in drug treatment trials, which has the advantage of
incorporating subjective, or data-based prior beliefs into the analysis.
Mitisiopoulos et al. [361], and Asbeck and Haimes [21] studied the approximation of the
partitioned multiobjective risk method (PMRM) as an alternative to the popular expected value.
Employing these risk functions allows decision-makers to rigorously consider risk-related policy
decisions without explicit expressions of their utility functions or explicit knowledge of relative
objective function weights. Classic (or ‘cumulative’) case-control designs do not admit inferences
about other risk ratios. Probabilities, risk differences and other quantities cannot be compared
without knowledge of the population incidence fraction. Similarly, density (or ‘risk set’) case-
control sampling designs do not allow inferences about quantities other than the rate ratio. Rates,
rate differences, cumulative rates, risks, and other quantities cannot be estimated unless auxiliary
information about the interlaying cohort such as the number of controls in each full risk set is
available. Most scholars who have considered the issue recommend reporting more than just risk
ratios, but auxiliary population information needed to do this is not usually available. King and
Zeng [272] addressed this problem by developing methods that allow valid inferences about all
relevant quantities of interest from either type of case-control study when completely ignorant or
only partially knowledgable about relevant auxiliary population information. In drug safety, when
a drug increases the risk of a common effect, such as the increase in thrombotic events with COX2
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inhibitors (see Section 2.3), we have no system in place to identify the risk. This problem is made
more serious because, for example, quadrupling the risk of a very rare event, although easy to
detect, produces very few actual cases, whereas a similar proportional increase in the frequency
of a common event such as stroke or myocardial infarction, will result in potentially hundreds of
thousands of cases with major public-health implications [110].
In the field of finance there is a considerable amount of literature on risk theory[259]. For
example, Esscher [132] reviews the probability function in the collective theory of risk, Cox [96] on
series of events, and Gerber and Pafumi [170], Cooper and Martin [92] and Elliott et al. [129] on
default risk and derivative products.
It must be pointed out that human behavior can play a large roˆle in some aspects of the theory
of risk. For example, Janssen and Tenkink [250] argue that the theory of risk homeostasis in traffic
(RHT) needs revision to account better for: risk taking must be considered as part of a more
general utility-maximizing process, partial compensation rather than exact homeostasis must be
considered as a rule for use of safety hardware, and development of hierarchical models of risk
taking in traffic is required. In the area of accident involvement, McKenna [341] concluded that
an increased knowledge of the limitations of human risk perception is important in understanding
how people react to human error and accident involvement. The effect of road layout and road
environment on driving performance, and driver’s physiology have also been investigated [104].
This highlights the fact that there are other factors that can modify risk taking behavior.
1.2.2 Rare Events
The investigation of rare events is a vast area with a long history. For the purposes of my investiga-
tion, it is not proposed to extensively review this field. Rather, some examples to show the variety
of approaches to the problem and theories to model it, and the various situations to which these
theories have been applied. Some of these references attempt to review this vast field of endeavor.
More information is received by learning an experiment has resulted in a rare event than from
the occurrence of a very likely event. Thus information is inversely associated with the probability
of the occurrence of that event [517] (also see [222, 350, 471, 546, 551]). In experiments where people
have access to information sources such as newspaper weather forecasts, drug-package inserts, all of
which provide convenient descriptions of risky prospects, they can make decisions from description.
Alternatively, when people must decide whether to back up their computer’s hard drive, cross a
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busy street, or go out on a date, however, they typically do not have summary description of
the possible outcomes or their likelihoods. For such decisions, people can call only on their own
encounters with such prospects, making decisions from experience. Decisions from experience
and decisions from descriptions can lead to dramatically different choice behavior. In the case
of decisions from description, people make choices as if they overweight the probability of rare
events, as described by prospect theory. Hertwig et al. [222] found that in cases of decisions from
experience, in contrast, people make choices as if they underweight the probability of rare events,
and explored the impact of two possible causes of this underweighting—reliance on relatively small
samples of information and overweighting of recently sampled information. These results indicate
that two different theories of risky choice may be required.
Rare events data, binary dependent variables of very low occurrence, such as, for example, wars,
vetoes, cases of political activism, or epidemiological infections, have proven difficult to explain
or predict. There are at least two reasons for this: First, popular statistical procedures, such as
logistic regression, can sharply underestimate the probability of rare events. King and Zeng [271]
have recommended corrections that outperform and change the estimates of absolute and relative
risks as much as some estimated effects reported in the literature. Secondly, commonly used data
collection strategies are grossly inefficient for rare events data. The fear of collecting data with too
few or poorly measured, explanatory variables, such as in international conflict data with more
than a quarter of a million dyads, only a few of which are at war. More efficient sampling designs
exist for making valid inferences, such as sampling all available events (such as wars) and a tiny
sample of nonevents (peace). This enables scholars to save as much as 99 percent of their data
collection costs or to collect much more meaningful explanatory variables. These authors provide
methods that link these two results, enabling both types of corrections to work simultaneously,
and software that implements the methods developed [271].
Safety Assessment
In the field of nuclear reactor safety, Thompson [518, 519] describes some reliability models. For
example, they compare the “per demand failure rate” method for calculating the annual probability
of a reactor accident with an equally reasonable event sequencing model. One aspect of safety
analysis is formulated as a maximum mark problem in a marked point process. The concept
of rare events that yields special computing formulae similar to those employed by practicing
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engineers implications for quantifying the safety of a nuclear reactor. This author shows that
several competing mathematical models are possible, but cautions that because there is so little
data for rare events, such as nuclear accidents, it is difficult to test these models. It is further
noted that there is still little known (in 1983) about the theory of safety assessment.
The “peaks over threshold” method resembles the previous one that used the maximum mark
problem. This is described by Falk [139] (chapter 2.3), who shows how it was applied to fix safer
levels for the sea-dykes in the Netherlands after the disastrous floods of 1953. This method uses
exceedances of rare events above a boundary magnitude using the Poisson approximation of the
sequence of exceedances.
Point Processes
Many seemingly deep results in point processes are readily accessible by representing them in terms
of random gap lengths between points. The possibility of representing point processes in terms
of sequences of random variables rather than probability measures makes them mathematically
simpler than general stochastic processes. They provide models for the placement of points (often
called arrivals) on the time axis according to some chance mechanism. Familiar examples are the
arrivals of radioactive particles at a Geiger counter, the successive collisions of a given particle with
other particles in the kinetic theory of an ideal gas, the arrivals of ships to be unloaded at a dock,
the arrivals of telephone calls at a switchboard. The independent variable need not be time, but
may be some other nonnegative quantity such as age, length, or area. An example of the latter
would be the finding of red blood corpuscles on the surface of a microscope slide [519].
Probabilistic modelling of rare events can be achieved by suitably truncated empirical point
processes, which, in turn, can be approximated by Poisson point processes in several ways. Point
process approximations are used in cases, where the probability of a particular event is very low, in a
population size n, and random variable p representing these events is binomially distributed. If the
probability is sufficiently low, the binomial distribution B(n, p) can be reasonably approximated by
the Poisson distribution Pn,p [139]. Hu¨sler and Schmidt [232] discuss the limits of point processes
which are generated by a triangular array of rare events. Such point processes are motivated
by the exceedances of a high boundary by a random sequence since exceedances are rare events
in this case. Their application relates to extreme value theory from where the method to treat
the asymptotic approximation of these point processes, in which they extend, unify and clarify
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some of the various conditions used in extreme value theory. Baccelli and McDonald [27] extended
Keilson [267] and Aldous [9] probability via the Poisson clumping heuristic that give expressions
for the asymptotic of the mean time until a rare event occurs, using the theory for stationary point
processes. They introduce two notions of asymptotic exponentiality in variance and asymptotic
independence and they also studied their implications on the asymptotics of the mean value of this
hitting time under various initial probability measures.
Poisson
Aldous [9] describes how the Poisson “heuristic” is used to model probabilistic extremes with
examples and provide a complete and accessible review of the vast literature on this subject.
Meyer [347] considers mixing sequences of dependent rare events and a Poisson-type limit theorem
for the probability that k events occur, and an application using an asymptotic distribution for
the number of upcrossings of a high level by certain stochastic processes. Barbour and Ma˚nsson
[32] described compound Poisson processes (independent events occurring at a constant underlying
rate) that are often used as approximate models, when describing the occurence of rare events.
These authors developed a method for showing how to close such approximations. Their approach
used Stein’s method directly, rather than by way of declumping and a marked Poisson process.
They discuss advantages and difficulties and describe illustrations of their procedure. The main
tool of the proof is the Chen-Stein Poisson approximation method and the application of sharp
large deviation results to estimate rare events. Unlike the one-dimensional case, the renewal
phenomenon no longer occurs in the three-dimensional model. Thus, the declumping appearing
sequence-by-sequence matching is no longer needed in the author’s proof.
Stochastic Adaptive Algorithms
There are many investigations that could be listed here, a few have been selected as examples here.
Thompson (pp. 100–111) [519] a competing risk theory, where k risks (for example, diseases and
accidents) compete for the lives of individuals. For each individual, one of these risks will ‘win’ and
the individual will die. The theory attempts to predict the consequences of adding and removing
risks. It is formulated as a continuous time Markov chain, that is a stochastic process where the
transition probabilities from an earlier to a later state depend only on the earlier state. In this model
risk removal (or addition) assumes an independence of the action of one risk to the others. However,
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as Prentice et al. [412] point out, this is not a reasonable assumption in biomedical data. Kaufman
et al. [265], for the field of software reliability for safety critical systems, have used the statistics
of extremes for the analysis of rare events, which they find particularly applicable to this field.
Statistics of extremes, which is based upon order statistics, is the study of the smallest or largest
random variables that are obtained from a series of independent observations. It has been shown
that, for most distributions, as the number of observations approaches infinity, the distribution of
either maximum or minimum values approaches one of three asymptotic forms. These are described
by Kaufman et al. [265] and they describe how this property is used. Rubinstein [437] has applied a
stochastic combinatorial optimization to the ant colony pheromone model to develop simple models
that applies the cross-entropy method for the estimation of probabilities of rare events. Cottrell
et al. [94] apply the theory of large deviation to the study of recursive stochastic algorithms
to produce a fast simulation technique for estimation of rare events. Asmussen et al. [24] have
studied distributions on F on [0,∞) such that for some T ≤ ∞, F ∗2(x, , x + T ] ∼ 2F (x, x + T ].
The case T = ∞ corresponds to F being subexponential, and their analysis showed that the
properties for T < ∞ are, in fact, very similar to this classical case. They develop a parallel
theory in the presence of densities, and they give applications to random walks, the key renewal
theorem, compound Poisson processes (independent events occurring at a constant underlying rate)
and Bellman-Harris branching processes. Frei and Scha¨r [157] present a statistical framework for
detection of probability trends in rare events with theory and application to heavy precipitation
in alpine regions. It embraced logistic regression for trend estimation and testing, and included a
quantification of the potential/limitation to discriminate a trend from the stochastic fluctuations
in the record. Their results from these data demonstrated the difficulty to determine trends of
very rare events, showed the need for long term data.
Rare Classes
Joshi [255] examined the prediction of rare classes by classifiers. This ability is important in
application in such fields as, document classification, network intrusion detection, and web-log
analysis. They suggest that the two most important metrics for effective prediction of a rare class
are: recall and precision with respect to the rare class and translate many different metrics into
this recall-precision perspective. The comparative relationships for varying levels of rarity of the
target class and various difficulties of learning problems were examined.
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Markov Chains
Keilson [267] presents the basic concepts needed to study Markov chains and provides a number
of working tools to quantify the ergodic and transient behavior of systems with many degrees
of freedom, such as those of system reliability, and explores rarity and exponentiality on limit
theorems regarding these. Marek [336] presented a convergence analysis algorithm and investigated
the possibility of computing stationary probability vectors of Markov chains containing rare events.
Mandjes [333] used state frequencies of a large number of Markov chains to analyze rare events
to gain insight into the likelihood of extreme fluctuations of the input rate of an asynchronous
transfer mode (ATM) switching element or an internet protocol (IP) router.
Simulation
Rare event simulation is an important area of simulation theory, producing algorithms that sig-
nificantly reduce the simulation time when analyzing problems that involve rare events. However,
existing rare event simulations are restricted to systems of limited complexity. An early exam-
ple was presented by Carter and Ignall [75] of a variance reduction technique for simulation that
is effective when the system characteristic to be estimated is strongly influenced by rare events.
Buyske et al. [74] describe a simulation model for medical follow-up studies where the majority of
study subjects do not experience the event of interest during the follow-up period. For example,
diseases such as, prostate, lung, colorectal, and ovarian cancer.They used a modification of the
GP family of weighted log-rank statistics that adapts to survival data with rare events. The usual
asymptotic properties, including convergence in distribution of the standardized statistics to the
standard normal, were considered and, for each p, a specific such model is identified so that the
corresponding modified GP statistic is asymptotically optimal. They found that their simulation
studies indicated that their proposed testing statistics could lead to efficiency improvement over
the original GP statistic when the ratio of the two hazard functions decreases over time. They
suggest other ways that the GP family of statistics can be extended. Asmusen [23] discusses im-
portance sampling, when simulating small, say of order 10−6 or less. When implementing the
established principle of choosing the importance sampling distribution as close to to conditional
distribution given the rare event as possible leads to large deviations calculations and experimental
change measure. This author surveys some of the standard examples where this approach works
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and supplements existing counterexamples with new ones. They found that difficulties often arise
as a consequence of reflecting barriers and presented an algorithm which can deal with this problem
in simple cases. They also consider the case of heavy-tailed distributions (see also [22]).
Temporal Methods
There are some rare events which we are interested more in the occurrence times of the event rather
than their excess above some boundary. Falk et al. (chapter 8 [139]) describe a general theory for
this type of rare event. Weiss and Hirsh [555] describe predicting network failures from network
alarm data and describe an genetic algorithm based machine learning system, timeweaver, that
predicts rare events by identifying predictive temporal and sequential patterns within time-series
data. Vilata and Ma [536] propose an approach to extract temporal patterns from data to predict
the occurrences of target events, such as computer attacks on host networks, or fraudulent trans-
actions in financial institutions.Investigating rare event probabilities in ATM multiplexes Gong
and Nananukul [178] used rational interpolants to tackle some of the computationally complex
performance analysis problems, in particular, cell loss probabilities in systems of small, medium
and large size. Glasserman it et al. [175] devote Part II to rare events in network queueing. Face
recognition is a canonical example of a rare event detection problem in which the target patterns
with much lower frequency than non-targets. Viola and Jones [537, 538] used a cascade architec-
ture with feature selection, based on the AdaBoost algorithm, to address the rare event nature of
the task. Wu et al, [576] introduced cascade learning algorithm based on forward feature selection,
which made the process two orders of magnitude faster.
Subset
Glasserman et al. [174] describe a multilevel splitting technique for estimating rare event proba-
bilities. These authors analyzed the performance of a splitting technique for the estimation of rare
event probabilities by simulation. A straight forward estimator of the probability event evaluated
the proportion of simulated paths on which the event occurs. This method reinforces promising
paths at intermediate thresholds by splitting them into subpaths which then evolve independently.
When implemented appropriately, it has the effect of dedicating a greater fraction of the compu-
tational effort to informative runs. They also examined the optimal degree of splitting at each
threshold as the rarity of the event increased. These models are restricted to models whose state
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spaces are infinite in only one dimension. In more complex cases it is not always clear how inter-
mediate thresholds should be defined to estimate a rare event probability. A better understanding
of the way rare events occur, for proper implementation of splitting in higher dimensions. Sanchez
and Higle [447] use a similar approach with a subset selection procedure for use in observational
studies of rare events. They departed from the traditional selection applications, which involve
experimental settings, because these problems, in the “real world”, are characterized by large,
uncontrollable sample sizes and extremely low incidence rates. This means that there are greater
analytical and computational burdens so these authors chose an approximation of a bound on the
selection probability function. They studied the behavior of a bound on the selection probability
function as the number of populations from which the selection is to be made increased. They
found a simply defined function that emerged from their asymptotic analysis that significantly re-
duced the computational burden for their procedure. They tested its performance on urban traffic
hazard data, in which sample sizes vary by an order of magnitude and incidence rates are virtually
0 and found it performed well. Haimes et al. [191] consider some aspects of single- and multiobjec-
tive decision-tree analysis. Li [294] take into account problems that have multiple objectives and
dynamic control characteristics, which is a characteristic of many sequential decision making prob-
lems. They chose the mathematical methodology of multiobjective dynamic programming with the
principle of optimality as its cornerstone. These authors review some of the progress in this field.
To apply dynamic programming to the separability conditions are crucial. These authors apply an
envelope approach that applies to a general class of non-separable dynamic programming problems.
A multiobjective approach was used as a separation strategy to transform non-separable dynamic
programming problems into a corresponding separable multiobjective dynamic programming set-
ting. They found that unless each overall objective function is of an additive form of corresponding
objectives at all stages, the decision-maker must adjust their preference among objectives along
a non-inferior trajectory. Frowhwein et al. [161, 162] extend this field employing multiobjective
decision trees, who believe that these new developments can advance the practise of incorporating
measures of risk of extreme events in its different facets into multistage decision masking.
Classification
A wide variety of complex systems generate asynchronous events, including nuclear power plants,
computer networks, governments, database systems and operation systems. Oates et al. [374]
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present their multi-event dependency detection (MEDD) algorithm for acquiring event correlation
rules from historical logs of asynchronous events. Given a new stream of events generated in real
time, the rules enable two important activities: clustering sets of related events and predicting
events that will occur in the future. The former activity supports data reduction so that human
monitors can more easily understand the state of the system generating the events, and the latter
activity facilitates prediction of future states of the system by reasoning about events that are
likely to occur.
Predicting a rare class effectively is an important problem. Definition of an effective classifier
regarding its evaluation metric is still very subjective and dependent upon application domain.
Joshi [255] examines a wide variety of point-metrics defined by recall and precision of the targeted
rare class. They were able to compare various metrics in an objective, domain independent manner.
Their criteria of suitability for the rare class problem is judged along the dimensions of learning
difficulty and levels of rarity. This author also proposed a way to compare classifiers directly based
on the relationship between recall and precision values as well as classification using “ripple down
structure” for rare classes [256].
Boosting
Boosting is a general method which attempts to “boost” the accuracy of any given learning al-
gorithm [456, 455]. Joshi et al. [257] studied the classification of rare events and used the meta
technique of boosting to improve the performance of a weak classifier. They evaluate three different
categories of boosting algorithm from the viewpoint of how they update the example weights in
each iteration and consider the effects on recall and precision of rare classes. This resulted in them
proposing to enhance two of the categories of algorithm. These enhancements improve recall and
precision in mining rare classes in synthetic data sets.
Medical Examples
The occurrence of rare, often undesired events, is common to many situations. At any given time
a computer system may break down, a baby may be born with a congenital malformation, an
industrial process may produce a defective item. Under normal circumstances, such events occur
at a constant low frequency. Should this frequency change, it is of interest to ascertain as quickly
as possible that a change has taken place. Kenett and Pollak [269] use the thalidomide episode
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in the 1960s and investigate the Page [382] procedure and a modification of it in relation to false
alarms and sudden verus gradual shifts in rate of rare events. Zhang et al. [597] describes a
tree-based method of analysis for prospective studies, which often involve rare events as outcomes,
and a primary concern is to identify risk factors and risk groups associated with the outcomes.
These authors discuss practical solutions to risk factor analyses in prospective studies and address
strategies to determine tree structures, to estimate relative risks, and to manage missing data in
connection with some important epidemiological problems. Mann et al. [334] and also Martin et al.
[337] used prescription-event monitoring (PEM) as a method of non-interventional observational
cohort pharmacovigilance. Such studies are undertaken as soon as possible after product launch.
They are essentially hypothesis generating in nature and seek out to exclude or identify, within
the limitations of their size, unexpected serious ADRs.
1.3 Data Mining
How we must adapt preconceptions to particular cases: What is the first business of
him who philosophizes? To throw away self-conceit. Epitectus A.D. c. 50–120 Book II,
chapter 17 [131].
Researchers in Information Systems (IS) have been investigating the usefulness of qualitative
methods for the past two decades. In this domain there has been an increasing interest in the
application of methods for analyzing qualitative data [350]. Data mining has been defined as a
data-driven exploratory process of knowledge discovery where the focus is on finding and extracting
useful patterns of information from large, complex databases [48]. Data mining is more than just
a method. It is an entire way of thinking about the organization and analysis of data, emphasizing
an active program of data management [76].
Although data mining arose from a more pragmatic analysis of large data sets accumulated
from retail sales [7], some of the theoretical basis for data mining can be found in grounded theory.
Grounded theory began as general method for comparative analysis as an alternative to methods
of social research that are too focussed on the verification of theories. Grounded theory adds a
prior step in the process that seeks to discover what concepts and hypotheses are relevant for the
area one wishes to research. It seeks to generate a theory to suit the area of investigation rather
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than theory generated by logical deduction from a priori assumptions. Some of the requirements
of a grounded theory are that it provides a strategy for handling data in research, providing modes
of conceptualization for describing and explaining, are clear enough to be readily operationalized
in quantitative studies when appropriate, and to be readily understandable to significant laymen.
Theory that can meet these requirements must fit the situation being researched, and work when
put into use. Generating a theory from data means that most hypotheses and concepts not only
come from the data, but are systematically worked out in relation to data in the course of the
research. This does not exclude theories and flashes of inspiration coming outside of the data,
but they then must be brought into relation to those data under investigation [173]. Thus the
theory is built up from observation, that is the theory is grounded in data [137]. Grounded theory
is inductive in contrast to the positivist deductive approach. It is derived inductively from the
phenomena it represents. However, a sophisticated understanding of grounded theory also rejects
simple inductive theory building. Theory building occurs in an ongoing dialogue between existing
theory and new insights generated from empirical observation. In practise, grounded theory and
thematic analysis involves the coding, sorting and organizing data [425]. The major difference
between grounded theory and other methods is its specific approach to theory development –
grounded theory suggests that there should be a continuous interplay between data collection and
analysis [350]. It should be noted here that this theory includes, positivist, interpretive and critical
epistemologies (for an in depth discussion on the philosophical perspectives of grounded theory see
Meyrs [350]).
Morse suggests that employing interview methods using grounded theory is narrowing the
contribution of qualitative inquiry to understand health and illness. Her recommendation is that
there needs to be a broadening of scope with the development of multiple qualitative methods [364].
The utility of data mining algorithms to qualitative health research for analysis of qualitative and
quantitative data in large complex databases created by the health informatics community is
discussed in [76].
Knowledge discovery in databases (KDD) focusses on the computerized exploration of large
amount of data and on the discovery of interesting patterns in them [140]. The challenges of large
collections of data, which vary greatly in the type of data, depending on the domain of the data
collection, has led to the development of more efficient and scalable tools to handle such data. This
work built upon the methodology and algorithms that researchers had previously used. [509]
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A survey of temporal KDD paradigms and method was conducted by Roddick ans Spiliopoulou
[428] who explore the outstanding problems in this area and a comprehensive literature review of
KDD to 1999 by Bradley et al. [64]. Many tools are available to develop and train learning
system models to evaluate their performance. For example, resampling techniques attempt to
obtain a characteristic sample of the whole data set, such as holdout, random subsampling, cross-
validation or bootstrapping to minimize the error rates [558]. These tools should analyze the data
in a transparent and unbiased fashion, with the aim of highlighting information worth a closer
examination [122].
Komar and Moore [275, 276] demonstrated that logistic regression can be a fast and accurate
data mining tool for life sciences data sets, competitive with modern tools like support vector ma-
chines and ball-tree based k nearest neighbor. These authors conducted an empirical examination
of the first assumption, and surveyed, implemented and compared techniques by which logistic
regression can be scaled to data with millions of attributes and records. Their results, on a large
life sciences data set, indicate that logistic regression can perform surprisingly well, both statisti-
cally and computationally, when compared with an array of more recent classification algorithms.
However, it must be noted generally with data mining that more features do not necessarily add
more value to the information gained [558]. For example, in gene expression microarray data, it
was found that filtering out fields representing genes which contributed little to the classification
of cancers improved performance [29].
Data mining brings together the challenges associated with large data sets of, scalability, high di-
mensionality, heterogenous and complex data, data ownership and distribution, and non-traditional
analysis. Researchers from different disciplines have focussed on developing more efficient and scal-
able tools to handle diverse types of data. In particular it draws on ideas such as, (i) sampling,
estimation, and hypothesis testing from statistics and (ii) search algorithms, modelling techniques,
and learning theories from artificial intelligence, pattern recognition, and machine learning, (iii)
ideas from other areas, including, optimization, evolutionary computing, information theory, sig-
nal processing, visualization, and information retrieval. [356, 509] However, it must be cautioned
that many models are simplifications of extremely complicated phenomena (in this thesis – Phar-
macoepidemiology and drug safety), and it is a mistake to assume that any particular model is
actually a true representation of the underlying process. What is hoped is that the model may be
an adequate description and perhaps useful for some purpose. [88]
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A prototypical example of a data mining problem is described by Mitchell [357] on a data
set of medical records of pregnant women to improve our medical decision making. This author
recommends that the machine learning algorithms used should go beyond learning to predict likely
outcomes, and learn to suggest preemptive actions to achieve the desired outcome. An example
of data mining in the field of drug discovery is reported by Shen et al. [473] who use a strategy
that employs variable selection quantitative structure-activity relationship (QSAR) models for
chemical database mining, which used a k nearest-neighbor (k-NN) method. The anticonvulsant
activity of nine compounds were synthesized and tested; four were exact database hits and five
were derived from hits with minor chemical modification. Seven of these nine were confirmed to be
active. Successful biomedical data mining and information extraction require a complete picture
of biological phenomena such as genes, biological processes and diseases as these exist on different
levels of granularity. To realize this goal, several freely available heterogeneous databases as well
as proprietary structured data sets have to be integrated into a single global customizable scheme.
Verschelde et al. [535] presented a tool to integrate different biological data sources by mapping
them to a proprietary biomedical ontology that has been developed for the purposes of making
computers understand medical natural language.
It is important to note here, particularly for a clinical context, that there is a vast difference
between statistical significance and clinical relevance. All that statistical significance tells you is
that the differences you obtain are unlikely to be due to chance/sampling variability. It does not
tell you how meaningful they are in the real world. In a medical context, we may lower someone’s
blood pressure a few points, and it may be statistically significant, but it will likely not reduce their
risk of subsequent heart disease much. [220, 221] This is a very important distinction, however, in
this study, the data available had individual patient details removed, which makes it more difficult
to make conclusions on clinical relevance.
1.3.1 Association Rules
Large amounts of data have been collected routinely in the course of day-to-day management
in business, administration, banking, the delivery of social and health services, environmental
protection, policing, and politics. These data are primarily used for accounting and management
of the customer base. However, it is also one of the major assets to the owner since it contains a
wealth of knowledge about the customers that can assist in the development of marketing strategies,
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political campaigns, policies and product quality control. Data mining techniques help process
these data that can be huge, constantly growing and complex. The discovered patterns point
to underlying mechanisms which help to understand the customers and can give leads to better
customer satisfaction and relations.
Agrawal et al. [7] applied an association rules algorithm to a large database of customer
transactions, each transaction consists of items purchased by a customer in a visit. These authors
presented an efficient algorithm that generated all significant association rules between items in
the database. An association rule is an implication or if-then-rule which is supported by data.
The algorithm incorporated buffer management and novel estimation and pruning techniques.
They applied this algorithm to sales data obtained from a large retailing company and showed
the effectiveness of this algorithm. Improvements to this algorithm are reported [6]. Interesting
patterns often occur at varied levels of support. The classic association mining based on a uniform
minimum support, such as Apriori, either misses interesting patterns of low support or suffers from
the bottleneck of itemset generation caused by a low minimum support. A better solution lies in
exploiting support constraints, which specify what minimum support is required for what itemsets,
so that only the necessary itemsets are generated. Wang et al. [547] presented a framework of
frequent itemset mining in the presence of support constraints. Their approach is to “push” support
constraints into the Apriori itemset generation so that the “best” minimum support is determined
for each itemset at runtime to preserve the essence of Apriori. This strategy is called Adapative
Apriori. Experiments show that Adapative Apriori is highly effective in dealing with the bottleneck
of itemset generation.
Rules produced by algorithms, such as Apriori, need to be mined, because of the vast numbers
of rules produced, to filter out rules of no interest. Many ways of looking at rules have emerged in
order to extract more interesting information. Maximum frequent sets (MFS) have been used to
improve algorithm performance [484]. The use of a “greaterthanexpectedvalue” interest measure
to identify the interesting rules in the output [245, 246, 483] alternative interest measures [379],
hash-based algorithm for mining association rules [387], association rules with adjustable accuracy
[388], an algorithmic framework for solving the projected clustering problem [5], the concept of a
restricted conditional probability distribution is used to explain an association rule [295], use of
hierarchical clustering to partition the initial rule set into thematically coherent subset [254], the
use of P-trees and T-trees [89]. DuMouchel and Pregibon have adopted a criterion based on the
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results of fitting an empirical Bayes model to the item set counts for interesting item sets [116].
The usefulness of association rule mining is not limited to business applications. It has been
applied to genomics and text categorization (Section 1.9.6). The concepts of “items” and “market
baskets” can be generalized and a theoretical model developed, for example, Hegland [215].
1.4 Classification
Pawlak [397] claims that knowledge is deep seated in the classificatory abilities of human beings
and other species. For example, knowledge about the environment is primarily manifested as
an ability to classify a variety of situations from the point of view of survival in the real world.
Complex classification patterns of sensor signals probably form fundamental mechanisms of every
living being. Classification on more abstract levels, seems to be a key issue in reasoning, learning
and decision making, not to mention that in science classification is of primary importance too.
All the real knowledge that we possess depends upon methods by which we distinguish the
similar from the dissimilar. The greater the number of natural distinctions this method compre-
hends, the clearer becomes our idea of things. The more numerous the objects which employ our
attention, the more difficult it becomes to form such a method [136].
Jardine and Sibson [251] discuss mathematical taxonomy and introduce the terms classificatory
system and taxonomic system to describe any set of subsets of a set of objects which in some way
conveys information about the objects. Where the term object is used to describe whatever are the
elements of a set which is decomposed into subsets in a classificatory system, whether the elements
be individuals or classes of individuals. The class of one classificatory system may be the objects
of another.
It is widely understood that protein functions can be exhaustively described in terms of no
single parameter, whether this be amino acid sequence or the three-dimensional structure of the
underlying protein molecule. This means that a number of different attributes must be used
to create an ontology of protein functions. Certainly much of the required information is al-
ready stored in databases such as Swiss-Prot (annotated protein sequence database), Protein Data
Bank, structural classification of proteins (SCOP) and the Munich information center for protein
sequences (MIPS). But the latter have been developed for different purposes and the separate data-
structures which they employ are not conducive to the needed data integration. Kuma and Smith
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[284] attempted to classify the entities in the domain of proteins, but were faced with a number of
cross-cutting principles of classification. Their question was: how to bring together these separate
taxonomies in order to describe protein functions? Their proposed answer is: via a careful top-level
ontological analysis of the relevant principles of classification, combined with a new framework for
the simultaneous manipulation of classifications constructed for different purposes.
Data mining applied to pharmacovigilance must ensure that the results of data mining should
be evaluated in the context of other relevant data and the need for a publicly accessible global
safety database, which is frequently updated [11]. It has been demonstrated in this thesis, the
inadequacy of the ADRAC data set, the one that we have access to is out-of-date and too small,
to properly test and develop methods that assist in pharmacovigilance.
1.4.1 Classification in Data Mining
An important component of many data mining projects is finding a good classification algorithm,
a process that requires careful consideration of experimental design to avoid statistically invalid
conclusions. This particularly the case in the case of very large data sets, which inevitably contain
statistically unlikely data. Salzberg [445] described several phenomena that can, if ignored, inval-
idate an experimental comparison. This author also discussed why comparative analysis is more
important in evaluating some types of algorithms than for others, and provided some suggestion
to avoid pitfalls. Furthermore, no single classification algorithm is the best for all problems and,
similarly for data mining, no single technique works best on all databases. Theoretic work has
shown that, with certain assumptions, no classifier is always better than another one [467, 568].
This is important to bear in mind, particularly in the case of “real world” data; different methods
may bring out different relevant aspects from the data.
Centroid-based text classification is one of the most popular supervised approaches to classify
texts into pre-defined classes. Based on the vector-space model, the performance of this classi-
fication particularly depends on the way to weight and select important terms in documents for
constructing a prototype class vector for each class. Different data sets require different weighting
systems. This problem has been addressed by Lernattee et al. [291, 292] who proposed a method
that uses homogenous centroid-based classification. The results from testing this model showed
that their system could improve classification accuracy.
Similarity search in database systems is becoming an increasingly important task in modern
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application domains such as multimedia, molecular biology, medical imaging, computer aided engi-
neering, marketing and purchasing assistance as well as many others. Brecheisen et al. [67] showed
how visualizing the hierarchical clustering structure of a database of objects can aid the user in
this time consuming task to find similar objects. Pattern discovery in temporal databases has been
investigated by Padmanabhan [381] extended work on frequent episodes in sequences to apply a
search for temporal logic patterns in temporal data sets.
1.5 Uncertainty and missing values
Traditional, that is probabilistic, approaches to uncertainty management tend to focus upon view-
ing uncertainty either as a frequentistic measure of randomness or in terms of a subjective measure
of confidence satisfying well circumscribed propositions. However, definitions of uncertainty in-
clude concepts such as: error, lack of confidence, imprecision, unreliability, variability, vagueness,
ignorance and ambiguity [279].
Uncertainty pervades life and can arise from many sources. It is present in most tasks that
require intelligent behavior, such as planning, reasoning, problem solving, decision making, classi-
fication and many others dealing with real world entities and data. Information and uncertainty
opposite sides of the same concept. Before the experiment is performed there is uncertainty about
the outcome. The performance of the experiment removes the uncertainty and the experimenter
receives information when which of the possible outcomes is known [407, 471, 517]. The repre-
sentation of uncertainty is a central issue in Artificial Intelligence (AI) and is being addressed in
many different ways, for a review see [278, 279, 443]. There is a variety of conceptions of vague-
ness in logical and philosophical literature (for examples see, [30, 56, 144, 168, 274, 441]). In the
present context, the main areas where the application of AI uncertainty management methods and
techniques concerns: missing, inaccurate, and imprecise information, and classification.
Uncertainty in the domain of knowledge representation, if we consider probability theory, we
find that the notion of uncertainty applies to atomic or conditional propositions. Therefore, con-
cepts such as ambiguity, inconsistency, incompleteness and irrelevance are not permitted, and are
not formally part of the Bayesian model [289]. More specifically, these aspects of uncertainty (in-
consistency or contradiction) have to be engineered out of the problem domain in order to make the
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calculus usable. That is not to say that such concepts cannot be dealt with within a probabilistic
framework, but some additional features must be added to support these extensions ([279] pp. 17–
46, see also [391]). Dawid [100] probes our common distinction of types of quantity: parameters
and observables and suggests that the Bayesian approach avoids such distinctions so each type
are considered as uncertain quantities. There have developed a number of different approaches
to structuring knowledge so that uncertainty can be incorporated into reasoning structures, such
as, the certainty factor model, fuzzy logic (Section 1.6), the Dempster-Shafer evidential reasoning,
non-monotonic logic, and argumentation [279, 499].
A method to induce decision rules from data with missing values where: (i) the format of
the rules is no different than rules for data without missing values, and (ii) no special features
are specified to prepare the original data or apply induced rules was presented by Weiss and
Indurkhya [557]. Their results demonstrated that their approach to classification can yield strong
results for mining data with missing values. Another similar study has been made by Li et al.
[296]. Many approaches to uncertainty management have been explored, for example: modelling
imperfect information in a deductive databases [163, 365, 393, 460], the elimination of noisy terms
on a class-by-class basis, rather than by selecting the most significant ones [401], term election in
text categorization [402], protein topology prediction [389, 390, 392], various forms of reasoning
under uncertainty that are based on rough sets [394], the qualitative analysis of a numerical model
of uncertainty [231, 395], to define a generalized likelihood function based on uncertainty for
different measures different types of classifiers [511]. For a review of current approaches to handling
imperfect information in data and knowledge bases, see Parsons [87, 279, 391].
1.6 Fuzzy logic
It has been suggested that natural languages are wholly vague, for example Russell [441] and
Black [55]. However, vague sentences seem to present difficulties for the application of of standard
logical apparatus – see Section 1.1.1. Formal logical systems are supposed to be relevant to the
assessment of informal arguments; but the classical logical systems, in which every well-formed
formula is either true or else false, seem inappropriate for the assessment of vague premises and/or
conclusions to call definitely true or false [188]. Zadeh proposed a revised logic of vagueness, who
concluded that “‘fuzzy thinking’ may not be deplorable, after all, if it makes possible the solution
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of problems which are much too complex for precise analysis” [591].
Stachowicz [487] points out that medicine is one field in which the applicability of fuzzy set
theory was recognized quite early in the mid-1970s. The main focus has been in the diagnosis of
disease. The process of classifying different sets of symptoms under a single name and determining
appropriate therapeutic actions becomes increasingly difficult. A single disease may manifest itself
quite differently in different patients at different stages. A single symptom may be indicative
of several different diseases. The presence of several diseases in a single patient may disrupt the
expected symptom pattern of any one of them. [Note: these observations are particularly pertinent
to my study. All one needs to do is replace the word ‘disease’ with the word ‘drug’ and ‘symptom’
with ‘ADR’.] The best and most useful descriptions of diseases often use linguistic terms that are
irreducibly vague. For example, hepatitis: “total proteins are usually normal, albumin is decreased,
alpha-globulin are slightly decreased, beta-globulins are slightly decreased, and gamma-globulins are
increased.” Fuzzy set theory can be used to compute with words when the available information
is too imprecise to use numbers. This imprecision can be exploited to achieve tractability of
complex problems, robustness, low solution cost and better rapport with reality. A key aspect of
computing with words is that it involves fusion of natural languages and computation with linguistic
variables. A linguistic variable AGE : T(AGE)=YOUNG, NOT YOUNG, VERY YOUNG, . . . ,
EXTREMELY OLD, . . . , ; with primary terms : YOUNG, OLD; the hedges : VERY, MORE
OR LESS, QUITE, EXTREMELY . . . ; connectives : AND, OR, EITHER, NEITHER; negation :
NOT.
As well as being vague, linguistic concepts’ meanings are almost invariably context-dependent.
For example. the meanings of young and old change when applied to different animal species.
or when applied to stars in astronomy. The context dependency involves not only meanings of
linguistic terms, but also meanings of operations on these terms. It is now experimentally well
established that various connectives of linguistic terms, such as, And, Or, Not and If-Then, have
different meaning in different contexts. The conversion of linguistic variables to fuzzy sets is
achieved by determining which of the t-norms, t-conorms, compliments, or other operations best
approximate the intended meaning of connectives. The various hedges are context dependent as
well.
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1.6.1 Fuzzy truth values
In fuzzy logic, truth values are no longer binary (true/false) but are multi-valued. The theory
of multi-valued logics was developed by Lukasiewicz [310, 311]. The set of truth values for the
n-valued logic: Tn = {0, 1/n-1. 2/n-1, 3/n-1, . . . , n-2/n-1, 1}. An example, in five-valued logic,
the truth values are: T5 = {0, 1/4, 1/2, 3/4, 1}. The logical connectives in multi-valued logics are:
¬p = (1−p); p∧q = min(p, q); p∨q = max(p, q); p =⇒ q = min(1, 1−p+q); p⇔ q = 1−|p−q|.
Fuzzy set theory can be used to give an interpretation to Lukasiewicz’s indenumerably many-
valued logic [189]. The claim, in fuzzy logic, that the metalinguistic predicates ‘true’ and ‘false’
are themselves fuzzy, and the adoption by Zadeh of fuzzy truth values, has been questioned by
Haack [189] in a section titled Is Truth Flat or Bumpy?. She is even more concerned at the more
radical view of Bradley [63] that there are no absolute truths and no mere errors; all truths and
all errors are relative. I incline to the latter view and I think it is a debate that is pertinent to
interpretation of medical data, but is too big an issue for this thesis.
1.6.2 Fuzzy relations
Compositions of fuzzy relations can be usefully employed. The composition of fuzzy relations P
: U × V and Q : V × W, denoted by P ◦ Q : U × W, is a fuzzy relation whose membership
function (MF) is: P ◦Q(u,w) = max
v∈V
t[P (u, v), Q(v,W )] ∀(u,w) ∈ U ×W, where t is any t-norm.
To calculate P ◦ Q when P and Q are expressed as relational matrices, the calculation of P ◦ Q
is almost the same as matrix multiplication, except that × and + are replaced by min and max,
respectively. To illustrate in medical diagnosis the use of matrices for computing compositions of
fuzzy relations, let:
X = {p1, p2, p3, p4}
Y = {s1, s2, s3}
Z = {d1, d2, d3, d4, d5}
be a set of patients, a set of symptoms, and a set of diseases, respectively. P : X × Y =⇒ [0, 1]
s1 s2 s3
p1 [{0.0, 0.3, 0.4},
p2 {0.2, 0.5, 0.3},
p3 {0.8, 0.0, 0.0},
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p4 {0.7, 0.7, 0.9}]
This relation describes how strongly the symptoms are manifested in the patients.
Q : Y × Z =⇒ [0, 1]
d1 d2 d3 d4 d5
s1 [{0.7, 0.0, 0.0, 0.3, 0.6},
s2 {0.5, 0.5, 0.8, 0.4, 0.0},
s3 {0.0, 0.7, 0.2, 0.9, 0.0},
This relation describes a segment of medical knowledge expressing how strongly each symptom
is associated with a disease. By performing the composition R = P ◦ Q4 in matrix form, we
obtain the association between patients and diseases and, hence, facilitates medical diagnosis.
R : P ×Q =⇒ [0, 1]
d1 d2 d3 d4 d5
p1 [{0.3, 0.4, 0.3 0.4, 0.0},
p2 {0.5, 0.5, 0.5, 0.4, 0.2},
p3 {0.7, 0.0, 0.0, 0.3, 0.6},
p4 {0.7, 0.7, 0.7, 0.9, 0.6}] [486, 487].
1.6.3 Fuzzy sets
The notion of fuzzy set was introduced first by Zadeh in 1965 [590], who later developed many
other methods of fuzzy logic based on this simple notion. The traditional way of representing
elements u of a set A is through the characteristic function:
µA(u) = 1, if u is an element of the set A, and
µA(u) = 0, if u is not an element of the set A,
that is, an object either belongs or does not belong to a given set.
In fuzzy sets an object can belong to a set partially; membership is a matter of degree [592]. The
degree of membership is defined through a generalized characteristic function called a membership
function:
µA : U → [0, 1]
where U is called the universe, and A is a fuzzy subset of U .
The values of the membership function are real numbers in the interval 0,1 where 0 means that
the object is not a member of the set and 1 means that it belongs entirely. Each value of the
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function is called a membership degree. One way of defining a membership function is through an
analog function, for example see [263] pp. 167-168. For good coverage of Fuzzy Set Theory with
an extensive Bibliography see [309].
As has been stated in Section 1.5, when dealing with the real world, certainty and precision
do not always apply and therefore traditional tools (scientific and probability theory) for formal
modelling, reasoning, and computing, which require crisp, precise and deterministic types of data
and information, become inadequate [600, 512].
Many concepts are by nature fuzzy, for example: causality, relevance, independence, cluster,
risk, and grammar. As Zadeh explains [594], “fuzzy logic” is not fuzzy logic. It is precise logic
of imprecision, where everything is allowed to be graduated (a matter of degree), and granulated.
Natural language is transformed by a process of precisiation to mathematical terms. Meaning is
crucial; understanding of meaning is a prerequisite to representation of meaning, representation of
meaning is a prerequisite to precisiation of meaning, and precisiation of meaning is a prerequisite
to mechanization of understanding of meaning to make the problem machine ‘understandable’.
In this project, fuzzy sets have been employed to classify ADRs so that they may be defined as
belonging to more than class defined by a degree of membership. Another way that fuzzy sets may
be employed could be to represent missing and uncertain values, for example utilizing the notion
of typicality [115, 577].
1.7 Rough set theory
While fuzzy logic recognized the fact that the real world does not operate with crisply defined
boundaries, some theorists now have pointed out another oversimplification, which is also shared
by conventional logic. Both forms of logic assume that the reasoning process is based on complete
information. Boolean logic and fuzzy logic both assume that knowledge is complete; one just
represents it with crisp categories, while the other depends upon variable membership-functions
to interpolate between adjacent “fuzzy” categories. Rough set theory, on the other hand, assumes
that knowledge systems are rife with errors and omissions, yet it strives to reach correct conclusions
nevertheless [253].
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1.7.1 Rough Sets
Some categories can be definable in one knowledge base (see Section 1.4) but undefinable in another
one. Thus, if a category is not definable in a given knowledge base, the question arises whether
it can be defined “approximately” in the knowledge base. In other words, we want to address
here the notion of vague categories. In this subsection I wish to describe the idea of rough set as
a means for representing vague categories. One can establish several intriguing and useful links
between rough set and fuzzy sets, for examples see [399].
Rough set analysis is one of the main application techniques to arise from rough set theory. It
provides a technique for gaining insights into properties of data, dependencies and the significance
of individual attributes in a database. It has important applications to AI and cognitive sciences, as
a tool for dealing with vagueness and uncertainty of facts, and in classification [185, 394]. Kawasaki
[266] developed a hierarchical clustering algorithm for documents based on a tolerance rough set
model, and Bi et al. [52, 53] have applied the Rough Set model to discover maximal associations
from a collection of text documents based on the approach of Agrawal [7]. In a similar fashion,
Beynon et al. [50, 51] use rough set theory for classification and rule induction for use in expert
systems. This type of use of rough sets could be very informative when applied to associations in
the ADRAC database, in addition to their use for dealing with uncertainty per se.
1.8 Soft Computing
Soft computing is a burgeoning area of data mining. It is characterized by a hybrid approach to to
data ming using a collection of methodologies, which tries to capitalize upon the strengths of a par-
ticular methodology in order to best fit that methodology to the particular stage in the data mining
process. These methodologies work together in a complimentary, rather than in a competitive way.
It has its foundation in AI the main tools used are: fuzzy logic to deal with uncertainty, neural com-
puting for learning, genetic algorithms for optimization, rough sets for handling granularity, and
computational theory of perception (CTP – reasoning with perception-based data [593]). Mitra et
al. [360] made a survey of the available literature on data mining using soft computing. These au-
thors provided a categorization, based on the different soft computing tools and their hybridizations
used, the data mining function implemented, and the preference criterion selected by the model.
The utility of the different soft computing methodologies is highlighted. Generally fuzzy sets are
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suitable for handling the issues related to understandability of patterns, incomplete/noisy data,
mixed media information and human interaction, and can provide approximate solutions faster.
Neural networks are non-parametric, robust, and exhibit good learning and generalization capabil-
ities in data-rich environments. Genetic algorithms provide efficient search algorithms to select a
model, from mixed media data, based on some preference criterion/objective function. Rough sets
are suitable for handling different types of uncertainty in data. Some challenges to data mining
and the application of soft computing methodologies are indicated. An extensive bibliography is
also included. An example of this approach is given in Pal et al. [383, 384, 385], who describe a
methodology for evolving a Rough-fuzzy multi layer perceptron with modular concept using a ge-
netic algorithm to obtain a structured network suitable for both classification and rule extraction.
The modular concept, based on “divide and conquer” strategy, provided accelerated training and
a compact network suitable for generating a minimum number of rules with high certainty values.
The concept of variable mutation operator was introduced for preserving the localized structure
of the constituting knowledge-based subnetworks, while they are integrated and evolved. Rough
set dependency rules are generated directly from the real valued attribute table containing fuzzy
membership values. Two new indices namely, “certainty” and “confusion” in a decision are defined
for evaluating quantitatively the quality of rules. The effectiveness of the model and the rule ex-
traction algorithm is extensively demonstrated through experiments along with comparisons. The
stages in the soft computing processes, in general are: (i) Data condensation (that is of selecting a
small representative subset from a very large data set), for example, Mitra et al. [358, 359], where
the accuracy of representation by the condensed set is measured in terms of the error in density
estimates of the original and reduced sets. (ii) Feature selection/extraction possibly involving, for
example, fuzzy discretization of feature space for a rough set classifier [436], or with neuro-fuzzy
approach [3, 101]. (iii) Genetic algorithms [171], to optimize neural networks, which are used at
the classification and feature selection stage [384].
1.9 Text categorization
In a library, a book can only be placed in one physical location on the shelves. However, it may
include a number of topics (categories), which give make it logically belong to more than one
category, that is it could potentially be assigned to more than one location. It is possible to
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deal with this problem conceptually by, for example, use of fuzzy sets (see Section 1.6) that allow
membership of a single entity (element – book) to more than one category. In addition, fuzzy sets
enable the quantification of ‘belongingness’ to each set. The methodologies vary, but their goal is
to map the semantic content of a block of text to general categories.
The automated categorization of texts into predefined categories has witnessed a booming
interest over the past decade and a half, due to the increased availability of documents in digital
form and the ensuing need to organize them. In the research community the dominant approach to
the problem was based on machine learning techniques: a general inductive process automatically
builds a classifier by learning, from a set of preclassified documents, the characteristics of the
categories. The advantages of this approach over the knowledge engineering approach (consisting
in the manual definition of a classifier by domain experts) are a very good effectiveness, considerable
savings in terms of expert manpower, and straightforward portability to different domains. This
survey discusses the main approaches to text categorization that fall within the machine learning
paradigm. Sebastiani [464] discussed in detail issues pertaining to three different problems, namely
document representation, classifier construction, and classifier evaluation. Yang and Liu [578, 579,
586] reported a controlled study of five text categorization methods. This paper gives a good
description of the goals and various approaches to the problem. They also point out the difficulty
of comparing the various methods because the results reported are not directly comparable. This
is why they attempt a controlled study. In an earlier study, Yang et al. [584] described a method
for mapping natural language texts to canonical terms that identify the contents of the texts that
used a least squares fit mapping function to represent weighted connection between words and
canonical terms. At this time their approach had superior power to discover synonyms or related
terms and to preserve the context sensitivity of the mapping. Hynek [235] has an extensive review
of document classification algorithms.
1.9.1 Linear classification methods
A number of linear classification methods such as the linear least squares fit (LLSF), logistic re-
gression, and support vector machines (SVM’s) have been applied to text categorization problems.
These methods share the similarity by finding hyperplanes that approximately separate a class of
document vectors from its complement. However, support vector machines were considered spe-
cial in that they have been demonstrated to achieve the state of the art performance. In order
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to understand whether such good performance is unique to the SVM design, or if it could also
be achieved by other linear classification methods, Zhang and Oles [599] compared a number of
known linear classification methods as well as some variants in the framework of regularized linear
systems. They discussed the statistical and numerical properties of these algorithms, and also pro-
vided some numerical experiments to illustrate these algorithms on a number of data sets. Barbara´
et al. [31] provided a method for classifying documents without labels because there can be cases
where class labels are not known. In an earlier medical application Yang and Chute [585] a LLSF
mapping method to an expert network to clinical classification and MEDLINE indexing.
1.9.2 Boosting
Many learning algorithms for pattern classification minimize the training data, with the aim of
minimizing error (the probability of misclassifying an example). One example of such a cost
function is simply the classifier’s error on the training data. For example Bartlett [33] has shown
that the error of a sigmoid network classifier is no more than the sampling average of the cost
function they define, which takes the value 1 when their function yf(x) is no more than θ and
0 otherwise, plus a complexity penalty term that scales as ‖w‖1/θ, where (x, y) ∈ X × {±1} is
a labelled training example, and ‖w‖1 is the sum of the magnitudes of the output node weights.
The quantity yf(x) is the margin of the real-valued function f , and reflects the extent to which
f(x) agrees with the label y ∈ {±1}. By minimizing squared error, neural network learning
algorithms implicitly maximize margins, which may explain their good generalization performance.
Similarly, boosting algorithms, which use convex combinations of classifiers, showed that, with high
probability over m random examples, every convex combination of classifiers from some finite class
H has error satisfying
Pr[yf(x) ≤ 0] ≤ Es [sgn(θ − yf(x))] +O
(
1√
m
(
logm log |H|
θ2
+ log (1/δ)
) 1
2
)
∀ θ > 0, where Es denotes the average over sample S.
One way to think of these results is as a technique for adjusting the effective complexity of
the function class by adjusting θ. Large values of θ correspond to low complexity and small
values high complexity. If the learning algorithm were to optimize the parameterized cost function
Essgn(θ − yf(x)) for, large values of θ, it would not be able to make a fine distinction between
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different functions in the class, and so the effective complexity of the class would be reduced.
The second term in the error bounds (the regularization term involving the complexity parameter
θ and the size of the base hypothesis class H) would be correspondingly reduced. In both the
neural network and the boosting settings, the learning algorithms do not directly minimize these
cost functions; they use different values of the complexity parameter in the cost functions only
in explaining their generalization performance (see Mason et al. [338]). Mason et al. [339] also
described this process in terms of functional gradient techniques for combining hypotheses.
Breiman [68] described a framework for understanding this process of adaptively reweighting the
training set, growing a classifier using the new weights, and combining the classifiers constructed to
date to reduce generalization error, was called “arcing at the edge”. This author described arcing
algorithms to minimize some function of the edge (a bound on the generalization error of a convex
combination of classifiers in terms of the margin).
Sebastiani [465] described AdaBoost.MHKR, an improved boosting algorithm, and its applica-
tion to text categorization. Boosting is a method of supervised learning, which has been successfully
applied to many domains, and has proven to be one of the best performers in text categorization
exercises so far. Boosting is based on the idea of relying on the collective judgement committee
of classifiers that are trained sequentially. In training the i-th classifier, special emphasis is placed
on the correct categorization of the training documents that have proven harder for the previously
trained classifiers. AdaBoost.MHKR is based on the idea to build, at every iteration of the learning
phase, not a single classifier, but a sub-committee of the K classifiers which, at that iteration, look
the most promising. These authors reported results using the standard Reuters-21578 benchmark
and found AdaBoost.MHKR was both more efficient to train and more effective than the original
AdaBoost.MHR algorithm.
Schapire and Singer [458] described several improvements to Freund and and Schapire’s AdaBoost
boosting algorithm [158, 159, 160], particularly in a setting in which hypotheses may assign con-
fidences to each of the predictions. The former authors show their analysis can be used to find
improved parameter settings as well as a refined criterion training weak weak hypotheses and de-
scribe a method for assigning confidences to predictions of decision trees. They then demonstrated
the application of the modified algorithms to multi-label problems where each example may belong
to more than one class.
Nardiello et al. [369] focused on two “boosting”-based learners for automated text classification,
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AdaBoost.MH and AdaBoost.MHKR. While the former is a realization of the well-known AdaBoost
algorithm specifically aimed at multi-label text categorization, the latter is a generalization of the
former based on the idea of learning a committee of classifier sub-committees. Both algorithms have
been among the best performers in text categorization experiments so far. A problem in the use
of both algorithms is that they require documents to be represented by binary vectors, indicating
presence or absence of the terms in the document. As a consequence, these algorithms cannot take
full advantage of the “weighted” representations (consisting of vectors of continuous attributes) that
are customary in information retrieval tasks, and that provide a much more significant rendition
of the document’s content than binary representations. These authors addressed the problem of
exploiting the potential of weighted representations in the context of AdaBoost-like algorithms
by discretizing the continuous attributes through the application of entropy-based discretization
methods. They presented experimental results on the Reuters-21578 text categorization collection,
showing that for both algorithms the version with discretized continuous attributes outperformed
the version with traditional binary representations. Boosting is a general method for improving
accuracy of any given learning algorithm. Schapire [457] reviewed some of the work on boosting
including AdaBoost’s training error and generalization error, boosting’s connection to game theory
and linear programming, the relationship between boosting and logistic regression, extensions od
AdaBoost for multiclass classification problems, methods of incorporating human knowledge into
boosting, and experimental and applied work using boosting.
1.9.3 Biological relationships
The biological literature databases continue to grow rapidly with vital information that is important
for conducting sound biomedical research and development. The current practises of manually
searching for information and extracting pertinent knowledge are tedious, time-consuming tasks.
Accurate and computationally efficient approaches in discovering relationships between biological
objects from text documents are important for boilogists to develop their models. Palakal et
al. [386]) present their approach to this problem of extracting relationships between multiple
biological objects that are present in a text document. It involves object identification, reference
resolution, ontology and synonym discovery, and extracting object-object relationships. Hidden
Markov Models (HMMs), dictionaries,and N-Gram models were used to set the framework to tackle
the complex task of extracting object-object relationships. They tested their object identification
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process using a corpus of one thousand Medline abstracts and found it produced an 81 percent
specificity for relationships. Another method for text pattern visualization using frameworks for
concept based retrieval [181].
1.9.4 Uncertainty
The notion of uncertainty (Section 1.5), which has a prominent place in the theory and experimental
practice of modern Physics. Peters and Koster [402] argue that the awareness of uncertainty may
also be of tremendous importance in the field of information retrieval, and in particular text
categorization. These authors [401, 402] introduced the criterion of uncertainty for term selection,
which is used to eliminate noisy terms on a class-by-class basis, rather than selection of the most
significant ones. This term is then compared with other criteria, such as information gain, simplified
χ2, term frequency, and document frequency, in a text categorization setting. They tested several
data sets and two algorithms and found the uncertainty criterion not to be the most aggressive
of the criteria, but its effect was found to be quite stable across data sets and algorithms. Bi et
al. [52] describe an approach based on rough set techniques for decision rule generation in text
classification. Their maximal association rule method (see Section 1.9.7) incorporated a method
for handling uncertainty and vagueness into computing lower and higher approximations.
1.9.5 Logistic regression
Logistic regression (LR) has been widely used in statistics for many years, and has received exten-
sive study in the machine learning community recently due to its close relations to support vector
machines (SVM) and AdaBoost [159, 160]. Zhang et al. [598] used a modified version of LR to ap-
proximate the optimization of SVM by a sequence of unconstrained optimization problems. They
found that their LR method to perform much better when the number of training examples is very
large. The problem of learning with positive and unlabelled examples arises frequently in informa-
tion retrieval (IR) applications. Lee and Liu [290] transformed the problem into one of learning
with noise by labelling all unlabelled examples as negative and use a linear function to learn from
noisy examples. For this they used logistic regression after weighting the examples to handle noise
rates greater than one half and appropriate regularization, the cost function of the LR problem
is convex, allowing an efficient solution. They also proposed a retrieval performance metric and
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found experiments on a text classification corpus to indicate their methods were effective.
Fuhr and Pfeifer [164] showed that former approaches in probabilistic information retrieval
are based on one or two of the three concepts abstraction, inductive learning, and probabilistic
assumptions. These authors proposed an approach that combines all three concepts. It is illustrated
for the case of indexing with a controlled vocabulary and they describe a probabilistic model first,
which was then combined with logistic regression, thus yielding a generalization of the original
model. They give experimental results for the theoretical model as well as for heuristic variants
and compare linear with logistic regression.
1.9.6 Term Association
A method that uses association rule mining that borrows from the market basket analysis [7] is
reported by Antonie and Zai˙ane [17] focussed on finding the best term association rules in a textural
database by generating and pruning, and using rules to build a text classifier. Their method proved
efficient and effective on well-known collections to test classifier performance. A similar method
was developed using mining association rules using multipass with inverted hashing and pruning
(MIHP) that sowed better perfomance for large text databases [227].
1.9.7 Maximal Association Rules
While most work on KDD has been concerned with structured databases, there has been little
work on handling the huge amount of information that is avilable only in unstructured document
collections. Feldman and Kloesgen [140] described a method for computing co-occurrence fre-
quencies of the various keywords labelling the documents, which used maximum association rules.
Regular associations are based on the notion of frequent sets: sets of attributes, which may appear
in many records. By analogy, maximal associations are based on the notion of frequent maximal
sets. Conceptually, a frequent maximal set is a set of attributes, which appear alone, or maximally,
in many records. For the definition of “maximality” these authors use an underlying taxonomy,
T , of attributes. This allowed them to obtain the “interesting” correlations between attributes
from different categories. Frequent maximal sets are useful for efficiently finding association rules
that include negated attributes. These authors evaluated their methodology on the Reuter-21578
document collection. Bi et al. [52, 53] investigated the applicability of a Rough Set model and
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method to discover maximal associations from a collection of text documents. They found that
the Rough Set approach to be both conceptually and computationally more elegant and efficient
than the established maximal association methods.
1.9.8 Thresholding
Thresholding strategies in automated text categorization are an under explored area of research.
Yang [580] presented an examination of the effect of thresholding strategies on the performance
of a classifier under various conditions. Lee et al. [288] note that the two main research areas in
statistical text categorization are similarity-based learning algorithms and associated thresholding
strategies. The combination of these two techniques significantly influences overall performance
of text categorization. After investigating two similarity-based classifiers and three thresholding
techniques, they describe a new learning algorithm known as the keyword association network
(KAN) and a new thresholding strategy, called RinSCut to improve performance over existing
methods.
1.9.9 Event Tracking
Automated tracking of events from chronologically ordered document streams is a new challenge for
statistical text classification. Existing learning techniques must be adapted or improved in order
to effectively handle difficult situations where the number of positive training instances per event
is extremely small, the majority of training documents are unlabelled, and most of the events have
short duration in time. Yang et al. [582, 583] adapted several supervised methods and combined
them to improve their event tracking capabilities.
1.9.10 Learning, cross-validation
Parameter tuning through cross-validation becomes very difficult when the validation set contains
no or only a few examples of the classes in the evaluation set. Yang et al. [581] addressed
this challenge by using a combination of classifiers with different performance characteristics to
effectively reduce the performance variance on average of the overall system across all classes,
including those not seen before.
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1.9.11 Hierarchical classification
Ruiz and Srinivasan [438, 439, 440] exploited the hierarchical structure of an indexing vocabulary
for a machine learning using a neural networks approach to text categorization. Sun et al. [497]
evaluate hierarchical text classifications and proposed an alternative top-down level-based clas-
sification method and report improved performance and a new performance measures: category
similarity and distance that consider the contributions of misclassified documents [498]. Yang et
al. [587] reported how they addressed the fact that real-world applications often require tens of
thousands of categories defined over a large taxonomy. Han and Lam [193] proposed a frame-
work which can exploit hierarchical structures of feature domain values to improve classification
performance.
1.9.12 Semantic features and domain knowledge
There has been work to extract semantic features from the text to assist the text categorization
that shows that how integration metadata information improves text classification methods [65,
228, 362, 363, 415, 416, 426, 434, 567] and using boosting [58]. Tailby et al. [507] have recently done
some work on email classification which uses domain knowledge to compensate for a lack of training
data. An important part of this thesis is to show the importance of utilizing domain knowledge
to make automated data analysis methods more meaningful. Ontologies (see Section 1.10.1) allow
the usage of features on a higher semantic level than single words for text classification purposes.
Bloehdorn1 and Hotho [59] explored such an enhancement of the classical document representation
through concepts extracted from background knowledge. Godbole et al. [176, 177] demonstrated
their interactive text categorization system called Hyper-interactive Text Classification (HiClass)
and used linear SVMs as an example of linear additive classification models. This made it possible
to incorporate human knowledge in the form of include/ignore rules for certain features while
learning certain classes.
1.9.13 Text categorization – concluding remarks
There has been a vast amount of activity in this area. As to which methods are suited to application
to drug safety data, this requires investigation. Some methods may be clearly not applicable, but
even for those that may be suited, some remarks from a practitioner in the text categorization field
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are worth noting:
Noteworthy improvements, vs. statistically significant improvements Even the papers that
carefully consider statistical significance tests are just asking the question: do I have
enough evidence to conclude method A is better than method B? The answer can be
safely yes, even if that difference in performance is very small.
But what we as readers & practitioners of data mining want in general is guidance about
which methods are going to be worth our trouble to learn & adopt. Substantial gains in
performance. Someone once suggested that each new publication about Reuters-21578
should have to improve by at least x% over all previous publications for reviewers to
accept it. This has its problems too, but it gets at a similar point.
I don’t actually want to throttle the number of publications, but I think we all would
like collaborative filtering to help find the papers that have ’noteworthy improvements.’
In any field, really.
And then there’s the matter of complexity. If you can improve my performance by 2%
by teaching me to add 0.2 for Laplace correction instead of adding 1, that’s worth it.
But if you tell me I can get 4% improvement by [extremely complicated method inserted
here], then it’s probably not worth my time, unless someone else is going to provide
the code for it and it has proven itself very robust (such as has happened for SVMs).
George Forman [152].
However, I think that small performance improvements from tweaking algorithms may be
dwarfed by use of semantic methods and domain knowledge mentioned in the previous section
1.9.12.
1.10 Ontology
The mere fact of appearing as an object at all is not enough to constitute reality. That
may be metaphysical reality, reality for God; but what we need is practical reality, reality
for ourselves; and, to have that, an object must not only appear, but it must appear both
interesting and important. William James chapter XXI pp. 643–644 [248].
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1.10.1 Background on ontology
Ontologies – specifications of what exists, or what we can say about the world – have been around
before Aristotle. Just as scientists have grappled with the reality of negative numbers, subatomic
particles, or the vital force, so have theologians and mystics grappled with the reality of God and
inner spiritual experiences. The nature of knowledge is an abiding question and has resulted in
people’s continuous attempts to find ways to express, word, or convey their own “knowledge”.
Physics and mathematics depend on specific symbolic languages, and many approaches to AI re-
gard finding the problems optimal representation as most of the solution. Recently, we have seen
an explosion of interest in ontologies as artifacts to represent human knowledge and as critical
components in knowledge management, the Semantic Web, business-to-business applications, and
several other application areas. Various research communities commonly assume that ontologies
are the appropriate modelling structure for representing knowledge. However, little discussion has
occurred regarding the actual range of knowledge an ontology can successfully represent. How
adequate a conception of knowledge is this? Clearly, we cant easily represent certain types of
knowledge (for example, skills or distributed knowledge). We can’t easily transform certain types
of representation into ontology-appropriate formats (for example, diagrammatic knowledge). Other
types of knowledge are extremely suited to ontological representation, such as taxonomic informa-
tion. Many definitions of ontology, for example Gruber [182], insist that an ontology specifically
represents common, shared conceptual structures. Does this requirement for publicity help guaran-
tee adequacy? And if so, can we talk of personal ontologies? Staab [485] brought together several
practitioners to debate these issues.
Ontology is that part of philosophy (or metaphysics) concerned with existence or being; those
features of an entity and its relationship with other entities that define its existence. In an Informa-
tion Systems context “ontology” has developed a number of specialized meanings that may appear
remote from this word’s original meaning. A web search engine, using “ontology” as the keyword,
returned about 354,000 pages with phrases such as: “gene ontology consortium”, “enabling a vir-
tual business”, “knowledge engineering and conceptual modelling”, sounding more practical than
philosophical. There are a large number of definitions, some examples are:
Â “Ontology is the theory of objects and their ties. The unfolding of ontology provides criteria
for distinguishing various types of objects (concrete and abstract, existent and non-existent,
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real and ideal, independent and dependent) and their ties (relations, dependencies and pred-
ication).” [http://www.formalontology.it/]
Â It has been conceived of as a mapping function of a total state function [72, 551].
Â AI has borrowed the term ontology from philosophy to mean a description of what the world
(or a certain domain) is made of [526].
Â or a most commonly cited one of Gruber [182], on the practical side: “An ontology is a
formal explicit specification of a shared conceptualization.” Which is motivated by a desire
to develop a specification of a representational vocabulary for a shared domain of discourse
– definitions of classes, relations, functions, and other objects and to promote the reuse of
software [183].
Â or in the description of the forthcoming International Conference on Formal Ontology in
Information Systems (FOIS-2006) for details see [45] and Appendix A.1.
A conceptualization in this context, refers to an abstract model of how people think about
things in the world, usually restricted to a particular subject area. An explicit specification means
the concepts and relationships of the abstract model are given explicit terms and definitions [184].
A typical reason for constructing an ontology of this type is to give a common language for sharing
and reusing knowledge about phenomena in the world of interest[226]. The distinction between
an ontology and a knowledge base must be made. An ontology provides the basic structure
around which a knowledge base can be built. They embody abstract knowledge required for data
integration and analysis [482]. An ontology provides a set of concepts and terms for describing
some domain, while a knowledge base uses those terms to represent what is true about some
real or hypothetical world. Thus, a medical ontology might contain definitions for terms such as
“leukemia” or “terminal illness”, but it would not contain the assertion that a particular patient
had some disease, although a knowledge base might [501], as an instance. Ontological analysis
clarifies the structure of knowledge. Without ontologies, or the conceptualizations that underlie
knowledge, there cannot be a language for representing knowledge. However, it is impossible to
represent the world in its full richness of detail. Therefore it is necessary to restrict attention
to certain aspects of phenomena which can be distinguished and are meaningful to a certain
goal or task; this is termed ‘ontological commitment’ [526]. Once a satisfactory ontology is
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developed, knowledge sharing is enabled because it captures the intrinsic conceptual structure
of the domain [79]. However, as pointed out by Soldatova and King [482], “within biology, the
enthusiasm for ontologies has been accompanied by a general lack of awareness of what ontologies
are and how to use them. This lack of awareness is reflected in the fact that many, perhaps all, ‘bio-
ontologies’ fail to follow international standards for ontology design and description. This failure is
important because it places serious restrictions on their applicability to knowledge sharing, reuse
and inference”. Indeed it is my impression from medical conferences, that the few advocates for
ontologies meet with much inertia and reluctance to make the huge commitments necessary to
develop and utilize ontologies. In a recent editorial [368], it was pointed out that much of the
most influential ontology work in biomedicine has been stimulated by the pressing needs of the
bench biologists themselves in managing the burgeoning quantities of data. This can result in less
than ideal ontologies, however, an increasing number of scientists are recognizing the importance
of learning about standards of good practise [548]. This is acknowledged by the National Center
for Biomedical Ontology [54]. At the same time, it has been pointed out (particularly in response
to criticisms [482]) that in rapidly evolving areas, such as microarray and high-throughput genomic
technologies, compromises between the ideal and pragmatics need to be made [353, 491].
I illustrate, in this thesis, with patient reaction ontologies, which are being used and developed,
but not nearly enough, and drug ontologies, which are even less accessible or utilized. One of the
main aims of this thesis is to demonstrate why the reaction and drug ontologies are important
in drug safety, particularly in ADR signal detection methodologies, and why they are in need of
further refinement.
It might be well to heed the caution of Heidegger [216]: “Basically, all ontology, no matter how
rich and firmly compacted a system of categories it has at its disposal, remains blind and perverted
from its ownmost aim, if it has not first adequately clarified the meaning of Being, and conceived
this clarification as its fundamental task”. For him, ontological inquiry is more primordial; he used
the term ‘ontical’ to apply to positivist sciences.
1.10.2 Ontology examples
As different ontologies develop, they are bound to have conflicts between them. Establishing
semantic interoperability among heterogeneous information sources has been a critical issue in
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the database community for the past two decades. Despite the critical importance, current ap-
proaches to semantic interoperability of heterogeneous databases have not been sufficiently ef-
fective. Ram and Park [421] proposed a common ontology called Semantic Conflict Resolution
Ontology (SCROL) that addressed the inherent difficulties in the conventional approaches, that
is, federated schema and domain ontology approaches. SCROL provides a systematic method
for automatically detecting and resolving various semantic conflicts in heterogeneous databases.
SCROL provides a dynamic mechanism of comparing and manipulating contextual knowledge of
each information source, which is useful in achieving semantic interoperability among heteroge-
neous databases. These authors have shown how SCROL can be used for detecting and resolving
semantic conflicts between semantically equivalent schema and data elements. In addition, they
presented evaluation results to show that SCROL can be successfully used to automate the process
of identifying and resolving semantic conflicts. Another consideration is desirable that ontologies
must be able to change dynamically, evolve. The development of Owl ontology language attempts
to address this problem [396, 530].
Another approach to mapping between different ontologies is that of Ehrig and Sure [127]. Also
the developments in the field of text categorization can be applied to addressing the problem of
ontology mapping by using external information (documents assigned to an ontology) to calculate
similarities between concepts [285, 496].
Relevance logic [16, 188] has become ontologically fertile. It extends beyond logical relations
among propositions to such that the distinction between relevant and irrelevant predications can
be made. Sometimes new formal systems challenge the accepted assumptions about the aims and
aspirations of formal logics. Relevance logic questions, not only the adequacy of the material
and strict conditionals, but also the classical conception of validity. The distinctive character of
Intuitionist logic derives in part from a challenge to the ‘logicist’ presumption of the priority of
logic over mathematics; and fuzzy logic breaks with the traditional principle that formalization
should correct or avoid, but not compromise with vagueness [188].
Smith [476] considered what sort of set theory results when restrictions are placed on the sorts
of elements which may form a set? Given an arbitrary relevance relation, one can formulate a
notion of set which will apply only to totalities of mutually relevant entities. Relevance might
signify for example: exists at the same time as, belongs to the same body as, is less than a certain
distance from. The resultant theory, which embodies topological constraints, can then be used as
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the basis for an account of relevance between propositions which is in the tradition of the relevant
logics of analytic implication. Medical science conceives the human body as a system comprised of
many subsystems at a variety of levels. At the highest level are bodily systems proper, such as the
endocrine system, which are central to our understanding of human anatomy, and play a key role
in diagnosis and in dynamic modelling as well as in medical pedagogy and computer visualization.
But there is no explicit definition of what a bodily system is; such informality is acceptable in
documentation created for human beings, but falls short of what is needed for computer repre-
sentations. Smith et al. [479] proposed a bodily system ontology that is intended as a first step
towards filling this gap. The human body is a system made of systems. The body is divided into
bodily systems proper, such as the endocrine and circulatory systems, which are subdivided into
many sub-systems at a variety of levels, whereby all systems and subsystems engage in massive
causal interaction with each other and with their surrounding environments. Smith et al. [480] of-
fered an explicit definition of bodily system and provide a framework for understanding their causal
interactions. Medical sciences provide at best informal accounts of basic notions such as system,
process, and function, and while such informality is acceptable in documentation created for human
beings, it falls short of what is needed for computer representations. In their analysis they provide
the framework for a formal definition of bodily system and of associated notions. Grenon et al.
[180, 477] proposed a modular formal ontology of the biomedical domain with two components, one
for biological objects, corresponding broadly to anatomy, and one for biological processes, corre-
sponding broadly to physiology. The result constitutes what might be described as a joint venture
between two perspectives – of so-called three-dimensionalism and four-dimensionalism – which are
normally regarded as incompatible. These authors outlined an approach that allows them to be
combined, and provide examples of its application in biomedicine. Furthermore, Smith et al. [481]
have stated that the rapidly increasing wealth of genomic data has driven the development of tools
to assist in the task of representing and processing information about genes, their products and
their functions. One of the most important of these tools is the Gene Ontology (GO), which is
being developed in tandem with work on a variety of bioinformatics databases. An examination
of the structure of GO, however, reveals a number of problems, which they believe can be resolved
by taking account of certain organizing principles drawn from philosophical ontology. They intend
to explore the results of applying such principles to GO with a view to improving GOs consis-
tency and coherence and thus its future applicability in the automated processing of biological
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data. Successful biomedical data mining and information extraction require a complete picture of
biological phenomena such as genes, biological processes and diseases as these exist on different
levels of granularity. To realize this goal, several freely available heterogeneous databases as well
as proprietary structured data sets have to be integrated into a single global customizable scheme.
Verschelde et al. [535] presented a tool to integrate different biological data sources by mapping
them to a proprietary biomedical ontology that has been developed for the purposes of making
computers understand medical natural language. Ceusters et al. [78] presented the details of a
methodology for quality assurance in large medical terminologies and describe three algorithms
that can help terminology developers and users to identify potential mistakes. The methodology
is based in part on linguistic criteria and in part on logical and ontological principles governing
sound classifications. They also outlined the results of applying the methodology in the form of a
taxonomy different types of errors and potential errors detected in SNOMED-CTr. Description
logics and other formal devices are frequently used as amenas for preventing or detecting mistakes
in ontologies. Some of these devices are also capable of inferring the existence of inter-concept
relationships that have not been explicitly entered into an ontology. A prerequisite, however, is
that this information can be derived from those formal definitions of concepts and relationships
which are included within the ontology. Ceusters et al. [77] presented an algorithm that is able
to suggest relationships among existing concepts in a formal ontology that are not derivable from
such formal definitions. The algorithm exploits cross-lingual information that is implicitly present
in the collection of terms used in various languages to denote the concepts and relationships at
issue. By using a specific experimental design, they were able to quantify the impact of cross-
lingual information in coping with underspecification in formal ontologies. The central hypothesis
of the collaboration between Language and Computing (L&C) and the Institute for Formal On-
tology and Medical Information Science (IFOMIS) is that the methodology and conceptual rigor
of a philosophically inspired formal ontology will greatly benefit software application ontologies.
To this end LinKBaser, L&Cs ontology, which is designed to integrate and reason across various
external databases simultaneously,has been submitted to the conceptual demands of IFOMIS’s
Basic Formal Ontology (BFO). With this, Fielding et al. [143] aimed to move beyond the level
of controlled vocabularies to yield an ontology with the ability to support reasoning applications.
Their general procedure has been the implementation of a meta-ontological definition space in
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which the definitions of all the concepts and relations in LinKBaser are standardized in a frame-
work of first-order logic. These authors described how this standardization had already led to
an improvement in the LinKBaser structure that allowed for mapping external databases with
a greater degree of coherence than before. They then demonstrated how this offered a genuine
advance over other application ontologies that have not submitted themselves to the demands of
philosophical scrutiny. In medical research, one of major challenges is to archive, access, and ana-
lyze various heterogeneous databases containing patient information gathered from a large volume
of data over a long period of time. Chong et al. [81] examined how the use of metadata and ontolo-
gies could support the management and integration of clinical research databases and presented
their ontology-based metadata management system developed for the Cadriovascular Research
Department at Mid America Heart Institute (MAHI). Using the concept of web services, their
system is globally accessible. The system is currently deployed on the existing medical information
system at MAHI and used for clinical research. Recently, to enhance the treatment of relations
in biomedical ontologies, Smith et al. [478] advanced a methodology for providing consistent and
unambiguous formal definitions of the relational expressions used in such ontologies in a way de-
signed to assist developers and users in avoiding errors in coding and annotation. The resulting
Relation Ontology can promote interoperability of ontologies and support new types of automated
reasoning about the spatial and temporal dimensions of biological and medical phenomena. This is
based on the the now widespread recognition that many existing biological and medical ontologies
(or ‘controlled vocabularies’) can be improved by adopting tools and methods that bring a greater
degree of logical and ontological rigor. They describe one endeavor along these lines, which is part
of the current reform efforts of the Open Biomedical Ontologies (OBO) consortium and which has
implications for ontology construction in the life sciences generally.
1.11 Conclusion
1.11.1 Risk and rare events
I have briefly reviewed the field of risk and rare events in a variety of settings that could have
relevance to drug safety. The recent pre-marketing drug trial disaster alluded to at beginning
of Section 1.1, which was characterized as very rare, underlines the importance of utilizing the
extensive work carried out in the theory of rare events and its application, particularly to risk
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assessment and prediction. There have been many methods developed to estimate probabilities.
There are Bayesian methods that utilize prior beliefs, both subjective and data-based. Methods
have been developed to detect if there is a change in risk. Changes in the risk of a common
event, for example heart attack, have greater overall effect than a change in the risk of a rare
event. Studies in the perception of risk on behavior has been studied in the realm of traffic
accidents, but some lessons from there are more widely applicable. Competing risk theory is
relevant, particularly where independence cannot be assumed. This is particulary relevant to
biomedical data. Occurrence times are sometimes of more interest based on temporal sequences.
Multi-event detection from historical logs applied to real time data have rules to: (i) cluster sets
of related events, (ii) predict events. There are splitting techniques for estimation of rare events
by simulation, which can be applied to multi-objective decision trees incorporating measures of
risk of extreme events into the stages of decision making. Popular methods for estimating rare
events, such as logistic regression, grossly underestimate them. Also data collection strategies are
inefficient for rare events. This particularly applies to the reliance on voluntary reporting for drug
safety data. Methods for identification of risk factors incorporating the management of missing
data have been developed. Prescription event monitoring is one such method.
1.11.2 Data mining
In view of the nature of drug safety data, data mining is examined. Association rules have been the
main application of data mining used in the thesis. Other data mining methods are very relevant
to drug safety data, particularly those dealing with missing values. The scale of this problem was
such that the focus of this work was on the fields having relatively few missing values. However,
application of methods to cope with this situation may be required for future work. The various
methods explored in this thesis may benefit from a soft computing approach whereby they are
integrated in a purposeful way.
1.11.3 Fuzzy logic
I have given some theory on fuzzy logic, which has been much used for processing medical data. This
work uses concepts that intersect with fuzzy sets and fuzzy relations which relates to covariability
(see Section 12.6) techniques mentioned in the title of the thesis.
54
1.11.4 Text categorization
The burgeoning field of text categorization, which, because of many general similarities between
the problem of assigning a block of text into categories of subjects described in the text, and the
problem of attributing adverse drug events (ADE) to other information relevant to that event. It
was text categorization software that was found capable of using the same drug safety data and
producing comparable results to algorithms described in this thesis that were specifically designed
to address problems inherent in these data. BoosTexter was the method used here and because it
worked so well, other text categorization methods should be investigated in future work.
Another application of text categorization and related semantic exploration methods can be
applied to extracting relevant information from the vast biomedical literature as an input to decision
support methods in drug safety methodology.
1.11.5 Ontology
It is important to relate drugs and adverse events in a systematic and coherent manner to the body
system. I show, in this thesis, how ontology can be employed to better structure data in order to
make it more widely accessible to many powerful and well established methodologies. I point to
where there is need for commitment to better ontologies, but how even incomplete ones can be
beneficial when applied to the analysis of drug safety data.
This review concludes on the adverse drug reaction literature, which is vast in its own right
and, because it is the main focus of this thesis, a separate chapter (Chapter 2) will be devoted to
it.
Chapter 2
Adverse Drug Events
2.1 Adverse Drug Reactions
An ADR is the onset of an untoward medical condition caused by the administration to a patient
of a therapeutic drug or drugs. There is a distinction between an ADR and an adverse drug event
(ADE), and various types of reaction have been defined – see Definitions, Section 12.6. An ADR
may be a minor condition such as a rash, or a severe condition such as a heart attack. Some
ADRs, such as the development of a rash after the administration of an ointment, may be detected
by a patient and raised with a health care professional. Other conditions, such as internal organ
dysfunction, may be detected only by a health care practitioner after the patient has presented at
a hospital or surgery.
It is interesting to note, in this context, that unpredictable events can also be beneficial. For
example, the role of statins in atherosclerosis seems to be straight forward: statins inhibit syn-
thesis of the serum low density lipoprotein (LDL)-cholesterol that contributes to the formation of
plaques in atherosclerosis, and less cholesterol means fewer plaques. However, evidence has been
accumulating that atherosclerosis involves inflammation in blood vessels, and that the inflam-
matory biomarker C-reactive protein (CRP) is a strong predictor of cardiovascular risk. Almost
concurrently, studies have indicated that statins work more broadly than first anticipated and
seem to have anti-inflammatory effects, as well as lowering CRP levels [126, 155, 156, 427]. Such
unexpected beneficial event information would be of as much interest as adverse events to post-
marketing surveillance interests. It should also be noted, in this context, that the sudden complete
withdrawal of rofecoxib from the market (see Section 0.2) may have been too extreme, because
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there is evidence that at low doses, COX-2 inhibitors (see Section 2.3) may be beneficial to some
patients [340]. It should be noted that spontaneous reporting systems were never intended to reveal
unexpected therapeutic benefits, nevertheless, the these data repositories could still contain such
information if looked for in the right way, for example, the paper by Lathers and Schraeder [286].
Post-marketing safety databases are large, sparse, full of biased, uncontrolled and incomplete
data [205]. This is largely due to the voluntary nature of such data, for example, the ADRAC
reporting system. Some of the benefits and problems of such a reporting system are discussed in
[2, 19, 71, 86, 99, 179, 197, 213, 298, 335, 409, 474, 520, 523, 531]. One of the major obstacles
in voluntary reporting is under reporting and the case for its necessity, and the part consumers
can play, is made by many authors, for example [91, 108, 141, 343, 380, 520, 529, 527, 532] .
Although the case intake and medical review is the first line of signal detection after reporter
submission, not every drug-event combinations is cumulatively assessed each time new report(s)
come in. Thus, the level of scrutiny is not the same across the entire database over time [205]. Some
of the complexities in the implementation of pharmacovigilance and the competence requirements
of pharmacoepidemiology are discussed by Waller et al., [545, 541, 544]. Abraham [2] describes how
the pharmaceutical industry is global, but post-marketing systems are national leads to deficiencies
in post-marketing response and uses Halcion (triazolam) ADRs in the Netherlands and the UK as
a case study.
It should be noted that in the ADRAC database, as well as drugs, there are vaccines listed.
It should be pointed out that, although many of the concepts relating to the evaluation of drug
safety are common to vaccines, there are a number of important differences for vaccine safety
methodology. First, unlike drugs that are given therapeutically to patients with disease, vaccines
are given prophylactically to healthy individuals. As a consequence, expectations about vaccine
safety are much higher than for therapeutic drugs. Secondly, there is a high population exposure
to vaccines. Thirdly, vaccines have the potential to affect the unvaccinated via herd immunity.
Finally, anti-vaccine lobby groups can affect the acceptance of a vaccine. [352]
2.1.1 Automated ADR Signal Detection
The detection of unknown and unexpected connections between drug exposure and adverse events
is one of the major challenges of pharmacovigilance. For the identification of possible connections in
large databases, automated statistical systems have been introduced with promising results. From
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the large numbers of associations so produced, the human mind has to identify signals that are likely
to be important, in need of further assessment and follow-up and that may require regulatory action
[346]. Many approaches have been tried for the analysis of adverse reaction data, such as: Fisher’s
Exact Test and matched pair designs (McNemar’s test) [521], reporting odds ratio (ROR), relative
risk (RR) [147], and Yule’s Q [532]. Recently, regulatory authorities, drug monitoring centers, and
pharmaceutical companies, have directed more attention to the development, implementation, and
deployment of computer-assisted signal detection systems. The three most commonly used methods
with the greatest published experience are: proportional reporting ratios (PRRs) [134, 211, 135,
532], an application of empiric Baysean screening (EBS) known as the mulit-item gamma Poisson
shrinker (MGPS) [37, 211, 505, 503], and the Bayesian confidence propagation neural network
(BCPNN) [38, 122, 211, 113]. One problem with PRRs and related methods is that very striking
signals for a particular drug will reduce the magnitude of the PRR for other signals with that drug
due to inflation of the denominator [43, 134]. This type of method is based on 2×2 contingency
tables, such as Reporting Odds Ratio (ROR), and Yule’s Q [532]. The Norwood-Sampson Model
has been applied to data in the United States of America and approved by the FDA, despite the
fact that it is subject to potential bias due to not allowing for a lag between occurrence and the
report date. Hillson et al. propose a modification of the Norwood-Sampson method to adjust for
this [223]. A common approach to the assessment of ADRs uses the Bayesian method [39, 95, 302],
which has met with success, but is very exacting regarding the quantification of expectations
[233]. Hutchinson comments on the Bayesian causality assessment of a series of reported cases of
suspected adverse drug reactions to ticlopidine, and thought that assessment of individual cases
is helpful because it incorporates additional information about the pattern and context of the
reaction to weigh the strength association in each case, and that the Bayesian approach is a real
contribution to the evaluation of adverse drug reactions [233]. There are yet other concerns about
assumptions of data homogeneity using BCPNN to identify signals in data that derives from 67
countries [297]. Whereas PRRs are easy to understand and implement and are low cost, they
generate a lot of signals [205]. Each method has its own advantages and disadvantages in respect
of applicability in different situations and possibilities for implementation [532].
These methods, as a class, can be referred to as disproportionality analysis signal detection
methods. Each algorithm may vary in specific details, but share the common operational feature
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of searching the database for disproportionally high associations or dependencies (such as, inter-
estingly large cell counts) between variables, usually drug and reaction, compared to reports for
that event in the entire database, or a control (that is, observed/expected ratio of probabilities or
cell counts). They differ in their precise model of expectedness, but to various degrees they use
the generality of all drugs and reactions in the database as a control [202, 299]. PRRs, in the drug
safety data context, essentially use all other drugs (besides the one of interest) as a control, and suf-
fer from the lack of denominator data (total doses of drug administered) [133, 373]. Alternatively,
EBS and BCPNN use the full generality of the database in that the unconditional probabilities
of drug and reaction across the entire database are used to derive an internal control. EBS and
BCPNN are Bayesian methods that involve additional mathematical modelling of the observed
and the expected ratios of probabilities/cell counts. Hauben provided a more detailed account of
these methods [202]. However, there is considerable semantic ambiguity and imprecision about
even basic terminology of what constitutes a signal [210].
Automated signal detection and data mining techniques are evolving rapidly, but several out-
standing issues remain problematic. These include the absence of a gold standard against which
to evaluate signal detection methods, lack of validation and comprehensive head-to-head compar-
isons of the various methods, lack of transparency of the Bayesian-based methods, lack of best
practices or recommended data mining protocols, the influence of AE dictionary structure on per-
formance characteristics, limited specificity, and potential for misapplication of these techniques
[202]. In one study there were 136 relevant DECs that triggered safety-related labelling changes
for 39 drugs during a 7-month period. PRRs generated a signal of disproportionate reporting with
almost twice as many drug-event combinations (DECs) as MGPS (77 versus 40). DECs generating
signals of disproportionate reporting with only PRRs were both medically serious and non-serious.
No medically important events were signalled by MGPS only [209]. Other difficulties with MGPS
are “signal leakage”, in which a signal truly associated with drug A may manifest as an apparent
signal with drug B due to the fact that the two drugs are frequently co-prescribed, and “signal
masking”, whereby a signal for drug A can be diminished in magnitude if drug B has a very dom-
inant signal in the database [504]. In a study by Kubota et al. [280] of Japanese spontaneous
reports, five methodologies (GPS, BCPNN, the method used in the UK Medicines Control Agency
(MCA), ROR, and PRR) were compared. It is not clear how these methodologies compare in this
study. For example, they note that the signalling criteria are substantially different in GPS from
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the other methods and the signals are characterized as possible signals.
Some of the logic (for example triage logic) for signal selection and follow-up are discussed
in relation to UMC data by Meyboom et al. [346] and St˚ahl et al. [493, 494]. Another related
issue is the lack of gold standard for signal detection. The ultimate measure of a signal detection
system is whether it results in signals being selected in advance of manual methods. A crucial
metric is the the time interval between initial signal detection and the accumulation of enough
well documented cases to establish a possible causal relationship with sufficient certainty [202].
However, there are many mechanisms leading to a “signal”, causal association, statistical associ-
ations related to various confounders (measured and unmeasured) effect modification, and other
stimuli, including statistical noise. To muddy the waters further, there are enthusiastic claims and
assertions, the published literature contains divergent results, there is a competitive commercial
element, biases and conflicts of interest [205]. Steps to address some of these issues the recently an-
nounced partnership between the World Health Organization Foundation Collaborating Centre for
International Drug Monitoring (UMC) and (i) Aris Global, which will provide subscription access
to the WHO-ADR Vigibase database of adverse events, greatly expanding the ability of organiza-
tions to benchmark the safety of their medical products [18], (ii) Lincoln Technologies involving
access to the WHO-ADR Vigibase and Lincoln provides user-friendly web access to signal scores
from the WHO data based on both Dr. William DuMouchel’s MGPS Empirical Bayes algorithm,
and PRR [525]. The goal of this pharmacovigilance is the protection of patients and this requires
the cooperation of many individuals [542]. Other vendors doing significant work/offering services
in this regard include: Galt Associates, DrugLogic, and ProSantos Corporation.
A recent article by Almenoff et al. [11], gives a perspective on the use of data mining in
pharmacovigilance that concludes that the results of data mining should be evaluated in the context
of other relevant data and the need for a publicity accessible global safety database, which is
frequently updated on a frequent basis. This is very relevant to this thesis, in which I demonstrate
the inadequacy of a small (by global standards) out-of-date data set, namely the ADRAC we
have access, to properly test and develop methods that assist in pharmacovigilance. To the other
issue that touches on clinical relevance, I would just make the general observation that data
mining divorced from the domain knowledge related to the particular data in question has little to
contribute.
Future developments in automated signal detection, besides the statistical data, will need to
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make more use of other criteria and considerations. For example, categorizing reactions on a
severity scale [346]. The following sections will cover some other relevant issues that need to be
incorporated into automated signal generating algorithms.
2.1.2 Reactions and Syndromes
Apart from identifying adverse reactions which may be attributable to particular drugs, the meth-
ods used so far, or modifications of them could prove to be suitable for recognizing syndromes.
Basically, a syndrome comprises several clinical abnormalities occurring simultaneously in an in-
dividual patient.
Examples
1. Cushing’s syndrome is a good example of a known syndrome. It is a hormonal disorder
caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol.
Sometimes called “hypercortisolism,” this syndrome involves truncal obesity (including a
‘buffalo hump’), moon facies, hypertension, fatigue, weakness, hirzsutism and amenorrhoea
in females, purple abdominal striae, oedema, glycosuria, and osteoporosis. This combination
of abnormal clinical features is associated with functioning tumours of the adrenal cortex,
prolonged high dose corticosteroid therapy (used in chronic asthma) [371].
2. Churg-Strauss Syndrome (CSS) is a systemic vasculitis. This disease was first described
in 1951 by Dr. Jacob Churg and Dr. Lotte Strauss as a syndrome consisting of “asthma,
eosinophilia (an excessive number of eosinophils in the blood), fever, and accompanying
vasculitis of various organ systems”.
3. ‘Oculo-muco-cutaneous syndrome’. Many years ago, the New Zealanders identified an ‘oculo-
muco-cutaneous’ syndrome in connection with practolol which has subsequently been re-
moved from the market [419].
4. Hauben [200, 204] described the mechanism of a reaction of skin and digital necrosis caused by
warfarin and related compounds, which is involved with cholesterol microembolization (mul-
tiple cholesterol emboli syndrome [234]). This reaction from the author’s clinical experience
is rare and not always associated with these anticoagulants.
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5. Bennett et al. [46] found thrombotic thrombocytopecnic purpura, a life-threatening, multi-
system disease characterized by thrombocytopenia, microangiopathic haemolytic anemia,
fever, neurologic changes, and renal abnormalities to be associated with Ticlopidine, an
antiplatelet drug. These authors suggest the related drug clopidogrel can also be associated
with this syndrome.
2.1.3 Predisposition
There are many factors that effect whether a given patient manifests an ADR, such as state of
health and genetic endowment. Bate et al. [40] note that the WHO data contain patient records
from different countries. This means that records from different countries may represent different
metabolic phenotypes, or different background disease burdens. One approach to elucidating con-
tributing factors to the development of ADRs is pharmacogenetics, which investigates the role of
different genes which may enhance an individual’s susceptibility or resistance to producing an ad-
verse reaction to a drug [73, 84, 105, 120, 238, 301, 332, 348, 406, 423, 429, 432, 472, 490, 552, 566].
There is some evidence of interactions between five genes and antihypertensive drug therapy on
blood pressure in a study by Schelleman et al. [461], but this study is not conclusive. Common
genetic variation of three human populations and health has recently been studied using whole-
genome patterns [224]. The variation of an individual to manifest an ADR is utilized in what we
term Potential Reactions (Section 4.6.2), which attempts to quantify predisposition based on ADR
report data. In genetic terms, a patient’s tolerance to a drug is their drug tolerance phenotype.
Phenotypes are determined by complex interactions among gene variants and environmental fac-
tors. In biomedicine, these interacting elements take various forms: inherited and somatic human
gene variants and polymorphisms, epigenetic effects on gene activity, environmental agents, and
drug therapies including drug combinations. The success of predictive, preventive, and personal-
ized medicine will require not only the ability to determine the genotypes of patients and to classify
patients on the basis of molecular fingerprints of tissues. It will also require an understanding of
how genetic perturbations interact to affect clinical outcome. Recent advances afford the capa-
bility to perturb genes and collect phenotype data on a genomic scale. To extract the biological
information in these data sets, parallel advances must be made in concepts and computational
methods to derive and analyze genetic interaction networks. Drees et al. report the development
and application of such concepts and methods [109].
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This type of knowledge, determining the impact of genetic polymorphisms causing ADRs, opens
the possibility of a better understanding of drug targets and the genes coding for them. This in
turn should lead to pharmacodynamic explanations of variability in therapeutic response as well
as the risk for ADRs, which will make feasible the development of molecular diagnostics to select
drugs that are safe for individual patients [66, 187, 224, 293, 349, 472] and assist future drug
development for safer and more effective drugs [300, 433]. Recent reports are helping to increase
our understanding of the genetic basis of individual variation of ADR risk and disease susceptibility.
Eichler [128] studying single nucleotide polymorphisms (SNPs) within the human genome has found
a great deal of variation between individuals just due to this type of genetic mutation. Ioannidis
et al. [242] have begun to develop tools for analyzing associations between genetic variation and
common diseases and Helgadottir et al. [217] have shown that, in the pathway that variants of
the gene ALOX5AP encoding arachidonate 5-lipoxygenase activating protein known to be to be
associated with risk of myocardial infarction, there is another gene. A haplotype of this gene
(HapK) spanning the LTA4H gene encoding leukotriene A4 hydrolase, confers a modest risk of
myocardial infarction in an Icelandic cohort. A study of three cohorts from the United States, also
shows that HapK confers a modest risk in European Americans, but confers a threefold larger risk
in African Americans (see also [510]). Lo´pez et al. [308] studied cytokine genetic polymorphisms
in patients treated with antimalarial agents used as disease-modifying antirheumatic drugs in
the treatment of systemic lupus erythematosus (SLE) and and other rheumatological diseases to
identify genetic predictors of treatment response. Individuals representing genetic variants of the
cytokines TNFα and IL-10 were studied and it was found that a relationship between antimalarial
treatment and low TNFα serum levels in SLE patients that were influenced by polymorphisms at
the IL-10 and TNFα gene promoters. This may have an important clinical application through the
identification of patients who are the most likely to benefit from antimalarial therapy. A recent
review by Pui et al. [414] of our understanding genetic factors involved in acute lymphoblastic
leukemia (ALL), which has resulted in a steady improvement in treatment outcome.
There is a recent study to implicate caffeine as a possible hazard to some genotypes, which
concludes that: “Intake of coffee was associated with an increased risk of nonfatal myocardial
infarction (MI) only among individuals with slow caffeine metabolism, suggesting that caffeine
plays a role in this association.” [93]
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2.1.4 Other Factors affecting ADRs – interactions
There are many factors that can influence whether a reaction occurs at all, or if it does, how
severe it becomes [85, 378]. One factor that must be considered is the mode of administration,
which has been demonstrated. For example, micronazide and warfarin with the potentiation of the
anticoagulation effect [367]. Dosage is an obvious area where attention needs to be focused [106]. In
some cases other factors make it very difficult to prove an association between a drug and a reaction,
for example, congestive heart failure and itraconazole, because in this case, usually patients are very
sick and taking many other medications [8]. Care must be taken with antieplteptic drug (AED)
selection in older adults, because the average nursing home patient receives six medications, has
age-related changes in protein binding, decreases in hepatic and renal clearance, and may have
alterations in gastrointestinal absorption. Leppik et al. [306] reviewed the drug interaction profiles
and compared properties of the first generation AEDs with newer agents to develop a more rational
approach for drug selection in older adults. This issue has also been raised in safe child and
adolescent psychopharmacology. Cohen [90] raised some issues in this context that can be applied
to pharmacology in general. How to decide on safety of combinations of drugs when data on such
combinations is scarce?
A recent review by Ding et al. [107] points to the consumption of chocolate may reduce the risk
of cardiovascular disease due to its high levels of stearic acid and antioxidant flavonoids. This study
suggests that the flavonoids are more active in this regard and the evidence is mixed regarding
stearic acid. Thus even a patients history of chocolate consumption could be a relevant “other
factor” of relevance to an ADR report.
Temporal relationships, such as time of onset of a reaction is most important when considering
the relationship between exposure to the drug and a subsequent AE. This is particularly important
in assessment of causality. A causal relationship is supported when the onset of an ADR coincides
with the expected peak tissue concentration of the drug [469]. A new classification system for
adverse drug reactions based on time course and susceptibility as well as dose responsiveness was
devised by Aronson and Ferner, which involves a three dimensional classification system based on
dose relatedness, timing, and patient susceptibility (DoTS) [20, 142]. Although this is an important
consideration, as far is this thesis is concerned, it is an issue for future investigation.
There are various mechanisms by which drugs interact with each other, including, modification
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of one drug’s receptor site by the other drug, transporter protein or metabolic enzyme [90, 194]).
Most of them can be divided into two general categories: pharmacokinetic and pharmacodynamic
interactions. With pharmacokinetic drug interactions, one drug affects the absorption, distribution,
metabolism, or excretion of another [435]. When pharmacodynamic drug interactions occur, two
drugs have additive or antagonistic pharmacologic effects. Either type of drug interaction can result
in adverse effects in some individuals. Because of the involvement of the body system components,
there is the added complication of genetic variation between individuals. The issue of interaction
can lead to a number of pitfalls:
1. failure to screen for drug interactions – multiple data sources are available to assist screening
for drug interactions. For example, Drug-Drug Interaction (DDI) Monographs [111] or FAQs
about drug-drug interactions [14],
2. failure to consider patient factors – some of these have been mentioned above,
3. failure to consider other medications,
4. failure to consider pharmacogenetics – genetic variability has also been mentioned above,
5. failure to consider quality of drug interaction information,
6. incorrect extrapolation of in vitro data to the clinical situation,
7. assuming that all members of a drug class will interact in a homogeneous manner,
8. assuming the onset of a drug interaction and the magnitude of the effect always will be the
same in every individual,
9. failure to consider the onset and time course of the drug interaction,
10. failure to appreciate the sequence of drug administration – this can influence the type of
adverse effects that can occur.
11. misunderstanding of basic pharmacokinetic principles related to the assessment of reports of
drug-drug interactions [201].
One study by Jansen et al., has demonstrated that the pervasive xenobiotic methoxyacetic acid
and the commonly prescribed anticonvulsant valproic acid, both short-chain fatty acids (SCFAs),
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dramatically increase cellular sensitivity to estrogens, progestins, and other nuclear hormone recep-
tor ligands. These compounds do not mimic endogenous hormones but rather act to enhance the
transcriptional efficacy of ligand activated nuclear hormone receptors by up to 8-fold in vitro and in
vivo. Detailed characterization of their mode of action revealed that these SCFAs function as both
activators of p42/p44 mitogen-activated protein kinase and as inhibitors of histone deacetylases at
doses that parallel known exposure levels. Their results define a class of compounds that possess a
dual mechanism of action and function as hormone sensitizers. These findings prompt an evalua-
tion of previously unrecognized drug-drug interactions in women who are administered exogenous
hormones while exposed to certain xenobiotic SCFAs. Furthermore, this study highlights the need
to structure future screening programs to identify additional hormone sensitizers. To further study
the genetic predisposition to reduced metabolism of drugs, Genaissance Pharmaceuticals, Inc. has
received a notice of allowance from the U.S. Patent and Trademark Office to test for a common
genetic variant in the CYP3A4 gene to predict whether or not an individual is a poor metabolizer
of certain drugs. It is estimated at least 50 percent of all drugs, including chemotherapeutic agents
and a wide variety of over-the-counter medications, are metabolized by the CYP3A4 enzyme. In-
dividuals with a reduced ability to metabolize these drugs may be exposed to higher levels of the
drug, placing them at risk for adverse drug reactions [405].
In a general study by Maitland et al. [316] on the comparative genomics analysis of human
sequence variation in the UGT1A gene cluster, which is the UDP-glucuronosyltransferase (UGT
– UDP = Uridine diphosphate) gene family. These are a set of endoplasmic reticulum-specific
enzymes that catalyze the transfer of glucuronic acid from uridinediphospho-glucuronic acid to
various lipophilic substrates. This reaction is crucial to the processing of bilirubin and endogenous
hormones, the elimination of therapeutic drugs from the circulation, and the inactivation of en-
vironmental toxins. Thus a better understanding of this gene family would be very beneficial to
our understanding of individual variation in response to drug therapy and more data on human
UGT1A genetic variants are expected to improve the robustness of their associations with the
efficacy and adverse events of drugs. Some preliminary studies of the UGT1A gene cluster have
been conducted on a Japanese population [442].
Drug-drug interactions are of importance, and alleged attributions of drug interactions are reg-
ularly published. However, such reports may not rule out other explanations, such as drug-disease
interactions [201]. The need for statistical methods that facilitate the identification of clinically
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important drug interactions that occur in a real world setting is discussed by van Puijenbroek
[533], Almenoff et al. and et al. [12].
There has been reported an analytic assay based on automated sample preparation and liquid
chromatography (LC) coupled with electrospray mass spectrometry (ESI-MS) was developed for
the quantification of 6 protease inhibitors (PIs) and 3 nonnucleoside reverse transcriptase inhibitors
(NNRTIs). The 6 PIs, amprenavir, indinavir, ritonavir, lopinavir, nelfinavir, and saquinavir, as well
as the three NNRTIs, nevirapine, efavirenz, and delavirdine, require a succinct analytic technique
for therapeutic drug monitoring in HIV/AIDS patients. The assay allows fast analysis of patient
samples for therapeutic drug monitoring (TDM) and has successfully been used for TDM and
pharmacokinetic drug-drug interactions studies [112, 125]. This type of technique has been also
used in strategies used to screen new drug entities as potential inhibitors of cytochrome P450
(CYP450) enzymes are now widely used to select candidates in the drug discovery process [57].
Another approach, by Fliri et al. [148, 149, 150], has been to find a link between ADR effect
patterns to a drug’s chemical structure. This study only used prescription drug labels to generate
their effect spectra, nevertheless, some interesting knowledge can be obtained. Some of these
methods are detecting interactions in individuals, but are expensive and time consuming.
There is still a need for the development of better automated signal detection methods that
can detect new drug-drug interaction signals from drug safety data [36]. It has been reported
that MGPS can be used used to explore both drug-event and multi-way associations (interactions,
syndromes). It has been used to study age/gender effects, to predict the safety profiles of pro-
posed combination drugs, and to separate contributions of individual drugs to safety problems in
polytherapy situations [154, 268].
There are software tools that warn about likely interactions based on known interactions. The
availability of individual patient DNA testing results can further refine prediction of likely in-
teractions for that patient. Recently a software tool GeneMedRx has been reported as a DNA
ready version of a software tool used by by physicians since 1997 to identify potential drug inter-
actions based on individual patient prescription, over-the-counter, and herbal medicine regimens.
GeneMedRx works both with and without DNA testing results [169].
The importance of the demographic profile of the patient in whom the AE developed is impor-
tant, however largely lacking in spontaneous reports. Also important is the presence of concomitant
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medications, since the signal may be a drug-drug interaction [298]. These issues are somewhat be-
yond the scope of this thesis, but are noted here to stress their relevance to signal detection.
2.2 Reaction and Drug Ontologies
The human body is a system made of systems and Smith [480, 479] has developed an ontology
that satisfies the requirements for computer representations (for more details, see Section 1.10.1.
The biggest challenge in summarizing safety data is the need to consolidate the massive amount
of data into a manageable format. Dictionaries can be used to bring order to the seeming chaos.
They are intended to bring some discipline to the vast number of descriptive terms that health
professionals and patients use for medical conditions, and an enormous array of medicines. By
abbreviating the descriptions and reducing them to some form of code or standard terms, it is
possible to record data effectively and concisely on a computer database, to search and summarize
information [70]. One way is to group the safety data into classes characterized by body systems
and determined in conjunction with underlying disease and treatments involved. Such pooling of
data through coding is especially helpful for rare events [82, 408].
2.2.1 System organ class (SOC) system
Reactions have been classified, in the Australian drug safety data, by ADRAC for ADR terms
using the body systems organ class (SOC) grouping. This is very beneficial for sparse data such
as these. The use to which this ontology is put is described in detail in Section 3.3.
2.2.2 MeDRA system to be adopted by ADRAC
ADRAC is in the process changing from the SOC ontology and will adopt the Medical Dictionary
for Regulatory Activities (MeDRA) in future. MeDRA, an International Conference on Harmo-
nization (ICH) initiative, is a standardized dictionary of medical terminology. It was developed
to share regulatory information internationally about medical products used by humans. Med-
DRA provides a set of terms which consistently categorizes medical information. The medical
terminology used was based upon the UK Medicines and Healthcare products Regulatory Agency
(MHRA) medical terminology and incorporates the World Health Organization Adverse Reaction
Terminology (WHO-ART), regulatory related terminology from the International Classification of
68
Diseases (ICD), and ICD with Clinical Modification (ICD-CM), Coding Symbols for a Thesaurus
of Adverse Reaction Terminology (COSTART), and Japanese Adverse Reaction Terminology (J-
ART) [212, 241]. The MedDRA terms are much finer grained than SOC, but there is no direct
mapping from SOC to MedDRA. This is an example of the difficulties facing the implementation
of ontologies (see Section 1.10.2). They are laborious to set up and often are not combatable with
similar existing ontologies.
These classifications based on body systems create problems for analysis because ADEs can be
distributed across multiple body systems. That is they only view the body as separated systems,
but do not have a view of the body as an integrated system of systems. Berry and Berry propose a
three-level hierarchical mixed model. The highest level is the collection of all body systems. Their
method allows for borrowing across body systems, but can allow for cases where the probability
that a drug has caused a type of AE is greater if its rate is elevated for several types of ADE
within the same body system than if the ADEs with elevated rates were in different body systems
[49]. Furthermore, it must be noted that the AE dictionary structure can profoundly affect the
signal detection performance characteristics and may influence the choice of data mining protocols.
Systematic comparisons of the effects of various AE dictionary structures/terminologies on the
performance of signal detection methodologies have not been published [202]. One examination of
MGPS using an extract of the FDA adverse event reporting system (AERS) was unable to detect
four potentially serious unexpected ADRs (Stevens-Johnson syndrome, toxic epidermal necrolysis,
seizures, skin ulcers) that were detected by traditional surveillence [206].
An appraisal of the MedDRA ontology for use in computerized queries in spontaneous reporting
systems for pharmacovigilance and some problems concerning the automated positioning of new
terms inside the MedDRA hierarchy are described by Bousquet et al. [61]. Henegar et al. use a
formal ontology of ADRs using description logic representations of MedDRA terms to group med-
ically related case reports and found this approach to increase the sensitivity of signal detection.
However, the huge work-load in the knowledge engineering step was limiting for their machine
learning approach [219]. Computerized queries in spontaneous reporting systems for pharmacovig-
ilance require reliable and reproducible coding of ADRs. Several studies have evaluated the domain
completeness of MedDRA and whether encoded terms are coherent with physicians’ original verba-
tim descriptions of the ADR. MedDRA terms are organised into five levels: SOC, high level group
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terms (HLGTs), high level terme (HLTs), preferred terms (PTs) and low level terms (LLTs). Al-
though terms may belong to different SOCs, no PT is related to more than one HLT within the
same SOC. This hierarchical property ensures that terms cannot be counted twice in statistical
studies, though it does not allow appropriate semantic groupings of PTs. For this purpose, special
search categories (SSCs) [collections of PTs assembled from various SOCs] have been introduced
in MedDRA to group terms with similar meanings. However, only a small number of categories
are currently available and the criteria used to construct them have not been clarified. Bousquet et
al. determined whether MedDRA contains the structural and terminological properties to group
semantically linked AEs in order to improve the performance of spontaneous reporting systems.
They suggest linking MedDRA to a third-generation system to allow the MedDRA structure to be
kept to ensure end users have a common view on the same data and the addition of new properties
to MedDRA [61].
2.2.3 Semantic Distance between ADR Terms
The work of Cedric Bousquet Äet al. who study the development of controlled vocabularies for
grouping AE terms. Computation of semantic distance between adverse drug reactions terms may
be an efficient way to group related medical conditions in pharmacovigillance case reports [236].
The WHO-ART and MedDRA terminologies used for coding ADRs do not provide formal defini-
tions of terms. In order to improve groupings, ADR terms were mapped to equivalent Snowmed CT
concepts through UMLS Metathesaurus. Such mappings were performed on WHO-ART terms and
automatically classified using a description logic definition expressing their synonymies [10]. Liter-
ature, specifically MEDLINE, is among the main sources of information used to detect whether a
drug may be responsible for adverse drug reactions cases. Garcelon et al. automate the search of
publications that correspond to a given ADR case: (i) by defining a general pattern for the queries
used to search MEDLINE and (ii) by determining the threshold number of publications capable
to confirm the ADR [167].
2.2.4 Anatomical-Therapeutic-Chemical (ATC) system for drugs
As AEs (ADRs) have been structured to assist in data consolidation, so there has been a need for
a similar kind of grouping to apply to drugs in drug safety data. This has been observed Hauben
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[202], particularly to have a logical data model for the management (“cleaning”) of drug dictionary
names for agents manufactured in different formulations and/or contained in combination products.
Moreover, there can be a marked variability in drug names in the various databases.
Part of this thesis has been the application of theWorld Health Organization (WHO) anatomical-
therapeutic-chemical classification of drugs (ATC) system [570] for the ADRAC database acting
upon a suggestion to me by Patrick Purcell of the TGA. My purpose is to demonstrate the use-
fulness of this system to facilitate data analysis methods as explained in Sections 2.2.4, 3.6, 6.6,
8.2, 10.2.3, 11.1, ??. It should be noted that the Bayesian Confidence Propagation Neural Net-
work (BCPNN) [38] uses ATC codes in the calculation of an information component (IC) for each
drug-ADR combination in the database. The IC is a logarithmic measure of disproportionality;
drug-ADR combinations with positive IC values represent combinations reported unexpectedly
frequently and negative values unexpectedly infrequently. An IC value of 0 is obtained when a
drug-ADR combination is reported as frequently as would be expected from general reporting of
that drug and general reporting of that ADR with all drugs in the database. Thus the entire
database is used as a background for comparison. Standard deviations are calculated for each IC
value.
2.3 Treatment of Chronic Inflammatory Disease
I have compiled an interesting case study, which highlights some of the issues pertinent to this
field, using the anti-inflammatory drug story – see Appendix A.2.
2.4 Further application of ADR Knowledge
As noted by Mann and Andrews [335] physicians and patients will be better served with richer
information on appropriate medication use. More comprehensive and accurate definition of med-
ication safety can help regulators and industry take appropriate action to improve safety—from
removal of unsafe products to protection of useful products from unwanted removal. Knowledge
gained by studying information from ADR report data is important for obtaining additional in-
dications for the existing compounds that are being prescribed [540]. A side affect of this KDD
could be another application of knowledge extraction from these data is that described by Bradley
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[62]. This is to find alternative uses or improved versions drugs already in use. Such a use of this
kind of data to obtain further information on the mode of action of drugs from the rarer types of
reaction, from a better understanding of the relationship these reactions to the type of patient, the
contextual information on the particular event could suggest new uses for old drugs. Examples of
such uses are, the use of sildenafil (Viagra) in erectile dysfunction, which now appears to have a
role in the control of pulmonary arterial hypertension [166, 463]; duloxetine (Cymbalta) in stress
urinary incontinence; and thalidomide (Thalomid) in severe erythema nodosum leprosum, and in-
flammatory bowel disease [466]. These are classic examples of drugs that ended up being used in
entirely unexpected ways.
Potential new disease indications for, or improved versions of, existing drugs are cropping up
in unlikely situations. A group led by Gutmann [186] has shown that the immunosuppressant
rapamycin could help treat childhood brain tumours. Bonora et al. [534] has shown that imatinib
(Gleevec; Novartis), for chronic myeloid leukaemia also has activity in type 2 diabetes. Kukreja et
al. [146, 145, 282, 283] have demonstrated that Viagra can also reduce heart damage in patients
on doxorubicin chemotherapy for breast cancer, leukaemia and sarcomas.
2.5 Methodology for Addressing the Research Questions
The next section details the reaction and drug ontologies applied to the ADRAC data that use
domain knowledge to meaningfully structure data in order to enhance the clinical significance of
the results Research Question 2. Another advantage to this approach is that the combinatorial
complexity of the data is significantly reduced, making it accessible to a broader spectrum of
methodologies. This is in line with Research Question 3.
Relating to Research Question 1., an investigation of a different approach has been explored,
which is outlined in Chapters 4, 6 and 5. This involves the assignment of weights to drug-reaction
combinations.
Two other approaches investigated in Chapters 8 and 9 address Research Questions 2–4. The
other methodology investigated was association rules. This relates to Research Questions 2 and 3.
Prior to structuring ADRAC data with drug ontologies, association rule methods did not appear
to be of much use. After reducing the combinatorial complexity of these data with ATC codes, the
association rule methods appear to be very promising. The association rule approach is extended
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in Chapter 9 to investigate the development of an ADR signal detection method incorporating
critical reaction terms.
Regarding Research Question 5. on interactions and syndromes, an extensive investigation was
not pursued. However, during the course of these studies, an indication of the usefulness of the
methods explored is pointed out and result to support this are reported in Section 4.6.3. This is
a topic of great interest at present. There is a need for much more work to be done in this area,
so further investigation of these methods regarding interactions and syndromes should be most
fruitful.
Finally, I was fortunate enough to get Bill DuMouchel, of Lincoln Technologies, to run a set
of ARRAC data on their MGPS implementation with the approval of the TGA – see Section 10.2
and Chapter 11.
2.6 Summary
Not all unexpected events are adverse, so an enhanced ability to detect these, as well as adverse
events would be beneficial. A better understanding of how drugs act in the body and the molecular
biology of the human body will make it possible to utilize the resource of existing drugs better. It
will also assist in the development of new drugs. Some of this is encapsulated in a case study that
I have complied – see Appendix A.2.
Post-marketing safety databases are large, sparse, full of biased, uncontrolled and incomplete
data [205]. This provides a very large but incomplete sample to work with. I have briefly reviewed
the problems for the analyst presented by such data. Some of the analytical methodologies that
I have reviewed in the previous chapter are applicable to the drug safety data. In particular the
collection of methods, which is covered by the term “data mining”, are definitely applicable. They
have been designed to analyze data whose character falls outside the requirements of exact methods.
The methods regularly employed for analysis of drug safety data are essentially exact methods
requiring complete data (no missing or incorrect values). This is why they need to be supplemented
by methods that overcome these limitations. In order to work at all they need to concentrate on the
fields in the data that are populated by values, namely, drugs and events. In this thesis I examine
the development of alternative exact methods, which also concentrate on this part of the drug
safety data. I use the term covariability techniques (Section 12.6) to describe these methods. The
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covariability techniques can perform their analysis in multi-dimensional space, whereas commonly
used drug safety methods use disproportionality, which is essentially two-dimensional analysis.
The development of automated methods means that even larger sets of data can be analyzed.
This is leading to the pooling of different national data sets to enable a more global analysis of the
products of a global pharmaceutical industry. The setting up of partnerships and data sharing is an
encouraging global trend. There is also a need for drug safety analytic methods to incorporate more
information, even when it is very incomplete. I demonstrate that reaction ontologies are one way
this can be done. Other capabilities desirable for these methods is the ability to detect evidence
of interactions and syndromes in the data. I report some progress in this direction from my study.
Another important characteristic that needs to be detected is an individual’s predisposition to
react to drugs in a particular way. This could be achieved by clustering records that show similar
reaction patterns. The increasing amount of pharmacogenetic information becoming available
can assist. For example, genotype information, as well as more patient historical data should be
included in drug safety reports. The notion of Musa Mammadov that we term ‘potential reaction’
[322, 323] may be able to address all of these problems. This is implemented as a vector of expected
values for events based on training with drug safety data. By measuring how much the observed
vector values differ from the potential reaction vector, a measure can be obtained that can indicate,
interactions, suspected drugs, patient predisposition, and syndromes, which are recognizable sets
of reactions.
Chapter 3
Application of Reaction and Drug
Ontologies
3.1 Introduction
The ADRAC data contains many reactions and many drugs. For the purposes of data consolidation
(discussed in Section 2.2) the classification system of SOC for reaction, which is used by ADRAC.
However, the ATC drug ontology has not been completely specified in ADRAC. A major part of
this project was to render a complete ATC classification of ADRAC data in order to demonstrate
the power that such data consolidation renders to the analysis of drug safety data, such as ADRAC.
3.2 Resources
Medical information was obtained from a variety of sources including requests for information
from Patrick Purcell of the TGA, Taber’s Cyclopedic Medical Dictionary [506], MIMS dictionary
[355, 354], Australian Medicines Handbook [15], Upsala Monitoring Center (UMC) [575], World
Wide Web.
3.3 Reaction Terms
See Appendix B.1.2. Preferred term is the low level reaction term used in this chapter.
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Figure 3.1: ADRAC SOC classes – Tree diagram of the system organ class hierarchy. System organ
class (SOC) – normal font, the number of preferred terms per class – italic font.
3.3.1 Critical Terms
From the third quarter of 1998, a new field has been added at the end of the WHO-ART file
which indicates Critical Terms. Critical terms are a subset of adverse reaction terms referring to,
or possibly being indicative of, serious disease states, which have been regarded as particularly
important to follow up. [571, 572] This is a very important component of expert knowledge, which
can be incorporated into the ontology of ADR signal detection (see Chapter 9). In this chapter
critical reaction terms are weighted to highlight associations which are likely to be of greater
interest and particularly those that are rare to sensitize the method to more serious events. It is
to be hoped that in the future there will be a categorization of reactions on a severity scale – see
[346].
3.4 System organ class
The biggest challenge in summarizing safety data is the need to consolidate the massive amount of
data into a manageable format. One way is to group the safety data into K classes characterized
by body systems and determined in conjunction with underlying disease and treatments involved.
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Figure 3.2: SOC reclassification – Tree diagram of the modified system organ class hierarchy. SOC
– normal font, the number of preferred terms per class – italic font.
Such pooling of data through coding is especially helpful for rare events [408, 82]. The WHO main-
tains such a classification of reaction terms [572]. These are groups of adverse reaction preferred
terms pertaining to the same system-organ, and are for some purposes used at the output side. A
preferred term can be allocated to a maximum of three different system-organ classes, for exam-
ple, respiratory depression is coded both under Respiratory disorders and Central nervous system
disorders. The allocation of a preferred term to system-organ classes is fixed and does not change
with specific reports. The first System Organ class listed for each preferred term is considered the
most important one. A complete list of the classes and their codes is given Table 3.1. This has been
done for Australian drug safety data by ADRAC for reactions using the systems organ class (SOC)
grouping; Table 3.2 and Figure 3.1 – see also [322, 317, 326]. In ADRAC there were nineteen SOC
classes and some terms were in more than one SOC class as just described. For the purpose of
testing the algorithms we are developing for drug safety analysis, the SOCs have been rearranged
to have only one SOC per reaction term by only using the most important one and reassigning
reactions in SOC ‘2000’ to ‘1800’. In this scheme there are only eighteen SOCs (SOC class code
‘2000’ reaction terms were reassigned to one of the remaining SOCs). The resulting changes are
summarized in Figure 3.2. In the original ADRAC classification the reaction terms can belong to
more than one SOC. In order to use the algorithms described here, it was necessary to simplify the
reaction term-to-SOC class relationship by removing all but the most generic reaction terms. It
is possible to use fuzzy representation to preserve this information, but was decided that for this
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stage, the tradeoff between a small information loss and the added complication required in order
to preserve it justified the development of the first prototype using only one unique SOC term.
Data sets have been generated based on this classification. One data set that uses all eighteen
SOCs, which uses all data has been named Mallreac and another described is Card20, which
includes all of the sub tree of SOC ‘1000’ (cardiovascular), SOC ‘1200’ (haemic and lymphatic
systems) Blood and SOC ‘0400’ (nervous system and special senses) Neuro, which has a third
level in the tree and has 79149 records.
The data set called Mallreac consists of all reactions grouped into eighteen classes. The
number of reaction terms and number of occurrences for each class is shown in Table 3.2, where
the occurrence is a cumulative count for each reaction class. There are a number of reaction classes
that have subclasses, which are listed in Table 3.3.
3.4.1 Five cardiovascular groups – Card20 data set
The cardiovasuclar group of reactions, which contains 159 reaction terms. The cardiovascular class
consists of four sub-classes. In this classification we will only consider records of ADRAC data
related to the cardiovascular type of reactions to produce an alternative utilization of SOC that is
acceptable to ADRAC as apposed to the grouping adopted in Chapter 4. This data set is called
Card20 consists of all records having at least one reaction belonging to one the four sub-classes.
In this data set some records may have a reaction from outside Cardiovascular group. We define
four classes according to these four sub-groups and a fifth class that contains reactions belonging
to any of the other 17 SOCs, given that the record contains at least one cardiovascular reaction.
The number of reaction terms and number of occurrences for each class is shown in Table 3.4,
where the occurrence is a cumulative count for each reaction class.
3.4.2 Haemic and lymphatic systems – Blood data set
The haemic and lymphatic systems SOC ‘1200’ contains three sub-classes consists of 84 reaction
terms (Table 3.2). The data set called Blood consists of the three subclasses (Table 3.3), red
blood cells disorders, 54 reaction terms, white cell and res disorders 84 reaction terms, platelet,
bleeding and clotting disorders 46 reaction terms.
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3.4.3 Nervous system and special senses – Neuro data set
The nervous system and special senses SOC ‘0400’ contains three sub-classes consists of 190 reaction
terms (Table 3.2). The data set called Neuro consists of the three subclasses (Table 3.3), central
and peripheral nervous system disorders , 106 reaction terms, autonomic nervous system disorders,
11 reaction terms, and special senses other, disorders, 4 reaction terms, which consists of the three
subsubclasses (Figure 3.1) combined.
3.5 Drug Terms
See Appendix B.1.3. Drug trade name term is the low level ADRAC term used in this chapter.
3.5.1 Suspect Codes
REACTION SUSPECT CODE (Adrsp) is a is a field in the ADRAC data defined as determining
the degree to which this drug is suspected of causing the adverse reaction, taking values, ‘I’ –
interaction, ‘O’ – other drug suspected, ‘S’ – suspected. The “Reaction Suspect Code” could be
useful to help identify which drugs are likely to cause reactions and help to remove “innocent
by-stander” drugs from the analysis [322].
3.6 Anatomical-Therapeutic-Chemical (ATC) system of drug
classification
Reaction ontologies have been used to some extent in approaches to automated ADR signal detec-
tion methods as noted in the Section 2.2.2. There has been some use of the ATC grouping in the
Bayesian Confidence Propagation Neural Network (BCPNN) [38] (sse Section 2.2.4).
There has been a need for a similar kind of grouping to apply to drugs in the ADRAC data,
which are currently listed by trade name [326]. In the ADRAC data, some of these trade names
were assigned anatomical-therapeutic-chemical classification (ATC) codes, but in cases where the
trade name had more than one ingredient, ATC codes were not assigned and many had no ATC
code. Moreover, the ATC codes that were assigned at the second lowest level (5 of the available
7-letter code). This section reports a draft classification where each ingredient was assigned an
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ATC code. Implementation of the ATC codes was done in order to enable: (i) the grouping of
the same substance into one code, and (ii) the grouping of related substances into more general
categories. The ADRAC implementation of the ATC codes is not complete so it was necessary to
use the WHO drug dictionary and other sources to reconcile any differences in terminology [454].
3.6.1 Problems concerning the ATC currently
The hierarchical spreadsheet format was difficult to convert to a relational database [454], it is
recommended that this format needs to be changed to one that makes this dictionary directly
accessible to automated queries, for example, in the form of a relational database, similar to mine.
It is not complete, for example Methylisothiazolinone, which is a preservative in cosmetics and
shampoo may harm developing nerve cells and affect foetal development [114, 400, 513], cannot be
found in the current WHO ATC dictionary.
The ATC classification made in the following section has a one-to-one correspondence between
drug trade name and ATC code. In cases where the trade name term represented multiple in-
gredients, an ATC term for multiple ingredients was selected. However, it is important to know
which of the multiple ingredients may be implicated. This complicates the issue of analysis, but
as will be demonstrated in Section 8.2, ATC coding makes powerful data mining tools, such as
association rules analysis applicable to these data. This will make possible the analysis of associ-
ation all ingredients to reactions. This will enable the application of grounded theory to the data
mining process (see Section 1.3) where no assumptions that an ingredient is inactive or a drug not
“suspected”. The association rules themselves can be examined to find associations of interest.
3.7 ATC Classification of drugs reported in ADRAC
3.7.1 Methods
Basis for drug classification
The ADRAC database uses the “drug trade name” field as the main field for drugs. This is not
satisfactory because the same drug can have more than one trade name. Also it is difficult to
group drugs using this field. The classification system implemented was the WHO Collaborating
Centre for Drug Statistics Methodology ATC codes in order to enable: (i) the grouping of the same
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substance into one code, and (ii) the grouping of related substances into more general categories.
To this purpose the ATC codes for drugs [560] have been purchased from Ms Kirsten Myhr, RELIS
Øst, Ulleva˝l University Hospital, 0407 OSLO (http://www.whocc.no/).
ATC embedded code
The ATC encoding system implements an embedded encoding system. It employs a seven character
coding. As an example the first member of the system will be used. The level we call level
0, the character is ‘A’, the level 1 is ‘A01’, level 2 is ‘A01A’, level 3 is ‘A01AA’ and level 4 is
‘A01AA01’. The embedded coding can be utilized to simplify database queries and algorithm
coding (implemented in program language). Employing this embedded coding, which resides in
the ATC code string, can be now utilized to aggregate the data at the required level. To aggregate
data, the ATC string is truncated to achieve the desired level of aggregation.
There was a need, for the purposes of associating ADRAC and ATC ingredient terms, to go
to level 4 (7 character). For details of the ATC hierarchy record counts, see Table 3.5 for level 0
ATC record counts, for levels 0 and 1; Figure 3.3 for all ingredients and Figure 3.4 for one-to-one
with trade name.
Sources and applications
The WHO ATC file was in Excel format. In order to be able to perform SQL queries to relate the
the ATC classification to the ADRAC data, a normalization of the WHO ATC table was necessary.
This was done with the assistance of the awk program of Unix. By this transformation tables were
made for each ATC level. This enabled the association of ATC codes to the ADRAC data, which
was stored in a relational database. There was an exact correspondence for only one third of the
ADRAC ingredient terms associated with a given trade name term to the ingredient terms in the
WHO ATC table. For the remaining associations of terms, firstly, synonyms or alternative spellings
of the terms was sought. If this information could not be found, pharmacological information was
sought in a MIMS dictionary or from a Google search of the internet in order to classify the
ingredient.
Where a correspondence between ADRAC and WHO ATC terms could not be found, new
terms were added to this ADRAC version of the ATC classification. If necessary extra classes were
added at appropriate levels to this version to accommodate the new terms.
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First Stage of classification of ADRAC data
All ADRAC DRUG TRADE NAME (trade name) instances that had ingredients (represented by
the DRUG INGREDIENT field) that matched ones in the WHO ATC file were assigned an ATC
code. In cases where more than one code was available for a particular ingredient, the most generic
one was chosen.
Second Stage of classification of ADRAC data
All ADRAC DRUG TRADE NAME (trade name) codes that had multiple ingredients were iden-
tified. Those ingredients in this list that had not been assigned an ATC code were matched, if
possible, to an ingredient in the WHO ATC file. If that ingredient could not be found in the WHO
ATC classes, sufficient information was sought to classify it into an existing WHO ATC class or
by adding more classes to it, as described in the previous section.
Third Stage of classification of ADRAC data
The remaining ADRAC DRUG TRADE NAME (trade name) codes that had not been assigned
an ATC code were classified as described in the previous subsection.
Final Stage of classification of ADRAC data
It is envisioned that there will be several versions of the ADRAC ATC classification for different
applications/methodologies. For the purposes of this present investigation, in cases where the
original drug code had more than one ingredient, a unique code was assigned from ATC codes
for combinations of ingredients. This was done in order to preserve a one-to-one correspondence
between original drug codes and the ATC codes facilitating comparison of the two drug classification
schema. This resulted in 1806 ATC drug terms from the 5081 drug trade name terms. Table 3.5
lists the drug terms for ATC level 0, giving counts of number of terms per class and the count
of the number of records in ADRAC that contain that class. Figure 3.4 displays the tree thus
generated for level 0 and level 1 with ADRAC record counts.
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3.7.2 Results
Only one ingredient (Chlorophenulum - in cough mixture) could not be identified. The results of
this classification of ADRAC data are given in terms of numbers of reports per class. There are
five levels of classes in the ATC system: level 0 had 14 classes, level 1 had 95, level 2 had 217,
level 3 had 581 and level 4 had 1785. This classification has the advantage that every ingredient
received an ATC code. It is not suited to the methods used in this thesis, which would require
modification to accommodate drugs with multiple ingredients.
The one-to-one classification of ADRAC data was used in the present work and are given in
terms of numbers of reports per class. There are five levels of classes in the ATC system: level 0 had
14 classes, level 1 had 92, level 2 had 227, level 3 had 602 and level 4 had 1809. This classification
preserves the one-to-one relationship to trade name for comparison purposes. However, where the
drug term involved multiple ingredients, a single code for combinations was used. This caused the
information referring to individual ingredients to be lost.
3.7.3 Discussion
Some ATC codes are assigned to combinations of ingredients. It is proposed to have a version that
continues the classification so that each combination of ingredients is assigned a single code. This
will mean that our current drug-relationship algorithms used for ADRAC data can use ATC codes
to compare the performance using trade name versus ATC code. The future development of these
algorithms will need to take advantage of the hierarchy of levels embedded in the ATC codes.
Inadequacy of trade name
The trade name of a drug may represent the same ingredient under multiple trade names or multiple
ingredients under one or more trade names, thus destroying a complete one to one relationship
from trade name to ingredient.
The ADRAC ATC implementation
The ADRAC ATC classification was started, but in these data, it was incomplete and only taken
to the five character (level 3) level. Whilst this is probably a sufficiently fine level for the purposes
of data analysis, it was too coarse for the purpose of matching ADRAC ingredients to WHO ATC
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ingredients, in which case it is necessary to go to the 7 character level (level 4). This classification,
because it is hierarchical, allows the grouping of data to different levels in the hierarchy. This
will make the ADRAC data more amenable to the application of optimization techniques (for
discussion see [326]), because it is now possible to greatly decrease the number of variables using
higher level drug terms in this classification. Furthermore, some methods commonly applied in
data mining [34, 198, 199, 417] should become applicable to ADRAC data. For example, I show
that the ATC code enables a useful application of association rules using the algorithm Apriori
(see – [4, 7, 547]) to investigate ADRAC data. This ATC classification will also facilitate the use
drug class information already ‘learnt’ to apply to drugs belonging to that class that have not been
previously encountered in the data [326].
Completing this classification will enable pooling of all data relating to a single ingredient,
rather than having it split between different trade names. This will be a major benefit. The fact
that there are several levels of granularity in this classification allows analysis at different levels. for
example, it facilitates the aggregation of classes of ingredients that are less likely to cause ADRs.
Methods that do not perform well with a large number of variables (for example association rules)
could become usefully employed in analyzing drug safety data now that it is possible to reduce
the number of drug terms using ATC classes. The tree structure of the ATC classification can be
exploited by methods that employ such structures or by neural networks. A benefit for predictive
methods is that information ‘learned’ for a class (of drug) can be used for new instances of that
class (new drugs). these codes also allow us to subdivide to lowest level supported by data, unless
not an important class, for example, vitamins [454].
The author of this thesis has previously published work on studies with antibiotics (the macrolides,
tetracyclines, chloramphenicol [172, 303, 312, 448, 449, 563]), (neomycin, nystatin, and strepto-
mycin [451, 452]).
3.7.4 Concluding Remarks
This section details the ontologies required for the investigations relating to research questions 2–4,
Section 0.3. System organ class grouping only was used in the early stages of my investigation.
The latter stages of my work utilized ATC codes and critical reaction terms as well. The first
investigation of new algorithms developed in collaboration with Musa Mammadov concentrated on
the SOC group of cardiovascular reactions, because this group has four similar-sized sub-groups.
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Table 3.1: WHO System Organ Classes
Code System Organ Class Name No. Critical*
0100 Skin and appendages disorders 11
0200 Musculo-skeletal system disorders 8
0300 Collagen disorders 6
0410 Central and peripheral nervous system disorders 73
0420 Autonomic nervous system disorders 0
0431 Vision disorders 14
0432 Hearing and vestibular disorders 5
0433 Special senses other, disorders 0
0500 Psychiatric disorders 22
0600 Gastro-intestinal system disorders 62
0700 Liver and biliary system disorders 11
0800 Metabolic and nutritional disorders 19
0900 Endocrine disorders 4
1010 Cardiovascular disorders, general 11
1020 Myo endo pericardial and valve disorders 11
1030 Heart rate and rhythm disorders 19
1040 Vascular (extracardiac) disorders 42
1100 Respiratory system disorders 29
1210 Red blood cells disorders 18
1220 White cell and RES † disorders 8
1230 Platelet, bleeding and clotting disorders 31
1300 Urinary system disorders 15
1410 Reproductive disorders, male 0
1420 Reproductive disorders, female 12
1500 Foetal disorders 10
1600 Neonatal and infancy disorders 33
1700 Neoplasm 34
1810 Body as a whole – general disorders 9
1820 Application site disorders 0
1830 Resistance mechanism disorders 5
2000 Secondary terms – events 2
2100 Poison specific terms 7
* Number of critical terms – see Section. 3.3.1 † RES – Reticuloendothelial system.
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Table 3.2: System Organ Classes in ADRAC
Code System Organ Class Name Terms* Occurrence† No. Critical‡
0100 Skin and appendages disorders 76 54221 11
0200 Musculo-skeletal system disorders 41 8808 6
0300 Collagen disorders 13 385 4
0400 Nervous system and special senses 190 47549 72
0500 Psychiatric disorders 46 19946 16
0600 Gastro-intestinal system disorders 112 34581 43
0700 Liver and biliary system disorders 31 7686 9
0800 Metabolic and nutritional disorders 59 4926 13
0900 Endocrine disorders 31 1201 2
1000 Cardiovascular system 159 27097 54
1100 Respiratory system disorders 54 13296 19
1200 Haemic and lymphatic systems 84 10226 55
1300 Urinary system disorders 46 5865 13
1400 Reproductive system 81 3412 6
1500 Foetal disorders 71 841 6
1600 Neonatal and infancy disorders 20 103 31
1700 Neoplasm 40 278 21
1800 Body as a whole 109 42396 8
*Number of reaction terms in class.
†Total occurrence of reaction class – cumulative count for numbers of records in each reaction class.
‡Number of critical terms – see Section. 3.3.1
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Figure 3.3: The ATC hierarchy.
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Table 3.3: System Organ Sub-classes in ADRAC
Code System Organ Class Name Terms* Occurrence‡ No. Critical§
0410 Central and peripheral nervous system disorders 106 34766 56
0420 Autonomic nervous system disorders 11 4581 0
0431 Vision disorders 59 5594 12
0432 Hearing and vestibular disorders 10 1320 4
0433 Special senses other, disorders 4 1288 0
1010 Cardiovascular disorders, general 28 13512 9
1020 Myo endo pericardial and valve disorders 21 810 8
1030 Heart rate and rhythm disorders 24 5901 15
1040 Vascular (extracardiac) disorders 86 6874 32
1210 Red blood cells disorders 54 13296 15
1220 White cell and res disorders 84 10226 4
1230 Platelet, bleeding and clotting disorders 46 5865 26
1400 Reproductive disorders, male or female‡ 4 248 0
1410 Reproductive disorders, male 15 1244 0
1420 Reproductive disorders, female 62 1920 6
1810 Body as a whole – general disorders 66 35363 7
1820 Application site disorders 18 6221 0
1830 Resistance mechanism disorders 25 812 1
*Number of reaction terms in class.
†Total occurrence of reaction class – cumulative count for numbers of records in each reaction class.
‡Depending on gender of patient.
§Number of critical terms – see Section. 3.3.1
Table 3.4: The Five Card20 Classes and the Four Cardiovascular System Organ Sub-Classes in
ADRAC
Class Code System Organ Class Name Terms* Occurrence†
1 1010 Cardiovascular disorders, general 28 13512
2 1020 Myo endo pericardial and valve disorders 21 810
3 1030 Heart rate and rhythm disorders 24 5901
4 1040 Vascular (extracardiac) disorders 86 6874
5 Non-cardiovascular reaction(s) ‡ 677 36394
* Number of reaction terms in class
† Total occurrence of reaction class – see text
‡ Given any 10xx SOC + any non-cardiovascular reaction terms(s) – see text
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Figure 3.4: The ATC hierarchy for classification with one-to-one ATC-to-Trade Name code rela-
tionship.
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Table 3.5: ATC level 0 with counts
ATC 0 ATC 0 NAME Trade count* Rptd count †
A ALIMENTARY TRACT AND METABOLISM 681 26728
B BLOOD AND BLOOD FORMING ORGANS 229 10633
C CARDIOVASCULAR SYSTEM 417 63773
D DERMATOLOGICALS 413 5902
G GENITO URINARY SYSTEM AND SEX HORMONES 248 8001
H SYSTEMIC HORMOINAL PREPARATIONS ¶ 127 8943
J ANTIINFECTIVES FOR SYSTEMIC USE 594 51050
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 220 8869
M MUSCULO-SKELETAL SYSTEM 207 20751
N NERVOUS SYSTEM 829 68198
P ANTIPARASITIC PRODUCTS, INSECTICIDES, REPELLENTS 99 2209
R RESPIRATORY SYSTEM 326 13887
S SENSORY ORGANS 109 1627
V VARIOUS 558 5776
*Count of Trade name codes for the particular ATC class (Trade count = Drug trade name code
count).
† Count of number of reports in ADRAC data (Rptd count = count of reports in ADRAC data)
for each drug class.
¶ Excluding sex hormone
Chapter 4
Preliminary Study of
Cardiovascular Reactions in
ADRAC Data
4.1 Introduction
Many non-Bayesian or frequentist forms of disproportionality approaches to ADR signal detection
(see Section 2.1.1) use measures to estimate risk that include relative risk (RR), odds ratio (OR),
reporting odds ratio (ROR), proportional reporting ratio (PRR), attributable risk, population
attributable risk and population attributable fractions and Yule’s Q. Such methods are dispro-
portionality analysis signal detection methods because they compare a given drug and reaction
compared to reports for that event in the entire database. As example, relative risk (RR), in the
context of the ADRAC data, it is the ratio of the rate of occurrence of a particular reaction in
people exposed to a particular drug, to the rate among those people exposed to all other drugs in
a SOC. A problem with RR is that it ignores sampling variations that depend on the sample size
(n), which can over-emphasize small samples. For example, if a rarely used drug causes a rarely
reported reaction, then the RR is going to be very high. This may not be a reliable estimate –
because n is small [34]. PRRs essentially use all other drugs (besides the one of interest) as a
control, and suffer from the lack of denominator data (= total doses of drug administered to the
entire population, that is ADR positive + ADR negative) [133, 373]. This lack of denominator
data (ADR++ADR−) is a characteristic of spontaneously reported data, so methods that reduce
the size of the control group should be more robust and give fewer false positive signals. For a
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study of ADRAC data using non-Bayesian or frequentist forms of disproportionality methods see
Barty [34].
In this Chapter I describe the first development of an Algorithm, in collaboration with Musa
Mammadov, that uses ADRAC data to investigate drug-reaction relationships in these data. Each
drug is weighted according to the reactions it is associated with; the more a particular drug is
associated with a particular reaction, the greater will be the weight for that drug/reaction pair.
A detailed account is given in Section 4.6 and [322, 323]. Further developments of this algorithm
are described in Chapters 5, 6, and [317, 331]. The grouping of the cardiovascular SOC subclasses
was different to that described in Chapter 3 and was deemed clinically questionable by ADRAC.
Thus all future analysis was in accordance with the SOC groupings described in Chapter 3.
This algorithm is based on the following scenario: given a patient taking some drug(s) can
we predict what kind of reaction(s) can occur. This problem relies on the availability of suitable
data from a sufficient number of reports of ADR cases using well developed methods [19, 41, 42,
197, 408, 424, 520]. One problem of ADRs is, for a given patient, who has taken a set of drugs
and manifests a set of reactions), to identify drug(s) responsible for these reactions. This is a
case of confounding by association and is the reason the programs STATFILE [34] and PROFILE
[198, 417] to filter out innocent bystander drugs. ADRAC data contains suspect codes assigned by
the committee to help with this problem and this will be explored further in Chapter 6.
The information collected in the ADRAC database consist of mainly two types of information:
Individual ADR report information, including “reason for use”, “history” and many other fields,
and information about drug(s) and reactions observed (for more details see [322]). At this stage
only the second type of information was utilized, because the former requires more of a data
mining approach to extract useful information (see [418] for a commentary on data mining in
pharmacovigilance). There are some issues which complicate the study of this problem: dosages,
frequency and duration of drugs taken. The use of dosage information is difficult because in
the ADRAC data different units (for example, liters, grams, milligrams, kilograms), which makes
standardization and scaling a significant problem. An association rule approach could effectively
deal with this problem, see Section 8.2. At this stage of investigation it was decided to neglect the
dosage information (a reasonable assumption given the WHO definition – above) and to apply two
different values: “Yes” – if drug was taken and “No” if not. This is, a common assumption used by
many researchers, although not always explicitly stated. For example see – [124, 198, 418, 531, 595].
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4.2 Methods
The ADRAC data has been converted to a relational database in Oracle. Information from the
ADRAC database was extracted and queried as required. Most of the computer program coding of
algorithms for this work been written in Fortran-90 and numerical experiments have been carried
out on a pentium 4 CPU 1400 MHz processor with 261 MB RAM.
4.3 Meta-SOC
The problem of finding an association between 1392 types of reaction that have been classified
in ADRAC1 and 7416 drugs which have been administered is a vast problem if a combinatorial
approach is taken. It is impossible to consider all possible combinations of drugs and reactions. To
further confound the issue, many ADR reports display more than one reaction while taking more
than one drug, making the association between drugs and reactions even more difficult.
The biggest challenge in summarizing safety data is the need to consolidate the massive amount
of data into a manageable format. This is described in Section 3.4, but in this Chapter a different
grouping system for reactions was used. This is described below. In became apparent that this was
not suitable for medical interpretation, but served as a starting point for developing the algorithms.
The ADRAC field of Systems Organ Class (Adsoc) relate the many kinds of reactions physio-
logically. There are 36 Adsoc codes, which was too many for the purposes of this analysis. In order
to aggregate the Adsoc categories in a meaningful way, 10 meta categories were created which were
physiologically related. These reaction super groupings used to facilitate this analysis are listed in
Table 4.1.
4.3.1 System Organ Class Codes in Meta Systems Organ Class Groups
The cardiovascular system (ADRAC code -‘1000’) was the only one studied in this section. There
are for subclasses, cardiovascular disorders, general (‘1010’), myo endo pericardial and valve disor-
ders (‘1020’), heart rate and rhythm disorders (‘1030’), vascular (extracardiac) disorders (‘1040’)
of this group. The types of reaction contained in each of these four sublasses is listed in Appendix
B.2.
The following general scheme was undertaken:
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Table 4.1: Numbers of reactions for the Meta System Organ classes
Meta Systems Organ Class Number of Reactions
1 CARDIOVASCULAR 160
2 HAEMATOLOGICAL/IMMUNE 174
3 FOETAL/NEONATAL 148
4 METABOLIC 314
5 NEOPLASM 70
6 NEURAL 308
7 RESPIRATORY 66
8 SKIN/MUSCLE/CONNECTIVE TISSUE 175
9 UROGENITAL 172
10 WHOLEBODY 188
1. A data set was formed, which contained all records from ADRAC1 having just reactions
from Cardiovascular group in the four subgroups listed in Appendix B.2.
2. For each drug a vector of degrees was defined, which show the degree of occurrence (mem-
bership) of each reaction group, that is forming fuzzy sets as described in Section 1.6. Therefore
the drug-reaction relationships are presented by these vector degrees. This method was tested for
prediction of meta-reactions (Sections 4.6, 4.7).
3. Bad and good outcomes were predicted on the basis of real observed reactions and, sepa-
rately, on the basis of defined (predicted) Potential Reactions (Sections 4.8, 4.9).
4.4 The cardiovascular group. The data set Card1
This group consists of 160 distinct reaction codes, which includes: aneurysm, angina, arrhythmia,
arteriosclerosis, cardiac arrest, limb embolism, gangrene, varicose vein.
To generate a data set, that was called Card1, the data set ADRAC1 was used from which
all records that have only reactions that relate to the cardiovascular group of reactions and that
do not have reactions to any other meta-systems organ class were chosen. Alternatively, records
could have been included that had reactions not included in the cardiovascular group. This is
the approach adopted in Chapter 5. The data set Card1 was formed, which contains all records
from ADRAC1 having just reactions included in the 160 of the Cardiovascular group. The number
of records in Card1 was 6703. Not all of the 160 reactions, and not all of the 7416 drugs were
represented in Card1. The number of reactions actually represented was 131 and the number of
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drugs was 1750. The fields in Card1 were: the number of the record in Card1 (from 1 to 6703),
the ADRAC ID number, the years from 1972 to 2001, age, weight, gender, the 131 reactions, the
1750 drugs; the last two features were: “reaction outcome” and “causality code”.
Figure 4.1: Graph of all reactions in each year in Card1.
4.4.1 Analysis of some reactions
In Card1 has 131 reactions; the average number of reactions per record for this cardiovascular
group is approximately 1.19, showing that a small number of records have two or more reactions.
The average number is two times less than that for all ADRAC data.
In Table 4.2 and Figure 4.1 presents the number of records per year (one record from 1971 is
not included). It can be seen that until 1991 the number of records per year remains under 200.
After 1991 the number of reactions per year start to rise. In the year 2000 the number of reactions
is approximately 4 times more than that of 1991. It should be noted that for the year 2001 the data
after August are absent. To see if this trend was unique to the cardiovascular SOC, the number
of records per year for all reactions was examined and the results are presented in Figure 4.2. It
can be seen that the same trend is observed.
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In Table 4.2 the number of death outcomes based on the REACTION-OUTCOME field, where
values “C” (death maybe drug) and “D” (Death as a reaction) were counted. From these data,
the percent death outcome does not seem to change.
Table 4.2: Card1. Number of records and death outcomes per year
Year Number Number of Percent of
of records death outcomes death outcomes
1972 22 1 4.5455
1973 139 6 4.3165
1974 82 6 7.3171
1975 132 4 3.0303
1976 82 2 2.4390
1977 94 5 5.3191
1978 137 6 4.3796
1979 116 1 0.8621
1980 87 1 1.1494
1981 85 2 2.3529
1982 122 1 0.8197
1983 149 3 2.0134
1984 134 4 2.9851
1985 118 5 4.2373
1986 124 3 2.4194
1987 189 2 1.0582
1988 166 4 2.4096
1989 162 11 6.7901
1990 195 12 6.1538
1991 194 18 9.2784
1992 248 7 2.8226
1993 270 8 2.9630
1994 295 10 3.3898
1995 261 8 3.0651
1996 284 3 1.0563
1997 367 9 2.4523
1998 662 4 0.6042
1999 757 4 0.5284
2000 698 21 3.0086
2001 331 11 3.3233
Total 6702 182 3.2363
In Table 4.3 the reactions that most frequently occur in Card1 are presented. In the last col-
umn, the number of death outcomes according to each reaction can be seen. Note that this number
is the sum of two kinds of death outcome, from the ADRAC data – C (Death, maybe drug) and D
(death as a reaction). Possibly the most serious reactions are: reaction 207 (CARDIAC ARREST)
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which had 32 death outcomes (6 of them as a reaction - D), reaction 670 (HYPOTENSION) which
had 21 death outcomes (3 of them D), reaction 1213 (SYNCOPE) which had 10 death outcomes
(3 of them D), reaction 858 (MYOCARDIAL INFARCTION) which had 19 death outcomes (3 of
them D), reaction 409 (EMBOLISM PULMONARY) which had 9 death outcomes (2 of them D),
reaction 209 (CARDIAC FAILURE) which had 15 death outcomes (3 of them D).
Table 4.3: Card1. Most common reactions associated with the cardiovascular group of reactions
N Preferred Reaction Occur- Death Death as
Code Name rence Outcome Reaction
1 670 HYPOTENSION 872 21 3
2 1071 PURPURA 548 4 1
3 915 OEDEMA DEPENDENT 544 1 0
4 1213 SYNCOPE 393 10 3
5 168 BRADYCARDIA 373 4 0
6 480 FLUSHING 359 0 0
7 636 HYPERTENSION 358 0 0
8 958 PALPITATION 344 0 0
9 1217 TACHYCARDIA 334 2 0
10 913 OEDEMA 311 1 0
11 920 OEDEMA PERIPHERAL 294 0 0
12 671 HYPERTENSION POSTURAL 241 0 0
14 1358 VASCULITIS 154 1 0
15 207 CARDIAC ARREST 153 32 6
16 996 PERIPHERAL ISCHAEMIA 131 1 0
17 209 CARDIAC FAILURE 127 15 3
18 1251 THROMBOPHLEBITIS DEEP 117 2 0
19 229 CEREBROVASCULAR DISORDER 109 16 0
20 554 HAEMORRHAGE NOS 109 8 0
21 858 MYOCARDIAL INFARCTION 108 19 3
22 468 FIBRILATION ATRIAL 105 4 0
23 448 EXTRA SYSTOLES 99 0 0
24 104 ARRHYTHMIA 95 5 2
25 568 HEART BLOCK 89 8 2
26 409 EMBOLISM PULMONARY 87 9 2
27 214 CARDIOMYOPATHY 79 3 0
29 390 ECG ABNORMAL 68 3 1
30 1219 TACHYCARDIA VENTRICULAR 63 2 0
31 1246 THROMBOPHLEBITIS 56 1 0
35 210 CARDIAC FAILURE LEFT 46 3 0
36 227 CEREBRAL HAEMORRHAGE 43 15 2
37 312 CYANOSIS 43 2 1
The most commonly encountered reaction is 670 (HYPOTENSION), which occurred 872 times.
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The other 4 reactions, 1071 (PURPURA), 915 (OEDEMA DEPENDENT), 1273 (SYNCOPE) and
168 (BRADYCARDIA), occurred more than 370 times. The majority of reactions occurred just 1
to 9 times.
Figure 4.2: Graph of all reactions in each year in ADRAC.
4.4.2 Drugs associated with the Cardiovascular group
The number of occurrences of individual drugs for Card1 was calculated. Table 4.4 shows the
highest 20 of these.
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Table 4.4: Card1: Most common drugs associated with the cardiovascular group of reactions
Order Drug code Drug Trade Name Occur- Occurrence Order
in Card1 in ADRAC rence in ADRAC in ADRAC
1 4719 NORVASC 628 2199 7
2 3694 LASTIX 222 3131 2
3 1232 CELEBREX 210 2740 4
4 543 ASPIRIN 209 2712 5
5 1974 DIGOXIN 183 2083 9
6 1535 CLOZARIL 178 1737 15
7 7387 ZOLOFT 139 4356 1
8 6170 SLOW-K 134 2223 6
9 7153 VIAGRA 123 784 84
10 2999 HAEMACCEL 121 334 207
11 3311 WARFARIN, SODIUM 108 1687 18
12 7239 INDERAL 108 1227 39
13 7134 VENTOLIN 105 2773 3
14 7309 ZANTAC 102 2188 8
15 3683 LANOXIN 101 1373 30
16 2780 FRUSEMIDE 96 1685 19
17 113 MINIPRESS 95 1239 38
18 4272 ADALAT 95 866 67
19 403 RENITEC 90 2008 10
20 5779 ANGININE 90 676 92
Many drugs included in the Card1 records are those that would be normally expected to be
used in the treatment of cardiovascular conditions. For example, digitoxin (5th) which is a car-
diac glycoside, Sodium warfarin (11th) and Sodium heparin (23rd) – anti-coagulants, Amiodipine
besylate (1st) – a calcium ion antagonist, Frusemide (2nd) – a diuretic, Glyceryl trinitrate (20th)
– a vasodilator.
There are also drugs that would be used more generally; such as, Aspirin (4th) and paracetamol
(68th) – analgesics, Diazepam (31st) – a sedative.
But some drugs, such as, Celebrex (3rd), which is an anti-inflammatory, Clozapine [95, 270,
404](6th) and Sertraline (7th), which are anti-psychotics, would not be used specifically for treat-
ment of cardiovascular conditions. This points to the fact that the records in Card1 would include
ADR reports which are specifically being treated for cardiovascular conditions and ones which are
having reactions of cardiovascular type, but which are being treated for non-cardiovascular condi-
tions.
In Table 4.4 the drug counts and order for cardiovascular can be compared with that for all
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ADRAC data (column 4 – Occurrence, column 6 – Order in ADRAC; also see Table 10.7), it can
be seen that Norvasc (Amiodipine besylate) was used (the most), 628 times in the cardiovascular
data and (seventh) 2199 times in the general data, Zoloft (Sertraline) (seventh) 139 times in the
cardiovascular data and (the first) 4356 times in the general data, Lastix (Frusemide) was the
second most used in both the cardiovascular data (222 times) and the general data (3181 times),
Ventolin (Salbutimole sulphate) (thirteenth) 105 times in the cardiovascular data and (third) 2773
times in the general data, Celebrex (third) 210 times in the cardiovascular data and (fourth) 2740
times in the general data, Aspirin (fourth) 209 times in the cardiovascular data and (fifth) 2712
times in the general data, Slow-K (Potassium chloride) (eighth) 134 times in the cardiovascular
data and (sixth) 2223 times in the general data, Zantac (Rantidine hydrochloride) (fourteenth)
102 times in the cardiovascular data and (eighth) 2188 times in the general data, Digitoxin (fifth)
183 times in the cardiovascular data and (ninth) 2083 times in the general data.
There are many reports of adverse reactions associated with various drugs. Celebrex has been
associated with cardiovascular reactions and deaths in Canada (also see Section 2.3) and three
cases involved concomitant use of warfarin [500]. Clozapine has been associated with myocarditis
and cardiomyopathy in Australia [270]. Cisapride appears to be cardiotoxic and is associated with
deaths in Canada and the United States [351]. Phenylpropanolamine is suspected (see Section
3.5.1) to cause haemorrhaging and stroke and has been removed from appetite suppressants and
cough and cold preparations in the United States and Canada, but not the United Kingdom [83].
Micronazole appears to interact with warfarin to produce bleeding [367]. Eight Selective Sero-
tonin Reuptake Inhibitors (SSRIs), fluoxine, paroxine, sertraline [102], fluvoxamine, venfaxine,
nefazodone, citalopram, trazodone are associated with adverse cardiovascular reactions with con-
comitant use of benzodiazepines. SSRI adverse reactions are usually of mild to moderate severity
but some are severe to fatal, for example, cardiac arrhythmias, unstable angina, and bleeding com-
plications. SSRIs appear to be linked with other drugs that are associated with thrombophlebitis,
for example, terfenadine, astemizole, quinidine, haloperidol, thioridazine, chlorpropamazine, chlo-
ral hydrate, erythromycin, corticosteriods, doxepin, amitriptyline, so it is important to consider
other drugs when SSRIs are used [97]. Calcium Channel Blockers (CCBs) nifedipidine and terfe-
nadine can produce arrhythmia in conjunction with anti funguls and macrolides and can be a lethal
combination [71]. Non-Steroid Anti-Inflammatory drugs (NSAIDs) have lead to 70,000 hospitaliza-
tions and 7,000 deaths annually in the United States annually [71]. Also NSAIDs increase the risk
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of blood dyscrasias or anaphalaxis; diclofenac causes aplastic anaemia, also oral contraceptives are
associated with cardiovascular disease including, venous thromboembolism, myocardial infarction,
and stroke [264].
4.5 The Data Set Card2
A relevant observation from the set of 131 reactions, 32 of which are presented in Table 4.3, is
that just 51 reactions occurred more than 20 times. Many reactions only occurred a few times.
For example, 19 reactions occurred only once, the rest of reactions occurred less than 15 times.
This situation makes it difficult to study drug-reaction relationships considering each reaction
separately, because a small number of records (for the majority of reactions) makes predictions
difficult, which is desirable in order to establish sound drug-reaction relationships. This is why
each reaction was not considered separately. Reactions were grouped and then drug-reaction
relationships were studied considering each of these classes as a group of reactions.
All 131 reactions that occurred in Card1 were utilized. A selection of the 37 reactions that
occurred most frequently is presented in Table 4.3. The four cardiovascular classes described in
Section 4.3.1 were used plus a fifth class was formed from records that have at least two reactions,
and further belonging to two different groups of meta-reactions. The first class contains 2162
records and 19 reactions, the second class contains 674 records and 37 reactions, the third class
contains 1807 records and 26 reactions, the fourth class contains 1343 records and 49 reactions,
the fifth class contains 717 records. The total number of records in these 5 classes is 6703. The
number of records, which have just one drug taken, is 3801 (56.7 percent of all records). Average
number of drugs per ADR report is 2.16.
These data were called Card2. Therefore instead of 131 reactions (in Card1) 5 groups of
reactions were used.
Note that in Card2 different classes can have common points; that is one combination of drugs
can cause different reactions (see Example 4.6.1 below). It is not the aim to form classes that
are separated. The data set Card2 was used to study drug-reaction relationships. Because the
algorithm described below does not classify drug-reaction relationships into distinct classes, they
are termed quasi-classes and the algorithm is named the quasi-classification algorithm (QCA). It
uses fuzzy sets as categories, that is, an element can be characterized by its degree of membership
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to more than one set – see Section 1.6.
4.6 The Fuzzy Classification Algorithm (QCA)
In its first incarnation, the algorithm was called the Quasi-Classification Algorithm (QCA) – Ap-
pendix C.1 [322, 323]. The algorithms used in Chapter 5 are based on this. An illustration how this
algorithm works using the four cardiovascular sub-classes with respect to all drug terms is given in
Figure 4.3. The drug-reaction relationship is a fuzzy set relationship this can also be characterized
as a covariability technique. Each drug term is related to each of the four cardiovascular reaction
classes by the degree (δi) each drug is associated with each class. The degree of occurrence is
based on the frequency a reaction class occurring for each drug. The algorithm traverses the list
of report records. For each drug, in the record, it updates its (δ) for each reaction class. So every
drug has a set of degrees for each reaction class, that is a fuzzy set as described in Section 1.6.
Figure 4.3: Diagram to illustrate fuzzy classification of drugs with respect to reactions.
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4.6.1 Fuzzy Classification
Consider a new observation a = (aj), j = 1, 2, 3, ...,K(a), which consists of a set (combination)
of drugs that were recorded in a ADR report. Note that some of the drugs are not necessarily
included in the set of drugs D, defined by training set A. That is, some drugs recorded in ADR
report can be considered to be new drugs, never encountered before. In this case,
∂i(aj) = 0, i = 1, 2, ...,m
for each new occurrence of a drug aj was taken. Therefore, for each drug recorded in a new ADR
report a , the vector of degrees ∂(a) is defined. Using these degrees, calculate a vector
D(a) = (Di(a)), i = 1, 2, ...,m.
Here the number Di(a) is a degree of association with the class Ai. For calculating each Di(a)
simply sum the corresponding degrees for each drug:
Di(a) =
K(a)∑
j=1
∂i(aj), i = 1, 2, ...,m. (4.6.1)
Denote Dmax = max{Di(a) : i = 1, 2, ...,m}.
Assume that a new observation a belongs to the class Ai. How is the observation a classified
using the vector of degrees? Here different methods could be used. QCA classification is done as
follows:
Take any number n ≥ 1, let:
1) the observation a is correctly classified if:
Di(a) ≥ Dmax
n
> 0, (4.6.2)
2) the observation a is misclassified if
Di(a) = 0, (4.6.3)
3) the observation a is unclassified if
0 < Di(a) <
Dmax
n
. (4.6.4)
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The classification rule presented has the following meaning. The condition (4.6.3) means that
the observation a, which belongs to the class Ai, is misclassified, if the degree Di(a) is equal
to zero; that is, such a drug has not yet been associated with such a reaction. This is a new event
that has never been observed before and therefore can not be predicted. If n = 1 was taken, then
the observation a is correctly classified if the degree Di(a) is a maximal degree among all degrees
calculated for this observation (that is Di(a) = Dmax > 0). If n = 2 then it can be said that the
observation a is correctly classified if the degree Di(a) is not zero and, at the same time, is not
so small (is not less than the half of the maximal number Dmax).
Therefore, the correctly classified observation corresponds to an event that has been encountered
before. Moreover if n = 1 this event occurred with highest degree.
In order to explain this classification consider an example.
Example 4.6.1.
According to Card2 assume that there are 5 classes and for some new (test) observation a just
one drug (say drug number 6531 - Tamoxsifen Citrate) was seen. In the data set Card2 (training
set) this drug occurred 21 times. 10 times it is seen alone (twice with A3, 8 times with A4 meta-
reactions) and 11 times it is seen in combination with other drugs. Assume that in the definition
of the vector degree was taken p∗ = 40. Then the vector degree D(a), calculated by (C.1.1), is
D(a) = (0.000, 0.000, 0.095, 0.381, 0.000). (4.6.5)
Consider the following cases.
1. If the observation a belongs to the first, second or fifth class then this observation will be
misclassified.
2. If n ≤ 4, then the observation a will be correctly classified if it belongs to the fourth class.
In this case two training examples, related to the drug 6531 are not classified. If the observation a
belongs to the third class it is also not classified. But this can not be taken as a normal situation,
if the occurrence of the third reaction can not be predicted by the training set; because in two
training examples, the third reaction has occurred. Therefore, the possibility of the occurrence of
the third reaction is high and if a belongs to the third class it will be meaningful to say that the
observation a is correctly classified. This can be done if the number n is increased.
3. If n = 5 then the observation a will be correctly classified if it belongs to the third or fourth
classes. In this case all training examples are classified.
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To take into account the training set completely the number n must be increased. Therefore
calculations were made taking different numbers n.
Remark 4.6.1. Instead of (4.6.2) the following condition be could used:
Di(a) > 0. (4.6.6)
This condition can be obtained from (4.6.2) if a sufficiently large number n was taken. But
(4.6.6) was not used because, in this case, the problem of the optimal definition of the degree
vectors ∂(d) = (∂i(d)), i = 1, 2, ...,m, for the prediction is trivial: take ∂i(d) > 0, for all drugs d
and for all i, then 100 percent can be correctly classified.
4.6.2 Potential Reactions
The meaning of the degree vectors ∂(d) and D(a)
The vector ∂(d) = (∂i(d)), i = 1, 2, ...,m, shows what kind of reactions might be caused by the drug
d, based on the sample upon which the algorithm was trained. Therefore the vectorD(a) = (Di(a))
can be considered as potential reactions which are expected to occur in ADR report a. But what
reactions actually occur depends on the individual characteristics of the patient. As discussed
in Section 2.1.3 there is a large variability among patients, both genetic, medical history and
environmental factors. Some reactions which have potentially high degrees could possibly not be
observed because of a low susceptibility of the patient to these reactions. If the reaction profile
(vector) actually recorded for an individual is different from that expected (potential reaction),
then this may be indicative of an ADR or an interaction.
The vector D(a) of potential reactions will be called Potential Reactions (PR).
Potential Reactions will be studied in the next sections. Here it is emphasized that, for example,
the expression (4.6.5) may have information value in terms of what reaction profiles expected to
occur for ADR report a.
4.6.3 Interaction of Drugs
An important problem of ADRs is the interaction of drugs. The interaction of drugs can be defined
as a case when two or more drugs together cause a reaction which is different from the reactions
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that would be expected if they were used alone. Using a vector of degrees of association calculated
for each drug could be a good tool to study the interaction problem more precisely. For the sake
of definiteness consider two drugs d1 and d2.
The notion of interaction can be defined in two different senses: general and particular.
G. Interaction as a general occurrence
In this case the most common reaction, which is likely to occur if these drugs were used together,
is different from the expected reactions related to these drugs taken individually. To illustrate, in
terms of vectors of degrees, two kind of such interactions can be defined:
G1. General Interaction Expected by a vector of degrees.
G2. General Interaction Unexpected by a vector of degrees.
P. Interaction as a particular case
In this case consider just one ADR report and a reaction occurring with this ADR report is
considered to be a interaction.
To explain these kinds of interactions consider one theoretical example. Assume that the drugs
d1 and d2 were used 50 times together and each of them was used 50 times alone. When these
drugs were used alone the frequency of reactions was as follows (consider 5 reactions):
d1 ⇒ (22, 20, 0, 5, 2), (4.6.7)
d2 ⇒ (2, 20, 0, 23, 5). (4.6.8)
The vector degrees was calculated by the formula C.1.1 taking p∗ = 40 :
∂(d1) = (0.22, 0.20, 0.00, 0.05, 0.02), (4.6.9)
∂(d2) = (0.02, 0.20, 0.00, 0.23, 0.05). (4.6.10)
A vector of degrees was calculated by formula 4.6.1 is:
D(d1+2) = (0.24, 0.40, 0.00, 0.28, 0.07). (4.6.11)
Consider two different distributions of reactions related with the 50 cases when these drugs
were used together:
d1+2 ⇒ (10, 30, 2, 8, 0), (4.6.12)
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d1+2 ⇒ (8, 10, 2, 8, 22). (4.6.13)
1. In the case of expression 4.6.12 the following situation arises: the first and fourth reactions
are the most common reactions for the drugs d1 and d2, respectively. But when these drugs were
used together the second reaction becomes the most common reaction. This is an Expected General
Interaction, because this does tally with expression 4.6.11.
2. In the case of expression 4.6.13 the following situation occurs: the first and fourth reactions
are the most common reactions for the drugs d1 and d2, respectively. But when these drugs
were used together the fifth reaction becomes the most common reaction. This is an Unexpected
General Interaction, because this does not tally with expression 4.6.11. Following the vector of
degrees expression 4.6.11 the occurrence of the fifth reaction is positive, but the fact that this
reaction will be the most common reaction is unexpected. Note that if one ADR report had the
fifth reaction, in this case, this reaction can not be defined as an interaction of drugs. That is why
this situation is called a General Interaction.
3. In both cases above two ADR reports with the third reaction can be considered as a Particular
Interaction. Each drug separately can not cause the third reaction, but this reaction can occur if
they were used together.
4.7 Card2: Results of numerical experiments obtained by
QCA
In this section the results of the numerical experiments are presented. To evaluate QCA k−fold
cross validation was used. Note that an alternative approach is to predict the reactions for the
next period (year) using the records of previous periods (years) as a training set. k−fold cross
validation was chosen in order to make prediction for earlier years too.
When using k−fold cross validation one problem arises, which is related to the fact that, as it is
shown in Section 4.4.1, the number of records is essentially increasing by year. Besides, some of the
drugs were just used in the later (or early) years. Therefore, to make the training set informative
for prediction, the records from all years need to be included in the training set. The the records
in Card2 were renumbered mixing the training set by years by dividing the records related to
each year into five parts. The first parts of each year were taken in the top, followed by the second
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parts of each year on to the fifth. After this renumbering, 10−fold cross validation was used, every
training set contained records from each year.
The following notations were used:
– p+tr is the percent of correctly classified examples in the training set;
– p−tr is the percent of misclassified examples in the training set;
– p+ts is the percent of correctly classified examples in the test set;
– p−ts is the percent of misclassified examples in the test set.
The algorithm QCA contains two parameters that should be chosen. These are the parameters
p∗ and n, making calculations taking different numbers n ≥ 1 in order to check how much difference
between Dmax and the degree that related (corresponds) to the reaction taking place.
The number p∗ can be chosen in the interval [0, 100], using 10−fold cross validation and making
calculations taking p∗ = 0, 5, ..., 100 for different numbers n = 1, 2, ... (see Table 4.5). In all cases
better results (for test sets) were obtained when p∗ ≥ 30. If the number p∗ decreased (to 0) then
the accuracy for the test sets decreased too (for n > 1).
In the calculations below p∗ = 40 was mainly used. Note that taking p∗ = 40 means that, if
some drug was used alone in at least 40 percent of all cases that this drug is used, then the degrees
for this drug are calculated from cases where the drug is used alone (first part of the formula
(C.1.1)). If p∗ = 100 then for all drugs the vector degrees are calculated by the second part of the
formula (C.1.1).
4.7.1 The Novelty Coefficient
As it has been mentioned in Section 2.1, one of the main difficulties that arises in the study of
drug-reaction relationships is the low level of repeating cases (events) in spite of the large number
of records. This can be observed from the brief analysis made in Section 4.4 where the majority
of reactions and drugs have occurred just 1–9 times. In Section 4.4 five meta-reactions were
introduced, instead of 131 reactions, in order to have a sufficient number of repeating cases. But
in the data set Card2 this problem still exists for the drugs.
Remark 4.7.1. One way to avoid this problem is to combine some similar drugs as a one meta-
drug (as it is done for reactions). This is why a classification such as ATC (Section 3.6) is so
useful.
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Therefore in Card2 the events (that is some drug(s) causing some meta-reaction) that are not
repeated. If this event is taken as a test example, then it can not be predicted by another part of
the data set (training set). This can be explained in the following example:
Assume that a new (test) ADR report x has used a drug d (alone) and this drug caused the
first meta-reaction. Assume also that a vector degree ∂(d) and therefore D(x), calculated by using
cases observed before (training set), is:
D(x) = (0, 0.50, 0.45, 0, 0).
This means that in all cases when the drug d was used before (alone or in combination with other
drugs) just the second and third meta-reactions have occurred and the first meta-reaction has
never occurred. Therefore, the event that the drug d caused, the first meta-reaction (for the new
example x) should be considered as a new event that can not be predicted.
A notion is therefore required that characterizes the number of non repeating cases in the data
set. Assume that there are N test examples and N− of them are the new events that can not be
predicted by the training set. Then the notion of the Novelty Coefficient (NC) is defined as:
NC =
N−
N
.
To calculate NC the algorithm QCA was applied, set p∗ = 100 in order to take all reactions that
occurred with a particular drug into account. In this case, if some reaction (say i) has occurred
for the ADR reports, which have this reaction with a particular drug (say d), then ∂i(d) > 0.
Therefore, every misclassified example (say a) by definition (4.6.3) can be considered as a new
event, because in this case Di(a) = 0. The number p−ts is the percentage of misclassified examples
in the test set. Thus NC can be defined by p−ts.
Note that the case Di(a) = 0 may have occurred as a result of one of the following two reasons:
A. Drug(s) that were recorded in the ADR report a have been used before (in the training set)
but never caused the kind of reaction that has been observed in any ADR report.
B. Drug(s) that were recorded in the ADR report a have never been used before; that is this
is the case when there are new drug(s).
NC for overall data
To calculate NC for Card2 k-fold cross validation was used. The results of numerical experiments
are presented in Table 4.6. It can be seen that the number p−ts is stable for different k-cross
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validation being 9–10 percent of test examples. Therefore it can be said that the Novelty Coefficient
for the data set Card2 is approximately 0.09.
NC by year
It is interesting to take test examples from some year and to calculate NC by using information
from previous years (training set). Calculations taking records from years 1992–2001 as a test set
were made, for example, if year 1995 was taken as a test set, then records from years 1972–1994
form the training set.
The results of numerical experiments are presented in Table 4.7. It can be seen that the number
p−ts is not stable and much higher than in Table 4.6. This might be expected because of reason B.
From Table 4.7 it can be seen that the Novelty Coefficient, calculated by years, for the data set
Card2 changes in the interval [0.13, 0.21]. This means that for some year(s) 20 percent of records
can be considered as new events which have never been observed before.
Remark 4.7.2. The results obtained here involves the Cardiovascular group, which contains all
records from ADRAC data having just these kinds of reactions. There could be examples that have,
together with these reactions, some other kind of reactions (not in the Cardiovascular group). These
examples were not included in the calculations. But even in the absence of these records the results
give a lot of information related to the Cardiovascular group of reactions.
4.7.2 Prediction of reactions by a given combination of drugs
In order to investigate this fuzzy set representation of drug-reaction relationships, the was trained
on a set of Card2 data and presented another set of Card2 data as a test set to examine its
predictive accuracy.
Applying the algorithm QCA taking p∗ = 40, using 10-fold cross-validation, making the calcu-
lations for different numbers n, gave the results presented in Table 4.8.
If n = 1, then the example is correctly classified if the degree corresponding to the reaction,
observed with this example, is a maximal (that is Dmax) in the degree vector D(a), called the
maximal degree rule. Approximately 60 percent of the training examples were correctly classified
by the maximal degree rule. Almost half of the test examples (42 percent) were correctly classified
by the maximal degree rule, which can be considered as a high percentage.
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The accuracy for the test set presented in Table 4.8 show that it is possible to make predictions
of reactions (in fact meta-reactions) by a combination of drugs. In other words the vector of
degrees of association defined for each drug can be considered as a sound method to describe the
drug-reaction relationships.
4.7.3 Potential reactions: the calculation of degrees for each drug using
all data Card2
Applying the algorithm QCA to the whole of data set Card2 for calculating vector degrees for
each drug, taking p∗ = 40, which means that if a drug was used alone at least 40 percent of all
cases that this drug is used, then a vector degrees is calculated by the cases that the drug was
used alone. For the 525 drugs the vector of degrees were calculated in this way. For the other part
of the definition of vector degrees, the cases when these drugs are used in combination with some
other drugs are also involved, the accuracy of the quasi classification, related to the these vector
degrees, for different numbers n is presented in Table 4.9.
These vector degrees will be used in Section 4.9.1 for prediction of bad and good outcomes.
The Fuzzy Derivative Method for classification was applied. In Section 4.8 a description of this
machine learning algorithm is given.
4.7.4 Interaction of Drugs
As can be observed from Table 4.9, the accuracy does not become 100 percent if the number n
was increased, for the three ADR reports in Card2 Interaction as a particular case (described in
Section 4.6.3) was observed.
1. The drug Enoxacin, anti-bacterial, d2306 ⇒ (0, 0, 0, 0, 1), that is, showed a fifth reaction
when taken alone once, and Nordiol (Lavonogesterol and oestrodiol), birth control, d4688 ⇒ (0, 0,
0, 2, 0), that is, showed the fourth reaction when taken alone in two records. A ADR report in
1995 recorded both these drugs and d2306+4688 ⇒ (0, 0, 1, 0, 0), exhibited the third reaction only,
but not the third or the fifth.
2. The drug Griseofulvin, anti-fungal, d2974 ⇒ (0, 1, 0, 0, 0), that is, showed a second reaction
when taken alone once, and Imferon d3275 ⇒ (1, 0, 0, 1, 0), that is, showed the first and fourth
reaction when taken alone once. A ADR report in 1975 recorded both these drugs and d2974+3275 ⇒
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(0, 0, 1, 0, 0), exhibited the third reaction only, but not the first, second or the fourth.
3. The drug Nefazodone hydrochloride, anti-depressant, d4526 ⇒ (2, 0, 0, 1, 0), that is, showed
the first and fourth reaction when taken alone in three records, and Tamoxifen citrate, birth
control, d6531 ⇒ (0, 0, 2, 8, 0), that is, showed the third and fourth reaction when taken alone in
ten records. A ADR report in 2000 recorded both these drugs and d4526+6531 ⇒ (0, 0, 0, 0, 1),
exhibited the fifth reaction only, but not the first, second, third or the fourth.
Note that the number of such cases could be large if the number p∗ is made smaller than 40. In
spite of this, if p∗ ≥ 50 such cases were not encountered. Therefore, to study interaction problems,
it is important not to use a large number p∗. On the other hand the number p∗ cannot be too small
either, because in this case, the number of occurrence of the drug alone may not contain enough
information about this drug.
Despite the fact that these three cases are based on few records, these results suggests that the
employment of vector degrees could be a useful way to discover drug-drug interactions as well as
the possibility of interactions between drugs and other factors.
4.8 The Algorithm FDM
The machine learning algorithm FDM was developed in [319, 320, 321, 327]. This method is based
on the notion of a fuzzy derivative introduced in [318]. This definition is quite different from the
notions used in the literature, where fuzzy derivatives are defined by using an ordinary derivative of
some functions. In [318] the notion of fuzzy derivative is used as a mathematical tool for describing
a relationship between two parameters. The main idea is to describe the influence of the change of
one parameter on another. In this work a version FDM2 developed in [327] was used. Taking the
character of the data into account, some changes in this algorithm were made, in particular, the
number of classes is taken as two, in this case – bad and good outcomes. This is described in detail
in [322], also see Appendices C.1.2: fuzzy derivative, C.1.3: the FDM classification algorithm.
4.9 Prediction of bad and good outcomes
In this section our aim is to predict the bad and good outcomes on the basis of Card2. Note that in
this data outcome information is presented by the feature REACTION-OUTCOME, which takes
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8 different values (see Appendix B.1.4). Two outcomes were formed as follows. The values 1 (A –
recovered without sequel), 2 (B – recovered with sequel), 5 (E – recovered without treatment) were
taken as a good outcome and the values 3 (C – death maybe drug), 4 (D – death as a reaction), 6
(F – not yet recovered) were taken as a bad outcome. The records with outcomes 7 (N – unrelated
death) and 8 (U – unknown) were not included.
Consider two classes: The first class consists of all records with good outcomes and second
class with bad outcomes. For analysis we will included the following features for every record: age,
weight, sex, the vector of reactions (5 dimensional) and outcome (1 – good, 2 – bad). The vector
of reaction was used in three versions:
P. Predicted Potential Reactions. In this case we write the vector of degrees of association
obtained in Section 4.7.3.
R. Real Reactions. In this case this vector consists of the numbers 0 and 1, having just one
feature with 1, which indicates the reaction that occurred with this ADR report. For example, if
a ADR report has a second reaction class the vector of reactions is (0, 1, 0, 0, 0).
C. Combined vector degrees. Predicted Potential Reactions and Real reactions were com-
bined as follows. We denote by Dh = (Dhi ) and D
r = (Dri ) the predicted potential and real
observed reactions, respectively. Combined vector degrees are defined as Dc = (Dci ), where
Dci =
{
Dhi if D
r
i = 0;
max{Dmax, Dri } if Dri = 1.
Note that Dmax = max{Dh1 , Dh2 , ..., Dh5}. For example, if Dh = (1.2, 0.0, 0.1, 0.7, 0.0) and
Dr = (0, 0, 1, 0, 0) then Dc = (1.2, 0.0, 1.2, 0.7, 0.0).
In this case for every ADR report the reaction that occurred has the maximal number in the
of vector of association degrees.
The datasets related to the versions P, R, C will be denoted by Card2.1, Card2.2 and Card2.3,
respectively. The classes in these datasets had some common points. That is, there are different
records in both classes in which all 8 features coincided. For classification we need to remove
these points. Obviously, the data Card2.2 has more such points. The the following was done:
from the first class in Card2.1 and Card2.2 we removed all records that have the same features as
other records in the second class (so these records are presented just in the second class as a bad
outcome). As a result the number of records in the first class is 2859, and in the second class is
1159.
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Therefore, the datasets Card2.1, Card2.2 and Card2.3 consist of the same records. The differ-
ence between them is that as a vector of reactions in Card2.1 the predicted vector degrees is used,
in Card2.2 we use the real vector of reactions and in Card2.3 the combined vector degrees were
used.
In the calculations below we use both statistical significance and error rate. Note that we are
interested in error rates rather than in statistical significance. The results for statistical significance
are presented to have some information about the number of correctly classified observations.
When we study error rate it is meaningful to use a cost matrix in the definition of error rates.
We proceed as follows: the error in the prediction of bad outcomes (that is, bad outcome is
predicted as a good outcome) is multiplied by 3. In the calculation of the error rate we use the
formula:
2859
4018
n1 − n1+
n1
+ 3 · 1159
4018
n2 − n2+
n2
.
Here ni and ni+ is the number of test examples and the number of correctly classified test examples,
respectively, in the class i (i = 1, 2).
The number 28594018 and
1159
4018 is the prior probability for the first and second class, respectively.
The number 3 is chosen taking into account the number of records in the classes and a possible
accuracy that can be achieved in these datasets.
Therefore, a default for these datasets is obtained when all records predict the second class. It
is 0.712. Note that a default for the statistical significance is 71.2.
We use the following notations:
– pts is the accuracy for the test set;
– p1ts is the accuracy for the test set for the first class;
– p2ts is the accuracy for the test set for the second class;
– etr is the error rate for the training set;
– ets is the error rate for the test set.
In the calculations the parameter α was taken as different numbers, with step 5. The parameter
β was taken as different numbers 1, 2, 3, 4, 5. For example, if α = 80− 100 β = 1− 3 this means
that we take α = 80, 85, 90, 95, 100, β = 1, 2, 3, and, therefore, 5 x 3 = 15 different sets of
classification rules are generated.
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4.9.1 Prediction of outcomes on the basis of reaction vectors
In this section the calculation was made taking just the reaction vector; that is, the features age,
weight, sex were not used. The results obtained are presented in Table 4.10. 10-fold cross validation
was used. Note that there are 5 reactions in each class. To make the training and test sets more
informative every test set is collected from the 10 percent from each reaction.
Note that accuracy in all cases is less than the default because of the changes made in the
algorithm FDM, in order to have better results for error rates. The error rates are less than
default, which means that it is possible to make a prediction of bad and good outcomes.
4.9.2 A benefit of the Potential Reactions Representation
An interesting observation that can be made from Table 4.10 is that in the prediction of good and
bad outcomes predicted vector of degrees of association – Potential reactions work better than real
observed reactions. This case is called An Effect of Potential Reactions (EPR). Now to explain
this effect.
Consider some ADR report x and assume that Dh, Dr, Dc are the vector reactions, correspond-
ing to the cases P, R, C, defined above.
1. First assume that this ADR report is correctly classified by the algorithm QCA by the
maximal degree rule; that is, the maximal number Dmax, in the vector of predicted potential
reactions Dh, is achieved for the reaction that occurred for this ADR report. Note that 58 percent
(59 for the first class and 56 for the second class) of observations in the data Card2.1 satisfy this
condition. Consider two cases.
1a. Assume that the number Dmax is much higher than the other degrees. For example let
Dh = (0.90, 0.00, 0.10, 0.00, 0.00); (4.9.1)
Dr = (1.00, 0.00, 0.00, 0.00, 0.00); (4.9.2)
Clearly in this case
Dc = (1.00, 0.00, 0.10, 0.00, 0.00). (4.9.3)
It is meaningful to expect that the result of the classification for this ADR report will be the
same for all data sets Card2.1, Card2.2 and Card2.3; because the vector prediction (4.9.1) is
very close to the vector of real reactions (4.9.2).
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1b. Assume that there are other reactions that have degrees close to the number Dmax. For
example assume that
Dh = (0.90, 0.80, 0.10, 0.00, 0.00); (4.9.4)
Dr = (1.00, 0.00, 0.00, 0.00, 0.00); (4.9.5)
Dc = (1.00, 0.80, 0.10, 0.00, 0.00). (4.9.6)
Compare these expressions. Note that the vector (4.9.4) contains information about drugs recorded
in this ADR report. This means that the first reaction will occur with the highest probability (in
fact this reaction does occur), but the probability of the second reaction is also high. In this case
it is meaningful to expect that the existence of the potential second reaction will effect on the
patient and, therefore, in the prediction of good and bad outcomes the information in the form
(4.9.4) (and (4.9.6)) will work better than (4.9.5).
Thus, summing the cases 1a and 1b it can be said that accuracy of the prediction of good and
bad outcomes for the patients, corresponding to the case 1, will be higher for the Card2.1 and
Card2.3 rather than Card2.2. In other words one can expect that for the ADR reports, which are
correctly classified by the algorithm QCA as a maximal degree rule, it is better to predict outcome
on the basis of the predicted potential reactions rather than reactions that actually occurred.
2. Now consider the case when the degree of the actual reaction is not maximal in the vector
degree Dh. 42 percent of observations in the data Card2.1 satisfy this condition. Moreover, 0.04
percent of records have degree equal to zero for the reaction that occurred (see Section 4.7.4). Let
Dh = (1.10, 0.20, 0.05, 0.00, 0.00); (4.9.7)
Dr = (0.00, 0.00, 1.00, 0.00, 0.00); (4.9.8)
Dc = (1.10, 0.20, 1.10, 0.00, 0.00). (4.9.9)
Compare these expressions.
The expression (4.9.7) works as follows. If the first reaction occurred. So information was lost,
which say that in fact the third reaction has occurred. One advantage of the expression (4.9.7) over
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(4.9.8) is that the former expression contains information about the existence of the first potential
reaction.
The expression (4.9.8) means that the third reaction has occurred. This expression contains
very important information about patient resistance to reactions. This is an advantage of the
expression (4.9.8) against (4.9.7). But in this case information that there exists the third potential
reaction was lost.
Therefore, both of the expressions (4.9.7) and (4.9.8) have an advantage and disadvantage. It
is difficult to say which expression will work better in the prediction of good and bad outcomes.
It is very likely the expression (4.9.9) will work better than both (4.9.7) and (4.9.8).
The conclusion from the cases 1 and 2. is that the combined vector of degrees will work better
than the other two. The results presented in Table 4.10 (see also Table 4.11 below) confirm this
fact. In all cases the accuracy for the test set and the error rates are better for Card2.3.
The results for Card2.1 and Card2.2 very close. In fact the results for Card2.1 would be
better than for Card2.2 if more ADR reports were correctly classified by the maximal degree rule
(case 1). The more there are such ADR reports the more of a difference between Card2.1 and
Card2.2 can be achieved.
4.9.3 Prediction of outcomes by age, weight, sex and reactions
In this section calculations were made using 8 features: age, weight, sex and vector reactions, using
10-fold cross validation. The test sets are chosen as in Section 4.9.1. Moreover, in the algorithm
FDM the couple of features (j1, j2) was chosen such that first feature related with information
about patient (age, weight, sex) and second feature related with reactions. In this way, when the
FDM algorithm was applied, the influence of each reaction on the characteristic parameters (age,
weight, sex) of the patient was considered. The results obtained are presented in Table 4.11.
These results show that in all cases both statistical significance and error rate are better for
Card2.3. This can be explained by the Effect of Potential Reactions. Although, the accuracy,
obtained in all cases, is less than default (69.0) The error rate for Card2.2 was higher than for
Card2.1. But statistical significance is better for Card2.1.
Therefore predicted reactions can also be used for outcome prediction. Results which can be
obtained in this way will be very close to the results that are obtained if exactly what kind of
reaction has occurred was known.
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The results of classification are not high, but error rates were less than default. At this stage
the aim was to see the drug-reaction relationships that could be obtained and the fact, that in all
cases the error rates are less than default, emphasizing that these relationships work.
Comparison of the results presented in Tables 4.10 and 4.11 allow the observation of one inter-
esting fact. Including information about patients (age, weight, sex) hardly affects the accuracy of
the outcomes. This means that these features do not contain sufficient information about patients
for good prediction.
4.10 Discussion
The representation of drug-reaction relationships as fuzzy sets allows much manipulation of com-
plex data in various ways. Other factors can be used to qualify the relationship, as shown in
the previous section (4.9.3). However, some features are expected to be of little value. There is
much investigation required to optimize the performance and establish the clinical relevance of the
algorithms’ results. Some observations on results presented in this chapter:
In Section 4.9.2 the results of the classification of outcomes could have been better if the
vector degrees for each drug is defined such that more ADR reports are correctly classified by the
maximal degree rule. Therefore the problem how to best define vector degrees must be studied. In
particular, it will be useful to apply some optimization techniques for solving this problem. This
is done in Chapter 7.
Another problem related with the vector of degrees, defined for each drug, is the definition of
vector degrees for a ADR report. That is, for example, if a ADR report records two drugs and for
each drug a vector of degrees is calculated, the question arises of how to define the combination
of these drugs. The formula 4.6.1, which is directly related to the calculation of vector of degrees
by the formula C.1.1 is the approach used here. This is an interesting problem which needs future
investigation.
Interaction of drugs
This problem is briefly discussed in Sections 4.6.3 and 4.7.4. This is very interesting problem
for future investigations. The fuzzy set representation means that their vectors can be combined
in different ways to represent different types of interaction – see Sections 1.6.2 and 1.6.3. It
was also demonstrated that by comparing the vectors of drugs when taken separately to the
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vectors of the same drugs taken in combination provides a means of readily detecting drug-drug
interactions. Three cases of possible interactions are given in support of the claim that the fuzzy set
representation of drug-reaction relationships offers much potential for investigation of interactions.
Interactions involving factors other than drugs can also be implemented in a similar way. It may
require a much larger data set to have sufficient cases for testing this approach.
Information about patients and other relevant factors
The problem of how to define reaction that could occur with a particular patient if the drugs are
taken were known can be represented using the vector of degrees to implement a fuzzy relationship
and the information about patients. It has been found that vector of degrees can be calculated
without any information about patients. Some useful information is contained in the drug and
reaction fields of the ADRAC data but necessarily lacks certain patient information for confiden-
tiality purposes. Nevertheless, it is possible to identify records that relate to the same patient,
with the assistance of the TGA. This type of information is relevant for a more detailed analy-
sis. Other important information is contained in fields such as: “reason for use”, “other factors”,
“drug previously used indicator”, “medication indication” to indicate if the drug was used to treat
an ADR. All these fields contain important information for more detailed analysis. However, as
detailed in Appendix B.1, so many values are absent in certain fields that little extra information
is to be gleaned from them. This is due to the voluntary nature of the reporting system.
Another important kind of information ignored by this present analysis relates to dosage. There
are fields that quantify the amount of drug administered. The amount of drug given (dose), the
frequency, duration, route, and the form of the drug are also important – see Appendix B.1.3.
The difficulty with using the fields in the ADRAC database is that, for example, dosage is given
in many different units and often not precisely quantified. This is useful information that should
be utilized in future investigations of this data. It should also be noted that, along with the ATC
codes, defined daily dose (DDD) are also supplied by the Upsala Monitoring Center (UMC) for
each ATC code [560], which can also be utilized.
Other fields that relate to ADRs, such as, “severity codes”, “hospitalization code”, “first dose
indication” – reaction after first dose, would be useful to rank reactions in some order of severity.
The “reaction suspect code” could be useful to help identify which drugs are likely to cause reactions
and help to remove “innocent bystander” drugs from the analysis, see Chapters 6, 7, 10, 11.
However, removal of drugs from the analysis must be done in such a way as not to eliminate any
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false negative drug-reaction associations.
4.11 Conclusion
The approach described in this section using fuzzy sets to characterize the relationship of drugs
and reactions in ADRAC data offers advantages over the disproportionality methods described
in Section 2.1.1. It is not restricted to a 2 × 2 comparison of drug and reaction pair to the
generality of all drugs and reactions in the database as a control. The fuzzy set implementation is
multi-dimensional. This means that vectors can be compared for expected versus observed. This
makes our method much more robust and flexible as to its mode of implementation. The concept
of potential reactions gives a measure of the expected of the drug-reaction vector. This can be
compared with the reaction profile observed for an individual record and large deviations from the
expected profile could indicate ADRs or interactions. The method investigated appears to be able
to detect drug-drug interactions. This is an aspect of drug surveillance that can benefit from more
precise methods for quantification. This method is robust and can incorporate other information
than drug and reaction information. However, as a method for generating signal, it may need to
be modified to be able to represent reactions at a finer level.
The application of the meta-SOC classification employed in this chapter was found to be unac-
ceptable for ADRAC so an alternative application of SOC was adopted for all subsequent investi-
gation. In this chapter the method adopted to minimize the combinational difficulty presented by
so many drug terms was addressed by formula C.1.1. A limitation is that this method only looks
at reaction classes and not individual reactions. It needs to be able to use hierarchically structured
data to do this. In future the application of the ATC classification for drugs is expected to prove
more appropriate, but will also require hierarchical methods. This view is to some extent borne
out by the fact that application of ATC code has made the ADRAC data accessible to a method
using association rules (see Section 6.3).
The application of the fuzzy derivative algorithm FDM appears to have value for prediction of
outcomes, but was only described here to support the claim that the notion of potential reaction
has informational value. However, no further use of FDM was made in this thesis.
The algorithm denoted QCA in this chapter, in future developments will be be referred to as
‘drug-reaction relationship’ algorithms or Algorithm A(p). Developments of this algorithm and
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further results and comparisons to a text categorization algorithm follow in Chapters 6, 5, 7. For
the purposes of brevity I will refer to these algorithms generically as ‘covariability’ algorithms.
This chapter has addressed research question 1. The method QCA uses a fuzzy set representa-
tion that is not based on disproporionality. At this stage its signal generating capability was not
tested, but there is some concern that the reaction classes were not fine-grained enough. Another
aspect of the fuzzy set representation is that it looks to be a useful way to represent interactions,
thus addressing research question 5. Three cases of possible interaction were presented.
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Table 4.5: Card2: Results obtained by QCA for 10-cross validation
p∗ n p+tr p
−
tr p
+
ts p
−
ts
0 1 61.3 1.12 42.5 17.01
10 1 60.8 0.40 42.2 14.48
20 1 60.1 0.11 42.2 12.60
30 1 60.2 0.05 42.2 11.48
40 1 60.0 0.04 42.2 10.78
50 1 60.0 0.00 42.1 10.28
60 1 59.8 0.00 41.9 10.04
70 1 59.7 0.00 41.9 9.87
80 1 59.5 0.00 41.6 9.78
90 1 59.4 0.00 41.6 9.75
100 1 59.4 0.00 41.6 9.75
0 2 81.1 1.12 60.6 17.01
10 2 82.9 0.40 62.7 14.48
20 2 83.7 0.11 63.9 12.60
30 2 83.6 0.05 63.9 11.48
40 2 83.9 0.04 64.3 10.78
50 2 84.1 0.00 64.5 10.28
60 2 84.1 0.00 64.5 10.04
70 2 84.7 0.00 64.5 9.87
80 2 84.0 0.00 64.5 9.78
90 2 84.0 0.00 64.5 9.75
100 2 84.0 0.00 64.5 9.75
0 6 94.6 1.12 75.8 17.01
10 6 96.1 0.40 79.1 14.48
20 6 97.1 0.11 81.2 12.60
30 6 97.3 0.05 82.0 11.48
40 6 97.5 0.04 82.5 10.78
50 6 97.7 0.00 82.9 10.28
60 6 97.8 0.00 83.0 10.04
70 6 97.8 0.00 83.1 9.87
80 6 98.0 0.00 83.4 9.78
90 6 98.0 0.00 83.5 9.75
100 6 98.0 0.00 83.4 9.75
Table 4.6: Card2. Accuracy of the misclassified examples obtained by QCA for different cross-
validation k (in all cases p−tr = 0)
k 3 4 5 10 20 30 40 50
p−ts 11.95 10.97 10.43 9.75 9.47 9.32 9.21 9.20
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Table 4.7: Card2. Accuracy of the misclassified examples obtained by QCA for different years (in
all cases p−tr = 0)
Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Ntrain 2530 2778 3048 3343 3604 3888 4255 4917 5674 6372
Ntest 248 270 295 261 284 367 662 757 698 331
p−ts 21.0 21.8 12.9 20.7 13.0 14.2 18.6 13.7 18.1 21.4
Table 4.8: Card2. Results obtained by QCA for 10-fold cross-validation taking different numbers
n and p∗ = 40 (in all cases p−tr = 0.04, p
−
ts = 10.78)
n 1 2 3 4 5 10 20 30 45
p+tr 60.0 84.0 90.9 94.0 96.2 99.0 99.8 99.9 100
p+ts 42.2 64.3 72.5 76.8 79.8 86.2 88.4 88.9 89.1
Table 4.9: Card2. Accuracy overall data obtained by QCA for different numbers n (p∗ = 40, in
all cases p−tr = 0.04)
n 1 2 3 4 5 10 40
Accuracy 59.2 83.4 90.6 93.9 95.8 99.0 99.96
Table 4.10: Prediction of outcomes on the basis of vector reactions (β = 1–5, †in all cases)
data α p1ts p
2
ts pts etr ets
Card2.2 † 50.4 69.3 55.8 0.623 0.619
Card2.1 80 48.3 70.7 54.7 0.397 0.622
Card2.3 80 58.3 63.6 59.9 0.464 0.612
Card2.1 90 50.3 69.0 55.7 0.397 0.622
Card2.3 90 59.6 63.9 60.8 0.456 0.600
Card2.1 100 50.6 68.3 55.7 0.399 0.625
Card2.3 100 59.5 62.8 60.5 0.455 0.610
Card2.1 75–95 51.2 68.8 56.3 0.376 0.617
Card2.3 75–95 61.2 61.8 61.3 0.453 0.608
Card2.1 80–100 50.9 68.3 55.9 0.377 0.624
Card2.3 80–100 60.5 62.7 61.1 0.451 0.604
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Table 4.11: Prediction of outcomes on the basis of age, weight, sex and vector reactions (β = 1–5)
data α p1ts p
2
ts pts etr ets
Card2.1 60-80 59.6 61.0 60.0 0.319 0.625
Card2.2 60-80 52.3 70.6 57.5 0.558 0.594
Card2.3 60-80 65.6 59.7 63.9 0.367 0.593
Card2.1 65-85 57.4 63.5 59.1 0.294 0.619
Card2.2 65-85 51.7 70.9 57.2 0.552 0.596
Card2.3 65-85 63.6 61.3 62.9 0.341 0.594
Card2.1 70-90 55.8 63.7 58.0 0.281 0.629
Card2.2 70-90 50.6 70.4 56.3 0.550 0.607
Card2.3 70-90 62.6 61.8 62.4 0.329 0.597
Card2.1 75-95 55.2 64.0 57.8 0.277 0.630
Card2.2 75-95 50.1 70.8 56.1 0.552 0.608
Card2.3 75-95 61.7 62.1 61.8 0.329 0.601
Card2.1 80-100 54.7 64.4 57.5 0.289 0.630
Card2.2 80-100 51.6 69.6 56.8 0.552 0.608
Card2.3 80-100 61.1 62.2 61.4 0.336 0.604
Chapter 5
Comparison of QCA and
BoosTexter Algorithms
5.1 Introduction
In the course of our investigations, we have sought to find other methods with which our methods
can be compared. This is in large part due to the lack of a gold standard for signal detection
alluded to in Section 2.1.1. Methods using text representation and structured text retrieval have
been used for ADR report records of treatments to use this health data to reason about or provide
advise on current or similar cases have been in use since the early 1990s – see [589]. Because the
problem of categorizing (classifying) a set of drugs with respect to reactions associated with them
in drug safety reports resembles the problem of classifying a set of documents with respect to a
set of labels (categories), it was decided to find some text categorization method that could use
drug safety data. The software BoosTexter [459] ( see – Section 1.9.2) proved suitable to run using
ADRAC data [324] and [326]. We thus cast the problem as a text categorization problem, where
each ADR report is considered as one document, and the set of drug(s) taken by this ADR report
is considered as a text related to this document; that is, each drug is considered as a word. It
can be seen from Section 1.9 that text categorization is currently a major area of investigation.
Because of there is a striking resemblance between a drug-reaction classification problem and text
categorization, it was decided to find suitable text categorization algorithms to compare with QCA.
It was found that BoosTexter, being a multi-class, multi-label classifier that could use ADRAC
data as input and produced a similar output. This made it a good candidate. Later developments
of the QCA algorithm, which are described in this chapter, were compared with BoosTexter using
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data described in Chapter 4 and the results are reported in this chapter. More results using the
SOC classification described in Section 3.4 are reported in Chapter 6.
5.1.1 BoosTexter
This has also been studied in Section 6.3.1.
The first data sets that were investigated were Card1 (see Section 4.4) and Card2 (see Section
4.5). The results of this part of the investigation was reported in [323]. The number of records,
which have just one drug taken, is 3801 (56.7 percent of all records); the average number of drugs
per ADR report is 2.16.
5.2 Statement of the problem
The main goal of ADR as follows:
Given a ADR report and drug(s) to predict what kind of reaction(s) can occur. Ideally, to
achieve this goal, the collection of all“necessary” information about the ADR report would be
gathered.
In this investigation a different approach was adopted, because this is not available in the
data used for this study. In general, to achieve this goal,two types of information are required:
Individual ADR report information and information about drug(s). In this work it is assumed that
the main goal can be achieved by solving the following problems separately:
P1. For each drug to define the all possible reactions (with corresponding weights) that can
occur; that is, to study “drug-reaction” relations not involving any other ADR report information.
P2. To predict the possible reaction(s) for a particular ADR report using information about
both the patient and the drug(s) (that is, drug-reaction relations).
In this investigation the problem P1 was considered. By nature, this problem can be considered
as a text categorization problem, where each ADR report is considered as one document, and the
set of drug(s) taken by this ADR report is considered as a text related to this document; that is,
each drug is considered as a word, which can be formulated as the problem P1.
Let X denote the set of all ADR reports and D denote the set of all drugs used by these ADR
reports. Let c be a finite number of possible reactions (classes). Given ADR report x ∈ X denoted
by D(x) the set of drugs taken by this patient. In ADRAC data the number of drugs reported for a
126
patient is restricted to 10. Denote by Y(x) = (Y1,Y2, . . . ,Yc) an c-dimensional vector of reactions
observed for the ADR report x; where Yi = 1 if the reaction i has occurred, and Yi = 0 if it has
not.
The goal of the study of drug-reaction relationships is to find a classifier h : D → Rc+, where
given drug d ∈ D the components hi of the vector h(d) = (h1, h2, . . . , hc) associate the “probabili-
ties” of the occurrence of the reactions i = 1, 2, . . . , c.
Here Rc+ is the set of all c-dimensional vectors with non-negative coordinates.
In the next step, given a set of drugs ∆ ⊂ D, a vector H = (H1,H2, . . . , Hc) needs to be defined,
where the component Hi indicates the probability of occurrence of the reaction i after taking the
drugs ∆. In other words, a function H : S(D)→ Rc+ needs to be defined, where S(D) is the set of
all subsets of D. Given ADR report x ∈ X and a set of drugs D(x), the notation H(x) = H(D(x))
will be used.
Therefore, a classifier will be denoted as the couple (h,H). To evaluate the performance of
different classifiers the closest of the two vectors H(x) and Y(x) needs to be measured; that is,
to define a distance dist(H(x),Y(x)). The better classifier should provide the minimal sum of all
distances. Therefore, a classifier (h,H) which minimizes the total sum is needed:
∑
x∈X
dist(H(x),Y(x)) → min . (5.2.1)
In this statement, the problem P1 is very similar to text categorization problems, but there are
some interesting points that should be mentioned in relation to P1. One of the main characteristics
of ADRs is that the number of drugs (that is words in the context of text categorization) for each
ADR report is restricted to 10, and for majority of ADR reports just one drug was used. This
complicates leaning and classification, but on the other hand, this allows the introduction of simple
and fast algorithms.
Some other characteristics which are of interest in terms of ADRs will be discussed below.
5.2.1 Potential Reactions
The vectors h(d) show what kind of reactions are caused by the drugs d ∈ D(x). Therefore the
vector H(x) can be considered as potential reactions which could occur with ADR report x. Some
reactions which have potentially high degrees may not be observed because of the strong resistance
of the patient to developing these reactions (see Section 4.6.2). The results obtained in Sections
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4.7.3, 4.9.2, 4.9.3 show that the information about influence of potential reactions (but which were
not reported to ADRAC) helps to make prediction of reaction outcomes (bad and good) more
precisely.
In this investigation two different methods for the definition of function H will be considered.
1. The linear function: Hsum = (H1, . . . , Hc).
For each subset ∆ ⊂ D define the components Hi as follows:
Hi =
∑
d∈∆
hi(d), i = 1, . . . , c.
In this case, for each ADR report x ∈ X there is Hsum(x) = (H1(x), . . . , Hc(x)), where
Hi(x) =
∑
d∈D(x)
hi(d), i = 1, . . . , c. (5.2.2)
The use of the function Hsum means that, the effects from different drugs were accumulated.
For example, if hi(dn) = 0.2 (n=1,2) for some reaction i, then in the patient’s body there exists a
potential of 0.4 for this reaction; that is, the two small effects (that is 0.2) becomes a greater effect
(that is 0.4).
2. The maximum function: Hmax = (H1, . . . , Hc).
For each subset ∆ ⊂ D define the components Hi as follows:
Hi = max
d∈∆
hi(d), i = 1, . . . , c.
In this case, each ADR report x ∈ X has Hmax(x) = (H1(x), . . . , Hc(x)), where
Hi(x) = max
d∈D(x)
hi(d), i = 1, . . . , c. (5.2.3)
In this case there is a non-linear function H. This means that if the patient’s body is tolerant to
the potential effect of 0.2 of a reaction, then it may also resist any number of such effects caused
by different drugs taken “at the same time”.
The study more sensible definitions of the function H is an interesting problem for future in-
vestigations. This problem is also related to the study of Interaction of Drugs (see Sections 4.6.3,
4.7.4). Ongoing related investigations (in particular, the results obtained in this investigation) will
help in the definition of a more sensible function H, and, therefore, to understand the mechanism
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of effects from different drugs. Drug exposure time is another important factor to take into con-
sideration [82]. The time when the administration of each drug d ∈ D(x) ceases and the decay
function of the drug. In a simple case we can describe this decay by the function exp (td − t),
where t ≥ td and td is the time of cessation of drug d. Then we can use the following formula for
the definition of H :
Hi(x) =
∑
d∈D(x)
f(td − t∗)hi(d), i = 1, . . . , c; (5.2.4)
where t∗ is the time of onset of reaction(s) and f(td− t) = exp (td− t) if t ≥ td, and f(td− t) = 0
if t < td.
5.3 Evaluation measure
In this investigation the following function was considered:
dist(H(x),Y(x)) =
c∑
i=1
[H¯i − Yi]2; (5.3.1)
where H(x) = (H1, . . . ,Hc), Y(x) = (Y1, . . . ,Yc) and the sign “bar” indicates a normalization:
H¯i = Hi∑
j=1,...,cHj
.
An alternative approach could be the Euclidian distance
dist(H(x),Y(x)) =
(
c∑
i=1
[H¯i − Yi]2
)1/2
. (5.3.2)
In the next example it is shown that the first formula, that will be used in this investigation,
provides more a reasonable evaluation.
Example 5.3.1. Assume that there are just 10 ADR reports xn, n = 1, . . . , 10, and just one
drug - d was used in all these cases. This in particular, means that Hsum(x) = Hmax(x) = h(d),
and the problem (5.2.1) has the same solution for the functions (5.2.2) and (5.2.3). Also assume
that there are 5 reaction classes and an occurrence of 6 times for the first reaction, 4 times for the
second reaction have been observed; that is,
Y(xn) = (1, 0, 0, 0, 0), for n = 1, . . . , 6;
Y(xn) = (0, 1, 0, 0, 0), for n = 7, . . . , 10.
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The most reasonable representation of the drug d could be h(d) = (0.6, 0.4, 0, 0, 0) which is an
optimal solution to the problem (5.2.1) with the distance (5.3.1). In the meantime, the optimal
solution to (5.2.1) with the distance (5.3.2) is h(d) = (1, 0, 0, 0, 0), which can not be taken as a
good representation. Moreover, a little change in the data, say 4 times the first reaction, 6 times
the second, completely changes this representation giving h(d) = (0, 1, 0, 0, 0).
In the literature on text categorization different kind of evaluation functions were used. In
particular, one-error, Coverage, Average Precision (see [459, 588]) and some others were mainly
used for multi-label problems. These measures are related to the label (class) prediction. One-error
measure could be used in this case, but it does not make a distinction between representations,
like h(d) = (0.6, 0.4, 0, 0, 0), h(d) = (0.9, 0.1, 0, 0, 0), h(d) = (0.4, 0.15, 0.15, 0.15, 0.15), although
the last two are not good representation for the example above.
Therefore, given a classifier (h,H), the average error (Eav) will be calculated as
Eav(h,H) =
1
|X |
∑
x∈X
c∑
i=1
[
Hi(x)∑
j=1,...,cHj(x)
− Yi(x)]2. (5.3.3)
Here |X | stands for the cardinality of the set X and either H(x) = Hsum(x) or H(x) = Hmax(x).
Now the problem P1 can be formulated as the following optimization problem:
Eav(h,H) → min; (5.3.4)
hi(d) ≥ 0, i = 1, ..., c, d ∈ D. (5.3.5)
5.3.1 A solution to the optimization problem
The function in (5.3.3) is non-convex and non-linear, and therefore can have many local minimum
points. The global optimum point needs to be found. The number of variables is |D| · c. For the
data Card2 was considered |D| = 1750 and c = 5. This gives a global optimization problem with
8750 variables, which is very hard to handle using existing methods. Note that, the number of
variables will be much greater if all ADRAC data was studied.
In this investigation one heuristic method for finding a “good” solution to the problem (5.3.4),(5.3.5)is
introduced. This method is based on the following proposition. According to the data Card2 it is
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assumed that for each ADR report only one reaction is associated. Denote by S the unit simplex
in Rc; that is,
S = {a = (a1, . . . , ac) : ai ≥ 0, a1 + . . . ac = 1}.
In this case for each h(d) ∈ S the components hi(d) indicates simply the probability of the occur-
rence of the reaction i.
Proposition 5.3.1. Assume that the set X consists of observations that have only one reaction
occurring and in all cases only one drug, say d, has been taken. Let n = n1+ · · ·+nc be the number
of observations in X and ni be the number of observations for which i-th reaction occurred. Then
the distribution h(d) = (h1, . . . , hc), where hi = ni/n, is a global minimum point for the problem
(5.3.4),(5.3.5) on the set S.
Proof: As mentioned above, when there is just one drug that has been taken then, Hsum(x) =
Hmax(x) = h(d) ∈ S and, therefore,
∑c
j=1Hj(x) = 1. From (5.3.3) it follows
Eav(h,H) =
c∑
i=1
[ni(hi − 1)2 + (n− ni)h2i ] → min .
Having
∂Eav(h,H)
∂hi
= 2(n− ni)hi = 0,
which implies hi = ni/n, i = 1, . . . , c. It can also be seen that
∂2Eav(h,H)
∂2hi
= 2n > 0, i = 1, ..., c and
∂2Eav(h,H)
∂hi∂hj
= 0, i 6= j.
5.3.2 Calculations of h(d) for each drug
Consider a training set X . Denote by D the set of all drugs used in the training set and by
D(x) the set of drugs has recorded in the ADR report x ∈ X . For each drug d ∈ D the following
numbers were calculated: N(d)- the number of occurrence of the drug in X , Na(d)- the number
of cases when this drug was used alone in X and P (d) = 100 · Na(d)/N(d)- the percentage of
the cases when the drug was used alone. Then define h(d) = (h1(d), . . . hc(d)) as follows:
hi(d) =

∑
{x: d∈D(x), |D(x)|=1}
Yi(x)
N(d) if P (d) ≥ p∗, Na(d) ≥ N∗;∑
{x: d∈D(x)}
Yi(x)
N(d)|D(x)| otherwise
(5.3.6)
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Note that Y(x) = (Y1(x), . . . ,Yc(x)) is the vector of reactions for the ADR report x.
The formula (5.3.6) has the following meaning. If the percentage of the cases where only one
drug was used is sufficiently high (greater than p∗) and the number of these cases is not so small,
then the weights for this drug are defined using the cases where the drug was used alone. This
tallies with Proposition 5.3.1. As a normalization factor, the number N(d) was used, instead of
Na(d), in order to decrease the weights if the percentage P (d) is not so large. Note that the weights
obtained in this way carry very important information, because they are defined by the cases when
a particular reaction and a particular drug are observed in a pure relationship.
If P (d) < p∗ or Na(d) < N∗ then the cases where a single drug was used (for the drug d )
is so small that it is not informative for the definition of weights. Thus cases where the drug was
also used in combination with other drugs need to be involved.
Remark 5.3.1. Note that the degree hi(d) is not a probability of the occurrence of the reaction
i; that is, the sum
∑c
i=1 hi(d) does not need to be equal 1.
5.3.3 Default values
When this is applied to unseen data (test examples) where new drugs or new reactions might be
involved, for each such a new drug d set hi(d) = 0, i = 1, . . . , c.
It is possible for some new example x, all drugs that have been recorded in this ADR report are
new. In the calculations below, for such an example x, set default values as H(x) = (1/c, . . . , 1/c)
which means that all reactions can occur with the same probability.
If for all examples x in the set X to define vectors H(x) as a default; that is, H(x) =
(1/c, . . . , 1/c), then it is not difficult to calculate that the average error is equal to (1− c)/c. For
the data Card2 there are 5 reaction classes and, therefore, the default average error for this data
is 0.800.
5.4 The algorithms
For this analysis two algorithms were used.
Algorithm 1. In this algorithm a classifier (h,H) was used, where h(d) for each drug d ∈ D
is calculated as in Section 5.3.2. The calculations are made using by H(x) = Hsum(x) and by
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H(x) = Hmax(x). The first function provided better results, so some calculation only taking max
function were made. Algorithm 1 needs to set a priori the numbers p∗ and N∗.
BoosTexter. the well known text categorization algorithm BoosTexter (version AdaBoost.MH
with real-valued predictions [459]) was also used. This algorithm produces predictions in the form
H(x) = (H1(x), . . . ,Hc(x)), where the numbers Hi(x) are real values which can be positive or
negative. To apply the measure described above, all these numbers needed to be made non-negative.
Let
Hmin(x) = min
i=1,...,c
Hi(x).
Then set H(x) = H(x), if Hmin(x) ≥ 0; and
H(x) = (H1(x)−Hmin(x), . . . ,Hc(x)−Hmin(x), if Hmin(x) < 0.
5.4.1 New events
The data set Card2 (Section 4.5) was used for this study. The events (that is some drug(s) cause
some reaction(s)) that are not repeated. If these events occur in a test set then they can not be
predicted by the other part of data (training set). This can be explained by the following example:
Assume that a new (test) ADR report x has used a drug d (alone) and this drug caused the
first reaction. Assume also that the vector of weights h(d) and, therefore, H(x), calculated by
using the all cases observed before (training set), is:
H(x) = (0, 0.50, 0.45, 0, 0).
This means that in all cases when the drug d was used before (alone or in combination with
other drugs) just the second and third reaction classes have occurred and the first reaction class
has never occurred. Therefore, the event that the drug d caused the first reaction (for the new
example x ) should be considered as a new event which could not be predicted.
That is why it is important to evaluate the number of repeating cases in the data set. Assume
that there are N test examples and N− of them are new events. Then the notion of the Novelty
Coefficient (NC) is defined as follows:
NC =
N−
N
.
To calculate NC applying Algorithm 1, by seting p∗ = 100 and N∗ = 0 in order to take all
reactions that occurred with a particular drug into account. In this case, if some reaction (say i)
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has occurred in the ADR reports, which have this reaction after having taken a particular drug
(say d), then hi(d) > 0.
Therefore, every example x for which Hi(x) = 0 can be considered as a new event.
Note that the case Hi(x) = 0 may have occurred as a result of the following two reasons:
New Reaction. Drug(s) that were recored in the ADR report x have been used before (in the
training set) but never caused the kind of reaction that has been observed in this ADR report. In
this case, the component of the vector H(x) , corresponding to the reaction, whose occurrence is
considered as a new event, is equal to zero. But, H(x) 6= 0; that is, there is a positive component
for some other reaction.
New Drug. Drug(s) that were recorded in the ADR report x have never been used before;
that is, this is the case when there is/are new drug(s). In this case there is a zero vector H(x) = 0.
In Table 5.1 presents the Novelty Coefficients, expressed as percentage, for the data set Card2,
calculated by years starting from 1996. It can be observed that it changes in the interval [0.13, 0.21].
This means that for some year(s) 20 percent of records can be considered as new events which have
never been observed before.
5.5 The results of numerical experiments
In this investigation the cardiovascular type of reactions in the data set Card2 only were studied,
in this section. Further results for other data sets are reported in the following sections: all 18
SOC classes, Mallreac – Section 6.3, the cardiovascular data set Card20 – Section 6.4. They
are presented there in order for direct comparison of BoosTexter with the results from Algorithm
A(p).
In the calculations below a test set records was taken sequentially from each year, starting from
1996 until 2001. For example, if records from 1999 are taken as a test set, then all records from
years 1972–1998 form a training set. First calculations were made by the algorithm AdaBoost.MH.
This algorithm was run choosing two different numbers of training rounds: n = 1000 and n = 2000.
The results obtained are presented in Table 5.1. In this Table also presents the numbers of records
in training and test sets. As mentioned before the test sets contain some new events defined above.
The number NC stands for the percentage of new events (examples) in the test set.
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Table 5.1: Card2. The results obtained by BoosTexter.
Year Number Records Average Error (1000) Average Error (2000)
Training Test NC Training Test Training Test
1996 3604 284 13.0 0.544 0.768 0.517 0.772
1997 3888 367 14.2 0.550 0.755 0.521 0.753
1998 4255 662 18.6 0.557 0.740 0.529 0.752
1999 4917 757 13.7 0.571 0.653 0.541 0.663
2000 5674 698 18.1 0.572 0.755 0.544 0.759
2001 6372 331 21.5 0.583 0.834 0.552 0.844
1000 and 2000 stand for the number of training rounds set for this algorithm.
Next applying Algorithm 1. Two versions: H = Hsum and H = Hmaxwere used. The calcu-
lations show that the results are not essentially changed for different values of p∗ and N∗ in the
regions p∗ ≥ 30, N∗ ≥ 0 and p∗ ≥ 0, N∗ ≥ 10. Some results are presented in Tables 5.2, 5.3. The
results show that, in the testing phase, the function Hsum provides slightly better results than the
function Hmax. In the training phase, the results obtained by the function Hsum are essentially
better, which is also important.
The comparison of the training errors in Tables 5.1 and 5.2 show that Algorithm 1 performs
much better than BoosTexter. Training errors were decreased by increasing the number of training
rounds, but test errors rise (see the results in Table 5.1 for training rounds 1000 and 2000).
It is interesting to compare the results for test sets in Tables 5.1 and 5.2. If the NC is small
(1996 and 1999) then Algorithm 1 performs better than BoosTexter. For the year 2000, which
has a large percentage of new events, the algorithm of BoosTexter performs better. This is a very
interesting result.
In Algorithm 1, default values were set H(x) = (0.2, 0.2, 0.2, 0.2, 0.2), if H(x) = (0, 0, 0, 0, 0);
that is, a new event was caused by a New Drug (Section 5.4.1). If a new event was due to a New
Reaction, then dist(H(x),Y(x)) ≥ 1, which essentially increases the Average Error.
The algorithm of BoosTexter classifies all such examples due to the fact that the drugs that
are not used still assign weights to the function H(x) and, therefore, all example are classified.
Surprisingly, in this way BoosTexter provides better results than the default values.
The results presented in Tables 5.1 and 5.2 show that the average error for test sets is slightly
less than the default (that is, 0.800) except the 2001 year which has a very high percentage of new
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Table 5.2: Card2. The Average error obtained for the test sets by Algorithm 1 with the function
Hsum for different numbers p∗, N∗.
Year p∗ = 0, N∗ = 10 p∗ = 40, N∗ = 5 p∗ = 40, N∗ = 10 p∗ = 40, N∗ = 20
Train. test Train. test Train. test Train. test
1996 0.499 0.757 0.502 0.753 0.502 0.754 0.502 0.756
1997 0.504 0.758 0.508 0.760 0.507 0.757 0.507 0.757
1998 0.517 0.760 0.515 0.759 0.515 0.758 0.515 0.758
1999 0.522 0.646 0.526 0.646 0.525 0.646 0.525 0.645
2000 0.521 0.781 0.524 0.780 0.529 0.780 0.524 0.780
2001 0.528 0.841 0.531 0.838 0.531 0.836 0.531 0.834
Table 5.3: Card2. The Average error obtained for the test sets by Algorithm 1 with the function
Hmax for different numbers p∗, N∗.
Year p∗ = 0, N∗ = 10 p∗ = 40, N∗ = 5 p∗ = 40, N∗ = 10 p∗ = 40, N∗ = 20
Train. test Train. test Train. test Train. test
1996 0.527 0.757 0.531 0.755 0.531 0.756 0.531 0.759
1997 0.532 0.760 0.535 0.762 0.535 0.759 0.536 0.758
1998 0.538 0.762 0.542 0.760 0.542 0.760 0.542 0.759
1999 0.548 0.649 0.550 0.649 0.550 0.649 0.550 0.647
2000 0.543 0.782 0.546 0.779 0.546 0.779 0.556 0.779
2001 0.549 0.852 0.551 0.850 0.551 0.848 0.551 0.846
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events (21.5). It would be interesting to see what results would be obtained if all the new examples
were removed from the test sets. Table 5.4 presents such results after removing new events.
It can be observed that, in all cases, the average errors in Table 5.4 are much less than those in
Tables 5.1 and 5.2. Also note that Algorithm 1 performs better than BoosTexter in both training
and test phases.
5.6 Conclusion
In this investigation drug-reaction relations have been studied on the Cardiovascular group of re-
actions from ADRAC data of Chapter 4. For each drug a vector of weights was defined, which
indicates the probability of occurrence of reactions. Such a presentation of drug-reaction associa-
tions and the accuracy of established presentations were evaluated applying two algorithms: text
categorization algorithm BoosTexter and a new Algorithm 1 similar to QCA in Chapter 4. These
algorithms were evaluated with the distance measure Average Error, which measures how far the
observed events differ from predicted events. The results show that Algorithm 1 performs better
than BoosTexter, but it is surprising how well BoosTexter performs. Of particular interest is the
fact that in the year in which the percentage of new events was highest, BoosTexter performed best
in the test set. It may well be the case that other text categorization methods can also be applied
usefully to drug safety data analysis. The next chapter continues this study the next generation
of our Algorithm A(p).
This chapter has addressed research question 1. Two methods were examined that are not
based on disproporionality, one developed for the purpose, the other applied as a kind of standard.
The covariability algorithm Algorithm 1, which is an improved version of QCA, and the text
categorization algorithm BoosTexter were both tested on the data set Card2 from the previous
chapter. Both algorithms assign weights to drug-event associations, but each does this differently.
Average Error was the measure applied to evaluate each algorithm’s performance in predicting
events. The fuzzy relations method performed better in most cases, but BoosTexter can perform
better on test sets when new events were more common. This means that further investigation
using both methods is warranted.
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Table 5.4: Card2. The results obtained by BoosTexter and Algorithm 1 (with p∗ = 100, N∗ = 0),
when tests sets do not contain new events.
Year Test Test* NC Boos.(1000) Boos.(2000) Alg.1(test*) Alg.1(train)
1996 284 247 13.0 0.745 0.747 0.692 0.502
1997 367 315 14.2 0.728 0.721 0.682 0.507
1998 662 539 18.6 0.685 0.690 0.662 0.515
1999 757 653 13.7 0.607 0.612 0.554 0.525
2000 698 572 18.1 0.697 0.696 0.693 0.524
2001 331 260 21.5 0.780 0.783 0.741 0.531
The results obtained for the Card2 after new events were removed from test sets. The term of new
events is defined in Section 5.4.1. Boostexter was set to run for 1000 and 2000 training rounds.
Test* – means the number of records in the test sets after removing new events. The number of
records in the training sets and training errors for BoosTexter as in Table 5.1.
Chapter 6
Further Development and
Evaluation of Algorithms
6.1 Introduction
This chapter continues the development of the fuzzy classification QCA algorithm and the compar-
ison with the BoosTexter algorithm, but the SOC classification of reactions described in Section
3.4 was used. Eighteen groups of reactions (out of 1224 reactions) were considered in order to have
a sufficient number of repeating cases. However, individual drug trade name terms were still used
as in Chapter 4. The Nordic anatomical therapeutic chemical (ATC) classification [560] provides
such a system. Because of this state of drug classification, a complete classification of ADRAC
drug codes was made, see Section 3.6. The next version of the drug-reaction association algorithms
have been named Algorithm A(p) still can only use single drug terms and cannot traverse the ATC
hierarchy. Some comparisons between trade name terms and the various ATC levels was made.
This is described in detail in this chapter.
6.2 Background
6.2.1 Statement of the problem
The general statement of the problem is described in Chapter 5 Section 5.2 because it also includes
a description of text categorization, which is considered there.
It also should be noted that, at this stage of the investigation, the classification of reactions is not
the major aim. Here the aim is to establish drug-reaction relations h(d) such that representations
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H(x), x ∈ X , are close to Y(x).
6.2.2 Potential Reactions
This is discussed in Sections 4.6.2, 5.2.1.
6.2.3 Evaluation measures
To evaluate the accuracy of established drug-reaction relations by a given classifier (h,H),
different measures were used.
Average Distance Error
This measure evaluates the closeness of the two vectors H(x) (predicted reactions) and Y(x)
(observed reactions). In this case, a distance dist(H(x),Y(x)) between these vectors was defined.
The better classifier should provide the minimal sum of all distances. Therefore, a classifier (h,H)
which minimizes the total sum of distances is required.
A common evaluation measure used in multi-label problems is the Hamming distance. But it
is not reasonable to use this distance here, because real valued weights H(x) are used.
In this investigation the following distance functions will be examined:
distp (H(x),Y(x)) =
c∑
i=1
(‖Y(x)‖)−p (H¯i − Yi)2, p = 0, 1, 2; (6.2.1)
where H(x) = (H1(x), . . . , Hc(x)), Y(x) = (Y1(x), . . . ,Yc(x)), ‖Y(x)‖ =
∑
j=1,...,c Yj(x) is the
number of reactions for the ADR report x, and the sign “bar” indicates a normalization:
H¯i(x) =
‖Y(x)‖∑
j=1,...,cHj(x)
Hi(x).
The role of number p can be explained as follows. Clearly
distp (H(x),Y(x)) =
c∑
i=1
(
(‖Y(x)‖)− p2 H¯i(x)− ‖Y(x)‖)−
p
2 Yi(x)
)2
,
and therefore, potential reactions are normalized such that the sum of these normalized potential
reactions can be represented as
c∑
i=1
(‖Y(x)‖)− p2 H¯i(x) = (‖Y(x)‖)1−
p
2 .
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In the distance dist0 this sum is equal to the number of reactions ‖Y(x)‖. In dist2 the
corresponding sum is equal to 1. dist1 can be considered as a middle version where this sum is√‖Y(x)‖, and 1 ≤√‖Y(x)‖ ≤ ‖Y(x)‖.
It would be interesting to consider the Euclidian distance. But some preliminary analysis
showed that this distance does not provide a reasonable evaluation.
Therefore, only the measures 6.2.1 will be examined. Given a classifier (h,H), the average
distance error will be calculated as
Epav =
1
|X |
∑
x∈X
distp (H(x),Y(x)) (6.2.2)
Here |X | stands for the cardinality of the set X .
Now formulating the problem P1 as the following optimization problem:
Epav → min; (6.2.3)
subject to : hi(d) ≥ 0, i = 1, ..., c, d ∈ D. (6.2.4)
In this investigation an algorithm will be described, which aims to minimize the average distance
error Epav. This aim changes by taking different numbers p = 0, 1, 2. A discussion of the most
reasonable choice of distance measures is one of the main goals of this investigation.
Other evaluation measures
The following measures used in [459] will also be considered.
1. One-error. This measure evaluates how many times the reaction, (say i) having the
maximal weight in the vector H(x), has not occurred (that is, Yi(x) = 0). In the case where
there is more than one reaction, having the same maximal weight in H(x), this measure needs
to be precisely defined.
Denote H∗(x) = {i ∈ {1, . . . , c} : Hi(x) = max{H1(x), . . . ,Hc(x)}}, and Y ∗(x) = {i ∈
{1, . . . , c} : i ∈ H∗(x) and Yi(x) = 1}. Then the one-error is defined as
Eone−error =
1
|X |
∑
x∈X
(
1− |Y
∗(x)|
|H∗(x)|
)
.
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The meaning of this measure can be clarified using a simple example. Assume that there are
two reactions having the maximal weight. If both of them have occurred then the error is zero, if
just one of them has occurred then error is 0.5, if none have occurred then the error is 1.
2. Coverage. This measure evaluates the performance of a classifier for all the reactions
that have been observed.
Given x ∈ X , denote by T (x) the set of all ordered reactions τ = {i1, . . . , ic} = {1, . . . , c}
satisfying Hi1(x) ≥ · · · ≥ Hic(x). Then according to a reaction vector (Y1(x), . . . ,Yc(x)), define
the rank and the error as:
rankτ (x) = max{n : Yin(x) = 1, n = 1, . . . , c}; errorτ (x) =
rankτ (x)
‖Y(x)‖ − 1.
Obviously, the number rankτ (x) and errorτ (x) depend on the order τ. One way to avoid
the dependence on ordering is to take the middle value of maximal and minimal ranks. In this
investigation this approach will be used. Define the rank as
rank (x) =
1
2
(rankmax (x) + rankmin (x));
where
rankmax (x) = max
τ∈T (x)
rankτ (x), and rankmin (x) = min
τ∈T (x)
rankτ (x).
The numbers rankmax (x) and rankmin (x) associated to the “worst” and “best” ordering,
respectively.
To define the average error - coverage, the formula will be used:
Ecov =
1
|X |
∑
x∈X
(
rank (x)
‖Y(x)‖ − 1
)
.
Note that, Ecov = 0 if a classifier makes a prediction such that for all x ∈ X the observed reactions
are placed at the top of the ordering list of weights Hi(x).
3. Average Precision.
One-error and coverage do not completely describe multi-label classification problems. In [459]
the average precision was used to achieve evaluation more completely, this measure also will be
used here. Similar to the average error, the average precision depends on a given order τ =
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{τ1, . . . , τc} ∈ T (x). So the average precision was defined as a middle value of average precisions
obtained by the “worst” and “best” ordering.
Let Y (x) = {l ∈ {1, . . . , c} : Yl(x) = 1} be a set of reactions that have been observed for the
ADR report x. Given order τ = {τ1, . . . , τc} ∈ T (x), (that is, Hτ1(x) ≥ · · · ≥ Hτc(x) ), define
the rank for each reaction l ∈ Y (x) as rankτ (x; l) = k, where τk = l. Then, Average Precision
will be defined as:
Pav =
1
|X |
∑
x∈X
1
2|Y (x)| (Pworst(x) + Pbest(x)) ;
where
Pworst(x) = min
τ∈T (x)
∑
l∈Y (x)
|{k ∈ Y (x) : rankτ (x; k) ≤ rankτ (x; l)}|
rankτ (x; l)
;
Pbest(x) = max
τ∈T (x)
∑
l∈Y (x)
|{k ∈ Y (x) : rankτ (x; k) ≤ rankτ (x; l)}|
rankτ (x; l)
.
6.2.4 A solution to the optimization
problem (6.2.3),(6.2.4)
The function in (6.2.2) is non-convex and non-linear, and therefore may have many local minimum
points. The global optimum point needs to be found. The number of variables is |D| · c. For
the data set Mallreac (see section 6.3), that will be considered, |D| = 5057 and c = 18. Thus
there exists a global optimization problem with 91026 variables, which is very hard to handle using
existing global optimization methods. Note that, local minimization methods were also tried but
were unsuccessful. This means that there is a clear need to develop new optimization algorithms
for solving problem (6.2.3),(6.2.4), taking into account some peculiarities of the problem.
In this investigation one heuristic method for finding a “good” solution to the problem (6.2.3),(6.2.4)
is suggested. This method is based on the proposition given below.
Denote by S the unit simplex in Rc; that is,
S = {h = (h1, . . . , hc) : hi ≥ 0, h1 + . . . hc = 1}.
In this case for each h(d) ∈ S the component hi(d) indicates simply the probability of the
occurrence of the reaction i.
Given drug d denote by X(d) the set of all records in X , which used just one drug – d.
Simply, the set X(d) combines all records where the drug d was used alone.
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Consider the problem:
∑
x∈X(d)
c∑
j=1
‖Y(x)‖−p · (Yj(x)− ‖Y(x)‖hj(d))2 → min, (6.2.5)
h(d) = (h1(d), . . . , hc(d)) ∈ S. (6.2.6)
Proposition 6.2.1. A point h∗(d) = (h∗1(d), . . . , h
∗
c(d)), where
h∗j (d) =
 ∑
x∈X(d)
‖Y(x)‖2−p
−1 · ∑
x∈X(d)
‖Y(x)‖1−p Yj(x), j = 1, . . . , c, (6.2.7)
is the global minimum point for the problem (6.2.5),(6.2.6).
Now, given drug d, consider the set Xall(d) which combines all records that used the drug
d. Clearly X(d) ⊂ Xall(d). The involvement of other drugs makes it impossible to solve the
corresponding optimization problem similar to (6.2.5), (6.2.6). In this case, the following heuristic
approach to find a “good” solution was used.
Denote by Ndrug(x) the number of drugs recorded in the ADR report x. Then, set:
h∗∗j (d) =
 ∑
x∈Xall(d)
‖Y(x)‖2−p
−1 · ∑
x∈Xall(d)
‖Y(x)‖1−p Yj(x)
Ndrug(x)
, j = 1, . . . , c. (6.2.8)
This formula has the following meaning. If Ndrug(x) = 1 for all x ∈ Xall(d), then (6.2.8)
provides global minimum solution. Let Ndrug(x) > 1 for some record x ∈ Xall(d). In this case,
assume that all drugs are responsible to the same degree; so only the part 1/Ndrug(x) of the
reactions Yj(x) was associated to this drug.
The calculation of weights for each drug
For each drug d define the sets X(d) – the set of all cases where drug d was used alone and Xall(d)
– the set of all cases where drug d was used. The set X(d) carries very important information,
because here the drug d and reactions are observed in a pure relationship. Therefore, if the set
X(d) contains a “sufficiently large” number of records, then it will be reasonable to define the
weights hj(d), (j = 1, . . . , c) by this set.
Consider two numbers: |X(d)| – the number of cases where the drug is used alone, and P (d) =
100|X(d)|/|Xall(d)| – the percentage of these cases. To determine whether the set X(d) contains
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enough records both numbers need to be used. A function φ(d) = a|X(d)|+ bP (d) is considered
to describe how large the set X(d) is.
Therefore, define h(d) = (h1(d), . . . hc(d)) as follows:
h(d) =
{
h∗(d) if φ(d) ≥ φ∗;
h∗∗(d) otherwise;
(6.2.9)
where h∗(d) and h∗∗(d) are defined by (6.2.7) and (6.2.8), respectively.
Remark 6.2.1. Note that the weight hi(d) is not exactly a probability of the occurrence of the
reaction i; that is, the sum
∑c
i=1 hi(d) does not need to be equal to 1.
Remark 6.2.2. the situation where obtains, for some new (test) examples, new drugs were in-
volved. For each such new drug d set hi(d) = 0, i = 1, . . . , c.
6.3 Results using the Eighteen SOC classes
In ADRAC there were nineteen SOC classes and some terms were in more than one SOC class.
For the purpose of testing the algorithms that are being developed for drug safety analysis, the
SOCs have been rearranged to have only one SOC per reaction term. In this scheme there are
only eighteen SOCs (SOC class code ‘2000’ reaction terms were reassigned to one of the remaining
SOCs). The data set denoted Mallreac is described in Section 3.4.
6.3.1 The algorithms
For this analysis two algorithms were used. The first algorithm A(p) which is introduced in this
investigation is described below. The second algorithm that was used is BoosTexter (version Ad-
aBoost.MH with real-valued predictions, [459]) which has a high performance in text categorization
problems and seems to be suitable for representing drug-reaction associations.
These two algorithms produce the weighted vector H(x) for each ADR report x which makes it
suitable for the applying distance evaluation measures. But the methods of calculating the vectors
H(x) are quite different: the algorithm A(p) uses only drugs that have been recorded in the ADR
report x, in contrast, BoosTexter uses all drugs in the list of attributes defined (that is, even drugs
that have not been recorded in ADR report x, are used for the calculation of the vector H(x)).
It was hoped that more accurate conclusions can be made by applying both quite different methods.
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The algorithm A(p) determines a classifier (h,H), where the weights h(d), d ∈ D, are defined
by (6.2.9), and the function H(x) is defined by (5.2.2). Three versions were considered: A(0),
A(1), A(2), corresponding to the distance functions distp, p = 0, 1, 2, respectively. Each of these
algorithms tends to minimize the average distance calculated by its own measure.
The second algorithm BoosTexter [459] produces predictions in the form H(x) = (H1(x), . . . ,Hc(x)),
where the numbers Hi(x) are real values which can be positive or negative. In other words, this
algorithm defines potential reactions that are of interest.
To apply the distance measures described above, all weights calculated by BoosTexter need to be
made non-negative. Let Hmin(x) = mini=1,...,cHi(x). Then set H(x) = H(x), if Hmin(x) ≥ 0;
and
H(x) = (H1(x)−Hmin(x), . . . ,Hc(x)−Hmin(x), if Hmin(x) < 0.
Therefore, two quite different algorithms – A(p) and BoosTexter were applied. It would be
interesting to compare the drug-reaction relations (that is, h(d)), produced by these algorithms.
To this purpose one example is considered.
Example 6.3.1. Assume that, the drug d, which was used alone in four cases: in one case the
first and second reactions and in the all other cases just the first reaction have been observed. h(d)
is represented as follows (the results for BoosTexter are normalized):
A(0): h(d) = (0.714, 0.286, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0);
A(1): h(d) = (0.800, 0.200, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0);
A(2): h(d) = (0.875, 0.125, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0);
BoosTexter (round=500): h(d) = (0.673, 0.327, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0);
BoosTexter (round=2000): h(d) = (0.675, 0.325, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0).
In this example the first reaction occurred four times and the second once. It can be seen that,
BoosTexter produces weights such that the weight for the first reaction is just two times greater
than for the second reaction, whereas, this difference is greatest for algorithm A(2). The interesting
question is: which drug-reaction representation is “better” – one which offers a big difference in
weights or one which offers a slight difference in weights in spite of big differences in distribution.
For this purpose different evaluation measures were used. Note that, in terms of One-error,
Coverage and Average Precision all the representations in Example 6.3.1 work similarly; that is,
the rank for the first reaction is 1 and for the second is 2. The effect of different drug-reaction
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representations can be observed considering the cases where more than one drug was used.
6.3.2 New drugs and events
A new drug (in the test set) was defined as a case when this drug either is a new drug which has not
occurred in the training set or has never been considered as a suspected (see Section 3.5.1) drug in
the training set. For all such new drugs d, set hi(d) = 0, i = 1, . . . , c. It is possible that for some
new (test) example all suspected drugs are new. This case s new event was called. This situation
mainly relates to the fact that, new drugs are constantly appearing on the market. To make
predictions for such examples creates “noise” for Algorithm A(p). Therefore, in the calculations
below, all new events from test sets were removed.
6.3.3 The results of numerical experiments
In the calculations below, a test set records was taken sequentially from each year, starting from
1996 until 2001. For example, if records from 1999 are taken as a test set, then all records from
years 1972–1998 form a training set. Table 6.1 summarizes the number of records in test and
training sets, and also the number of new events removed.
Table 6.1: The Mallreac Training and Test Sets
Year Number of Records
Training Test Removed*
1996 79660 7734 410
1997 87804 8090 715
1998 96609 9361 774
1999 106744 11216 840
2000 118880 11244 671
2001 130795 6186 191
*“Removed” means how many records were removed from test set.
First calculations were made by the algorithm BoosTexter. This algorithm was run choosing
different numbers of training rounds. The results obtained for 6000 rounds are presented in Tables
6.2 and 6.3. Table 6.3 presents the results obtained for One-error, Coverage and Average Precision.
Next the algorithms A(0), A(1) and A(2) were applied, corresponding to the distance functions
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Table 6.2: TheMallreac Results Obtained by A(0), A(1), A(2) and BoosTexter for Average Error
for Distance Measure p = 1
Year Drugs A(0) A(1) A(2) BoosTexter
Training Test Training Test Training Test Training Test
1996 all drugs* 0.695 0.740 0.678 0.731 0.693 0.751 0.817 0.820
sus. drugs† 0.679 0.740 0.661 0.732 0.681 0.759 0.816 0.820
1997 all drugs 0.696 0.740 0.679 0.734 0.694 0.755 0.817 0.824
sus. drugs 0.680 0.743 0.663 0.737 0.683 0.762 0.817 0.825
1998 all drugs 0.697 0.737 0.680 0.731 0.694 0.751 0.818 0.818
sus. drugs 0.681 0.748 0.664 0.742 0.684 0.767 0.817 0.818
1999 all drugs 0.697 0.726 0.680 0.722 0.694 0.751 0.817 0.820
sus. drugs 0.681 0.722 0.665 0.718 0.683 0.749 0.816 0.820
2000 all drugs 0.696 0.756 0.680 0.752 0.693 0.783 0.817 0.815
sus. drugs 0.681 0.755 0.665 0.753 0.683 0.787 0.817 0.815
2001 all drugs 0.697 0.749 0.682 0.747 0.695 0.781 0.817 0.809
sus. drugs 0.684 0.749 0.668 0.748 0.687 0.787 0.817 0.809
The algorithm BoosTexter2 1 [459] was set to run for 6000 training rounds.
*“all drugs” means that the drug-reaction weights are calculated assuming all drug(s).
† suspected “sus. drugs” means that only suspected drug(s) reported in ADRAC data were used.
distp, p = 0, 1, 2, respectively. A function φ(d) = |X(d)| + P (d) was used to describe the infor-
mativeness of the set X(d). A number φ∗ also needs to be set. The calculations show that the
results are not essentially changed for different values of φ∗ in the region φ∗ ≥ 50. A large number
φ∗ = 1000 was set in the calculations, which means that for the majority of drugs weights are
calculated by formula (6.2.8). The results are presented in Tables 6.4 and 6.5.
Table 6.2 presents the results for the average distance errors comparing algorithm A(p) to
BoosTexter for average error. On the basis of this measure algorithm A(p) performs consistently
better than BoosTexter. This means that the formulae (6.2.9) for definition of weights h(d) provides
a “good” approximation for the minimal solution to the Problem (6.2.3), (6.2.4).
The results for the other measures (one-error, coverage and average precision) for BoosTexter
are given in Table 6.3, and for A(p) in Tables 6.4 and 6.5. It can be seen that, for all drugs,
comparing Tables 6.3 and 6.4, the performance of A(p) and BoosTexter are very similar. When
the suspected drugs are compared (Tables 6.3 and 6.5), algorithm A(1) performs better than
BoosTexter. The comparison of results obtained for other evaluation measures (Tables 6.4 and
6.5) reveals differences in the performance of these three versions. Observe that by One-error
measure A(1) performs better than the others, by Coverage A(2) performs better and by Average
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Table 6.3: The Mallreac Results Obtained by BoosTexter for One-Error, Coverage and Average
Precision
Year Drugs Eone−error Ecov Pav∗
Training Test Training Test Training Test
1996 all drugs 0.463 0.533 1.580 2.134 63.93 57.06
sus. drugs 0.485 0.533 1.686 2.208 62.50 55.87
1997 all drugs 0.466 0.541 1.601 2.185 63.67 56.76
sus. drugs 0.486 0.560 1.708 2.243 62.27 55.64
1998 all drugs 0.469 0.539 1.630 2.147 63.29 56.84
sus. drugs 0.489 0.558 1.730 2.197 62.00 56.25
1999 all drugs 0.471 0.507 1.651 2.038 63.07 59.26
sus. drugs 0.490 0.503 1.747 2.015 61.86 59.72
2000 all drugs 0.471 0.553 1.665 2.059 62.98 56.94
sus. drugs 0.488 0.549 1.747 2.036 61.95 57.35
2001 all drugs 0.475 0.557 1.683 2.112 62.69 55.70
sus. drugs 0.490 0.565 1.754 2.117 61.79 55.37
The algorithm BoosTexter2 1 [459] was set to run for 6000 training rounds
*Average Precision is presented in percent.
Precision both A(1) and A(2) perform better. In all cases A(0) has a worse performance. Therefore,
it can be concluded that, the definition of distance measure, taking p =1 or 2, is preferable than
p=0.
As has been shown in Example 6.3.1, the algorithm A(2), in comparison with A(1), generates
drug-reaction representations with greater differences in weights. The results presented in Table
6.4, for One-error and Coverage, obtained by the algorithms A(1) and A(2), allow some very
interesting conclusions to be made:
– if it is One-error that is of interest, (that to say, the probability of occurrence of the reaction
which has the greatest weight) then it is better to use drug-reaction representations with small
differences in weights;
– if it is Coverage that is of interest, then it is better to use drug-reaction representations with
big differences in weights. Note that, in all cases, the results are improved if only suspected drugs
are used.
Below only the results obtained by A(1) and BoosTexter are considered.
The comparison of the training errors in Tables 6.2, 6.3, 6.4 and 6.5 shows that A(1) performs
generally better than BoosTexter. Training errors for BoosTexter can be decreased by increasing
the number of training rounds (results not presented), but in this case test errors increase. This
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Table 6.4: The Mallreac Results Obtained by A(0), A(1) and A(2) for Different Evaluation
Measures – using all drugs
Year Algorithms Eone−error Ecov Pav*
Train Test Train Test Train Test
1996 A(0) 0.494 0.538 1.930 2.304 60.03 55.70
A(1) 0.471 0.526 1.655 2.112 63.10 57.72
A(2) 0.497 0.538 1.512 2.013 63.46 58.30
1997 A(0) 0.496 0.542 1.949 2.355 59.73 55.41
A(1) 0.473 0.534 1.676 2.193 62.88 57.22
A(2) 0.498 0.551 1.532 2.102 63.26 57.24
1998 A(0) 0.497 0.536 1.971 2.288 59.54 56.45
A(1) 0.475 0.525 1.701 2.146 62.60 57.81
A(2) 0.501 0.562 1.556 2.068 62.99 56.96
1999 A(0) 0.497 0.515 1.980 2.185 59.52 58.42
A(1) 0.474 0.504 1.720 2.043 62.49 59.81
A(2) 0.501 0.532 1.578 1.979 62.84 59.28
2000 A(0) 0.498 0.568 1.982 2.365 59.45 53.74
A(1) 0.474 0.559 1.724 2.180 62.47 55.49
A(2) 0.499 0.575 1.584 2.061 62.87 56.67
2001 A(0) 0.502 0.563 1.998 2.288 59.15 54.04
A(1) 0.478 0.550 1.735 2.125 62.22 56.11
A(2) 0.502 0.571 1.595 2.043 62.64 56.68
*Average Precision is presented in percent
should be expected, because the algorithm BoosTexter is not designed to minimize some distance
measures, instead it tends to achieve good performance for the other evaluation measures.
There are two important points that make using the algorithm A(1) preferable for the study
drug-reaction associations.
1. BoosTexter does not calculate weights for each drug. For example, until the year 2000,
where 5057 drugs were used. BoosTexter running for 6000 rounds defines weights only for 4521
drugs to this year. In contrast, A(1) calculates weights for each drug encountered, which is very
important (in this case drug-reaction relations for all drugs were established).
2. The algorithm BoosTexter classifies examples so that drugs that are not used are still
assigned weights to the function H(x). In the other words, reactions are predicted not only by
drugs actually used, but also, drugs which were not taken.
In spite of these two points, the application of the algorithm BoosTexter is useful, because
this algorithm, based on quite different method, provides very important information about the
possible accuracy of the prediction that could be achieved.
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Table 6.5: The Mallreac Results Obtained by A(0), A(1) and A(2) for Different Evaluation
Measures – using only suspected drugs
Year Algorithms Eone−error Ecov Pav*
Train Test Train Test Train Test
1996 A(0) 0.472 0.520 1.806 2.236 61.98 57.28
A(1) 0.453 0.510 1.547 2.057 64.76 59.14
A(2) 0.469 0.518 1.410 1.984 65.13 59.38
1997 A(0) 0.474 0.531 1.827 2.303 61.70 56.75
A(1) 0.454 0.519 1.566 2.156 64.56 58.29
A(2) 0.470 0.532 1.429 2.071 64.93 58.38
1998 A(0) 0.474 0.520 1.840 2.238 61.61 57.80
A(1) 0.456 0.516 1.586 2.106 64.33 58.86
A(2) 0.471 0.549 1.451 2.038 64.71 57.96
1999 A(0) 0.473 0.503 1.847 2.141 61.61 59.37
A(1) 0.456 0.492 1.599 2.010 64.26 60.66
A(2) 0.472 0.518 1.469 1.955 64.57 60.08
2000 A(0) 0.476 0.566 1.855 2.343 61.43 54.15
A(1) 0.456 0.558 1.611 2.135 64.16 56.38
A(2) 0.473 0.564 1.482 2.041 64.48 57.24
2001 A(0) 0.481 0.554 1.878 2.271 60.99 54.43
A(1) 0.462 0.542 1.631 2.090 63.80 56.91
A(2) 0.478 0.562 1.502 2.022 64.11 57.36
*Average Precision is presented in percent
One more important fact should also be noted. In all cases above the results obtained are
much better than the default values ( default values are defined assuming that for each record all
reactions can occur with the same weight). This emphasizes that it possible to study drug-reaction
relations, not involving other information about patients. The drug-reaction relationships could
then be used, together with the patient information, to enhance the prediction of reactions that
may occur.
6.4 Five cardiovascular groups
The data set called Card20 is described in Section 3.4.1.
6.4.1 The results of numerical experiments
In the calculations below records were taken as a test set sequentially from each year, starting
from 1996 until 2001. For example, if records from 1999 are taken as a test set, then all records
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from years 1972–1998 form a training set. Table 6.6 summarizes the number of records in test and
training sets, and, also, the number of new events removed.
Table 6.6: Card20; The Training and Test Sets
Year Number of Records
Training Test Removed*
1996 12600 1092 55
1997 13747 1155 99
1998 15001 1523 160
1999 16684 1764 151
2000 18599 1999 151
2001 20749 1070 52
*“Removed” – means how many records were removed from test set. For example, in 1996 there
are 1147 records and 55 of them are new events. Then, the number of records in the test set for
this year is 1092 (= 1147− 55).
First,calculations by the algorithm BoosTexter were made . This algorithm was run choosing
different numbers of training rounds. The results obtained for rounds 500 and 2000 are presented
in Tables 6.7 and 6.8. In the Table 6.7 the Average Distance Error Epav (p = 0, 1, 2) are presented
(see section 6.2.3). The different distance functions, One-error, Coverage and Average Precision,
results are presented in Table 6.8. It can be seen, for example, that in Table 6.7 the best Average
Distance Error measures were achieved using p = 2 (formula 6.2.1) and that 2000 training rounds
gave better results than 500. Table 6.8 gives the results for BoosTexter using measures, One-error,
Coverage and Average Precision for 500 and 2000 training rounds. For One-error, only the training
set performed consistently better in each year for 2000 training rounds. The test sets for One-error
were slightly better for 500 training rounds except for the year 2001, where 2000 training rounds
gave better results.
The Algorithm A(p) – see section 6.3.1, A(0), A(1) and A(2), were investigated corresponding
to the Average Distance Error functions distp, p = 0, 1, 2, respectively (formula 6.2.1). The
function φ(d) = |X(d)|+φ(d) was used to describe the informativeness of the set X(d) (see section
6.2.4). A number φ∗ also needs to be set. The calculations show that the results are not essentially
changed for different values of φ∗ in the region φ∗ ≥ 30., so φ∗ = 80 for the calculations for formula
(6.2.9). The results are presented in Tables 6.9 and 6.10.
In Table 6.9 the results for the Average Distance Error is presented. Notice that Algorithm
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Table 6.7: The Card20 Average Distance Error Obtained by BoosTexter for (p = 0, 1, 2)
Year Rounds* E0av E1av E2av
Training Test Training Test Training Test
1996 500 0.735 0.811 0.453 0.477 0.318 0.319
2000 0.695 0.817 0.428 0.479 0.302 0.319
1997 500 0.739 0.782 0.454 0.478 0.318 0.337
2000 0.696 0.801 0.428 0.488 0.301 0.342
1998 500 0.740 0.774 0.454 0.508 0.319 0.383
2000 0.700 0.794 0.430 0.518 0.302 0.389
1999 500 0.740 0.749 0.457 0.491 0.323 0.371
2000 0.701 0.761 0.434 0.497 0.308 0.373
2000 500 0.739 0.782 0.459 0.496 0.327 0.363
2000 0.702 0.792 0.437 0.499 0.312 0.363
2001 500 0.740 0.804 0.461 0.499 0.329 0.355
2000 0.705 0.791 0.440 0.492 0.315 0.352
* The Algorithm BoosTexter2 1 [459] was set to run for 500 and 2000 training rounds
A(0) performs better than others for the first Average Distance Error (p = 0), the algorithm A(1)
performs better for the second Average Distance Error (p = 1) and the algorithm A(2) performs
better for the third Average Distance Error (p = 2). This means that the formula (6.2.9) for
definition of weights h(d) appears to provide a “good” approximation for the minimal solution to
Problem (6.2.3), (6.2.4). Comparing the Average Distance Error Epav of BoosTexter with 2000
training rounds (Table 6.7) and Algorithm A(p) (Table 6.9), A(2) p = 2 gave consistently better
results than E2av of BoosTexter for each year. Similarly, A(1) p = 1 compared with E
1
av ,
and A(0) E0av of BoosTexter for each year, performed better. It should be noted that, in some
instances, the difference BoosTexter and Algorithm A(p) was small.
The comparison of results obtained for other evaluation measures (Table 6.10) reveals differences
in the performance of these three versions. Notice that by One-error measure A(1) performs better
than the others, by Coverage A(2) performs better and by Average Precision both A(1) and A(2)
perform better. In all cases A(0) has a worse performance. Therefore, it can be conclude that, the
definition of distance measure, taking p =1 or 2, is preferable than p=0.
As has been shown in Example 6.3.1, the algorithm A(2), in comparison with A(1), generates
drug-reaction representations with greater differences in weights. The results presented in Table
6.10, for One-error and Coverage, obtained by the algorithms A(1) and A(2), allow for some
very interesting conclusions to be made:
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Table 6.8: The Card20 Results Obtained by BoosTexter for One-error, Coverage and Average
Precision
Year Rounds* Eone−error Ecov Pav†
Training Test Training Test Training Test
1996 500 0.241 0.238 0.560 0.618 80.91 79.56
2000 0.209 0.253 0.477 0.600 83.54 79.51
1997 500 0.240 0.245 0.566 0.598 80.80 79.93
2000 0.209 0.273 0.480 0.615 83.46 78.86
1998 500 0.239 0.285 0.568 0.686 80.78 77.60
2000 0.208 0.297 0.482 0.696 83.43 77.19
1999 500 0.241 0.239 0.574 0.562 80.64 81.31
2000 0.212 0.244 0.490 0.567 83.18 81.12
2000 500 0.240 0.290 0.569 0.675 80.78 78.08
2000 0.214 0.295 0.492 0.677 83.10 77.77
2001 500 0.243 0.302 0.577 0.689 80.61 77.13
2000 0.219 0.293 0.503 0.672 82.79 77.79
* The algorithm BoosTexter2 1 [459] was set to run for 500 and 2000 training rounds
† Average Precision is presented in percent
– if One-error is of interest (that is to say, the probability of occurrence of the reaction which
has the greatest weight) then it is better to use drug-reaction representations with small differences
in weights;
– if Coverage is of interest, then it is better to use drug-reaction representations with big
differences in weights.
Below only the results obtained by A(1) and BoosTexter will be concentrated on.
The comparison of the training errors in Tables 6.7 and 6.9 shows that A(1) performs much
better than BoosTexter. The training errors for BoosTexter can be decreased by increasing the
number of training rounds, but in this case test errors increase (see the results in Table 6.7 for
training rounds 500 and 2000). This should be expected, because the algorithm BoosTexter is not
designed to minimize some distance measures, instead it tends to achieve good performance for
the other evaluation measures.
6.4.2 Using Suspect Codes
The comparison of using only suspected drugs with all drugs are presented in Table 6.11.
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Table 6.9: The Card20 Results Obtained by A(0), A(1) and A(2) for Average Distance Error
p = 0, 1, 2
Year p A(0) A(1) A(2)
Training Test Training Test Training Test
1996 0 0.608 0.793 0.611 0.802 0.641 0.840
1 0.390 0.467 0.383 0.467 0.387 0.480
2 0.289 0.317 0.278 0.313 0.270 0.314
1997 0 0.612 0.769 0.614 0.774 0.644 0.813
1 0.391 0.474 0.384 0.469 0.388 0.479
2 0.288 0.339 0.277 0.329 0.269 0.326
1998 0 0.614 0.738 0.618 0.741 0.647 0.774
1 0.392 0.484 0.386 0.476 0.389 0.483
2 0.289 0.368 0.278 0.355 0.270 0.350
1999 0 0.616 0.735 0.619 0.741 0.650 0.780
1 0.395 0.475 0.389 0.467 0.393 0.474
2 0.293 0.355 0.282 0.340 0.274 0.333
2000 0 0.615 0.792 0.620 0.815 0.653 0.886
1 0.396 0.499 0.389 0.503 0.394 0.530
2 0.294 0.365 0.282 0.361 0.275 0.367
2001 0 0.619 0.787 0.624 0.795 0.657 0.828
1 0.400 0.493 0.393 0.492 0.398 0.503
2 0.298 0.357 0.286 0.353 0.278 0.353
6.5 Discussion
One interesting conclusion can be made comparing the results obtained in Tables 6.7 and 6.9 (dis-
tance measures). In year 2000, BoosTexter gives better results for the test set, although in the
training phase the algorithm A(1) provides better results, which might be expected because it aims
to minimize the average distance error. This situation, together with the drug-reaction represen-
tations produced by these algorithms, leads to the conclusion that, some changes in distributions
of reactions have occurred after year 1999. That is, for example, the distribution of: 4 times the
first reaction and 1 times the second reaction, for some drug, might be changed to: 4 times the
first reaction and 3 times the second reaction.
There are three important points that make using the algorithm A(1) preferable for the study
drug-reaction associations.
1. BoosTexter does not necessarily calculate weights for each drug. For example, until the year
2000, where 2916 drugs were used. BoosTexter defines weights for only 1837 drugs for training
round = 2000, and 500 drugs for training round = 500 (one drug for each round) to this year.
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Table 6.10: The Card20 Results Obtained by A(0), A(1) and A(2) for One-error, Coverage and
Average Precision
Year Algorithms Eone−error Ecov Pav*
Train Test Train Test Train Test
1996 A(0) 0.235 0.239 0.553 0.612 81.36 79.71
A(1) 0.219 0.245 0.510 0.592 82.61 80.02
A(2) 0.223 0.275 0.450 0.570 83.72 79.65
1997 A(0) 0.233 0.263 0.552 0.645 81.41 78.66
A(1) 0.217 0.263 0.510 0.630 82.63 78.98
A(2) 0.221 0.295 0.450 0.601 83.78 78.83
1998 A(0) 0.232 0.283 0.551 0.690 81.45 77.57
A(1) 0.217 0.277 0.512 0.662 82.58 78.39
A(2) 0.221 0.311 0.454 0.635 83.68 78.01
1999 A(0) 0.233 0.254 0.556 0.586 81.39 80.42
A(1) 0.219 0.260 0.517 0.573 82.46 80.61
A(2) 0.225 0.270 0.461 0.546 83.48 80.99
2000 A(0) 0.232 0.293 0.549 0.689 81.57 77.55
A(1) 0.219 0.303 0.512 0.666 82.60 77.89
A(2) 0.225 0.338 0.457 0.646 83.58 77.24
2001 A(0) 0.237 0.303 0.561 0.718 81.21 76.77
A(1) 0.222 0.305 0.520 0.693 82.39 77.34
A(2) 0.228 0.319 0.467 0.679 83.35 77.37
* Average Precision is presented in percent
In contrast, A(1) calculates weights for each drug encountered, which establishes drug-reaction
relations for all drugs. This problem can be overcome by having more training rounds. Results
using 6000 training rounds are reported in [326].
2. The algorithm BoosTexter classifies examples so that drugs that are not used are still
assigned weights to the function H(x). In the other words, reactions are predicted not only by
drugs actually used, but also, drugs which were not taken. This approach is reasonable for text
categorization, but for ADR problems this may seem to be inappropriate, because this leads to the
situation where it could be said that, for example, ADR report x has the first reaction, because
he/she did not take drug d. However, it does not necessarily mean that this would adversely affect
the performance for characterizing drug-reaction associations. Indeed from a grounded theory
perspective (see Section 1.3), this would be imposing restrictions on how to view the data. Thus
rules concerning ADRs occurring in the absence of a drug are valid and may be useful. Also
Galavotti et al. [165], in the field of text categorization, have exploited negative evidence in their
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Table 6.11: The results for Card20 obtained by the algorithm A(p), p = 0, 1, 2.
Year Ev. Measure A(0) A(1) A(2)
Training Test Training Test Training Test
1996 Ecov all drugs* 0.553 0.605 0.510 0.586 0.450 0.562
sus. drugs† 0.507 0.588 0.464 0.571 0.415 0.556
Pav all drugs 81.36 79.81 82.61 80.05 83.72 79.79
sus. drugs 82.86 80.21 83.94 80.03 84.49 79.75
1997 Ecov all drugs 0.552 0.638 0.510 0.620 0.450 0.589
sus. drugs 0.509 0.613 0.464 0.589 0.417 0.570
Pav all drugs 81.41 78.94 82.63 79.42 83.78 79.24
sus. drugs 82.80 79.69 83.95 80.23 84.51 79.95
1998 Ecov all drugs 0.551 0.679 0.512 0.650 0.454 0.621
sus. drugs 0.509 0.672 0.465 0.641 0.417 0.625
Pav all drugs 81.45 77.83 82.58 78.68 83.68 78.40
sus. drugs 82.79 78.01 83.89 78.58 84.47 78.41
1999 Ecov all drugs 0.556 0.585 0.517 0.573 0.461 0.545
sus. drugs 0.515 0.569 0.471 0.562 0.424 0.543
Pav all drugs 81.39 80.46 82.46 80.63 83.48 81.03
sus. drugs 82.66 80.92 83.75 80.92 84.35 80.88
2000 Ecov all drugs 0.549 0.691 0.512 0.668 0.457 0.647
sus. drugs 0.512 0.682 0.470 0.651 0.423 0.633
Pav all drugs 81.57 77.54 82.60 77.88 83.58 77.23
sus. drugs 82.70 77.77 83.73 78.23 84.37 77.60
2001 Ecov all drugs 0.561 0.712 0.520 0.685 0.467 0.672
sus. drugs 0.525 0.713 0.480 0.683 0.435 0.667
Pav all drugs 81.22 76.89 82.39 77.50 83.35 77.55
sus. drugs 82.29 76.92 83.49 77.38 84.07 77.58
*“all drugs” means that the drug-reaction weights are calculated assuming all drug(s).
† suspected “sus. drugs” means that only suspected drug(s) reported in ADRAC data were used.
system using feature selection and classifier induction, but incorporate a novel variant of the k-
NN method. They reported results of systematic experimentation on the standard Reuters-21578
benchmark.
3. The source code for BoosTexter is not available, so it is not possible to tailor it to this
particular application. This has a positive aspect in that it can be used as a standard method,
because there is a large body of results reported in the literature using this algorithm. The data
sets may differ, but the characteristics of this algorithm are becoming well established.
4. A(p) defines drug-reaction relationships for each drug, whilst BoosTexter defines drug-
reaction relationships for a subset of drugs and some of these drugs included are the list of “weak
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hypotheses” multiple times with different weights. In other words, for some drugs (say d), Boos-
Texter generates different vectors (say hk(d), k = 1, . . . ,K), depending on the order in the list of
“weak hypotheses”. This feature makes it impossible to use BoosTexter for solving other problems
like evaluation of suspected drugs and drug-drug interactions [330].
In spite of these points, the application of the algorithm BoosTexter is useful, because this
algorithm, based on quite different method, provides very important information about the possible
accuracy of the prediction that could be achieved. In the absence of any suitable ‘benchmarks’,
BoosTexter was found useful because it is a high performance algorithm designed to address multi-
class, multi-label problems. More specifically, it was able to input the same data that the drug-
reaction ‘classification’ algorithm, Algorithm A(p), used and output values in a form that enabled
an exact comparison between the two types of algorithm.
One more important fact should also be noted. In all cases above the results obtained are much
better than the default values, which are defined by assuming that for each record all reactions can
occur with the same weight. This emphasizes that it possible to study drug-reaction relationships,
not involving other information about patients. The drug-reaction relationships could then be used,
together with the patient information, to enhance the prediction of reactions that may occur. The
study of more sensible definitions of the function H, defined in Section 5.2.1, is an interesting
problem for future investigations. Also the application of the formula (5.2.4) is a very interesting
problem for future investigations which also needs to take into account many other factors such as
the metabolism and elimination of drugs. Drug exposure time will be another important factor to
take into consideration [82].
A common evaluation measure used in multi-label problems is the Hamming distance. This
measure was considered, but it was not reasonable to use this distance with the data used here,
because real valued weights H(x) were used. It would be interesting to consider the Euclidian
distance. However, some preliminary analysis showed that this distance does not provide a rea-
sonable evaluation. The clinical importance of finding an appropriate distance measure between
expected values derived from training data and observed values from new data is to improve signal
detection. Given an observation of a patient’s reaction to a certain drug, the distance measure
should be able to facilitate the timely detection of unknown ADRs.
Concerning the application of optimization to the problem discussed in Section 6.2.4, an attempt
to use local minimization methods was made but this was unsuccessful. To address this problem
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the Anatomical-therapeutic-chemical Classification (ATC) codes were applied to the ADRAC trade
name drug codes used for the data in this investigation, Section 6.6. The ATC codes classify
individual ingredients that belong to 14 classes in the first level, 95 in the second level, 217 in the
third, 581 in the fourth and 1785 in the fifth. It is anticipated that this will make these data more
amenable to the application of optimization techniques as well as methods commonly applied in
data mining (see Section 6.3).
6.6 Using ATC Classification with Algorithm (p = 1)
There is a need for a similar kind of grouping to apply to drugs in ADRAC data, which are currently
listed by trade name, to group drugs in a similar way that the SOC classification groups reactions,
(Section 6.1). Table 3.2 lists the reaction terms giving counts of number of terms per class and
the count of the number of records in ADRAC that contain that class. In the ADRAC data, some
of these trade names were assigned anatomical-therapeutic-chemical classification (ATC) codes,
but in cases where the trade name had more than one ingredient, ATC codes were not assigned.
This investigation reports an ad hoc classification where each trade name code was assigned a
corresponding ATC code.
6.6.1 Methods
See Section 3.7.1 for description of the ATC implementation used here.
In this section, in addition to the data sets Mallreac and Card20, two other data sets,
Haemic and lymphatic systems Blood (Section 3.4.2) and Nervous system and special senses
Neuro (Section 3.4.3) were studied.
6.6.2 Results
The results of this classification of ADRAC data are given in terms of numbers of reports per class.
There are five levels of classes in the ATC system: level 0 had 14 classes, level 1 had 92, level 2
had 227, level 3 had 602 and level 4 had 1809.
The results from drug-reaction association algorithms, which aim to minimize the Average
Distance Error Epav, results of trade name drug codes (with 5081 drug terms) and the same
algorithm using ATC drug codes (with 1806 drug terms) were compared. The calculations below
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take, as a test set, records sequentially from each year, starting from 1996 until 2001. For example,
if records from 1999 are taken as a test set, then all records from years 1972–1998 form a training
set.
In Table 6.12 the cardiovasuclar group of reactions were considered, which consists of 159
reaction terms. The cardiovascular class consists of four sub-classes. In this investigation records
of ADRAC data related to the cardiovascular type of reactions only were considered. All records
were collected having at least one reaction from these four sub-groups and called this data set
Card20 (SOC ‘1000’) is described in [328]. It should be noted that the distance measures of
one-error (Eone−error) and the average error - coverage ( Ecov ) the smaller the value the better.
Average Precision Pav is expressed as a percentage; the larger the value of Pav, the better.
Two other SOC classes that were examined: (i) SOC ‘1200’ (Haemic and lymphatic systems)
this data set was called Blood and the results of this analysis are presented in Table 6.13, (ii)
SOC ‘0400’ (Nervous system and special senses) this data set was called Neuro and the results of
this analysis are presented in Table 6.14.
Finally, an algorithm that compares all eighteen SOC classes reported in [328] was run and
these results are presented in Table 6.15.
From these results it can be seen that the utilization of the ATC codes does not always give
better results, but is expected that exploitation of the different levels in the ATC hierarchy will be
beneficial – see Section 3.7.3.
6.6.3 Conclusion
In this investigation drug-reaction relations using the system organ class grouping of reactions from
ADRAC data were studied. Fuzzy relations are presented in the form of a vector of weights. Two
algorithms, a modification of QCA and BoosTexter, were applied each based on quite different
methods.
To develop new algorithms taking into account the peculiarities of ADRs is an important
problem. The development of these algorithms should help for the extraction of more useful
information from ADRAC data. In particular, the study of drug-reaction associations, drug-drug
interactions and the influence of other data fields contained in the ADRAC data are interesting
problems for future investigation.
The fact that the numerical results reported do not show a consistent improvement of the
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distance measures using ATC codes warrants further investigation, but would require some modi-
fications of the algorithm to use the ATC hierarchy.
In the next chapter I will show further development of our fuzzy relations algorithms regarding
optimization, prediction of suspected drugs and drug interactions.
This chapter has addressed research question 1. Two methods were examined that are not
based on disproporionality, one developed for the purpose, the other applied as a kind of standard.
The covariability algorithm A(p) (improved upon QCA and Algorithm 1 by including further
optimization) and the text categorization algorithm BoosTexter were both tested on the data sets
described in Section 3.4. Both algorithms assign weights to drug-event associations, but each does
this differently. As well as average error, one-error, coverage and average precision, were also
applied to measure classification effectiveness. The algorithm A(p) performed consistently better
for average error, but very similar to BoosTexter for one-error, coverage and average precision.
Using only suspected drugs, algorithm A(1) was better than BoosTexter and both were better
than with all drugs. Using values of p = 0, 1, 2 to change the distance definition, A(0) is always
worse. For one-error, A(1) is better than A(2), for coverage, A(2) is better than A(1), and for
average precision, A(1) and A(2) were similar.
The results using drug trade name were compared to the different levels of ATC drug classi-
fication, thus addressing research question 3. For this comparison, no consistent improvement in
performance was observed using A(1). BoosTexter was not investigated with ATC codes, because
it was worthwhile given the results from algorithm A(1). The main focus of the ATC ontology is
discussed in Chapters 8 and 9 where it will be demonstrated that the power of the ATC ontol-
ogy lies in its hierarchical structure. Hence, methods that do not exploit this feature cannot be
expected to show big improvements.
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Table 6.12: Card20 – All drugs – Results Obtained for One-error, Coverage and Average Precision,
comparing Trade Name and ATC coding
Year code Eone−error Ecov Pav*
Training Test Training Test Training Test
1996 Trade 0.216 0.247 0.494 0.585 82.83 79.98
ATC1† 0.286 0.247 0.712 0.649 76.65 78.49
ATC3† 0.275 0.245 0.659 0.639 77.95 78.74
ATC4† 0.261 0.248 0.631 0.631 78.96 78.84
ATC5† 0.249 0.253 0.594 0.617 80.04 78.99
ATC7† 0.234 0.239 0.546 0.578 81.35 80.28
1997 Trade 0.215 0.254 0.495 0.608 82.80 79.71
ATC1 0.282 0.292 0.701 0.683 76.89 76.62
ATC3 0.273 0.294 0.659 0.678 77.99 76.83
ATC4 0.260 0.289 0.632 0.667 78.96 77.22
ATC5 0.249 0.293 0.595 0.670 80.00 77.14
ATC7 0.234 0.232 0.547 0.603 81.32 80.26
1998 Trade 0.215 0.285 0.496 0.674 82.78 77.88
ATC1 0.283 0.392 0.700 0.810 76.86 71.95
ATC3 0.274 0.388 0.658 0.862 77.93 71.30
ATC4 0.262 0.388 0.634 0.848 78.83 71.59
ATC5 0.252 0.382 0.601 0.806 79.77 72.31
ATC7 0.232 0.274 0.547 0.665 81.36 78.44
1999 Trade 0.218 0.250 0.502 0.566 82.67 80.82
ATC1 0.294 0.394 0.711 0.759 76.37 72.42
ATC3 0.286 0.351 0.677 0.700 77.31 74.89
ATC4 0.262 0.263 0.629 0.603 79.08 79.53
ATC5 0.251 0.239 0.592 0.571 80.10 81.00
ATC7 0.234 0.238 0.553 0.565 81.26 81.30
2000 Trade 0.218 0.291 0.500 0.677 82.70 77.89
ATC1 0.305 0.325 0.716 0.775 75.96 74.74
ATC3 0.270 0.304 0.645 0.733 78.52 76.31
ATC4 0.260 0.306 0.624 0.727 79.25 76.16
ATC5 0.249 0.279 0.588 0.666 80.24 78.42
ATC7 0.234 0.280 0.550 0.659 81.35 78.48
2001 Trade 0.225 0.305 0.514 0.687 82.29 76.99
ATC1 0.307 0.297 0.722 0.754 75.83 76.07
ATC3 0.278 0.300 0.662 0.731 77.96 76.51
ATC4 0.264 0.298 0.633 0.735 78.96 76.34
ATC5 0.254 0.286 0.600 0.719 79.90 77.15
ATC7 0.240 0.298 0.563 0.684 80.97 77.25
* Average Precision is presented in percent.
† See Section 3.7.1
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Table 6.13: Blood Results Obtained for One-error, Coverage and Average Precision, comparing
Trade Name and ATC coding
All drugs Suspected drugs only
Year code Eone−error Ecov Pav* Eone−error Ecov Pav*
Train Test Train Test Train Test Train Test Train Test Train Test
1996 Trade 0.257 0.297 0.471 0.517 83.93 81.62 0.247 0.288 0.442 0.469 84.65 82.71
ATC1 0.436 0.334 0.887 0.585 71.84 79.72 0.413 0.308 0.861 0.564 73.01 80.98
ATC3 0.375 0.301 0.742 0.541 75.99 81.33 0.343 0.277 0.669 0.510 78.23 82.76
ATC4 0.352 0.281 0.685 0.528 77.61 82.02 0.333 0.266 0.637 0.505 79.00 82.94
ATC5 0.324 0.270 0.610 0.468 79.60 83.32 0.306 0.254 0.561 0.454 80.96 84.07
ATC7 0.285 0.293 0.538 0.492 81.95 82.12 0.273 0.273 0.491 0.441 83.08 83.66
1997 Trade 0.256 0.354 0.477 0.636 83.86 78.24 0.244 0.299 0.439 0.532 84.78 81.32
ATC1 0.428 0.354 0.860 0.673 72.48 77.48 0.404 0.344 0.839 0.683 73.56 77.63
ATC3 0.374 0.342 0.734 0.612 76.13 78.84 0.335 0.309 0.656 0.591 78.65 80.18
ATC4 0.346 0.328 0.675 0.604 77.96 79.36 0.327 0.311 0.630 0.601 79.26 79.97
ATC5 0.316 0.328 0.596 0.609 80.06 79.35 0.302 0.318 0.557 0.597 81.09 79.67
ATC7 0.285 0.328 0.536 0.608 81.98 79.43 0.271 0.295 0.486 0.536 83.25 81.49
1998 Trade 0.252 0.344 0.474 0.646 83.98 78.28 0.241 0.300 0.434 0.581 84.98 80.71
ATC1 0.423 0.370 0.848 0.702 72.80 76.59 0.397 0.317 0.820 0.634 74.11 79.53
ATC3 0.363 0.302 0.710 0.582 76.91 80.95 0.331 0.281 0.647 0.554 78.92 82.04
ATC4 0.343 0.311 0.666 0.594 78.15 80.38 0.326 0.281 0.630 0.565 79.30 81.74
ATC5 0.314 0.310 0.596 0.598 80.12 80.22 0.299 0.307 0.556 0.571 81.21 80.69
ATC7 0.284 0.325 0.534 0.614 82.06 79.45 0.267 0.291 0.486 0.555 81.35 81.55
1999 Trade 0.254 0.311 0.478 0.594 83.90 80.83 0.239 0.266 0.437 0.518 85.03 82.90
ATC1 0.417 0.353 0.832 0.741 73.23 76.77 0.390 0.332 0.803 0.713 74.63 77.98
ATC3 0.356 0.311 0.699 0.644 77.32 79.75 0.328 0.294 0.640 0.635 79.14 80.50
ATC4 0.340 0.312 0.664 0.635 78.31 79.83 0.322 0.302 0.624 0.637 79.52 80.08
ATC5 0.313 0.297 0.601 0.607 80.09 80.91 0.297 0.286 0.557 0.576 81.25 81.43
ATC7 0.282 0.309 0.539 0.603 82.04 80.61 0.265 0.268 0.488 0.527 83.41 82.74
2000 Trade 0.248 0.287 0.470 0.571 84.22 81.89 0.237 0.252 0.435 0.518 85.12 83.26
ATC1 0.404 0.317 0.810 0.649 74.08 79.60 0.383 0.313 0.793 0.649 75.02 79.70
ATC3 0.355 0.285 0.697 0.576 77.39 81.69 0.325 0.283 0.638 0.569 79.27 81.90
ATC4 0.336 0.288 0.657 0.582 78.59 81.52 0.318 0.277 0.619 0.569 79.73 82.05
ATC5 0.308 0.297 0.595 0.585 80.41 81.15 0.293 0.279 0.556 0.550 81.41 82.16
ATC7 0.280 0.295 0.532 0.577 82.26 81.46 0.261 0.263 0.481 0.512 83.65 83.22
2001 Trade 0.248 0.371 0.468 0.710 84.26 76.73 0.234 0.331 0.433 0.663 85.26 78.41
ATC1 0.425 0.416 0.835 0.814 73.01 7.59 0.391 0.365 0.795 0.747 74.74 76.35
ATC3 0.347 0.354 0.683 0.680 77.90 77.65 0.319 0.321 0.631 0.654 79.62 79.37
ATC4 0.327 0.346 0.643 0.662 79.13 78.26 0.313 0.320 0.614 0.637 79.99 79.54
ATC5 0.303 0.347 0.587 0.676 80.71 77.86 0.287 0.342 0.546 0.644 81.77 78.48
ATC7 0.273 0.367 0.522 0.709 82.66 76.86 0.258 0.344 0.476 0.660 83.84 78.12
* Average Precision is presented in percent.
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Table 6.14: Neuro – Suspected drugs only – Results Obtained forOne-error, Coverage and Average
Precision, comparing Trade Name and ATC coding
Year code Eone−error Ecov Pav*
Training Test Training Test Training Test
1996 Trade 0.378 0.472 0.658 0.786 76.32 70.93
ATC1† 0.509 0.507 0.912 0.877 67.90 68.35
ATC3† 0.499 0.507 0.886 0.870 68.52 68.22
ATC4† 0.462 0.476 0.820 0.814 70.91 70.30
ATC5† 0.435 0.476 0.759 0.793 72.75 70.69
ATC7† 0.408 0.477 0.711 0.795 74.46 70.63
1997 Trade 0.385 0.481 0.668 0.812 75.91 70.28
ATC1 0.507 0.490 0.905 0.864 68.10 69.18
ATC3 0.501 0.521 0.885 0.889 68.41 67.46
ATC4 0.461 0.472 0.817 0.807 70.98 70.71
ATC5 0.439 0.469 0.763 0.799 72.54 70.82
ATC7 0.412 0.490 0.715 0.792 74.22 70.23
1998 Trade 0.389 0.461 0.672 0.723 75.66 72.24
ATC1 0.505 0.522 0.901 0.915 68.20 67.30
ATC3 0.495 0.496 0.872 0.838 68.86 69.38
ATC4 0.464 0.508 0.821 0.845 70.82 68.91
ATC5 0.442 0.491 0.768 0.821 72.32 69.82
ATC7 0.419 0.471 0.721 0.740 73.85 71.57
1999 Trade 0.392 0.436 0.669 0.693 75.61 73.69
ATC1 0.512 0.564 0.910 1.011 67.78 64.34
ATC3 0.490 0.493 0.857 0.824 69.30 69.71
ATC4 0.470 0.525 0.827 0.846 70.44 68.28
ATC5 0.446 0.487 0.761 0.737 72.24 71.54
ATC7 0.418 0.435 0.715 0.691 73.98 73.71
2000 Trade 0.391 0.473 0.664 0.813 75.70 70.39
ATC1 0.512 0.518 0.886 0.871 68.03 67.95
ATC3 0.485 0.514 0.827 0.870 69.91 68.04
ATC4 0.461 0.500 0.795 0.852 71.29 68.82
ATC5 0.443 0.491 0.745 0.828 72.62 69.39
ATC7 0.418 0.475 0.710 0.808 74.07 70.34
2001 Trade 0.396 0.455 0.675 0.721 75.34 72.25
ATC1 0.513 0.495 0.886 0.795 67.99 69.97
ATC3 0.491 0.500 0.840 0.828 69.44 68.85
ATC4 0.465 0.499 0.801 0.835 71.05 68.77
ATC5 0.446 0.498 0.756 0.824 72.34 68.93
ATC7 0.421 0.455 0.717 0.718 73.82 72.34
* Average Precision is presented in percent.
† See Section 3.7.1
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Table 6.15: Results Mallreac Obtained for One-error, Coverage and Average Precision with all
18 Reaction classes, comparing Trade Name and ATC coding
All drugs Suspected drugs only
Year code Eone−error Ecov Pav* Eone−error Ecov Pav*
Train Test Train Test Train Test Train Test Train Test Train Test
1996 Trade 0.496 0.552 1.919 2.424 60.05 55.45 0.472 0.520 1.806 2.236 61.97 57.28
ATC1 0.621 0.590 2.537 2.641 50.03 51.23 0.622 0.584 2.501 2.586 50.43 51.82
ATC3 0.564 0.566 2.293 2.498 54.29 53.44 0.543 0.542 2.205 2.389 55.96 55.37
ATC4 0.0.550 0.553 2.210 2.438 55.41 54.05 0.533 0.534 2.126 2.340 56.84 55.60
ATC5 0.531 0.546 2.100 2.329 57.05 54.89 0.509 0.526 1.999 2.205 58.80 56.58
ATC7 0.517 0.542 2.012 2.317 58.38 55.72 0.494 0.516 1.902 2.157 60.22 57.65
1997 Trade 0.498 0.571 1.939 2.532 59.76 55.01 0.474 0.531 1.827 2.303 61.70 56.75
ATC1 0.618 0.580 2.571 2.662 50.04 51.65 0.619 0.583 2.543 2.631 50.36 51.77
ATC3 0.564 0.554 2.314 2.518 54.18 53.67 0.544 0.542 2.225 2.438 55.82 54.84
ATC4 0.551 0.548 2.227 2.439 55.27 54.14 0.534 0.536 2.140 2.357 56.72 55.26
ATC5 0.534 0.551 2.117 2.383 56.77 54.57 0.512 0.531 2.011 2.290 58.52 56.06
ATC7 0.518 0.555 2.024 2.422 58.20 55.27 0.495 0.520 1.911 2.246 60.08 57.21
1998 Trade 0.499 0.550 1.956 2.441 59.62 56.40 0.474 0.520 1.840 2.238 61.61 57.80
ATC1 0.615 0.580 2.593 2.563 50.14 52.32 0.616 0.576 2.564 2.531 50.47 52.75
ATC3 0.564 0.545 2.330 2.434 54.08 54.55 0.543 0.526 2.237 2.347 55.75 56.04
ATC4 0.550 0.538 2.240 2.350 55.21 55.35 0.533 0.523 2.153 2.265 56.64 56.58
ATC5 0.534 0.536 2.141 2.273 56.62 55.84 0.512 0.519 2.034 2.188 58.37 57.19
ATC7 0.517 0.545 2.044 2.356 58.10 56.41 0.493 0.515 1.298 2.174 60.05 58.04
1999 Trade 0.498 0.533 1.965 2.371 59.63 58.63 0.473 0.503 1.847 2.141 61.61 59.37
ATC1 0.612 0.595 2.596 2.509 50.32 52.09 0.612 0.597 2.561 2.502 50.68 52.12
ATC3 0.562 0.555 2.345 2.264 54.07 55.34 0.542 0.548 2.252 2.245 55.71 55.86
ATC4 0.549 0.549 2.248 2.214 55.19 55.71 0.532 0.544 2.160 2.199 56.61 56.09
ATC5 0.533 0.547 2.146 2.208 56.59 56.77 0.512 0.533 2.039 2.113 58.31 57.31
ATC7 0.519 0.532 2.053 2.218 58.00 58.11 0.495 0.512 1.935 2.074 59.91 58.79
2000 Trade 0.499 0.584 1.965 2.480 59.60 54.14 0.476 0.566 1.855 2.343 61.43 54.15
ATC1 0.610 0.608 2.590 2.583 50.50 50.30 0.610 0.608 2.553 2.587 50.89 50.26
ATC3 0.562 0.589 2.339 2.339 54.14 52.39 0.543 0.590 2.250 2.402 55.72 52.35
ATC4 0.551 0.582 2.240 2.322 55.26 53.05 0.534 0.581 2.160 2.318 60.59 53.10
ATC5 0.537 0.572 2.141 2.275 56.53 53.75 0.517 0.569 2.040 2.257 58.14 53.76
ATC7 0.519 0.570 2.046 2.331 58.08 54.38 0.496 0.561 1.936 2.266 59.89 54.38
2001 Trade 0.503 0.567 1.981 2.367 59.28 53.89 0.481 0.554 1.878 2.271 60.99 54.43
ATC1 0.610 0.590 2.597 2.554 50.46 51.03 0.610 0.591 2.565 2.530 50.82 51.20
ATC3 0.566 0.570 2.361 2.363 53.84 52.83 0.549 0.563 2.284 2.301 55.21 53.55
ATC4 0.555 0.574 2.262 2.323 54.84 52.91 0.540 0.577 2.186 2.272 56.06 53.26
ATC5 0.540 0.572 2.156 2.262 56.23 53.37 0.522 0.572 2.063 2.214 57.69 53.83
ATC7 0.521 0.557 2.062 2.277 57.78 54.14 0.501 0.546 1.961 2.214 59.44 54.73
* Average Precision is presented in percent.
Chapter 7
Optimization, Drug-drug
Interaction and Suspected Drug
Evaluation
7.1 Preface
This chapter continues the development of the fuzzy relations algorithms and the comparison of
algorithm A(p) with the BoosTexter algorithm using the nervous system and special senses –
Neuro data set described in Section 3.4.3 [329]. Multi-label classification is an important and
difficult problem that frequently arises in text categorization. The accurate identification of drugs
which are responsible for reactions that have occurred is one of the important problems of adverse
drug reactions (ADR). In this chapter the similarities of these two problems are investigated to
analyze the usefulness of drug reaction relationships for the prediction of possible reactions. A
new method for the determination of responsibility for subsets of drug(s), out of all drugs recorded
in a particular ADR report, in reactions that have been observed will also be introduced. This
method is applied for the evaluation of the level of correctness of suspected (see Section 3.5.1)
drugs reported in nervous system and special senses type reactions in the ADRAC database as
well as to the problem of interaction of drugs. This is reported in [329].
7.2 Introduction
When classifying a set of objects, the problem is determining what classes these objects belong to,
based on certain descriptors of the given objects. An example is text categorization, (see Section
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1.9) where an incoming message or document is labelled by some predefined classes. These cate-
gorization problems have been solved using approaches that utilize finding discriminant functions.
It is assumed in these approaches that a Gaussian distribution is present in each class. Another
approach that has been used is the least squares fit approach. Finding a linear separator is an ap-
proach that does not have any distributional assumptions. Using a perceptron with minimization
of the training error, this linear separator can be found. Logistic regression is another approach
that has been used in information retrieval and text categorization. Closely related to support
vector machines, logistic regression has a lot of success in categorizing text.
Techniques have been developed for feature selection in text categorization problems where the
interest has been primarily focused on classification rather than determining features (words) that
signify a particular document in a particular class.
During studies of adverse drug reactions, ADR records include a list of drugs taken and a list
of reactions that have been experienced. The main concern with these adverse drug reactions is
”Which drug is responsible for which action?”. This is indeed a classification problem, but the
focus is on determining features (drugs) to properly classify (reaction), rather than classifying
based on the set of drugs recorded in a ADR report.
This chapter considers a situation in which there are n records. In the case of text categorization
these would be documents and in the case of ADRs each record would represent a patient with a
number of drugs taken and various reactions that were observed or reported. Let the records or
objects be x1, ..., xn,, where n is the number of records (documents/ADR reports);
Each record (document/ADR report) is a vector of terms (words/drugs): xi = (xi1, ..., xi,m),
i = 1, ..., n. So m is the number of terms (words/drugs). xij = 1 if the word (drug) j is used in
record i, xij = 0 if not.
In a classification task there may be two disjoint classes (binary classification), many disjoint
classes (multi-class classification) or multiple overlapping classes (multi-label classification). In
many cases multi-class classification problems are reduced to many binary classification problems.
These categorization problems have been solved using approaches that utilize finding discriminant
functions. It is assumed in these approaches that a Gaussian distribution is present in each class.
Another approach that has been used is the least squares fit approach. Finding a linear separator
is an approach that does not have any distributional assumptions. Using a perceptron with min-
imization of the training error, this linear separator can be found. Logistic regression is another
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approach that has been used in information retrieval and text categorization. Closely related to
support vector machines, logistic regression has a lot of success in categorizing text.
Techniques have been developed for feature selection in text categorization problems where the
interest has been primarily focused on classification rather than determining features (words) that
signify a particular document in a particular class.
During studies of adverse drug reactions (ADRs), ADR report records include a list of drugs
taken and a list of reactions that have been experienced. The main concern with these adverse
drug reactions is ”Which drug is responsible for which action?”. This is indeed a classification
problem, but the focus is on determining features (drugs) to properly classify (reaction), rather
than classifying based on the set of drugs recorded in a ADR report.
In this chapter a situation in which there are n records was considered. In the case of text
categorization these would be documents and in the case of ADRs each record would represent a
ADR report with a number of drugs recorded and various reactions that were observed or reported.
Let the records or objects be x1, ..., xn,, where n is the number of records (documents/ADR
reports);
Each record (document/ADR report) is a vector of terms (words/drugs): xi = (xi1, ..., xi,m),
i = 1, ..., n. So m is the number of terms (words/drugs). xij = 1 if the word (drug) j is used in
record i, xij = 0 if not.
In a classification task there may be two disjoint classes (binary classification), many disjoint
classes (multi-class classification) or multiple overlapping classes (multi-label classification). In
many cases multi-class classification problems are reduced to many binary classification problems.
A. Binary classification: Two classes y ∈ {−1, 1}.
Each document (ADR report) belongs to one of these classes. Denote by yi the class for xi, i =
1, ..., n; that is, yi = −1 or yi = 1. The problem is to find a weight vector w = (w1, ..., wm);wi ∈ R
(that is, weight for each word) such that, the values wxi and yi (i = 1, ..., n) are close overall.
Denote the scalar product of two vectors a and b by ab. Closeness can be assessed in many ways
but considering the least squares fit or the logistic regression approach leads to the optimization
problems below.
1. Least squares fit (LLSF) aims to solve:
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w = arg inf
w
1
n
n∑
i=1
(wxi − yi)2. (7.2.1)
2. Logistic regression (LR) aims to solve:
w = arg inf
w
1
n
n∑
i=1
ln(1 + e−wxiyi). (7.2.2)
B. Multi-label classification:
Let c be the number of classes. Each record (document/ADR report) can belong to a number of
these c classes (reactions). Denote by yi = (yi1, ..., yic) the vector of classes for xi, i = 1, ..., n.two
different versions for the representation of the vector yi will be considered.
1). yij = 1, if xi belongs to the class j, and yij = −1 if not.
2). yij = 1, if xi belongs to the class j, and yij = 0 if not.
7.3 Optimization Approaches to Feature Weighting
The problem is to find a weight matrixW = (w1, ..., wm); that is, a weight vector wj = (w1j , ..., wcj)
for each feature (word/drug) j; such that, the vectors Wxi and yi (i = 1, ..., n) are close overall.
Closeness can be assessed in many ways but considering the least squares fit or the logistic regres-
sion approach [586, 587] leads to the optimization problems below:
Least squares fit (LLSF) aims to solve :
Wllsf = arg inf
W
1
n
n∑
i=1
(‖Wxi − yi‖)2. (7.3.1)
Logistic regression (LR) aims to solve:
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Wlr = arg inf
W
1
n
n∑
i=1
ln(1 + e−yiWxi). (7.3.2)
In fact, the existence of different numbers of classes for different ADR reports/documents
(one may belong to one class, another may belong to many classes) means that the errors de-
scribed by (7.3.1) and (7.3.2) may not be comparable (the error obtained for multi-class ADR re-
port/document can be equal to the sum of errors from many single class ADR reports/documents).
This is very important, at least, for ADR problems. As a result, the weights may not be best de-
fined as a solution to (7.3.1) or (7.3.2).
Therefore, (see (7.6.6)) the following formula for determining a classifier was considered so that
the errors are more effectively measured (the versions of algorithm A(p), p = 0, 1, 2, see section
7.6):
Wp = arg inf
W
1
n
n∑
i=1
(‖yi‖)−p ·
c∑
j=1
( ‖yi‖∑c
l=1Hi,l
Hij − yij
)2
; (7.3.3)
whereHij =
∑m
q=1 wjqxiq, and ‖yi‖ is the number of positive coordinates in the vector (yi1, ..., yic),.
In the application of this approach to the Australian Adverse Drug Reaction (ADRAC) database,
‖yi‖ is the number of reactions that occurred for ADR report i). To explain the advantage of this
formula consider one example.
Example 7.3.1. Assume that there is just one word/drug (m = 1), there are 5 classes (c = 5)
and there are 4 ADR reports/documents (n = 4), where, the first document belongs to the all 5
classes, and the other 3 documents belong to the first class. An optimal weight matrix (vector
in this example) W = (w1, w2, ..., w5) needs to be found. Note that, this is a typical situation in
ADR problems, where one drug can cause different reactions (and in different combinations).
Consider both cases (1) and (2). In the calculations, the weight for the first class is set to be
one.
Case 1. In this case the vectors for each class are: y1 = (1, 1, 1, 1, 1), yi = (1,−1,−1,−1,−1)
for i = 2, 3, 4, 5. Thus:
LLSF: W = (1, 0, 0, 0, 0);
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LR: W = (1, 0, 0, 0, 0);
A(0) : W = (1, 0.42, 0.42, 0.42, 0.42);
A(1) : W = (1, 0.06, 0.06, 0.06, 0.06);
A(2) : W = (1, 0, 0, 0, 0).
Observe that, in this case, the methods LLSF and LR have failed to produce sensible results.
For this case function (7.3.3), for p = 0, 1, works well.
Case 2. In this case the class vectors (or vectors of reactions) are: y1 = (1, 1, 1, 1, 1), yi =
(1, 0, 0, 0, 0) for i = 2, 3, 4, 5. Thus:
LLSF: W = (1, 0.25, 0.25, 0.25, 0.25);
LR: W = (1, 1, 1, 1, 1);
A(0) : W = (1, 0.62, 0.62, 0.62, 0.62);
A(1) : W = (1, 0.25, 0.25, 0.25, 0.25);
A(2) : W = (1, 0.06, 0.06, 0.06, 0.06).
It can be seen that, LR fails in the second case too, whilst all others work well. In this simple
example, LLSF = A(1), but in general, when there are combinations of more than one word/drugs
are involved, the outcome will be different.
Comparison of the weights for the algorithms A(p), p = 0, 1, 2, shows that, the difference
between weights for the first class and the others is minimal for A(0), and is maximal for A(2).
Which one is better? Of course, this question cannot be answered definitively without further
exploration; for different situations different versions could be better. That is why, it is very useful
to consider different versions p = 0, 1, 2.
This example shows that, it is more convenient to represent the vector of classes as in the
second case; moreover, formula (7.3.3) is more preferable than formulae (7.3.1) and (7.3.2). This
is the way class membership will be encoded.
Using functions like (7.3.3) is required to solve a complicated optimization problem, but the
choice of a more reasonable distance functions is important.
In the next sections the application of this approach to the study of the drugs that are the most
suspect or responsible for the adverse drug reactions observed in ADR reports shall be concentrated
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upon. The Nervous system and special senses class consists of three sub-classes. In this chapter
the part of the ADRAC data related to the nervous system type of reactions will be considered: all
records having at least one reaction from these three sub-groups this data set was called Neuro.
In this data set some records may have a reaction from outside the nervous system and special
senses group which were define three classes according to these three sub-groups and additionally
a fourth class that contains reactions belonging to the other 17 SOCs (see section 3.4.3). For the
number of records see Table 7.1 below.
7.4 Drug-reaction representations
Denote by X the set of all ADR reports and by D the set of all drugs used by these ADR reports.
Let c be a finite number of possible reactions (classes). Given ADR report x ∈ X , denote by
Y(x) = (Y1(x),Y2(x), · · · ,Yc(x)) a c-dimensional vector of reactions observed for this ADR report;
where Yi(x) = 1 if the reaction i has occurred, and Yi(x) = 0 if it has not. Let D(x) be the set
of all drugs taken by the ADR report x. In the ADRAC data, the number of drugs reported for a
ADR report is restricted to 10. Some of these drugs are reported as suspected drugs responsible
in the reactions Y(x). Therefore, divide the set D(x) into two parts: DS(x) - the set of suspected
drugs and DN(x) – the set of non-suspected drugs. Clearly D(x) = DS(x) ∪DN(x), and it may
be DN(x) = ∅. Also note that, in the ADRAC data, for some ADR reports, suspected drugs are
reported in the form of interaction.
The goal of the study of drug-reaction relationships is to find a function h : D → Rc+, where
given drug d ∈ D the components hi of the vector h(d) = (h1, h2, . . . , hc) are the weights (“proba-
bilities”) of the occurrence of the reactions i = 1, 2, . . . , c. Here Rc+ is the set of all c-dimensional
vectors with non-negative coordinates.
In the next step, given a set of drugs ∆ ⊂ D, a vector
H(∆) = (H1(∆),H2(∆), . . . , Hc(∆)), (7.4.1)
needs to be defined, where the component Hi(∆) indicates the probability of occurrence of the
reaction i after taking the drugs ∆. In other words, a function H : S(D)→ Rc+ needs to be defined,
where S(D) is the set of all subsets of D.
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Let ∆ ⊂ D. The vectors h(d) show what kind of reactions are caused by the drugs d ∈ ∆. There-
fore the vector H(∆) can be considered as potential reactions which could occur after taking the
drugs ∆. But what kind of reactions will occur? This will depend upon the individual characteris-
tics of the patient as well as external factors. Different patients can have different predispositions
for different reactions. Some reactions which have potentially high degrees of occurrence may not
be observed because of the strong resistance of the patient to developing these reactions. But the
existence of these potential reactions could have an influence on the patient somehow. The results
obtained in [322] have shown that the information about the existence of potential reactions (but
which were not reported to ADRAC) helps to make prediction of reaction outcomes (bad and good)
more precise.
The function H can be defined in different ways and it is an interesting problem in terms of
ADR(s). The linear (sum) function H(∆) [322] will be used, where the components Hi(∆) are
defined as follows:
Hi(∆) =
∑
d∈∆
hi(d), i = 1, . . . , c. (7.4.2)
The use of this function means that, the effects from different drugs are accumulated. For example,
if hi(dn) = 0.2 (n=1,2) for some reaction i, then there exists a potential of 0.4 for this reaction;
that is, the two small effects (that is 0.2) become a greater effect (that is 0.4).
Given ADR report x ∈ X , potential reactions H(x) = H(∆) corresponding to the set of
drugs ∆ ⊂ D(x) can be defined. If ∆ = D(x), thus H(x) = HA(x) .= H(D(x)), which means
that all the drugs recorded in the ADR report x are used in the definition of potential reactions;
whereas, if ∆ = DS(x), then H(x) = HS(x) .= H(DS(x)), which means that suspected drugs
are only used, neglecting all the others. The potential reactions H(x) = HN (x) .= H(DN(x))
can also be considered.
Therefore, drug-reaction relationships will be represented by vectors h(d), d ∈ D. The definition
of these vectors depends on the drugs that are used in the calculations: either all drugs or only
suspected drugs can be used. The evaluation of different drug-reaction representations can be
defined by the closeness of two vectors: H(x), the vectors of potential (predicted) reactions, and
Y(x), the vectors of observed reactions. The evaluation measure Average Precision will be used,
presented in Section 7.5, to describe the closeness of these reaction vectors.
In this section the study the usefulness and correctness of the suspected drugs reported in
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ADRAC data is investigated.
The usefulness of suspected drugs is examined in the prediction of reactions. For this, first
vectors h(d) by using all drugs, and then by using only suspected drugs were defined. In this way,
potential reactions HA(x) and HS(x) were obtained, respectively. The closeness of these reactions
to the observed reactions Y(x) over the all training and test sets was evaluated. The calculations
are made by the algorithms BoosTexter ([459]) and A(p) described below. Note that, in all cases,
the suspected drugs (that is, potential reactions HS(x)) provided better results. This means that
the suspected drugs in the ADRAC data are identified “sufficiently correctly”.
Consider the case when the drug-reaction relations h(d) are defined by using only suspected
drugs. Potential reactions related to the suspected and non-suspected drugs were calculated.
To evaluate the correctness of suspected drugs, the convex combination of these two vectors of
potential reactions was found, which provides the minimal distance to the observed reactions. The
weighting of the suspected drugs, in this optimal combination, is taken as an evaluation value of
the correctness of suspected drugs. The calculations are made only by the algorithm A(p). Note
that the algorithm BoosTexter could not be used to evaluate correctness.
7.5 Evaluation Measure: Average Precision
To evaluate the accuracy of established drug-reaction relations by a given classifier (h,H); that
is, to evaluate the closeness of the two vectors H(x) (predicted reactions) and Y(x) (observed
reactions) the Average Precision measure considered in [459] was used. Note that, this measure
allows evaluation in multi-label classification problems to be achieved more completely.
Let Y (x) = {l ∈ {1, . . . , c} : Yl(x) = 1} be the set of reactions that have been observed for
the ADR report x and H(x) = {H1(x), · · · ,Hc(x)} be potential reactions calculated for this
ADR report. Denote by T (x) the set of all ordered reactions τ = {i1, . . . , ic} satisfying the
condition
Hi1(x) ≥ . . . ≥ Hic(x);
where ik ∈ {1, . . . , c} and ik 6= im if k 6= m.
In the case, when the numbers Hi(x), i = 1, · · · , c, are different, there is just one order
τ satisfying this condition. But if there are reactions having the same potential reactions then
potential reactions can be ordered in different ways; that is, in this case the set T (x) contains
174
more than one order.
Given order τ = {τ1, . . . , τc} ∈ T (x),
define the rank for each reaction l ∈ Y (x) as rankτ (x; l) = k, where the number k satisfies
τk = l. Then Precision is defined as:
Pτ (x) =
1
|Y (x)|
∑
l∈Y (x)
|{k ∈ Y (x) : rankτ (x; k) ≤ rankτ (x; l)}|
rankτ (x; l)
.
Here, the notation |S| was used for the cardinality of the set S. This measure has the following
meaning. For instance, if all observed reactions Y (x) have occurred on the top of ordering τ then
Pτ (x) = 1. Clearly the number Pτ (x) depends on order τ. Define
Pbest(x) = max
τ∈T (x)
Pτ (x) and Pworst(x) = min
τ∈T (x)
Pτ (x),
which are related to the “best” and “worst” ordering. Therefore, it is sensible to define the Precision
as the midpoint of these two versions: P (x) = (Pbest(x) + Pworst(x))/2.
Average Precision over all records X will be defined as:
Pav =
1
|X |
∑
x∈X
P (x).
7.6 The Algorithm A(p)
Given a vector V = (V1, · · · , Vc), with nonnegative coordinates, the notation
‖V ‖ =
c∑
i=1
Vi (7.6.1)
will be used.
Let x ∈ X .Define the distance between predicted potential reactions H(x) = (H1(x), . . . ,Hc(x))
and observed reactions Y(x) = (Y1(x), . . . ,Yc(x)) as:
dist (H(x),Y(x)) =
c∑
i=1
(H¯i(x)− Yi(x))2; (7.6.2)
where the sign “bar” stands for a normalization with respect to the number of observed reactions
‖Y(x)‖ :
H¯i(x) =
{ ‖Y(x)‖
‖H(x)‖ Hi(x) if ‖H(x)‖ > 0;
0 if ‖H(x)‖ = 0.
(7.6.3)
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The Algorithm A(p) uses the following distance measure (assume that ‖Y(x)‖ > 0):
distp (H(x),Y(x)) = ‖Y(x)‖−p · dist (H(x),Y(x)), p = 0, 1, 2. (7.6.4)
Note that, these distance functions are slightly different from the Linear Least Squares Fit (LLSF)
mapping function considered in [586, 587].
The difference between distances distp, p = 0, 1, 2 can be explained as follows. Consider the
case ‖H(x)‖ > 0. The following representation is true:
distp (H(x),Y(x)) =
c∑
i=1
(ai − bi)2;
where ai =
‖Y(x)‖1− p2
‖H(x)‖ Hi(x), bi = ‖Y(x)‖−
p
2 Yi(x), and clearly
c∑
i=1
ai =
c∑
i=1
bi = ‖Y(x)‖1−
p
2 .
In the distance dist0 (that is, p = 0) the sums
∑
i ai and
∑
i bi are equal to the number of
reactions ‖Y(x)‖. For dist1 and dist2 the corresponding sums are equal to
√‖Y(x)‖ and
1, respectively. dist1 can be considered as a middle version, because the number of reactions
‖Y(x)‖ ≥ 1 and therefore
1 ≤
√
‖Y(x)‖ ≤ ‖Y(x)‖.
It is not difficult to observe that the following property holds:
distp (λH(x),Y(x)) = distp (H(x),Y(x)), for all λ > 0. (7.6.5)
The algorithm A(p) aims to define drug-reaction relations h(d) minimizing the average distance
distp (H(x),Y(x)) over all training examples. In other words, consider the following optimization
problem:
Epav =
1
|X |
∑
x∈X
distp (H(x),Y(x)) → min; (7.6.6)
subject to : hi(d) ≥ 0, i = 1, ..., c, d ∈ D. (7.6.7)
Here |X | stands for the cardinality of the set X , and H(x) is a potential reactions for the ADR
report x ∈ X . Note that, taking different numbers p = 0, 1, 2, A(p), p = 0, 1, 2 produces different
versions, which generate different drug-reaction representations h(d).
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7.6.1 Calculation of weights for each drug. A good solution to the
optimization problem (7.6.6),(7.6.7).
The function in (7.6.6) is non-convex and non-linear and has many local minimum points. There-
fore, a global optimization problem results. The number of variables is |D| ·c. For the data Neuro,
|D| = 3705 and c = 4. Thus a global optimization problem with 14820 variables is obtained, which
is very hard to handle using existing global optimization methods. This means that there is a
clear need to develop new optimization algorithms for solving problem (7.6.6),(7.6.7), taking into
account some peculiarities of the problem.
In this chapter one heuristic method for finding a “good” solution to the problem (7.6.6),(7.6.7)
is suggested. This method is based on proposition 6.2.1 and formulae: 6.2.5, 6.2.6, 6.2.7.
(S) (Single). The set X(d) carries very important information, because here the drug d and
reactions are observed in a pure relationship. Therefore, if the set X(d) contains a “sufficiently
large” number of records, then it will be reasonable to define the weights hj(d), (j = 1, . . . , c) only
by this set neglecting all the mixed cases.
Consider two numbers: |X(d)| – the number of cases where the drug is used alone, and P (d) =
100|X(d)|/|Xall(d)| – the percentage of these cases. To determine whether the set X(d) contains
enough records both numbers need to be used. Consider a function φ(d) = a|X(d)| + bP (d) to
describe how large the set X(d) is.
Therefore, if the number φ(d) ≥ p∗, where p∗ is a priori given number, then the set X(d)
only was used to calculate weights h(d); in other words, formula (6.2.7) was used, which provides
a global minimum h(d) = h∗(d) for the part of data X(d) ⊂ X . In the calculations below the
number p∗ is set to be 1000.
Denote by D′ the set of all drugs from D is the way in which the weights are calculated.
(M) (Mixed). If the set X(d) is not “sufficiently large”; that is, φ(d) < p∗, then the set
Xall(d) must be used, which contains ADR reports x ∈ X having more than one drug taken. In
this case h(d) = h∗∗(d) was used; where
h∗∗j (d) =
 ∑
x∈X(d)
‖Y(x)‖2−p
−1 · ∑
x∈X(d)
‖Y(x)‖1−p rem (Yj(x))|∆′′(x)| , j = 1, . . . , c. (7.6.8)
Here, given a ADR report x, the set ∆′′(x) = ∆(x) \ D′ combines all drugs the weights for
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which are not calculated in the first step. Note that, ∆(x) is the set of drugs corresponding to the
ADR report x, and either ∆(x) = D(x) (all drugs) or ∆(x) = DS(x) (suspected drugs) will be
considered.
rem (Yj(x)), j ∈ {1, · · · , c}, stands for the “remaining” part of the reaction Yj(x), associated
with the drugs ∆′′(x). For the calculation of rem (Yj(x)) see Section 7.6.2.
This formula has the following meaning. If |∆′′(x)| = 1 for all x ∈ Xall(d), then, given
rem (Yj(x)), j = 1, · · · , c, formula (7.6.8) provides a global minimum solution (similar to (6.2.7)).
If |∆′′(x)| > 1, for some ADR report x ∈ Xall(d), then the assumption that all drugs in
∆′′(x) are responsible to the same degree was used; that is, for this ADR report, only the part
1/|∆′′(x)| of the reactions rem (Yj(x)) was attributed to this drug.
Therefore, h(d) = (h1(d), . . . hc(d)) was defined as follows:
h(d) =
{
h∗(d) if φ(d) ≥ p∗;
h∗∗(d) otherwise;
(7.6.9)
where h∗(d) and h∗∗(d) are defined by (6.2.7) and (7.6.8), respectively.
Remark 7.6.1. Note that the weight hi(d) is not exactly a probability of the occurrence of the
reaction i; that is, the sum
∑c
i=1 hi(d) does not need to be equal to 1.
7.6.2 Calculation of rem (Y(x))
Consider a particular ADR report x ∈ X . The set of drugs ∆(x) (which could be all drugs or
suspected drugs recorded in this ADR report) was divided into two parts:
∆(x) = ∆′(x) ∪∆′′(x);
where for each drug d, in the set ∆′(x), the vector h(d) has already been defined by (6.2.7), and
the set ∆′′(x) combines all the other drugs. Note that it may be ∆′(x) = ∅.
Set H(x) = G(x) + Z(x) where the sum G(x) = ∑d∈∆′(x) h(d) defines a part of potential
reactions associated with the drugs ∆′(x), and Z(x) the other (unknown) part which will be
defined by the drugs ∆′′(x) : Z(x) =
∑
d∈∆′′(x) h(d).
A reasonable assumption is that all drugs in ∆′′(x) are responsible in the observed reactions
Y(x) at the same degree; that is, equal parts 1/|∆′′(x)| of Z(x) were associated to each drug in
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∆′′(x). Therefore, after accepting such an assumption, only Z(x) needed to be found, which is an
optimal solution to the problem
distp (H(x),Y(x))→ min .
This problem is equivalent(see (7.6.4)) to
dist(H(x),Y(x)) =
c∑
i=1
(H¯i(x)− Yi(x))2 → min, (7.6.10)
where the “bar” stands for a normalization with respect to the reactions Y(x) (see (7.6.3)).
For a particular ADR report x, for sake of simplicity the sign x, will be dropped. Therefore,
to find the vector Z = (Z1, · · · , Zc), the following problem needs to be solved:
c∑
i=1
(
‖Y‖ (Gi + Zi)∑
j=1,...,c(Gj + Zj)
− Yi
)2
→ min, (7.6.11)
subject to : 0 ≤ Zi, Gi + Zi ≤ Zmax, i = 1, ..., c. (7.6.12)
Given Zmax, is denote by φ(Zmax) the optimal value of the objective function in the problem
(7.6.11),(7.6.12).
Proposition 7.6.1. The vector Z∗ = (Z∗1 , · · · , Z∗c ), where
Z∗i = Z
max −Gi, i = 1, · · · , c,
is the optimal solution to the problem (7.6.11),(7.6.12). Moreover, φ(Zmax)→ 0 as Zmax →∞.
This proposition shows that for the optimal solution Z∗ the the sums Z∗i + Gi, i = 1, · · · , c,
are constant being equal to Zmax.
Also note that, the distance φ(Zmax) is decreased by increasing the number Zmax. Note that,
Zmax serves to restrict the values Zi in order to get
max
i=1,··· ,c
(Gi + Zi) = 1, (7.6.13)
which means that the ADR report x would be taken into account with the weight 1 (like the ADR
reports in X(d)). Therefore, a number Zmax needs to be chosen close to 1.
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The number Zmax is defined as follows. Denote G0 = max{Gi : i = 1, · · · , c, Yi = 0},
G1 = max{Gi : i = 1, · · · , c, Yi = 1}. Then, set
Zmax = max{1, G0 + ε, G1}, where ε > 0.
The choice of such a number Zmax has the following meaning. First note that, if G0 < 1 and
G1 ≤ 1 then there is a number ε > 0 such that Zmax = 1; that is, (7.6.13) holds. On the other
hand, if G0 ≥ 1 and G0 ≥ G1, then the weights Z∗i +Gi, corresponding to the occurred reactions
i (that is, Yi = 1) will be grater than the weights Z∗i + Gi, corresponding to the non-occurred
reactions. In this case, choosing the number ε > 0 smaller, a closer approximation to (7.6.13) is
obtained.
Therefore, rem(Yj(x)) will be defined as
rem (Yj(x)) = Z∗j = Zmax −Gj , j = 1, · · · , c. (7.6.14)
7.7 Evaluation of correctness of suspected drugs reported
Drug-reaction representations in the form of a vector of weights allow the correctness of suspected
drugs reported to be evaluated.
Consider a particular ADR report x and let D(x) be the set of drugs used by this ADR report
and Y(x) be the set of observed reactions. The set D(x) consists of suspected drugs DS(x) and
non-suspected drugs DN(x). The aim of this section is to evaluate how correctly suspected drugs
are identified.
The method of evaluation is based on distance measure (7.6.2). Assume that for each drug
d ∈ D the vector of weights h(d) are calculated. Then potential reactions HS(x) and HN (x) can
be defined, corresponding to the sets of suspected drugs and non-suspected drugs, respectively.
Thus
HSi (x) = Hi(DS(x)) =
∑
d∈DS(x)
hi(d), i = 1, · · · , c;
HNi (x) = Hi(DN(x)) =
∑
d∈DN(x)
hi(d), i = 1, · · · , c.
The method, used in this chapter for the evaluation of suspected drugs, can be identified as “all
suspected drugs versus all non-suspected drugs”. To do this, consider convex combinations of these
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two group of drugs and try to find the optimal combination which provides the maximal closeness
to the observed vector of reactions. In other words a combination of suspected and non-suspected
drugs which is optimal in the sense of distance (7.6.2) is required. Before considering convex
combinations, care must be exercised concerning the “comparability” of the vectors HS(x) and
HN (x) in the sense of scaling. For this reason, it is meaningful to consider convex combinations
of normalized (see (7.6.3)) vectors H¯S(x) and H¯N (x). Therefore
H¯(x, µ) = µ H¯S(x) + (1− µ) H¯N (x), 0 ≤ µ ≤ 1 (7.7.1)
was defined. Note that, ‖H¯S(x)‖ = ‖H¯N (x)‖ = ‖Y(x)‖ and, therefore, ‖H¯(x, µ)‖ = ‖Y(x)‖ for
all µ ∈ [0, 1].
The number µ indicates the proportion of suspected and non-suspected drugs in the definition
of potential reactions. Clearly, H¯(x, 1) = H¯S(x) and H¯(x, 0) = H¯N (x), which implies
dist(H¯(x, 1),Y(x)) = dist(HS(x),Y(x)) and dist(H¯(x, 0),Y(x)) = dist(HN (x),Y(x)).
The combination of all drugs with the same weight; that is, the vector HA(x) = H(D(x)) =
HS(x) + HN (x) is also included in (7.7.1). To confirm this, it is sufficient to consider the case
‖HS(x)‖ > 0 and ‖HN (x)‖ > 0. In this case ‖HA(x)‖ = ‖HS(x)‖ + ‖HN (x)‖ > 0. Take
µ′ = ‖HS(x)‖/‖HA(x)‖ ∈ (0, 1) to get (see (7.6.3))
H¯(x, µ′) = µ′ ‖Y(x)‖‖HS(x)‖H
S(x) + (1− µ′) ‖Y(x)‖‖HN (x)‖H
N (x)
=
‖Y(x)‖
‖HA(x)‖H
S(x) +
‖Y(x)‖
‖HA(x)‖H
N (x) = H¯A(x);
which implies
dist(H¯(x, µ′),Y(x)) = dist(H¯A(x),Y(x)) = dist(HA(x),Y(x)).
Consider the following minimization problem with respect to µ;
f(µ) .= dist (H¯(x, µ),Y(x)) =
c∑
i=1
(H¯i(x, µ)− Yi(x))2 → min; 0 ≤ µ ≤ 1. (7.7.2)
The optimal solution µ∗ to problem (7.7.2) gives an information about the correctness of definition
of suspected drugs. For instance, if µ∗ = 1 then it can be seen that the suspected drugs provide
the better approximation to the observed reactions than if the other drugs were involved. This
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situation is referred to as 100 percent correctness. Whereas, if µ∗ = 0 then non-suspected drugs
provide better approximation to the observed reactions and it can be concluded that in this case
suspected drugs are defined completely wrong. Therefore, the optimal value µ∗ can be considered
as an evaluation measure for the correctness of suspected drugs.
From (7.6.4):
Proposition 7.7.1. The optimal solution µ∗ to the problem (7.7.2) is optimal with respect to the
all distance measures distp, p = 0, 1, 2; that is, given vectors of weights h(d), d ∈ D(x), for all
p = 0, 1, 2 the following inequality holds:
distp(H¯(x, µ∗),Y(x)) ≤ distp(H¯(x, µ),Y(x)), for all µ ∈ [0, 1]
is obtained. This proposition shows that, given ADR report x ∈ X and given vectors of weights
h(d), the definition of correctness of suspected drugs, as an optimal value µ∗, does not depend on
choice of distance functions dist and distp, p = 0, 1, 2.
It is clear that, problem (7.7.2) can have many optimal solutions µ∗; that is, different proportions
of suspected and non-suspected drugs can provide the same closeness to the observed reactions. In
this case the correctness of suspected drugs will be defined, as the maximal value among the all
optimal solutions µ∗ :
µ∗(x) = max{µ∗ : µ∗ is an optimal solution to (7.7.2)}. (7.7.3)
The reason for such a definition can be explained; for instance, if µ∗ = 1 (only suspected drugs)
and µ∗ = 0 (only non-suspected drugs) are the two different optimal solutions, giving the closest
approximation to the observed reactions, then there would be no reason to doubt about the cor-
rectness of suspected drugs.
Problem (7.7.2) can be easily solved. Let
A =
c∑
j=1
(zi ‖Y(x)‖ − z Yi(x))
(
zi ‖H¯N (x)‖ − z H¯Ni (x)
)
;
B =
c∑
j=1
(H¯Ni (x) ‖Y(x)‖ − ‖H¯N (x)‖Yi(x)) (zi ‖H¯N (x)‖ − z H¯Ni (x)) ;
where zi = H¯Si (x)− H¯Ni (x), z = ‖H¯S(x)‖ − ‖H¯N (x)‖. Then, it is found that the derivative of the
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function f(µ), defined by (7.7.2), in the following form:
f ′(µ) =
2
(zµ+ ‖H¯N (x)‖)4 (Aµ+B). (7.7.4)
From (7.7.4) is obtained
Proposition 7.7.2. The optimal solution µ∗(x) to the problem (7.7.2) can be found as follows.
1) Let A = 0. Then
µ∗(x) =
 0 if B > 0;1 otherwise.
2) Let A > 0. Then
µ∗(x) =
 0 if B > 0;min{1, −B/A} otherwise.
3) Let A < 0. Then
µ∗(x) =
 0 if f(0) < f(1);1 otherwise.
Therefore, the correctness of suspected drugs for a particular ADR report x has been defined.
Given set of ADR reports X , Average Correctness of suspected drugs will be calculated as
Psus =
1
|X |
∑
x∈X
µ∗(x). (7.7.5)
7.7.1 Remark on correctness
The above definition of correctness of suspected drugs can be considered as a method where the
group of suspected drugs (already defined) are taken versus the group of non-suspected drugs. In
fact, drug-reaction representations in the form of vectors of weights allows more general statements
of this problem, for example:
Consider a ADR report x ∈ X . Let D(x) = {d1, d2, · · · , d|D(x)|} be the set of drugs that have
been taken, and h(d), d ∈ D(x), be the vectors of weights for these drugs. A |D(x)|−dimensional
vector v = (v1, v2, · · · , v|D(x)|) is introduced, where the i-th component vi indicates the degree of
responsibility of the drug di in the observed reactions. In this case, potential reactions can be
defined as follows:
H(x, v) =
|D(x)|∑
i=1
vi h(di).
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Consider the following optimization problem:
dist (H(x, v),Y(x)) → min; 0 ≤ vi ≤ 1, i = 1, · · · , |D(x)|. (7.7.6)
If, for instance, the optimal value for a particular drug i is 0.6 (that is, vi = 0.6) then it can be
said that the degree of responsibility of this drug in the observed reactions is 0.6. Such information
about drugs is more complete than just saying “suspected” or “non-suspected”. But the application
of this method encountered the absence of any such kind of classification of suspected drugs in the
ADRAC data.
A special case, when each variable vi takes only two values, can also be considered: 1 (which
means that i is a suspected drug) and 0 (which means that i is a non-suspected drug). In this case,
a combinatorial optimization problem which is to find an optimal subset of drugs that provides
the closest approximation to the observed reactions is obtained.
The application of problem (7.7.6) allows the study of suspected drugs in each report more
precisely. Determining which drug from the set of drugs have been taken is responsible, is a very
important problem in terms of ADRs. But there are some issues that should be mentioned.
Such a precise statement of the problem should be accomplished with more precise definitions of
function H(x) (in this chapter (7.4.2)was used), then weights h(d), which have even more impact
on the results. First of all the times of starting and withdrawing drugs should be taking into
account. Such information is presented in the ADRAC data but more research needs to be done
in this area. The other factor that could be helpful for more precise definitions of weights h(d),
relates to the amount of general use of each drug, and the difficulty of getting such information is
the major factor in ADR problems.
7.8 Interaction of drugs
Interaction of drugs is one of the main problems of ADR. In [322] this problem was considered from
a statistical point of view. Interaction of drugs was defined as a case when these drugs together
cause a reaction which is different from the reactions that could have occurred if they were used
alone – see Section 4.7.4. In this chapter the aim is to study the possibility of using vectors of
weights h(d) calculated for each drug d, for drug-drug interactions. In other words, to check the
closeness of potential reactions to the observed reactions for ADR reports having interactions of
184
drugs. In this way the accuracy with which the potential reactions used for the prediction of
reactions in drug-drug interaction cases could be established.
The following two methods for the evaluation of correctness will be used.
1). First the methodology developed in the previous section will be used. The set of drugs
D(x), taken by a particular ADR report x, was divided into two subsets: I(x) is the set of drugs
which are reported as interaction, O(x) is the set of all other drugs.
Since the main concern is drug-drug interactions, only records x where the set I(x) contains at
least two drugs and the set O(x) is not empty will be considered.
As in the previous section, potential reactions HI(x) and HO(x) were defined, corresponding
to the drugs I(x) and O(x), respectively. Consider convex combinations of these vectors:
H(x, µ) = µHI(x) + (1− µ)HO(x).
Similar to (7.7.2) and (7.7.3), the maximal optimal value µ = µ∗∗(x) which minimizes the distance
dist (H(x, µ),Y(x)), will be taken as the degree of responsibility of the drugs I(x) in the observed
reactions Y(x).
Given a set of ADR reports the X , Average Responsibility of drugs in interaction will be
calculated as
Pint =
1
|X |
∑
x∈X
µ∗∗(x). (7.8.1)
The evaluation measure presented in Section 7.5 then was applied. This provides a precision
P (x) calculated for each ADR report x having interaction effects of drugs.
The numbers µ∗∗(x) and P (x) give some information about each interaction case. For instance,
if µ∗∗(x) = 1 and P (x) = 1, (that is, 100 percent) then it can be concluded that the potential
reactions defined by the drugs I(x) provide 100 percent correct prediction of reactions. Therefore,
in this case, it can be said that the potential reactions could be used for reaction predictions in
the case of interactions.
7.9 The results of numerical experiments
For this analysis two algorithms were used. The first algorithm A(p) is described above. The second
algorithm that was used is BoosTexter which has shown good performance in text categorization
185
problems. These two algorithms produce the weighted vector H(x) for each ADR report x. The
methods of calculating the vectors H(x) are quite different: A(p) uses only drugs have been taken
by the ADR report x, whilst BoosTexter uses all drugs in the list of (“weak hypotheses” generated
(that is, the drugs that have not been taken by the ADR report x, are used for the calculation
of the vector H(x)). It is hoped that, the application of these two quite different methods can
improve accuracy.
Three versions of the algorithm A(p) will be considered, corresponding to the distance functions
distp, p = 0, 1, 2, respectively. Each of these versions tends to minimize the average distance
calculated by its own distance measure.
The weights for each drug are calculated by formula (7.6.9). A function φ(d) = |X(d)|+ P (d)
was used to describe the informativeness of the set X(d). A number p∗ also needs to be set. The
calculations show that the results are not essentially changed for different values of p∗ in the region
p∗ ≥ 30, therefore set p∗ = 80 in the calculations.
The second algorithm that was used was algorithm BoosTexter ([459]). The main reason for
using this algorithm is that it produces predictions in the form H(x) = (H1(x), . . . , Hc(x)),
where the numbers Hi(x) are real values which can be positive or negative. In other words, this
algorithm defines potential reactions that are of interest.
To apply the distance measure described above, all weights calculated by BoosTexter non-
negative need to be made. Let Hmin(x) = mini=1,...,cHi(x). So set H(x) = H(x), if Hmin(x) ≥
0; and
H(x) = (H1(x)−Hmin(x), . . . , Hc(x)−Hmin(x), if Hmin(x) < 0.
In the calculations below, this algorithm was run with the number of rounds set at 3000. Note
that BoosTexter defines a weak hypothesis using one drug at each round. In the Data there are
2896 suspected drugs. Therefore, choosing the number of rounds 3000, alows the possibility of
using all suspected drugs.
7.9.1 New drugs and events
This is described in Section 6.3.2.
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7.9.2 Training and test sets
In the calculations below records sequentially from each year were take as a test set, starting from
1996 until 2001. For example, if records from 1999 are taken as a test set, then all records from
years 1971-1998 form a training set. In Table 7.1 the number of records in test and training sets
summarized, and the number of new events removed. In the second part of this table presents the
number of records in training and test sets having at least two drugs.
Table 7.1: Neuro. The training and test sets.
Test Number of Records Records with ≥ 2 drugs
Year Training Test Removed* Training Test
1996 28866 2770 195 6270 597
1997 31831 2996 308 6905 552
1998 35135 3447 485 7513 673
1999 39067 4592 339 8290 494
2000 43998 3848 342 8801 519
2001 48188 2283 107 9329 433
*‘Removed’ means the number of records removed from the test set. For example, in 1996 there
are 2965 records and 195 of them are new events. Then, the number of records in the test set for
this year is 2770(=2965-195)
7.9.3 The effectiveness of using suspected drugs for reaction predictions.
Prediction of reactions
Consider calculations for two cases. First consider all drugs as suspected; that is, the suspected
drug code in ADRAC was not employed. In the second case only suspected drugs were considered
(that is, ones coded as suspected). The results obtained by the algorithms A(p) and BoosTexter
are presented in Table 7.2. The results for Average Precision are presented in percentages. In
these tables “All” means that all drugs were used for definition of the reaction weights for drugs,
and “Sus” means that only suspected drugs were used.
From Table 7.2 observed that, in all cases, the results obtained for training sets are better if
only the suspected drugs are considered. This means that, definition of weights h(d) by using only
suspected drugs provides more accurate approximation to the observed reactions. The weights
obtained in this way also work, in general, better in test sets. This emphasizes the effectiveness of
determining suspected drugs in each adverse drug reaction case.
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Table 7.2: The results obtained for Average Precision (Pav) by using all (All) drugs and suspected
(Sus) drugs.
Test drugs BoosTexter A(0) A(1) A(2)
Year Training Test Training Test Training Test Training Test
1996 All 79.03 72.19 75.55 70.25 78.67 73.35 78.35 73.36
Sus 78.08 72.35 76.32 70.93 79.19 73.47 79.03 73.71
1997 All 78.91 72.29 74.98 69.26 78.47 72.73 78.17 72.85
Sus 77.82 71.49 75.91 70.28 78.94 72.88 78.76 72.94
1998 All 78.67 74.07 74.72 71.35 78.25 74.31 77.92 74.55
Sus 77.61 73.64 75.66 72.24 78.71 74.66 78.49 74.91
1999 All 78.45 75.16 74.55 73.64 78.15 75.67 77.83 75.58
Sus 77.49 75.36 75.61 73.69 78.59 76.06 78.39 76.20
2000 All 78.41 73.68 74.62 70.25 78.19 73.82 77.88 73.83
Sus 77.56 73.58 75.70 70.38 78.59 73.77 78.39 74.04
2001 All 78.27 73.30 74.39 71.11 78.10 73.43 77.77 73.77
Sus 77.43 73.24 75.34 72.25 78.44 74.31 78.27 73.97
The algorithm BoosTexter2 1 [459] was set to run 6000 training rounds. Average Precision is
presented in percent
The next problem is to define suspected drugs more accurately. The fact that using only
suspected drugs provided better results allows the conclusion that, in the ADRAC data (at least
records related to the nervous system and special senses type of reactions) suspected drugs are
defined “sufficiently correctly”. In the next section the aim is to evaluate this “correctness”.
The algorithms BoosTexter and A(p) define the potential reactionsH(x) in quite different ways.
There are some important points that make using the algorithm A(p) preferable for the study of
drug-reaction associations.
First note that, the algorithm A(p) calculates weights for each drug, which is very important
because in this case drug-reaction relations for all drugs were established. BoosTexter does not
calculate weights for each drug. Moreover, BoosTexter classifies examples so that drugs that are
not used are still assigned weights in the function H(x). In the other words, reactions are predicted
not only by drugs actually used, but also, drugs which were not taken. This leads to the situation
where it could be said that, for example, ADR report x has the first reaction, because he/she did
not take some drugs (which are in the list of “weak hypothesis” generated by BoosTexter). But
anyhow, applying the algorithm BoosTexter is very useful for having some idea about the possible
“maximal” accuracy that could be achieved in reaction predictions.
One of the advantages of the algorithm A(p) includes the determination of weights for each
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drug, and, then the classification of reactions, observed for each ADR report, on the basis of drugs
actually recorded in this ADR report. This advantage allows the use the algorithm A(p) to study
the identification of suspected drugs and of drug-drug interactions.
7.9.4 Evaluation of correctness of suspected drugs reported
In this section evaluate the correctness of suspected drugs reported will be examined. The method-
ology is described in Section 7.7. As mentioned above, BoosTexter can not be used for this. So
only the algorithm A(p) is used.
The results obtained in the previous section have shown that potential reactions calculated by
using suspected drugs provide more accurate predictions of reactions. Therefore, in the calculations
below weights for each drugs will be calculated only by suspected drugs.
The case when a ADR report records only one drug, is not interesting to consider, because in
this case there is no doubt that the drug used should be a suspected drug. That is why, records
having two or more drugs that have been taken were considered. The number of ADR reports in
training and test sets are presented in Table 6.1.
Table 7.3: Evaluation of correctness of suspected drugs (Psus) obtained by Algorithm A(p)
Test A(0) A(1) A(2)
Year Training Test Training Test Training Test
1996 75.4 68.9 75.5 69.1 75.2 68.8
1997 74.9 68.7 75.0 68.7 74.8 69.3
1998 74.7 69.1 74.9 69.2 74.8 69.6
1999 74.6 83.5 74.6 83.5 74.5 83.9
2000 75.0 88.6 75.2 88.6 75.0 88.0
2001 75.7 68.6 75.7 68.1 75.4 67.9
The results are presented in Table 7.3. It can be seen that, the suspected drugs reported in
the ADRAC data are determined with sufficiently high accuracy. For instance, the accuracy 78.0
means that, in the optimal combination of suspected and non-suspected drugs which provides the
closest approximation to the observed reactions, the suspected drugs are used with weight 0.78
(non-suspected - 0.22). This could be considered as a high degree of “responsibility”.
Note that, the correct identification of suspected drugs in each new report is a very important
problem. The method described here provides an alternative method which can be used for this
189
purpose.
7.9.5 Interaction of drugs
As mentioned previously, the study of interactions of drugs is one of the interesting problems. The
possibility of using vectors of weights in drug-drug interactions is considered here. In other words,
the closeness of potential reactions (calculated by a vector of weights) to the observed reactions in
drug-drug interaction cases is to be evaluated. For the evaluation of closeness two measures were
used: Average Responsibility - Pint and Average Precision Pav.
For this analysis the records having more than 3 drugs were considered, where some of drugs
were reported as an interaction (in ADRAC data the value 2 was associated to this drugs) and the
others were reported as non-suspected (the value 0 was used in this case). Of course, to make the
problem of evaluation of drug-drug interactions meaningful, the records for which both parts are
not empty sets need to be considered.
Table 7.4: Evaluation of drug-drug interactions by using a vector of weights obtained by Algorithm
A(p)
Test Number of Pint Pav
Year records A(0) A(1) A(2) max A(0) A(1) A(2) max
1996 14 57.1 57.1 57.1 57.1 59.5 63.7 67.3 72.0
1997 17 59.9 63.8 63.2 65.8 74.0 77.9 77.5 81.9
1998 28 67.9 73.6 71.7 78.4 66.5 84.1 87.9 92.1
1999 5 80.0 83.8 88.4 88.9 80.0 80.0 83.3 90.0
2000 5 00.0 06.5 22.5 22.5 45.0 51.7 65.0 65.0
2001 27 55.9 59.7 61.6 69.0 75.6 86.4 86.7 89.9
96 58.6 63.6 63.5 68.1 69.0 78.8 81.3 85.2
The results obtained are presented in Table 7.4. Training sets are used for the calculating of
weights for each drug. As in the previous section, the weights are calculated by using suspected
drugs. Then the evaluation of interaction of drugs is made only using the test sets, because, in the
training sets, the interaction of drugs (as suspected) are used for the calculation of weights. The
number of cases in the test sets are also presented in Table 7.4.
In the last row of Table 7.4, presents the average results obtained by all test sets which combines
62 cases. The results obtained by the algorithm A(2) is: Pint = 70.2, Pav = 80.7. The first number
means that, in the observed reactions, the “degree of responsibility” of the drugs, in interaction
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cases, is 70.2 percent. The second number indicates high accuracy in the prediction of these
reactions. This emphasizes that, drug-drug interaction cases could be successfully explained by
the weights calculated for each drug.
In fact the accuracy of this method could be much higher if the weights could be more “cor-
rectly” calculated. To show this, the following was done:
First note that, the numbers Pint and Pav are the average values of µ∗∗(x) and P (x) calculated
for each ADR report x. Different versions A(p) provide different values µ∗∗(x) and P (x). The
corresponding maximal values obtained by different versions were taken, and then the average
responsibility and precision calculated. The results obtained are presented in the columns “max”
in Table 7.4. It can be seen that these results are much better than the results obtained by a
particular version.
The following figures show interactions in years 1973–2001 using the version of Algorithm A(p)
that uses the suspect drug code of ADRAC comparing trade name code for drugs with the ATC
codes from Section 3.6: Figure 7.5 for all reaction classes, Figure 7.6 for the Blood SOC data set,
Figure 7.7 and for the Neuro SOC data set.
7.10 Conclusion
In this chapter a new optimization approach to study multi-label classification problems was used.
In particular the focus has been on drug-reaction relations in the domain of the nervous system
and special senses group of reactions from the ADRAC data. The covariability algorithm A(p) and
the text categorization algorithm BoosTexter were both tested on the Nervous system and special
senses – Neuro data set described in Section 3.4.3. The suggested method of representation
for drug-reaction relations in the form of a vector of weights is examined in the prediction of
reactions. In particular it was shown that, the suspected drugs reported in the ADRAC data
provide more accurate drug-reaction information. The suggested method was applied for the
evaluation of correctness of suspected drugs. The results obtained have shown that the reactions
that occurred in the cases of interaction of drugs reported in the ADRAC data, could be predicted
by this method with sufficiently high accuracy.
The ATC codes tend to give better results, but not consistently. To get the full benefit of this
hierarchy, a method that can exploit the hierarchical structure needs to be used. In the next two
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chapters I demonstrate methods that can do this.
This chapter addresses research question 5 because it further investigates drug interactions
and an alternative method for determining suspected drugs. Both methods use vectors of weights
that are tested against potential reaction vectors using the average precision measure of distance
with algorithm A(p). BoosTexter was also used particularly for determining maximal accuracy
achievable. Results using drug trade name and the different ATC levels were also examined for
interaction and suspected drug evaluation. In this case too, as seen in the previous chapter, the
results were not consistent, sometimes being better than for trade name and sometimes the same
or worse.
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Table 7.5: Drug-drug interactions – All 18 SOC reaction classes, Suspected drugs code version of
Algorithm A(p)
Year NumRec* TradeN§ ATC1¶ ATC3¶ ATC4¶ ATC5¶ ATC7¶
1973 8†, 9‡ 56.2† 67.4‡ 72.2‡ 76.3‡ 70.9‡ 61.4‡
1974 9†, 10‡ 89.6† 86.0‡ 88.5‡ 87.8‡ 78.9‡ 83.9‡
1975 3 78.3 100 100 100 97.4 100
1976 3 60.2 33.3 41.0 21.6 33.3 60.8
1977 7 94.0 82.4 100 91.7 100 92.6
1978 3 66.7 100 66.7 66.7 100 66.7
1979 10 87.4 60.1 56.2 70.0 76.8 85.3
1980 18 81.1 78.9 71.8 77.7 82.4 83.9
1981 15 90.2 80.0 72.6 79.4 81.8 88.4
1982 34 84.4 77.6 86.0 81.2 81.7 87.5
1983 26 82.5 82.3 78.9 79.6 88.0 82.5
1984 39 80.1 86.2 84.3 81.3 78.6 84.3
1985 16 92.2 93.8 93.8 89.0 91.4 82.8
1986 14 66.4 75.0 54.3 76.6 73.2 71.3
1987 11 58.5 81.8 72.7 68.4 79.4 79.3
1988 6 74.7 66.7 66.7 66.7 74.5 68.1
1989 9 66.7 58.1 79.1 95.3 87.6 74.0
1990 8 73.8 75.0 87.5 100 87.5 87.5
1991 6 100 100 96.4 83.3 100 100
1992 15 82.7 80.0 91.7 65.0 77.6 84.3
1993 17 74.9 82.4 76.5 89.6 83.9 81.5
1994 38 92.0 88.3 86.7 92.6 92.2 91.9
1995 44 79.9 83.3 82.3 86.0 85.8 80.7
1996 49 86.2 91.8 87.3 83.6 88.1 88.6
1997 56 80.4 82.8 85.0 79.9 82.1 80.1
1998 82 71.3 77.8 85.5 84.7 75.8 71.9
1999 30 84.9 81.2 86.6 77.3 79.0 82.3
2000 17 97.5 99.1 86.2 88.2 86.7 94.0
2001 61 85.4 69.1 72.9 77.2 81.2 80.4
* NumRec – number of records
§ TradeN – drug trade name code
¶ ATCx, x = 1, 3, 4, 5, 7. – ATC code as explained in Section 3.7.1
† First number of records
‡ Second number of records
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Table 7.6: Drug-drug interactions – Blood SOC reactions, Suspected drugs code version of Algo-
rithm A(p)
Year NumRec* TradeN§ ATC1¶ ATC3¶ ATC4¶ ATC5¶ ATC7¶
1973 2 50.0 0 72.2‡ 76.3‡ 70.9‡ 61.4‡
1974 1 100 100 100 100 100 100
1975 3 100 100 100 100 100 100
1976 0
1977 3 79.4 100 66.7 66.7 66.7 65.5
1978 1 100 100 100 100 100 100
1979 2†, 3‡ 100† 66.7‡ 54.5‡ 66.7‡ 66.7‡ 66.7‡
1980 4 44.8 50.0 58.3 60.5 78.2 90.9
1981 5†, 6‡ 64.3† 83.3‡ 86.3‡ 60.0‡ 52.9‡ 65.7‡
1982 5 83.8 62.9 100 87.5 84.7 80.0
1983 9 86.6 98.7 77.8 91.9 94.5 67.9
1984 11 76.2 78.8 72.7 89.9 81.6 81.2
1985 2 50.0 100 100 100 100 100
1986 4 79.4 100 100 100 100 100
1987 3 66.7 66.7 66.7 66.7 66.7 66.7
1988 1 98.2 100 100 2.9 0 100
1989 2 100 100 100 100 100 100
1990 4 75.0 100 100 75.0 75.0 75.0
1991 5 91.7 80.0 76.6 76.6 98.2 80.0
1992 7 73.3 85.7 92.3 90.3 79.5 89.2
1993 11 86.3 90.9 90.9 90.9 97.4 89.3
1994 18 80.6 94.4 100 100 100 89.1
1995 22 83.1 95.5 90.9 90.9 83.7 93.1
1996 29 76.7 95.0 88.4 89.3 78.2 73.1
1997 17 75.3 99.2 85.6 97.7 88.2 84.7
1998 31 83.9 95.3 93.5 96.0 96.8 84.2
1999 9 74.8 88.9 89.9 88.9 77.8 63.2
2000 3 66.7 100 100 100 79.4 61.1
2001 17 86.8 94.1 90.6 94.1 98.7 90.0
* NumRec – number of records
§ TradeN – drug trade name code
¶ ATCx, x = 1, 3, 4, 5, 7. – ATC code as explained in Section 3.7.1
† First number of records
‡ Second number of records
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Table 7.7: Drug-drug interactions – Neuro SOC reactions, Suspected drugs code version of Algo-
rithm A(p)
Year NumRec* TradeN§ ATC1¶ ATC3¶ ATC4¶ ATC5¶ ATC7¶
1973 3†, 4‡ 100† 75.0‡ 100‡ 71.2‡ 100† 100†
1974 4†, 5‡ 52.6† 80.0‡ 40.0‡ 40.0‡ 34.4‡ 40.0‡
1975 1 100 100 100 40.7 67.3 100
1976 2 7.9 50.0 0 9.1 11.1 11.7
1977 2 50.0 100 50.0 100 100 50.0
1978 0
1979 5 8.0 80.0 40.0 80.0 100 100
1980 10 52.9 70.0 55.0 50.0 55.4 58.4
1981 8 62.5 62.5 37.5 62.5 62.5 44.2
1982 16 56.6 62.5 62.5 67.7 73.1 52.1
1983 14 44.9 35.7 32.6 50.0 61.6 44.0
1984 17 77.1 82.4 58.3 70.7 74.4 76.1
1985 9 44.4 77.8 55.6 66.7 66.7 55.6
1986 6 46.4 66.7 38.4 66.7 66.7 33.3
1987 2 50.0 50.0 50.0 0 0 0
1988 4 70.3 50.0 75.0 75.0 50.0 65.5
1989 4 75.0 75.0 25.0 25.0 25.0 50.0
1990 1 0 0 0 0 0 0
1991 61 75.4 0 0 67.2 0 0
1992 4 93.1 100 75.0 74.8 100 89.3
1993 7 42.9 42.9 28.6 57.1 57.1 57.1
1994 12 79.5 66.7 62.3 59.5 83.3 75.0
1995 13 63.3 69.2 53.9 61.5 59.3 61.5
1996 14 57.1 57.1 53.7 35.7 42.9 35.7
1997 17 59.9 47.1 64.7 47.3 64.7 76.5
1998 28 67.9 79.7 67.5 64.3 55.5 67.9
1999 5 8.0 80.0 45.4 80.0 80.0 89.7
2000 5 0 60.0 40.0 40.0 5.6 20.0
2001 27 55.9 62.9 46.9 55.6 45.1 59.2
* NumRec – number of records
§ TradeN – drug trade name code
¶ ATCx, x = 1, 3, 4, 5, 7. – ATC code as explained in Section 3.7.1
† First number of records
‡ Second number of records
Chapter 8
Application of an Association
Rules Method to ADRAC Data
8.1 Preface
The work described in this chapter, and that in Chapter 9, was done in collaboration with Sasa
Ivkovic using his Mine Associate suite of methods (described in [247]) and adapting some of these
methods to use the ADRAC data.
8.2 Association rules
Association rules (AR) methods have been applies to large data sets for some time as mentioned
in Section 1.3.1. Association rule mining is a form of data mining used to discover interesting
relationships amongst two or more attributes in data. Association rules were introduced by Agrawal
et al. [7] and originated with the problem of supermarket basket analysis. In basket analysis
association rules were used to find associations between the items bought by a customer in order
to find which items were frequently bought together.
An association rule is an expression of the form X ⇒ Y [support/confidence], where X and Y
are sets of items that are often found together in a given collection of data. The attribute group on
the left hand side of the arrow is called the antecedent or “left hand side” (LHS) and the group of
attributes on the right hand side of the arrow is called the consequent or “right hand side” (RHS).
The interesetingness and usefulness of an association rule has been based on support and confidence
measures. The support is the percentage of transactions in the database containing both X and Y.
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The confidence is the conditional probability of Y given X, for example, confidence = P (Y |X).
In this study we measure interestingness of discovery by measuring differences between groups.
A group represents a variable of interest (attribute-value) selected by the user. For example,
by selecting attribute-values sex Male and sex Female as variables of interest the user is able to
look for differences between these two groups. The generated association rules are organized by
separating the discovered rules into rule sets. Each rule set contains association rules that share a
common consequent. For example, association rules sex Male ⇒ age 30to40 and sex Female ⇒
age 30to40 represent a rule set because they share the same consequent. If the discrepancy between
the confidence values of these two association rules is substantially high, these groups are considered
different on the basis of age group 30 to 40, otherwise the groups are considered similar on this age
group. Such findings can be useful to suggest hypotheses to the user. For example, if male and
female groups are considered similar on the basis of age group 30 to 40, the user may infer the null
hypothesis “There is no difference in the proportion of 30 to 40 age group between the males and
females”. By grouping related association rules into rule sets, (association rules with a common
RHS but different LHS), we are able to visually display groups (user selected variables of interest)
and their differences.
Non-Bayesian or frequentist forms of disproportionality AR generators discover association rules
without grouping the discovered rules. The interestigness of a generated association rule is based
on the minimum support and confidence threshold. Association rules that meet the user specified
threshold are considered to be interesting. Analysts than decide how surprising the finding is. In
this approach the value of confidence as a single measure does not reflect interestingness. The
goal is to group related association rules into rule sets, automatically calculate deviations between
confidences in each rule set and graphically display findings.
8.3 Methods
The association rules algorithm [7] and methods for grouping them as described in [244, 245, 246,
247]. Applying a drug classification to ADRAC drug terms makes these data more meaningful when
analyzing them by methods that work best with a limited number of variables. The ability to reduce
the number of drug terms using the ATC hierarchy facilitates the application of the association rules
data mining algorithms [7]. The results below are preliminary results from grouping association
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rules by content using ADRAC data classified to the highest (14 classes) ATC level.
Association rules generated were first looked at using data fields such as. age, weight, height,
causality code, and outcome code. From these rules, no particularly interesting associations were
apparent as also observed in Section 4.9.3 also see Section 4.9.3 and [322]).
Definition 8.3.1. Rule definition: If antecedent ⇒ consequent.
Example from first rule below:
R1 1700⇒ numOfReact=1 82.19%
if first reaction is 1700 (R1 1700) then records containing only one reaction (numOfReact=1),
confidence = 82.19%;
as conditional probability P: P(numOfReact = 1 | R1 1700) = 0.8219;
that is, 82.19% of records with first reaction (field) being reaction 1700, had only one reaction.
8.4 Investigating Drugs at ATC Level 1
8.4.1 Reactions
SAME RULE SETS – different groups/same characteristic
R1 – First Reaction
Reactions same 1: This rule set shows if the first reaction is ‘neoplasm’ (‘1700’) 82.19% of these
ADR reports have only one reaction. In this rule set the lowest is: if the first reaction is ‘body as
a whole’ (‘1800’), 35.34% of these ADR reports have only one reaction.
R1 1700⇒ numOfReact=1 82.19%
R1 0900⇒ numOfReact=1 74.40%
R1 1400⇒ numOfReact=1 74.34%
R1 0700⇒ numOfReact=1 70.66%
R1 1300⇒ numOfReact=1 69.17%
R1 1500⇒ numOfReact=1 67.46%
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R1 0100⇒ numOfReact=1 64.23%
R1 1200⇒ numOfReact=1 61.69%
R1 0800⇒ numOfReact=1 55.56%
R1 0600⇒ numOfReact=1 52.75%
R1 0300⇒ numOfReact=1 52.27%
R1 1000⇒ numOfReact=1 49.79%
R1 0400⇒ numOfReact=1 44.86%
R1 0200⇒ numOfReact=1 42.58%
R1 1100⇒ numOfReact=1 40.23%
R1 0500⇒ numOfReact=1 37.50%
R1 1800⇒ numOfReact=1 35.34%
Reactions same 2: This rule set shows if the first reaction is ‘liver and biliary system disorders’
(‘0700’), 33.12% of ADR reports will have ‘antiinfectives for systemic use’ (J) as the first drug.
The lowest member of this rule set is if the first reaction is ‘neoplasm’ (‘1700’), 04.11% of ADR
reports will have ‘antiinfectives for systemic use’ (J) as the first drug.
R1 0700⇒ D1 J 33.12%
...
R1 0300⇒ D1 C 45.83%
R1 1500⇒ D1 C 06.75%
...
R1 1700⇒ D1 J 04.11%
8.4.2 Drugs
SAME RULE SETS – different groups/same characteristic
D1 – Drug 1
Drugs same 1: This rule set shows if the first drug is ‘antiinvectives for systemic use’ (J),
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56.98% of ADR reports have only one reaction. The lowest member of this rule set is if the first
drug is ‘antiparasitic products’ (P), 36.47% of ADR reports have only one reaction.
D1 G⇒ numberOfReactions=1 58.60%
D1 D ⇒ numberOfReactions=1 56.98%
D1 C ⇒ numberOfReactions=1 53.12%
D1 R⇒ numberOfReactions=1 52.98%
D1 S ⇒ numberOfReactions=1 52.39%
D1 A⇒ numberOfReaction=1 50.45%
D1 N ⇒ numberOfReaction=1 50.33%
D1 M ⇒ numberOfReactions=1 50.08%
D1 H ⇒ numberOfReactions=1 49.87%
D1 B ⇒ numberOfReactions=1 49.03%
D1 J ⇒ numberOfReactions=1 47.08%
D1 V ⇒ numberOfReactions=1 45.77%
D1 L⇒ numberOfReactions=1 44.74%
D1 P ⇒ numberOfReactions=1 36.47%
Drugs same 2: This rule set shows if the first drug is ‘dermatologicals’ (D), 39.57% of ADR
reports have the first reaction ‘body as a whole’ (‘1800’). The lowest member of this rule set is if
the first drug is ‘cardiovascular system’ (C), 13.41% of ADR reports have the first reaction ‘body
as a whole’ (‘1800’).
D1 D ⇒ R1 1800 39.57%
D1 S ⇒ R1 1800 26.14%
...
D1 C ⇒ R11800 13.41%
Drugs same 3: This rule set shows if the first drug is ‘sensory organs’ (S),25.03% of ADR re-
ports have the first reaction ‘nervous system disorders’ (‘0400’). The lowest member of this rule
set is if the first drug is ‘blood’ (B), 08.99% of ADR reports have the first reaction ‘nervous system
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disorders’ (‘0400’).
D1 S ⇒ R1 0400 25.03%
D1 N ⇒ R1 0400 20.50%
D1 R⇒ R1 0400 16.49%
...
D1 B ⇒ R1 0400 08.99%
Drugs same 4: This example shows that taking drug ‘antiinvectives for systemic use’ (J) you
are most likely to get reaction ‘0100’ Taking drug ‘anti invectives for systemic use’ (J) for the
second time may not increase a chance for greater number of reactions.
D1 J ⇒ R1 0100 29.87%
D2 J ⇒ R1 0100 30.54%
...
D2 L⇒ R1 0100 13.30%
DIFFERENT RULE SETS – same group/different characteristics
Cardiovascular drugs – very continuous
This shows that if the first drug is ‘cardiovascular system’ (C), then it is likely that the second,
third and fourth drugs are of group C.
Rule set 18: D1 C ⇒ D2 C 28.22%
Rule set 194: D1 C ⇒ D3 C 18.37%
Rule set 211: D1 C ⇒ D4 C 10.81%
Antiinfectives
This shows that if the first drug is ‘antiinvectives for systemic use’ (J),18.25% of ADR reports
have the second drug in group J.
Rule set 191: D1 J ⇒ D2 J 18.25%
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Other drugs – non continuous
In these examples, the rules span over different rule sets.
Spanning continuous 1: This shows that if the first drug is ‘various’ (V), 82.32% of ADR re-
ports have not recorded a second drug, 91.32% have not recorded a third drug, and 95.76% have
not recorded a second drug, have not recorded a fourth drug.
D1 V ⇒ D2 0 82.32%
D1 V ⇒ D3 0 91.32%
D1 V ⇒ D4 0 95.76%
Spanning continuous 2: This shows that if the first drug is‘dermatologicals’ (D), 73.85% of
ADR reports have not recorded a second drug, 86.56% have not recorede a third drug, and 91.74%
have not recorded a fourth drug. At the low end of this rule set it can be seen that if the first drug
is‘cardiovascular system’ (C), 46.09% have not recorded a second drug, 86.56% have not taken a
third drug, and 71.20% have not recorded a fourth drug.
D1 D ⇒ D2 0 73.85%
D1 D ⇒ D3 0 86.56%
D1 D ⇒ D4 0 91.74%
...
D1 C ⇒ D2 0 46.09%
D1 C ⇒ D3 0 61.20%
D1 C ⇒ D4 0 71.20%
8.4.3 Findings
By using method of grouping generated association rules by their content several possibly inter-
esting findings were observed:
1. Amongst all ADR reports that recorded ‘skin disorders’ (R1 0100), 32.95% percent of these
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had recorded drug J (which is far more than any other drug).
Association Rule 1: R1 0100⇒ D1 J 32.95%
2. Amongst all ADR reports that recorded ‘musculo-skeletal system disorders’ (R1 0200), the
three most common drugs were found; J, C and N:
Association Rule 1: R1 0200⇒ D1 J 24.77%
Association Rule 2: R1 0200⇒ D1 C 23.32%
Association Rule 3: R1 0200⇒ D1 N 21.54%
3. Amongst all ADR reports that recorded ‘collagen disorders’ (R1 0300), the two most com-
mon drugs were C and N:
Association Rule 1: R1 0300⇒ D1 C 45.83%
Association Rule 2: R1 0300⇒ D1 N 21.97%
All other drugs were 4% on average.
4. By using this approach a very rare group of ADR reports (37 cases) that reported having
neonatal and infancy disorders (R1 1600) was found. It was discovered that the strongest associ-
ation between a reaction and drug was between R1 1600 and drug N (nervous system) 64.9% of
ADR reports having reaction ‘1600’ had taken drug N.
Association Rule 1: R1 1600⇒ D1 N 64.9%
Further investigation of this group of ADR reports was conducted (R1 1600 and D1 N) and it
was discovered that: 37% had two reactions:
Association Rule 1: R1 1600 AND D1 N ⇒ numberOfReactions=2 37%
16% had taken drug N again
Association Rule 2: R1 1600 AND D1 N ⇒ D2 N 16%
25% had reaction R2 0400
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Association Rule 3: R1 1600 AND D1 N ⇒ R2 0400 25%
This last finding demonstrates the power of this method of grouping by rule content for finding
rare associations that may be of interest. Using a traditional association rule approach such rare
associations would not be found because its support is so low.
8.5 Investigating Drugs at ATC Level 3
While most of KDD tools are using Association Rules to find most common and frequently used
items, our KDD tool allows us to look at the micro population and explore rare items. Use of this
technique focuses on discovery of “interestingness”, and on differences (or similarities) between
discovered groups of rules. A generic measure of interestingness is based on a user-defined threshold,
which includes Association Rules (AR) that are above the specified threshold. For example, only
rules with confidence above 40% will be used. We call this “Frequency based interestingness”.
However, this method allows only well known associations to be recovered. The Mine Associate
measure of interestingness is based on “content” of AR which means that rules containing the same
consequent, we group rules into rule sets (called iso consequent) and visually display confidences
for each rule set. This approach automatically suggests hypotheses to the user because the rules
in the rule set are connected according to their content. Struck with an interesting rule set the
user is able to further explore and test the suggested hypothesis that s/he finds interesting [247].
Applying a drug classification to ADRAC drug terms makes these data more amenable to
analysis by methods that work best with a limited number of variables. The ability to reduce the
number of drug terms using the ATC hierarchy facilitates the application of the association rules
data mining algorithms [7]. I report here some preliminary results from grouping association rules
by content using ADRAC data.
8.5.1 Drugs as consequent
Figure 8.2 (detail in Figure 8.3) shows 47 rule sets generated, which have the first drug field as
the consequent (D1, which is the first drug field of the ADRAC record). The legend lists all the
ATC3 level drugs and the X-axis groups related antecedents. Starting from the left-hand side, year
group (yrG . . . ), age group (ageG . . . ), sex (sex . . . ), outcome (out . . . ), second drug (D2 . . . ),
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third drug (D23 . . . ), second reaction (R2 . . . ). In the group “ageG 6to12” several ATC class ‘D’
(DERMATOLOGICALS) stood out, notably D1 D08, in Figure 8.2. It was decided to focus on
this drug class. Figure 8.4 shows the absolute vales for ATC3 subclasses for D and Figure 8.5
shows the ATC3 percentages. It can be seen that D01, D02, D05, D08, and D10 were the highest.
The rule sets involving just ATC3 level subclasses of class D were examined, see Figure 8.6. In this
figure it can be seen that D1 D10 (ANTI-ACNE PREPARATIONS) showed a marked difference
in the groups: ageG 13to20 and ageG 21to25. To focus on this group it can be seen in Figure
8.7 (detail in Figure 8.8), that the counts for “D1 D10 AND ageG 13to20”: females (sex F) 36,
males 61, out 1 (outcome ‘A’ or 1 – recovered without sequel – Section B.1.4), out 6 29 (not yet
recovered), out 8 (unknown), yrG 77to81 3, yrG 82to86 4, yrG 87to91 10, yrG 792to96 17, and
yrG 97to01 63.
This shows that by grouping the rules by content one can more easily focus on smaller and
smaller subgroups.
8.5.2 Reaction class as consequent
To demonstrate some of the features of this method I will show some association rules looking at
all 18 SOC reaction classes in reaction field 1. In the legend Figure 8.9 “R1 SOC” antecedent
represents the SOC of the first reaction. and characteristic number 54 (sex F – consequent)
represents sex female. It can be seen that: (i) Some reaction classes contain a many female ADR
reports, (ii) others have a very few, (iii) among all ADR reports that recorded foetal disorders
(reaction class 1500) 94% are female, (iv) among all ADR reports that recorded endocrine disorders
(reaction class 900) more than 70% are males.
We can filter the graph output by showing very few or many characteristics Figure 8.10 shows
99 characteristics. Reactions are listed in the legend, where the top entry, R1 100 means the first
reaction field is SOC 100 (skin and appendage disorders – see Saunders [454]); the consequent
on the x-axis, for example, D1 A02 is the first drug field is drug class A02 (drugs for acid related
disorders – see Saunders [454]), D2 0 means no drug in second drug field, R3 1000 is third reaction
field is SOC 1000 (cardiovascular) and R3 0 no reaction in that field, ageG 13to20 means age group
13–20 years, nreac 1 means number of reactions in record equals 1, out 4 outcome code 4 (death
as a reaction – see Mamedov et al. [322]), sex X – sex not recorded, yrG 72to76 means year group
1972–1976. In this graph we can select for age group differences and similarities between reaction
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classes – see Figure 8.11.
In Figure 8.12 I show SOC 1600 (neonatal and infancy disorders) and focus on a rare group of
ADR reports with this disorder – 52 ADR reports (only 0.04%). We are interested to explore further
the characteristics of 13 to 20 years old ADR reports with reaction 1600, displayed in Figure 8.13,
where 33% of ADR reports with neonatal and infancy disorder are teenagers – 17 ADR reports.
All teenage ADR reports with this disorder are female (17/17 – 100%). Almost half recovered
without sequel (7/17 – 41%). 30% of these ADR reports took drug class N06 (psychoanaleptics).
30% of these ADR reports took drug class N02 (analgesics). 5% took NO2 as a second drug.
Thus this method is able to ‘drill down’ with the aid of the drug and reaction ontologies to
reach fine level associations. In the following section we apply the drug and reaction ontologies,
along with the critical term ontology to develop a more sensitive adverse event signalling method
than presently exists.
8.6 Investigating Drugs at ATC Level 5 and individual Re-
actions
For this investigation I chose some drugs that have been recalled over the years by ADRAC [26],
the United Kingdom [335] and worldwide [488] including those reviewed in Section 2.3.
8.6.1 Rules with Death Outcomes
In this section I illustrate this method using two observational groups involving two ADRAC out
come codes, outcome 3 – “Death could be drug”, and outcome 4 – “Death as reaction”. It was
found that there are 1182 cases of ADR report deaths due to reaction which makes 0.86% of all
cases and 742 cases of ADR report deaths possibly due to drug which makes 0.54% of all cases in
our ADRAC drug reaction database.
By exploring the differences and similarities between these two ADR reports groups (outcome
4 and outcome 3) as illustrated in Figure 8.1, which shows the differences and similarities between
certain attributes for ADR reports whose outcome was either 3 or 4. We can notice the following:
All ADR reports (both groups) had most commonly taken drugs: M04AA01 (Allopurinol),
N02BA01 (Acetylsalicylic acid – aspirin) and N05AH02 (Clozapine) – left-hand side of graph, and
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had most commonly experienced reactions 207 (cardiac arrest) and 320 (death).
8.6.2 Death as reaction ADR reports (outcome 4)
1. Almost 45% of these ADR reports (represented by blue line) had reaction 320 (rule set 5),
2. more than 10% of outcome 4 ADR reports had taken N05AH02 drug,
3. had more second reactions than outcome 3 ADR reports,
4. had drastically increased number of cases from years 1997 to 2001.
Death could be drug (outcome 3)
1. Mostly older ADR reports,
2. most common taken drugs: M04AA01 and N02BA01,
3. most common reaction 207 (Cardiac arrest),
4. had drastically increased number of cases in 1997 to 2001 years.
As illustrated in Figure 8.1, 4% of ADR reports who died possibly due to drug had taken drug
N02BA01. We further explore these ADR reports (Figure 8.14) and notice the following:
1. 48 reported deaths for this group of ADR reports (outcome 3 and N02BA01),
2. all ADR reports are over 60 years old,
3. 41% had one reaction (20 cases),
4. there are equal number of males and females.
As illustrated in Figure 8.1, more than 10% of patients who died possibly due to drug had taken
drug N05AH02. We further explore these ADR reports (Figure 8.15) and notice the following:
1. 78 reported deaths for this group of ADR reports (outcome 4 and N05AH02),
2. most patients are middle aged,
3. 78% had reaction 320 (61 cases),
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4. there are more males than females.
This illustrates that this method can be used to “drill down” through the rules in order to find
rare associations, which may be of interest.
8.7 Discussion
The association rules methods use categorical data values. This means that they can directly access
categorical values that comprise the majority of data values in the ADRAC data. The drug-drug
relationship algorithms used in Chapter 4, and sections 3.5, 3.6, 3.7, 3.8 and 5.2, require numerical
values necessitating conversion of categorical data values into numerical ones. The kinds of fields
that would be of interest for such an analysis would ones such as, dosage amount, start date and
halt date of drug and date of onset of reaction.
An area of drug safety detection methods that has had very little investigation is that of
drug-drug interactions and syndromes [Andrew Bate – personal communication]. It is expected
that, now association rule methods can be applied to drug safety data, it should be relatively
easy to find rules that detect such multiple occurrences. It should also be noted that, because
the algorithms investigated in chapters 4, 5, 6, see Sections 4.6.3, 4.7.4, 4.10 detect interactions,
suggests that association rules are also capable of detecting interactions and are likely to prove
useful for syndromes as well.
Some ATC codes are assigned to combinations of ingredients. These were used to assign a
single code to drug trade name codes that represent multiple ingredients. This will mean that our
current drug-relationship algorithms used for ADRAC data can use ATC codes to compare the
performance using trade name versus ATC code. The future development of these algorithms will
need to take advantage of the hierarchy of levels embedded in the ATC codes. Furthermore, it
makes these data more accessible to methods that have difficulty when the number of variables
is excessive. It is anticipated that the ATC classification will lead to enhanced signal detection
capabilities of many algorithms.
8.7.1 The ADRAC ATC implementation
A preliminary investigation using using association rules [4, 7, 547] has been made and it was found
that the number of drug terms needed to be reduced considerably for it to be used with ADRAC
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data. The investigation here of association rules utilizing the ATC hierarchy promises to be very
interesting. Grouping the rules by content provides a useful method of combining related rules
in a more meaningful way. The visualization tools help the user navigate the rules with options
selecting and filtering different rule combinations. By starting at a high level in the classification
(both drug and reaction) hierarchy, it is then possible to still find associations at the lowest level.
For example, between individual drugs and reactions. This mode of reducing the combinatorial
complexity in the data, and association rules generated from them, exploits the structure in the
drug and reaction ontologies. Applying knowledge to structure the data reduces combinatorial
complexity.
8.7.2 Future investigations
The ATC ontology, because it is hierarchical, allows the grouping of data to different levels in the
hierarchy. This will make the ADRAC data more amenable to the application of optimization
techniques (Chapter 7, for discussion see [326]), because it is now possible to greatly decrease the
number of variables using higher level drug terms in this classification. Furthermore, some other
methods commonly applied in data mining [417] should become applicable to ADRAC data. This
ATC classification will also facilitate the use of drug class information already ‘learnt’ by some
algorithm to apply to drugs belonging to that class that have not been previously encountered in
the data [326]. That is information about a drug class can be used to compare whether a new drug
is behaving typically for the class or if it is not.
These developing methods, based on the ontologies exploited in the current study, for ADR sig-
nal detection is anticipated to lead to a significant improvement on the non-Bayesian or frequentist
forms of disproportionality ADR signal detection methods. A prototype method is described in
the next chapter.
8.8 Conclusion
One of the main goals of completing an ATC classification of ADRAC data was to structure these
data so as to make them accessible to powerful existing tools such as the Apriori association rule
generator with methods for analyzing the rules in the Mine Associate suite of tools (see Section
12.6). The fact that there are several levels of granularity in this classification allows analysis at
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different levels. I have demonstrated that, using the ATC and SOC ontologies this association
rule methods can explore even very rare associations in the ADRAC data. This preliminary
investigation of association has already produced exciting results. Many of the associations found
may not be novel, but there is the potential for the discovery of interesting associations that
are otherwise difficult to find. This highlights the benefits for drug safety data in having a drug
ontology as well as a reaction ontology to make it accessible to much more powerful data processing
methods. Using such methods could make the detection of drug/drug interactions and drug-
syndrome associations easier to find.
This chapter has addressed research questions 2 and 3. The ATC ontology has structured the
data so that: (i) the number of drug variables can be drastically reduced, (ii) so that finer levels
of granularity can be accessed via a tree structure. This has meant that Mine Associate that was
hitherto not able to perform a analysis of drug safety data can now preform a meaningful analysis.
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Figure 8.1: Outcomes 3 and 4 differences and similarities.
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Figure 8.2: Rules for drug D1.
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Figure 8.3: Rules for drug D1.
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Figure 8.4: Absolute values for dermatological drugs.
Figure 8.5: Percentage values for dermatological drugs.
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Figure 8.6: Anti-acne preparations – differences.
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Figure 8.7: ADR reports 13 to 20 years old and Anti-acne preparations (D1 D10).
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Figure 8.8: ADR reports 13 to 20 years old and Anti-acne preparations (D1 D10) – detail.
Figure 8.9: Reaction Classes differences and similarities.
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Figure 8.10: Graph Output Filtering - reaction characteristics (R1 SOC code – SOC of first reac-
tion field; D1 ATC code – ATC class of first drug field).
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Figure 8.11: Age group characteristics - closer view.
Figure 8.12: SOC 1600 Neonatal and infancy disorders.
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Figure 8.13: Teenagers with Neonatal disorders.
Figure 8.14: Death could be drug (outcome 3) and D1 N02BA01.
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Figure 8.15: Death as reaction (outcome 4) and D1 N05AH02.
Chapter 9
Signal Detection Method using
ADE Ontologies
9.1 Introduction
9.1.1 Drug Recalls and alerts
There have been numerous drugs removed from the market for various reasons. In Australia
the TGA have recalled many drugs from the market (see the Australian Adverse Drug Reac-
tions Bulletin – http:www.tga.gov.au/adr/aadrb.htm). Some examples are: December 2004, none
of the SSRI antidepressants, and indeed no antidepressant, is currently approved in Australia
for the treatment of major depressive disorder (MDD) in children and adolescents (persons aged
less than 18 years) – increased risk of suicidality; rofecoxib (Vioxx) recalled in October 2004
– increased risk of cardiovascular events; phenylpropanolamine in 1983 in appetite suppressant
products – haemorrhagic stroke; alert in May 2001: bupropion (Zyban SR) – skin reactions, psy-
chiatric disturbances, the nervous system, and the gastrointestinal tract, and leflunomide (Arava)
is an immuno-modulatory/ immunosuppressant agent used for the treatment of active rheumatoid
arthritis in adults, – liver dysfunction, haematological disorders, severe skin reactions and pul-
monary dysfunction; in August 2001 Cerivastatin, one of the statin class of drugs taken to lower
cholesterol, was withdrawn from sale worldwide – severe damage to muscle, which can be in the
form of rhabdomyolysis where there is breakdown of muscle cells and release of myoglobin which
in turn can lead to kidney damage.
In 1982 the UK took action to remove benoxaprofen (Opren) from the market because of
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concerns about its association with unusual photosensitivity and liver necrosis in the elderly, in-
cluding deaths and was withdrawn from the market in August 1982 [123, 470]. The antidepressant
nomifensine was introduced into the market in 1976 in West Germany, but a decade later was
withdrawn in 1986 because it was associated with acute haemolytic anemia with serious clinical
sequelae [492]. A number of drugs associated with drug-inducted prolongation of the QTinterval
and its subsequent degeneration into torsade de pointes, such as prenylamine in 1988, terodiline in
1991 [468, 562], followed by terfenadine, astemizole, cisapride, sertindole, grepafloxacin, droperidol,
and levoacetylmethadol [335, 468]. It is probably worth noting when discussing the issue of drug-
induced QT-prolongation and torsade de pointes that over the time periods for which the noted
drugs were marketed there have been dramatic developments in scientific evaluation of drug effects
on cardiac repolarization that really makes this event rather distinctive among adverse events [203].
These examples serve to show the need for an improved ADR signal detection method. The
ADRAC data we have does not have sufficient reports of some of the drugs for them to be detectable.
For example, vioxx only has 299 reports, which is insufficient to support a strong signal. Thus to
adequately test this method, a much larger dataset with more recent reports is needed.
9.1.2 Critical Terms
See Section 3.3.1.
9.2 Method
This method seeks to find if there exists any association between any particular drug or drug class
and a set of critical reactions using a tree structure. For example an association rule R1 drug =
M01AH01 ⇒ reaction = 636 [confidence 35%] means that 35% of ADR reports that recorded drug
M01AH01 (Celecoxib) had reaction with code 636 (hypertension). This association can also be
represented as conditional probability
P (reaction = 636 | drug =M01AH01)
In this study the non-Bayesian or frequentist forms of disproportionality AR approach is not
directly used. We organize generated association rules by separating the discovered rules into
rule sets. Each rule set contains association rules that share a common consequent. For example
association rules drug = M01 ⇒ cardiovascular reactions and drug = M02 ⇒ cardiovascular
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reactions represent a rule set because they share the same consequent.
We generate the tree using a breadth first search. The root of the tree denotes the top drug class
level (for example, M) and children nodes denote a subclass of the parent node (for example, M01,
M02 and M03) and leaves denote a particular drug (for example, M01AH01). During traversal of
the tree we find if another level of the tree needs to be generated according to the convergence
criteria. The details of these algorithm are as follows:
Step 1. We select the top drug class and and a reaction class of interest. For example we
select drug class M and reaction class – cardiovascular reactions (SOC1000) .
Step 2. We generate the next level of the drug class as child nodes of the tree. We find the set
of children for the drug classes that are associated with the selected reaction class. For example
for drug class M we find children M01, M02, M03 and M04 and then for each child we generate
group of association rules for class – cardiovascular reactions (SOC1000).
R1 drug = M01 ⇒ cardiovascular reactions [conf]
R2 drug = M02 ⇒ cardiovascular reactions [conf]
R3 drug = M03 ⇒ cardiovascular reactions [conf]
R4 drug = M04 ⇒ cardiovascular reactions [conf]
If the discrepancy between the confidence values of these association rules is substantially high,
this group is considered different on the basis of cardiovascular reactions, otherwise the group is
considered similar. If the group is considered different by using the χ2 test we find if there is a
significant difference in frequencies. We generate a contingency table containing frequencies and
calculate the chi-square value. If we find significant differences we choose child(ren) with maximum
frequency. Figure 9.1 illustrates breadth search steps.
Figure 9.1 depicts such a traversal. For example, if drug class M is chosen, the children M01,
M02, M03, M04, M05, M09 are examined. M01 is found to be significant, so its children, M01A,
M01B, M01C, are examined. M01A is found to be significant, so its children, M01AA, M01AB,
M01AC, M01AE, M01AG, M01AH, M011AX are examined. M01AH is found to be significant, so
its children, M01AH01, M01AH02 are examined. M01AH01 (see Figure 9.3, where reaction class
SOC1000 was chosen) is found to be significant. The algorithm terminates at this leaf.
Step 3. We continue the above step 2 until:
• the lowest level of drug class is found or,
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• χ2 test fails. This means that this particular drug class level is responsible for the reactions
Once search process terminates we generate association rules for drug(s) and adverse reactions.
A drug can be either drug class (for example, M01AH) or drug (for example, M01AH01). Adverse
reactions (ADR) are reactions belonging to the same reaction class. For example ADR 67, 68,104
belong to cardiovascular reaction class (SOC1000) as illustrated in Figure 9.3. Association rules
displayed in Figure 9.3 are used for descriptive purposes. For example, the highest bar in this figure
shows that almost 15% of ADR reports recording drug M01AH01 with cardiovascular reactions
had experienced ADR 636 (hypertension). This finding could be represented as an association rule
drug = M01 AND cardiovascular reactions ⇒ hypertension [conf 14%]
Generating signals using overlapping time windowing approach
Once an association between a particular drug and a set of significant reaction classes has been
found from above, we plot the frequency of the significant reaction classes over time. A time
window length of 3 has been considered with a phase shift of 1 time interval. This overlapping
time window with a sift helps to smooth the signals. For each time frame we use a χ2 test to
find the signals which indicates a sudden increase in the number of reactions. Depending on the
percentage of critical terms reported from the time of signal back to the start time, we label the
signal. The system that we have adopted, for this investigation, specifies six different types of
signals illustrated in Figure 9.2. These are as follows: OK (15% or below), notice (between 15%
and 30% ), strong notice (between 30% and 40%), warning (between 40% and 50%), strong warning
(between 50% and 60%), Alert(60% or above). Furthermore we look at the support of frequencies
of all reactions from time of start to time of signal.
9.3 Results
This method was tested on a range of different drugs. Just a small sample of the results are
presented here to show drugs that produce different levels of signal.
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9.3.1 Celebrex and cardiovascular (SOC 1000)
The output if drug class M and cardiovascular reactions are selected, the algorithm does a tree
traversal as just described in Section 9.2. Then the histogram in Figure 9.3 is displayed and the
following output is made:
“Cardiovascular system reactions for drug M01AH01 Celecoxib (total of 282 reactions)
1) Celecoxib (M01AH01) makes 1.95% ( cases) of all records (out of 137279) 2) 22.18%
(593 cases) of ADR reports recording Celecoxib had CRITICAL reactions overall 3)
77.82% (2080 cases) of ADR reports recording Celecoxib had NON CRITICAL reactions
overall 4) 43.62% (123 cases) of ADR reports recording Celecoxib with Cardiovascular
system reactions – CRITICAL and they make 4.60 of all ADR reports recording Cele-
coxib 5) 56.38% (159 cases) of ADR reports recording Celecoxib with Cardiovascular
system reactions - NON CRITICAL and they make 5.95 of all ADR reports recording
Celecoxib”
“Cardiovascular system – reaction monthly counts for drug M01AH01 - Celecoxib (to-
tal:282 for 22 months)”
Monthly counts are given in Figure 9.4.
“Null hypothesis: There are no ADR signals in this time span is REJECTED WARN-
ING (46.27% critical and 53.73% non critical reactions (out of 67) before the signal on
200002) (position 4)”
Overlapping window counts are given in Figure 9.5.
“Null hypothesis: There are no ADR signals in this time span is REJECTED High
Frequency WARNING (42.42% critical and 57.58% non critical reactions (out of 231)
before the signal on 200011)”
The anti-inflammatory celecoxib gave a warning signal in November 2000. The fact that it
gave a strong signal for so early may means that it needs to be calibrated to find an appropriate
sensitivity—sensitivity presently used is arbitrary. The other COX2 inhibitor rofecoxib (vioxx) was
also tested and gave no signal. However, rofecoxib only had 299 reports in ADRAC compared to
2892 for celecoxib. The COX2 inhibitors were introduced to the market in 1998 and as outlined in
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Appendix A.2, rofecoxib was withdrawn in August 2004. It is unfortunate that we only have data
until 2001, because these two drugs would provide interesting examples to follow to the present
day.
It would be expected if we had ADRAC data going beyond 2001 that there would be many
more reports including vioxx (rofecoxib), which would also give a strong signal.
9.3.2 Heparin and haemic and lymphatic system (SOC 1200)
The output if drug B01AB01 and haemic and lymphatic system reactions are selected, the his-
togram in Figure 9.6 is displayed and the following output is made:
“Haemic and lymphatic systems reactions for drug B01AB01 Heparin (total of 220
reactions)
Heparin (B01AB01) makes 0.53% (cases) of all records (out of 137279) 2) 37.15% (269
cases) of ADR reports recording Heparin had CRITICAL reactions overall 3) 62.85%
(455 cases) of ADR reports recording Heparin had NON CRITICAL reactions overall
4) 87.27% (192 cases) of ADR reports recording Heparin with Haemic and lymphatic
systems reactions – CRITICAL and they make 26.52 of all ADR reports recording
Heparin 5) 12.73% (28 cases) of ADR reports recording Heparin with Haemic and
lymphatic systems reactions - NON CRITICAL and they make 3.87 of all ADR reports
recording Heparin”
The most frequent reaction, THROMBOCYTOPENIA (1243) 160 cases severity 10.
Monthly counts are given in Figure 9.7.
“Haemic and lymphatic systems – reaction monthly counts for drug B01AB01 - Heparin
(total:220 for 123 months)
Null hypothesis: There are no ADR signals in this time span is REJECTED ALERT
(88.64% critical and 11.36% non critical reactions (out of 44) before the signal on
198612) (position 24)”
Overlapping window counts are given in Figure 9.8.
“Overlapping Time Window (X3) for Haemic and lymphatic systems - 121 time slots
drug B01AB01 – Heparin
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Null hypothesis: There are no ADR signals in this time span is REJECTED Very low
frequency ALERT (86.67% critical and 13.33% non critical reactions (out of 180) before
the signal on 199807)”
Thus Heparin was found to give a strong signal for haemic and lymphatic systems, on which it
acts, being an blood anticoagulant.
9.3.3 Paracetamol and cardiovascular (SOC 1000)
Paracetamol was chosen as a control for the method because it would be expected not to give a
strong signal. The output if drug N02BE01 and cardiovascular reactions are selected, the histogram
in Figure 9.9 is displayed and the following output is made:
“Cardiovascular system reactions for drug N02BE01 Paracetamol (total of 20 reactions)
1) Paracetamol (N02BE01) makes 0.25% ( cases) of all records (out of 137279) 2)
22.81% (78 cases) of ADR reports recording Paracetamol had CRITICAL reactions
overall 3) 77.19% (264 cases)of ADR reports recording Paracetamol had NON CRITI-
CAL reactions overall 4) 25.00% (5 cases)of ADR reports recording Paracetamol with
Cardiovascular system reactions - CRITICAL and they make 1.46 of all ADR reports
recording Paracetamol 5) 75.00% (15 cases) of ADR reports recording Paracetamol
with Cardiovascular system reactions – NON CRITICAL and they make 4.39 of all
ADR reports recording Paracetamol
Null hypothesis: There are no ADR signals in this time span is ACCEPTED No SIG-
NAL”
9.3.4 Paracetamol and Haemic and lymphatic systems (SOC 1200)
The output if drug N02BE01 and haemic and lymphatic systems reactions are selected, the his-
togram in Figure 9.10 is displayed and the following output is made:
“Haemic and lymphatic systems reactions for drug N02BE01 Paracetamol (total of 11
reactions)
1) Paracetamol (N02BE01) makes 0.25% ( cases) of all records (out of 137279) 2) 22.81%
(78 cases) of ADR reports recording Paracetamol had CRITICAL reactions overall 3)
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77.19% (264 cases) of ADR reports recording Paracetamol had NON CRITICAL reac-
tions overall 4) 27.27% (3 cases) of ADR reports recording Paracetamol with Haemic
and lymphatic systems reactions – CRITICAL and they make 0.88 of all ADR reports
recording Paracetamol 5) 72.73% (8 cases) of ADR reports recording Paracetamol with
Haemic and lymphatic systems reactions – NON CRITICAL and they make 2.34 of all
ADR reports recording Paracetamol
Non-sliding windows graph Haemic and lymphatic systems - reaction monthly counts
for drug N02BE01 – Paracetamol (total:11 for 11 months)
Null hypothesis: There are no ADR signals in this time span is ACCEPTED
NO SIGNAL”
In both cases Paracetamol did not produce any signal, thus confirming that our method is not
overly sensitive.
9.3.5 Drugs for the Nervous System and Cardiovascular Reactions
To see the tree traversal for nervous system (Figure 9.11) select “N” for drug class and cardio-
vascular system for SOC class. The algorithm traverses down the ATC tree and finds the drug
Clozapine (N05AH02). It has found the drug having the most cardiovascular reactions. The in-
dividual reactions for this drug are illustrated in Figure 9.12, the blue gives the frequency of the
reaction and the red indicates the critical term status of the particular reaction (10 if critical, 1
otherwise). The inclusion of critical terms provides a means of assessing the seriousness of reac-
tions, which in turn can be used to give the level of warning indicated. Reports are grouped by
date as already described in Section 9.2 and this is illustrated in Figure 9.13 showing the monthly
reaction counts for this drug. Here the signalling algorithm evaluated this drug and gives a report:
“Null hypothesis: There are no ADR signals in this time span is REJECTED... ALERT...There is
signal on 199908 (position 34).” This drug has produced a signal in August 1999. This algorithm
has traversed all the way down the ATC tree and produced a warning with its time of occurrence.
This shows the method finding the strongest signal when drug for the nervous system are
selected and the cardiovascular system reaction class selected also selected.
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9.3.6 Antiinfectives and Liver Reactions
The signal detection algorithm described above (9.2) works in the following way. It requires the
selection of an ATC code at any level and the selection of a reaction class to proceed down the ATC
tree to find nodes with significant reaction frequencies. For example, letter ‘J’ was entered into our
system (‘J’ represents drug level 0) which represents anti-infective drugs (antibiotics). Our system
found a very strong association between anti-infective drugs and reaction class ‘SOC 0700’ (‘Liver
and biliary system disorders’). In the next phase associations between anti-infective drugs and
liver related disorders were looked for. There are 29 reaction terms for liver related disorders and
they make 4284 cases. Our system has found that drug ‘J01CR02’ has the strongest association
with liver related disorders amongst all anti-infective drugs.
The following results were automatically obtained:
Drug J01CR02 corresponds to:
1) Trade name 338 – Amoxicillin and clavulanate
2) Trade name 589 – Amoxicillin and clavulanate
3) Trade name 591 – Amoxicillin and clavulanate
4) Trade name 592 – Amoxicillin and clavulanate
Liver and biliary system disorders reactions for drug J01CR02 Amoxicillin and clavu-
lanate (enzyme inhibitor) (total of 305 reactions)
1) Amoxicillin and clavulanate (J01CR02) makes 1.01% (cases) of all records (out of
137279)
2) 19.88% (275 cases) of ADR reports recording Amoxicillin and clavulanate had CRIT-
ICAL reactions overall
3) 80.12% (1108 cases) of ADR reports recording Amoxicillin and clavulanate had NON
CRITICAL reactions overall
4) 38.03% (116 cases) of ADR reports recording Amoxicillin and clavulanate with Liver
and biliary system disorders had CRITICAL reactions and they make 8.39% of all ADR
reports recording Amoxicillin and clavulanate
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5) 61.97% (189 cases) of ADR reports recording Amoxicillin and clavulanate with Liver
and biliary system disorders had NON CRITICAL reactions and they make 13.67% of
all ADR reports recording Amoxicillin and clavulanate.
When drug level 0: J – antiinfective drugs and reaction class: SOC 0700 – Liver and bil-
iary system disorders are selected, the algorithm proceeds until drug level 7: J01CR02
– Amoxicillin and clavulanate is produced – see Figure 9.14 for illustration. The drug
J01CR02 count was 1383 and SOC 0700 count was 4284 with 29 for reaction terms.
Critical reaction terms: 584 (HEPATITIS), and 585: (HEPATITIS CHOLESTATIC)
were the most prominent, each being almost 20% of SOC 0700 reaction terms.
This algorithm also reports on the signal output for liver and biliary system disorders:
“reaction monthly counts for drug J01CR02 - Amoxicillin and clavulanate (total:305
for 128 months).
Null hypothesis: There are no ADR signals in this time span is REJECTED STRONG
NOTICE (37.12% critical and 62.88% non critical reactions (out of 264) before the
signal on 199901) (position 102).” – see Figure 9.15.
Using the overlapping time window for monthly counts, the following output what
produced: “Overlapping Time Window (X3 – three monthly periods) for Liver and
biliary system disorders – 126 time slots drug J01CR02 – Amoxicillin and clavulanate
Null hypothesis: There are no ADR signals in this time span is REJECTED Low
Frequency STRONG NOTICE (37.22% critical and 62.78% non critical reactions (out
of 266) before the signal on 199902)”
– see Figure 9.16.
This shows a tree traversal for anti-infective drugs and liver and biliary system disorders. In
this case only a strong warning level was reached.
9.4 Discussion
In this chapter I have presented case studies that illustrate the way in which the ontologies and
the ADR signal detection approach work hand in hand to allow a user to understand at each level
of the tree what may be involved in an adverse reaction to a drug or drug class, also see [453]. I
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chose examples of drugs that illustrated where a known signal is detected in particular reaction
classes and one drug were a signal should not be detected and indeed is not, for the reaction classes
in which the other two drugs gave signals. I have shown that, by selecting a root level drug class
and a reaction class, the method traverses the ATC tree to find nodes at the next level that have
significantly more reactions. Then a report is generated on what was found. These examples show
that the method behaves as expected. More extensive testing and refinement of this method is
planned. This can be fully automated for more extensive searches for signals.
9.5 Conclusion
The ATC ontology enables pooling of all data relating to a single ingredient, rather than having it
split between different trade names. without this, the straight application of association rules would
not be useful. This approach provides a means for reducing the computation of all association rules
and trying to filter them. This approach is stepwise meaningful because the ontologies provide
meaning. The tree structure of the ATC ontology was exploited to develop an adverse event
signalling method that can ‘drill down’ the ATC tree to find individual drugs that have significantly
more reactions in a given SOC. Then, using the critical term ontology, monthly reaction frequencies
are examined to produce warnings when reactions rise to a significant level. A time windowing
approach was used to smooth reaction frequencies. Thus the application of ontologies to drug
safety data enables a significant advance in adverse event signalling methodology.
An important way in which to strengthen signals would be to attach a seriousness weighting
to each reaction (other than critical ones) – see Section 2.1.1. This would enable rules containing
serious reactions to be prioritized, particularly if they have low support.
This chapter has addressed research questions 2 and 3. The ATC ontology has structured the
data so that: (i) the number of drug variables can be drastically reduced, (ii) so that finer levels of
granularity can be accessed via a tree structure. This also relates to research question 1, whereby
a new approach, based on association rules which exploit the ATC tree structure and incorporate
the critical reaction term ontology as a means to control the method’s sensitivity by giving serious
reactions increased weight, has been initiated. This investigation was limited by the fact that we
only had records to the year 2001. Another limitation of the Australian drug safety data for testing
our method is its size by global comparison. Many of the drugs that have been withdrawn from
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the global market never reached the Australian market.
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Figure 9.1: Tree traversal of signal algorithm (antiinflammatories).
Figure 9.2: Critical terms used to generate warning levels.
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Figure 9.3: Celecoxib (M01AH01) cardiovascular reactions (SOC1000).
Figure 9.4: Celecoxib (M01AH01) cardiovascular reactions (SOC1000) – monthly reactions.
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Figure 9.5: Celecoxib (M01AH01) cardiovascular reactions (SOC1000) – overlapping window re-
actions.
Figure 9.6: Heparin (B01AB01) Haemic and lymphatic systems reactions (SOC1200).
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Figure 9.7: Heparin (B01AB01) Haemic and lymphatic systems reactions (SOC1200) – monthly
reactions.
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Figure 9.8: Heparin (B01AB01) Haemic and lymphatic systems reactions (SOC1200) – overlapping
window reactions.
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Figure 9.9: Paracetamol (N02BE01) cardiovascular reactions (SOC1000).
Figure 9.10: Paracetamol (N02BE01) haemic and lymphatic systems reactions (SOC1200).
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Figure 9.11: Tree traversal – nervous system.
Figure 9.12: Reactions for Clozapine (N05AH02) for reaction class 1000 – Cardiovascular system.
red = 10 – critical reaction; blue reaction term count
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Figure 9.13: Timing of reactions Clozapine (N05AH02) for reaction class 1000 – Cardiovascular
system.
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Figure 9.14: Liver and biliary system disorders and Amoxicillin (J01CR02).
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Figure 9.15: Liver and biliary system disorders and Amoxicillin (J01CR02) monthly counts.
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Figure 9.16: Liver and biliary system disorders and Amoxicillin (J01CR02) overlapping window
counts.
Chapter 10
Results from ADRAC data run on
Lincoln Technology’s MGPS
10.1 Introduction
In this and the following Chapter I investigate ADRAC data with a method that was designed
specifically for ADR data, the Bayesian the mulit-item gamma Poisson shrinker (MGPS), see
Section 2.1.1. This required the agreement of Bill DuMouchel to use Lincoln Technologies’ imple-
mentation of MGPS and approval by the TGA in Canberra. Some results of an ADRAC data run
of MGPS are reported below in Section 10.2.
10.2 Analysis of ADRAC data with Lincoln Technologies
MGPS Implementation
It has been an important development in my work to analyze the ADRAC data using a standard
drug safety tool. I did try to use GPS with ADRAC data, but this does not use multi-item data
as does BoosTexter. Also the particular implementation of GPS by Belmont Research appeared to
have a bug that I wasn’t able to work around (see Barty [34]). I decided to contact Bill DuMouchel
at Lincoln Technologies to get a working version of the multi-item GPS, MGPS. In view of the
fact that the installation of MGPS is quite involved, Bill offered to do a one-off run of ADRAC
data for me. After getting the necessary approval from the TGA, the results of this MGPS run
are reported here.
Bill DuMouchel using Lincoln Technologies’ implementation of MGPS has provided me with
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results of an ADRAC data run. A description of the input and output files is given in Appendix
D.1. The following section gives a description of the formatting requirements for the input data.
10.2.1 Specification
The data formatting requirements are detailed in correspondence from Bill DuMouchel:
06/24/05 7:47 am . . .
For a single coding of drugs and events, with minimal drill-down, we would normally
just require three tables: an Items table, an Itemtype table, and a Covariates table.
An item is a generic term that refers either to a drug or to an adverse event. These are
usually the only two types of items. Covariates refer to descriptors of the case report
such as the age or gender of the patient, or the date the report was submitted to the
regulator. The tables can be in simple ASCII flat file format.
The Items table has two fields: ReportID – identifier of the case ItemName – name of
a drug or event included in this report If there are N reports and each report has an
average of n items, there will be Nn rows in the Items table.
The Itemtype table has two fields: ItemName – name of a drug or event ItemType –
says whether this is a drug or an event (Could just be “D” or “E”) If there are Md
different drugs and Me different events, there are Md+Me rows in this table.
The Covariates table has K+1 fields, if there are K covariates: ReportID – identifier of
the case Variable1 – value of the first covariate (e.g. age in years, or “Unknown”) ...
VariableK – value of the Kth covariate (e.g. calendar year of the report date) If there
are N reports, there will be N rows in this table.
The Items table is sorted by ReportID and within that by ItemName. The ItemType
table is sorted by ItemType and within that by ItemName. The Covariates table is
sorted by ReportID.
You are not allowed to have a drug with exactly the same name as an event with this
setup. Drug names and event names can have spaces and other punctuation embedded
in them. We usually use tab-separated fields, so tabs should not appear as part of a
name.
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. . .
10/14/05 3:24 am . . . our covariates table could be the fields 1, 3, 4, 6 from your
Mallreac.txt table, and yes, we would use a tab-separated format with the addition of
a first record for column headings.
We would need the Age variable grouped into a few (say from 3 to 7 or so) age-interval
categories. Age group and gender can be alpha text labels, you don’t have to make
them numeric, and they can contain any character except tab. The same goes for your
field 1, which should be sorted as a text string rather than a number. Prepending
leading zeros to get 000001, 000002, . . . , 000010, is preferred so that “10” doesn’t come
between “1” and “2” in the sort. The order of the covariates doesn’t matter (i.e. age
can come before or after year or gender, etc.)
The “year” covariate could also be grouped. You might have many fewer reports in
earlier years than later, so grouping the earlier years might save on ”degrees of freedom”.
I’m not sure how many years you have, and about how many reports per year. Having
at most 10 to 15 year groups is preferable.
We usually include “unknown” as a separate group for age and gender. (7 age groups)
* (3 genders) * (10 time intervals) = 210 possible covariate strata Is about right.
For the Items table, an example would be
000001 <tab >D Aspirin
000001 <tab >D Codeine
000001 <tab >E Headache
000001 <tab >E Nausea
000002 <tab >D Albuterol . . . Etc.
We usually prepend “D ” and “E ” to distinguish drugs from events. Drug and event
names can include spaces, since you will have tab separation. You could supply two
versions of the Items table, one with nonsuspect drugs included and one with them
omitted, if you want to compare the two types of analysis.
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*************** this, can I identify each drug-RecordID pair with its corresponding
suspect code in the Items table and each event with its corresponding SOC in the Item
type table? I have modified the ADRAC SOC so that events have only one SOC.
***************
I’m not sure what you are getting at in the above passage. We don’t actually need to
have the ”Item types” table for a minimal analysis. But a third table that provides the
SOC for each event term would allow us to redo the analysis at the SOC level.
–Bill
10.2.2 Description of ADRAC Data Sent for Analysis
The data sent to Bill DuMouchel comes from the data set called Mallreac described in Section
3.4. They were formatted according to the specifications set out in the previous section 10.2.1. For
a description of the input files and their location see Appendix D.1.1.
10.2.3 Results
The result file field definitions are given in Appendix D.1.3.
Two MGPS analyses were performed. The first used the original Drugs and Events (DE),
which consisted ADRAC drug trade name and prefferred reaction term (event). The second col-
lapsed Drugs into Classes (C)1 and collapsed Events into SOC categories (S), and then analyzed
the association between Classes and SOCs. The files with names that begin with “item-counts”
and ”strata-counts” provide summary counts for each item and each stratum for the D-E analysis
and the C-S analysis. A file named “Hyperparameters.txt” provides the estimates of the gamma
mixture prior distribution parameters that were used in the Bayesian estimation see Table 10.1.
The parameters α (Alpha), β (Beta) and P are explained in the subsection “Technical Summary
of MGPS” in Appendix D.1.3. Here the formulation of Poisson representation of λ is described.
λ = E[N/E], where N is the observed frequency of the itemset, and E is a baseline (null hy-
pothesis) count. In order to estimate λij = µij/Eij , where Nij ∼ Poisson(µij), they assume a
superpopulation model for µij (prior distribution) based on a mixture of two gamma distributions
(a convenient 5-parameter family of distributions that can fit almost any empirical distribution):
1As explained in the subsection “Drug Event Counts below”. ‘C’ in this in this particular data set does not in
fact collapse drugs. It is, in fact, the ATC classification of drugs at the finest (level 5) level.
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pi(λ;α1, β1, α2, β2, P ) = P g(λ;α1, β1) + (1− P ) g(λ;α2, β2)
g(λ;α, β) = βαλα−1e−βλ/Γ(α)
was used.
Table 10.1: Hyperparameters for ADRAC data
ItemseType Statistic Alpha1 Beta1 P1 Alpha2 Beta2 P2
DE Estimate 0.03289 0.09952 0.1576 4.716 4.899 0.8424
DE St.Error 0.006539 0.003002 0.004286 0.1262 0.1315 0.004286
DDE Estimate 4.59 11.07 0.08625 223.1 243.3 0.9138
DDE St.Error 1.196 2.959 0.01405 81.62 88.32 0.01405
DEE Estimate 0.6844 0.5789 0.007532 0.07667 0.5183 0.9925
DEE St.Error 0.311 0.2284 0.005024 0.007488 0.005675 0.005024
CS Estimate 0.8289 0.5415 0.1628 8.433 8.768 0.8372
CS St.Error 0.07453 0.05387 0.01567 0.4985 0.542 0.01567
CCS Estimate 41.91 72.92 0.09547 329 375.3 0.9045
CCS St.Error 16.69 26.52 0.02856 82.01 91.73 0.02856
CSS Estimate 1.746 3.372 0.6746 10.8 10.58 0.3254
CSS St.Error 0.06427 0.1223 0.02815 1.401 1.204 0.02815
10.2.4 Drug-event counts
The MPGS data output contains general numerical information about the ADRAC data which
will be presented in this chapter in order to provide a framework to compare the MPGS analysis
with other methods investigated in this thesis. This section deals with the drug event counts. The
analysis done by Linclon technologies is presented in four tables. Tables 10.5 and 10.7 are dug trade
name and event. As already explained in Section 3.6 the trade name has two main inadequacies:
(i) the same ingredient may be listed multiple times, for example in Table 10.7 paracetamol and
panedeine forte are the same ingredient (paracetamol); (ii) many trade names represent multiple
ingredients. The ATC classification I have applied to the ADRAC data overcomes inadequacy (i)
where similar ingredients have the one code. However, in order to preserve a one-to-one correspon-
dence with trade name terms, ATC codes for combinations were used for drugs having multiple
ingredients. Thus inadequacy (ii) remains. I have a classification that assigns ATC codes for each
ingredient for drugs containing multiple ingredients, but the methods investigated in this study
were not able to use this extra information in their present form. This information cannot afford
to be lost, so methods that can use this information need to be developed. In the present context,
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it is difficult to compare between the four tables presented in this section for the following reason.
The two DE tables (10.5 and 10.7) and the table in the following section (Tables 10.8, 10.9, and
10.10) compare trade name drug terms to preferred reaction terms, whereas the two CS tables
(10.2 and 10.6) and the table in the following section (Tables 10.11, 10.12, and 10.13) compare
ATC drug ingredient terms to SOC reaction classes. the use of ‘C’ as a prefix to ATC term implies
that this is a drug class, whereas, the ATC codes supplied were in fact low level drug terms, not
drug classes. Because this was a one-off analysis, this fact got lost. To compare trade name terms
with ATC terms the following further comparisons would need to be made: CE (ATC ‘leaf’ level –
preferred term) and DS (trade name – SOC) and to extend to triples: CEE, CCE, DSS and DDS.
This could be done without any change to the input files. It would be of interest to make the
further input files to represent ATC classes the various ATC levels:
if C = A01AA01 then,
G = A01AA
H = A01A
I = A01
J = A
and where:
D = trade name
E = preferred term
S = SOC.
It would then be interesting to format the ADRAC data to make the drug classes G—J and
examining the combinations with the events E and event classes S. For example, CE with DE
would compare drug trade name and ATC level 5 at the event level; DS with CS would compare
drug trade name and ATC level 5 to SOC event classes. Since there is no grouping of trade name
used by ADRAC, it is only useful to compare the lower ATC levels (0–4: J, I, H, G), namely: JE
& JS, IE & IS, HE & HS, GE & GS. This must await the installation of MGPS locally the number
of runs required for a satisfactory analysis would exceed that of the current arrangement with Bill
DuMouchel.
I will start my comparison of the MGPS results using Table 10.2, which shows MGPS counts
and the counts of the SOC groups given in Chapter 3. The MGPS counts for all reaction classes
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Table 10.2: Counts for Ingredient-SOC (CS) event class
SOC Name Item code Count* ADRAC Count†
Skin and appendages disorders S 0100 40406 54221
body as a whole S 1800 34395 42396
nervous system and special senses S 0400 33333 47549
gastro-intestinal system disorders S 0600 25584 34581
cardiovascular system S 1000 21513 27360
psychiatric disorders S 0500 14746 19946
respiratory system disorders S 1100 10791 13296
haemic and lymphatic systems S 1200 8473 10226
musculo-skeletal system disorders S 0200 7590 8808
liver and biliary system disorders S 0700 6733 7686
urinary system disorders S 1300 4773 5865
metabolic and nutritional disorders S 0800 4142 4926
reproductive system S 1400 3054 3412
endocrine disorders S 0900 1109 1201
foetal disorders S 1500 587 841
collagen disorders S 0300 365 385
neoplasm S 1700 264 278
neonatal and infancy disorders S 1600 88 103
neoplasm S 1700 264 278
Total 217946 283080
* Number of records counted by MGPS
† Number of records in ADRAC
total 217946, which is less than the 283080 obtained from an ADRAC database query that counted
the number of ADR report records that contained the reaction terms (preferred) corresponding to
each class. Both these totals are greater than the total number of report records, which is 137297.
The reason for this is due to the fact that some report records may contain more than one reaction
term that belongs to any given SOC reaction class and thus will be counted n − 1 extra times,
where n = the number of reaction terms for that given SOC.
In Table 10.5 the highest event counts from the DE analysis are presented. To help compar-
ison to Table 10.2, SOC names have also been added. It can be seen that skin and appendages
disorders, body as a whole, nervous system and special senses, gastro-intestinal system disorders,
cardiovascular system, psychiatric disorders, respiratory system disorders, and haemic and lym-
phatic systems are well represented. This table shows which individual reactions are the most
common, when ordered by either RR, EBGM or EXCESS.
In Table 10.7 the 53 highest drug counts are presented. To help comparison to Table 10.6,
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the ingredients have also been added. It can be seen that the order of drugs is similar in each
table. The differences are mainly due to the replication of the same ingredient under different
trade names, which spits the ingredient counts. For example, frusemide second and nineteenth,
ranitidine eighth and forty fourth, digoxin ninth and thirtieth, paracetamol twenty ninth and forty
sixth, and bactrim forty seventh and fifty third. This shows one advantage of the ATC classification
to bring all drug terms for a particular ingredient under one code.
10.2.5 Drug-event Results for DE ordering by RR, EBGM and EXCESS
I have selected just three (RR, EBGM and EXCESS) of the several estimators used in MGPS (see
Appendix D.1.3 in order to select different views of the results. These views highlight some of the
problems in this type of data and illustrate how an improved ontology drug and reaction terms
could enhance the analysis by MGPS and other methods.
Table 10.3 summarizes the the complete table that Table 10.5 list the top 53 terms of drug-event
(DE) counts for ADRAC events. The purpose of this table is to show the overall distribution of
reactions terms in their SOC classes and to form a basis for comparing their position when the
data are ordered by the three measures RR, EBGM and EXCESS. In this table, event position
with respect to its SOC class are as follows:
skin and appendages disorders occupy: 1 2 4 5 9 36 50;
gastro-intestinal system disorders: 3 7 11;
nervous system and special senses: 6 10 19 21 23 29 34 53;
body as a whole: 8 12 14 17 20 22 25 26 30 39 47 51;
respiratory system disorders: 13 27 28;
liver and biliary system disorders: 15 42;
musculo-skeletal system disorders: 16 33;
cardiovascular system: 19 24 35 40 45 48 49 52;
psychiatric disorders: 31 32 37 41 44 47;
haemic and lymphatic systems: 36 43.
This is expected to be the same order as presented in Table 10.3, because we are just looking
at frequency of event occurrence.
The results for drug-event (DE) ordering by RR, EBGM and EXCESS are presented in Tables
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10.8, 10.9, and 10.10.
In Table 10.8 the records are ordered by RR, and event position with respect to its SOC class
are as follows:
neoplasm: 1 8;
nervous system and special senses: 2 3 5 10 25 32;
urinary system disorders 4;
cardiovascular system: 6 14 27;
body as a whole: 7 20 22 30 33 37 40;
skin and appendages disorders: 11 12 24 26 28 35;
gastro-intestinal system disorders: 13 21 38 39;
respiratory system disorders: 15 16 29 36 41 42;
musculo-skeletal system disorders: 17;
haemic and lymphatic systems: 23 34;
metabolic and nutritional disorders: 19 31.
The positioning of the SOC classes follows a similar order to that in Table 10.3, with the
exception of neoplasm, which is first seen at position 420 in this table, whereas it occurs twice in the
top 10 ordering by RR. The first position is occupied by the drug methoblastin, an antineoplastic
agent, is associated with bladder carcinoma. RR gives this as a strong association, but this could
just be an example of confounding by indication; the event being due to the patient’s condition.
It can also be noted that, when the DE’s are ordered on RR, for the other two estimators, their
values with respect to their ranges (see Table 10.4), in the case of EBGM, moderately low (3–50),
which is in the top of the lower half and covering 50% of the overall EBGM range. For EXCESS
the values were around zero (-0.02–0) in the 4th lowest sixteenth part of the range of values for
EXCESS. Thus RR looks at a different part of the DE pair distribution than the overall event
frequency ordering.
In Table 10.9 the records are ordered by EBGM, and event position with respect to its SOC
class are as follows:
body as a whole: 1 33 36;
haemic and lymphatic systems: 2 11 12 32 34;
nervous system and special senses: 3 6 15 19 24 27 30 31 40;
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cardiovascular system: 4 35 39;
urinary system disorders 7 15 22 36;
metabolic and nutritional disorders: 8 10 18 29 38 42;
collagen disorders: 9 17;
skin and appendages disorders: 12 41;
gastro-intestinal system disorders: 16 26 38 39;
musculo-skeletal system disorders: 25;
psychiatric disorders: 21;
reproductive system: 23;
foetal disorders: 25;
endocrine disorders: 28.
The positioning of the SOC classes follows a similar order to that in Table 10.3, however
haemic and lymphatic systems and collagen disorders were more prominent with foetal disorders
and endocrine disorders also better represented. When the DE’s are ordered on EBGM, the other
two estimators’ values with respect to their ranges (see Table 10.4) are, in the case of RR (61–
661), is below one half maximum and covering 39% of the total range for RR. EXCESS was in
the low positive range (0.004–36), which is in the 2nd eighth part and 9% of the range of values
for EXCESS. It also should be noted that the values of RR and EBGM are very similar. Thus
EBGM ‘looks’ at a different part of the DE pair distribution than RR or the overall event frequency
ordering.
In Table 10.10 the records are ordered by EXCESS, and event position with respect to its SOC
class are as follows:
body as a whole: 1 2 4 9–11 22 23 32 38;
respiratory system disorders: 3 18 29 35;
skin and appendages disorders: 5 8 12 14–17 19 24 25 30 34 36 38–40 42;
cardiovascular system: 6 7 20;
liver and biliary system disorders: 13 27;
nervous system and special senses: 21 29;
haemic and lymphatic systems: 26;
musculo-skeletal system disorders: 31 33.
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The positioning of the SOC classes follows a similar order to that in Table 10.3, however rarer
SOCs were not represented. When the DE’s are ordered on EXCESS, the other two estimators’
values with respect to their ranges (see Table 10.4), in the case of RR (2–23), which is below one
fiftieth maximum and covers 1.4% of the entire range of RR. EBGM (2–32) is below one quarter
maximum and covers 33% of the entire range of EBGM. Also the values of RR and EBGM are
very similar. It should be noted that many skin reactions are associated with antibiotics (compare
CCS EXCESS – Table 11.14). These doubles could be combined by using a higher level in the
ATC drug classification.
10.2.6 Drug-‘class’ Results for CS ordering by RR, EBGM and EXCESS
The results for drug-class (CS) ordering by RR, EBGM are presented in Tables 10.11, 10.12, and
10.13.
In Table 10.11 the records are ordered by RR, and event position with respect to its SOC class
are as follows:
neoplasm: 1–4 6 10 13 21 28 38 41;
metabolic and nutritional disorders: 5 8 17;
urinary system disorders 7 31;
collagen disorders: 9 11 12 14;
neonatal and infancy disorders: 15 18 19;
foetal disorders: 20 24–26 30 32–36 39;
endocrine disorders: 29;
haemic and lymphatic systems: 37 42;
liver and biliary system disorders: 40 43.
This gives a different ordering of events with respect to their reaction classes to DE ordered by
RR. The SOC that were ordered well down in overall events counts (neoplasm, collagen disorders,
neonatal and infancy disorders, foetal disorders, endocrine disorders) rank much higher with or-
dering by RR. The parts of the value ranges of the other two estimators being compared: EBGM
(1.77–25.324), which covers 93% of its range. EXCESS (-0.036– + 0.02), which is in the 3rd lowest
eighth part of the range of values for EXCESS.
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In Table 10.12 the records are ordered by EBGM, and event position with respect to its SOC
class are as follows:
collagen disorders: 1–3;
foetal disorders: 4–7 16 21 22 34;
neoplasm: 8 28 31 32 36;
liver and biliary system disorders: 9 12 14 30 35 38;
urinary system disorders 10 13;
endocrine disorders: 11 12 19 20 24;
metabolic and nutritional disorders: 15 18 23 26 39 41;
reproductive system: 17;
respiratory system disorders: 25;
haemic and lymphatic systems: 27 29 37 40 42 43.
Here we also see SOC class events, which are ordered lower down in the overall event ordering,
featuring much more prominently (collagen disorders, foetal disorders, and neoplasm). The parts
of the value ranges of the other two estimators being compared: RR (6.5–131), which covers
approximately 50% of its range, from the middle of the lowest sixteenth to a little above the
middle of the range. EXCESS (0.02–199.248), which covers approximately 16.6% of its range and
is in the 2nd quarter of the range of values for EXCESS. Many of the values of RR and EBGM
are similar.
In Table 10.13 the records are ordered by EXCESS, and event position with respect to its SOC
class are as follows:
skin and appendages disorders: 1–3 7 8 11 15 19–22 27 35;
liver and biliary system disorders: 4 13 17;
body as a whole: 5 13 17;
haemic and lymphatic systems: 6 14;
psychiatric disorders: 9 37;
respiratory system disorders: 31 38;
musculo-skeletal system disorders: 18 29 33;
nervous system and special senses: 24 28 30 41 43;
gastro-intestinal system disorders: 26 32 40.
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The positioning of the SOC classes follows a similar order to that in Table 10.3, but the rarer
SOCs were not represented. When the DE’s are ordered on EXCESS, the other two estimators’
values with respect to their ranges (see Table 10.4), in the case of RR, are below one fiftieth
maximum, and for EBGM (1.3–13), which covers approximately 5% of the range and is in the
lowest sixteenth of this range. EBGM (1.33–7.265), which covers approximately 23% of the range
and is in the lowest quarter of this range. Most of the values of RR and EBGM are similar.
10.2.7 Drug-event Results for triples and interactions
The rest of the investigation on MGPS results continues in the next chapter, Chapter 11.
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Table 10.3: SOC Positions in Reaction Term Count Table
SOC Name Position of Reaction Term in Count Table
Skin and appendages disorders 1 2 4 5 9 36 50 65 57 81 98 99 145 156 160 176 184 195 208 227 239
251 273 275 276 280 287 296 305 318 319 323 325 345 374 391 *
gastro-intestinal system disorders 3 7 11 58 62 70 71 74 77 89 97 101 108 127 152 158 165 167 177 220 224
226 246 256 272 274 282 294 298 308 339 359 363 365 367 378 387 *
nervous system and special senses 6 10 19 21 23 29 34 53 60 64 78 85 87 88 94 111–114 123 124 131 140 141
144 146 149 154 159 163 168 170 181 183 185 191 203 211 217–219 225
229 231 232 240 245 250 254 257 264 268 269 284 286 288 293 299 301
304 311 329 332 333 358 361 368 371–373 379 382 384 385 399 400 *
body as a whole 8 12 14 17 20 22 25 26 30 39 47 51 55 73 83 95 100 102 126 132 135 139
164 69 171 179 180 204 223 314 343 346 355 360 362 369 375 390 397 *
respiratory system disorders 13 27 28 66 79 143 147 161 178 193 200 203 213 262 263 267 295 316 322
354 356 364 370 *
liver and biliary system disorders 15 42 54 93 214 216 279 395 *
musculo-skeletal system disorders 16 33 61 92 136 142 206 210 277 283 289 312 *
cardiovascular system 19 24 41 45 48 49 52 57 59 68 72 84 96 103 115 129 130 134 152 172 173
187 189 192 194 196 209 221 223 234 236 241 243 252 278 285 290 291 310
331 334 340 347 349 350 376 377389 392 *
psychiatric disorders 31 32 37 41 44 47 56 63 82 90 97 110 120 137 138 151 186 197 199 222 248
259 297 300 320 342 344 348 *
haemic and lymphatic systems 36 43 86 104 105 107 109 119 122 128 166 212 230 238 265 270 307 327 330
335 337 388 396 *
metabolic and nutritional disorders 69 106 125 150 155 175 182 215 237 247 251 292 302 353 366 380 381
393 394 *
urinary system disorders 75 76 117 121 133 148 162 190 198 207 228 235 244 249 255 260 383 *
reproductive system 80 118 174 201 202 242 266 281 303 309 313 315 326 336 338 341 352 386 *
endocrine disorders 116 253 306 321 324 328 *
foetal disorders 258 317 357 *
collagen disorders 271 351 *
neoplasm 420 632 680 697 702 706 721 723 736 753 832 858 860 865 941 946 964 971
1001 1003 1018 1050 1067 1078 1099 1125 1139 1148 1154 1171 1216 †
neonatal and infancy disorders 611 620 647 648 991 1004 1038 1046 1049 1052 1075 1085 1091 1150 1158
1183 1188 1205 1217 †
* Only reaction terms belonging to this SOC in the top 400.
† All records for this class in the list of occurrence in ADRAC of reaction terms.
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Table 10.4: MGPS Range of values for DE, DEE, DDE, CS, CSS, CCS with respect to RR*,
EBGM†, and EXCESS‡ Estimators
Drug-Event Estimator Minimum Maximum
DE RR 0.05 1538
EBGM 0.049 89.76
EXCESS -91.838 311.758
CS RR 0.022 238.199
EBGM 0.026 25.324
EXCESS -361.795 840.712
DEE RR 0.12 12889
EBGM 0.095 369.602
EXCESS -16.277 119.201
DDE RR 0.138 53621.869
EBGM 0.241 69.386
EXCESS -23.898 43.939
CSS RR 0.045 264.798
EBGM 0.072 43.638
EXCESS -365.593 153.966
CCS RR 0.069 1039.417
EBGM 0.196 22.331
EXCESS -90.673 91.118
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 10.5: 54 Highest Counts for Events
Preferred Term Item code SOC Count
RASH E 1081 Skin/appendages disorders 10887
PRURITUS E 1048 Skin/appendages disorders 10643
NAUSEA E 874 gastro-intestinal syst. 9955
URTICARIA E 1334 Skin/appendages disorders 8239
RASH MACULO-PAPULAR E 1084 Skin/appendages disorders 6396
HEADACHE E 566 nervous syst./special senses 6310
VOMITING E 1378 gastro-intestinal syst. 6022
FEVER E 466 body as a whole 5942
RASH ERYTHEMATOUS E 1082 Skin/appendages disorders 5744
DIZZINESS E 358 nervous syst./special senses 5220
DIARRHOEA E 347 gastro-intestinal syst. 4408
ABDOMINAL PAIN E 2 body as a whole 4275
DYSPNOEA E 384 respiratory system disord. 3657
FATIGUE E 461 body as a whole 3171
HEPATIC FUNCTION ABNORMAL E 580 liver/biliary system 3088
MYALGIA E 851 musculo-skeletal system 2997
FACE OEDEMA E 456 body as a whole 2931
HYPOTENSION E 670 cardiovascular system 2928
PARAESTHESIA E 965 nervous syst./special senses 2895
MALAISE E 795 body as a whole 2644
SWEATING INCREASED E 1212 nervous syst./special senses 2575
INJECTION SITE REACTION E 718 body as a whole 2544
CONFUSION E 280 nervous syst./special senses 2492
FLUSHING E 480 cardiovascular system 2449
APPLICATION SITE REACTION E 100 body as a whole 2417
CHEST PAIN E 237 body as a whole 2376
BRONCHOSPASM E 191 respiratory system disord. 2240
COUGHING E 299 respiratory system disord. 2153
TREMOR E 1304 nervous syst./special senses 2148
THERAPEUTIC INEFFICACY E 1235 body as a whole 2069
SOMNOLENCE E 1183 psychiatric disorders 2050
AGITATION E 24 psychiatric disorders 2031
ARTHRALGIA E 111 musculo-skeletal system 1993
VISION ABNORMAL E 1371 nervous syst./special senses 1959
TACHYCARDIA E 1217 cardiovascular system 1910
THROMBOCYTOPENIA E 1243 haemic/lymphatic syst. 1884
INSOMNIA E 719 psychiatric disorders 1863
ANGIOEDEMA E 69 Skin/appendages disorders 1758
RIGORS E 1131 body as a whole 1702
PURPURA E 1071 cardiovascular system 1651
ANOREXIA E 74 psychiatric disorders 1648
JAUNDICE E 733 liver/biliary system 1624
NEUTROPENIA E 902 haemic/lymphatic syst. 1594
HALLUCINATION E 564 psychiatric disorders 1526
SYNCOPE E 1213 cardiovascular system 1503
DEPRESSION E 330 psychiatric disorders 1473
PAIN E 955 body as a whole 1468
OEDEMA E 913 cardiovascular system 1457
PALPITATION E 958 cardiovascular system 1435
PHOTOSENSITIVITY REACTION E 1009 Skin/appendages disorders 1430
ASTHENIA E 123 body as a whole 1418
OEDEMA PERIORBITAL E 919 cardiovascular system 1406
CONVULSIONS E 286 nervous syst./special senses 1406
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Table 10.6: 53 Highest Counts for Drug Ingredient
Drug Ingredient Item code Count
Frusemide C C03CA01 5137
Acetylsalicylic acid C N02BA01 5026
Sertraline C N02CC10 4511
Digoxin C C01AA05 4082
Ranitidine C A02BA02 3399
Salbutamol C R03CC02 3227
Simvastatin C C10AA01 3145
Amoxycillin C J01CE50 3109
Paracetamol C N02BE01 3046
Enalapril C C09AA02 3011
Paracetamol, combinations excl. psycholeptics C N02BE51 2991
Celecoxib C M01AH01 2887
Allopurinol C M04AA01 2493
Metoclopramide C A03FA01 2423
Amlodipine C C08CA01 2400
Captopril C C09AA01 2361
Carbamazepine C N03AF01 2240
Atenolol C C07AB03 2220
Potassium chloride C A12BA01 2215
Diazepam C N05BA01 2195
Flucloxacillin C J01CF05 2179
Diclofenac C M01AB05 2153
Metoprolol C C07AB02 2081
Prednisolone C H02AB06 2069
Intermediate-acting sulfonamides, combinations C J01EC20 2034
Clozapine C N05AH02 2010
Warfarin C B01AA03 1985
Erythromycin C J01FA01 1969
Sulfamethoxazole and trimethoprim C J01EE01 1963
Temazepam C N05CD07 1923
Specific immunoglobulins C J06BB30 1909
Naproxen C M01AE02 1896
Verapamil C C08DA01 1867
Heparin C B01AB01 1859
Glyceryl trinitrate C C01DA02 1854
Phenytoin C N03AB02 1848
Methyldopa C C02AB01 1814
Hydrochlorothiazide C C03AA03 1809
Indomethacin C M01AX81 1745
Beclomethasone dipropionate C R01AC80 1713
Pethidine C N02AB02 1638
Paroxetine C N06AB05 1635
Gentamicin C J01GB03 1625
Prazosin C C02CA01 1611
Nifedipine C C08CA05 1609
Propranolol C C07AA05 1605
Levothyroxine C H03AA01 1587
Ampicillin C J01CA01 1586
Amoxicillin and clavulanate C J01CR02 1570
Omeprazole C A02BC01 1533
Morphine C N02AA01 1512
Metronidazole C J01XD01 1500
Meglumine diatrizoate C V08AA20 1482
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Table 10.7: 53 Highest Counts for Drug-Event (DE) drugs
Drug Trade Name Drug Ingredient Item code Count
ZOLOFT SERTRALINE D 7387 4261
LASIX FRUSEMIDE D 3694 3143
VENTOLIN SALBUTAMOL D 7134 2752
CELEBREX CELECOXIB D 1232 2738
ASPIRIN Acetylsalicylic acid D 543 2704
SLOW-K POTASSIUM CHLORIDE D 6170 2215
NORVASC AMLODIPINE D 4719 2177
ZANTAC RANITIDINE D 7309 2176
DIGOXIN DIGOXIN D 1974 2045
RENITEC ENALAPRIL D 5779 1983
PREDNISOLONE PREDNISOLONE D 5452 1911
VOLTAREN DICLOFENAC D 7230 1739
CLOZARIL CLOZAPINE D 1535 1732
FLUCLOXACILLIN FLUCLOXACILLIN D 2669 1723
MAXOLON METOCLOPRAMIDE D 4009 1716
AMOXIL AMOXYCILLIN D 335 1681
MODURETIC AMILORIDE D 4327 1669
TEGRETOL CARBAMAZEPINE D 6581 1667
FRUSEMIDE FRUSEMIDE D 2780 1657
WARFARIN WARFARIN D 7239 1652
PETHIDINE PETHIDINE D 5215 1633
ALDOMET METHYLDOPA D 183 1539
GENTAMICIN GENTAMICIN D 2862 1537
AROPAX PAROXETINE D 519 1441
ZOCOR SIMVASTATIN D 7372 1437
CAPOTEN CAPTOPRIL D 1120 1433
ZYLOPRIM ALLOPURINOL D 7412 1427
HEPARIN HEPARIN D 3055 1426
PANADOL PARACETAMOL D 5029 1376
LANOXIN DIGOXIN D 3683 1361
NAPROSYN NAPROXEN D 4463 1321
INDOCID INDOMETHACIN D 3315 1290
TENORMIN ATENOLOL D 6617 1255
DILANTIN PHENYTOIN D 1984 1253
ZYBAN BUPROPION D 7408 1226
AMPICILLIN AMPICILLIN D 351 1218
CHLOTRIDE HYDROCHLOROTHIAZIDE D 1389 1215
MINIPRESS PRAZOSIN D 4272 1210
BETALOC METOPROLOL D 782 1208
VALIUM DIAZEPAM D 7087 1202
STEMETIL PROCHLORPERAZINE D 6342 1195
INDERAL PROPRANOLOL D 3311 1183
TEMAZEPAM TEMAZEPAM D 6599 1163
RANITIDINE RANITIDINE D 5718 1142
LOSEC OMEPRAZOLE D 3884 1101
PARACETAMOL PARACETAMOL D 5070 1099
BACTRIM TRIMETHOPRIM-SULFAMETHOXAZOLE D 657 1089
PANADEINE FORTE PARACETAMOL/CODEINE D 5025 1050
TRIPLE ANTIGEN DIPHTHERIA-TETANUS-PERTUSSIS VACCINE D 6932 1044
FELDENE PIROXICAM D 2550 1035
CECLOR CEFACLOR D 1195 1003
MOGADON NITRAZEPAM D 4329 983
BACTRIM TRIMETHOPRIM-SULFAMETHOXAZOLE D 658 948
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Table 10.8: MGPS Drug Trade Name-Event (DE) Ordered by Relative Ratio
Drug Trade Name Preferred Term RR* EBGM† EXCS‡
METHOBLASTIN BLADDER CARCINOMA 1538 3.106 0
OPHTHETIC KERATITIS 1465.524 3.103 0
FUL GLO KERATITIS 1465.524 3.103 0
ALLBEE WITH C HYPERPHOSPHATAEMIA 1167.795 2.539 -0.001
TRANYLCYPROMINE SEROTONIN SYNDROME 1102.536 3.083 -0.001
BREVIDIL-E THROMBOPHLEBITIS 952.476 3.071 -0.001
CALCIUM CHLORIDE SKIN NECROSIS 851.615 3.06 -0.001
PSORALEN CARCINOMA 805.263 3.054 -0.001
CANTHAXANTHINE RETINAL DISORDER 784.76 3.051 -0.001
CLOMID CATARACT SUBCAPSULAR 781.057 17.794 0.002
BENZOYL PEROXIDE DERMATITIS CONTACT 717.247 3.041 -0.001
TRYPTOPHAN SCLERODERMA 705.266 3.039 -0.001
ULTRAFRESH MOUTHWASH GINGIVITIS 688.428 3.036 -0.001
INTRAVAL THROMBOPHLEBITIS 687.245 3.036 -0.001
BRONCOSTAT BRONCHITIS 641.777 17.55 0.002
BRONCOSTAT PLEURISY 631.594 3.025 -0.001
SLENDER PATCH CRAMP LEG 628.147 3.024 -0.001
INTAL FORTE CAPILLARY FRAGILITY INCREASED 600.965 3.018 -0.001
HUMALOG HYPOGLYCAEMIC REACTION 595.696 3.017 -0.001
TESTOSTERONE IMPLANTS INJECTION SITE ABSCESS STERILE 585.693 3.015 -0.001
RESPAX NEBULISING SOLN TOOTH DISCOLOURATION 576.545 3.012 -0.001
NUPERCAINE THERAPEUTIC RESPONSE PROLONGED 550.461 3.005 -0.001
MOXALACTAM COAGULATION TIME INCREASED 545.328 3.004 -0.001
BANLICE MOUSSE HAIR DISCOLOURATION 526.759 2.999 -0.001
MAXIDEX GLAUCOMA 515.867 49.844 0.264
DISOPYRAMIDE CHLOASMA 513.082 2.994 -0.001
UNIPARIN-CA THROMBOEMBOLISM 504.087 2.992 -0.001
PROCTOSEDYL PRURITUS ANI 499.073 2.99 -0.001
XYLOCAINE 10% SPRAY LARYNGITIS 497.627 17.162 0.002
ISOCAL THERAPEUTIC RESPONSE DECREASED 493.474 2.988 -0.001
MONOTARD HM HYPOGLYCAEMIC REACTION 490.998 2.987 -0.001
VAGIFEM ANTICHOLINERGIC SYNDROME 487.5 2.986 -0.001
IMMUCYST INFECTION TBC 481.61 2.984 -0.001
AVLOSULFON HAEMOLYSIS 474.165 2.981 -0.001
TRYPTOPHAN SKIN HYPERTROPHY 468.079 2.979 -0.001
NITROFURANTOIN CHEST X-RAY ABNORMAL 467.44 2.979 -0.001
MIVACURIUM CHLORIDE THERAPEUTIC RESPONSE PROLONGED 463.7 2.978 -0.001
HIFLUOR TOOTH DISORDER 456.099 2.975 -0.001
ASCABIOL PROCTITIS 455.452 2.974 -0.001
MIVACRON THERAPEUTIC RESPONSE PROLONGED 443.75 16.956 0.003
DESERIL PLEURAL FIBROSIS 441.153 2.969 -0.001
CHLOROPTIC CORNEAL ULCERATION 437.5 2.967 -0.001
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 10.9: MGPS Drug Trade Name-Event (DE) Ordered by Empirical Bayesian Geometric Mean
Drug Trade Name Preferred Term RR* EB† EXS‡
WAXSOL OTITIS EXTERNA 200.702 89.76 4.908
DAPSONE ANAEMIA HAEMOLYTIC 110.717 76.371 12.58
SABRIL VISUAL FIELD DEFECT 178.117 69.127 2.738
DICLOXACILLIN THROMBOPHLEBITIS 107.641 68.467 8.463
PENICILLAMINE MYASTHENIA GRAVIS-LIKE SYNDROME 217.435 65.545 1.676
DEPO-MEDROL ARACHNOIDITIS 125.118 64.027 4.381
SURGAM CYSTITIS 66.934 62.049 69.39
LITHIUM CARBONATE DIABETES INSIPIDUS 136.676 61.589 3.169
DESERIL RETROPERITONEAL FIBROSIS 136.797 58.562 2.688
PROTAPHANE HYPOGLYCAEMIA 135.48 58.308 2.702
PRIMAQUINE METHAEMOGLOBINAEMIA 179.17 57.014 1.533
DAPSONE METHAEMOGLOBINAEMIA 174.864 56.547 1.557
WAXSOL EARACHE 93.222 55.816 5.568
ELOCON ROSACEA 166.508 55.596 1.607
ENDOXAN-ASTA CYSTITIS HAEMORRHAGIC 360.136 54.973 0.521
DE-NOL TOOTH DISCOLOURATION 138.176 51.854 1.802
HYDRALAZINE LE SYNDROME 63.583 51.356 16.597
ACTRAPID HYPOGLYCAEMIA 66.831 50.792 11.871
MAXIDEX GLAUCOMA 515.867 49.844 0.264
CIPROXIN TENDINITIS 63.782 48.976 11.98
LAMISIL TASTE LOSS 54.401 48.925 36.815
BUFFERED SALINE LAXATIVE HYPERPHOSPHATAEMIA 413.294 48.582 0.321
PROSTIN E2 VAGINAL GEL UTERINE PERFORATION 196.437 48.384 0.837
ERYTHROCIN IV DEAFNESS 101.894 48.252 2.608
PROSTIN E2 VAGINAL GEL FOETAL DISTRESS 115.904 48.191 1.991
DALACIN C COLITIS PSEUDOMEMBRANOUS 58.403 47.871 16.809
MYODIL ARACHNOIDITIS 366.773 47.81 0.356
AMIODARONE HYPERTHYROIDISM 58.93 47.579 15.222
VALPROATE SERUM CARNITINE DECREASED 134.92 47.468 1.436
A-200 PYRINATE CORNEAL ULCERATION 72.104 47.263 6.064
AMIODARONE CORNEAL DEPOSITS 66.676 45.762 6.872
ACTILYSE CEREBRAL HAEMORRHAGE 278.497 45.761 0.447
BCG VACCINE INJECTION SITE ABSCESS 99.193 44.877 2.16
DAPSONE HAEMOLYSIS 85.574 44.078 2.826
MINOCYCLINE HYPERTENSION INTRACRANIAL 660.623 2.53 0.004
LANOXIN HAEMATURIA 67.446 42.893 4.895
KABIKINASE BACK PAIN 62.183 41.693 5.662
MONOTARD HYPOGLYCAEMIA 84.625 41.472 2.331
ADRIAMYC CARDIOMYOPATHY 66.921 39.929 3.694
MYDRIACYL GLAUCOMA 151.732 39.833 0.052
MINOXIDIL HIRSUTISM 148.047 39.553 0.722
MODECATE NEUROLEPTIC MALIGNANT SYNDROME 62.175 39.438 4.392
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 10.10: MGPS Drug Trade Name-Event (DE) Ordered by EXCESS
Drug Trade Name Preferred Term RR* EBGM† EXCS‡
TRIPLE ANTIGEN FEVER 3.774 3.753 311.758
BANANA BOAT SUNSCREEN THERAPEUTIC INEFFICACY 9.756 9.716 286.49
RENITEC COUGHING 6.978 6.956 286.123
TRIPLE ANTIGEN CRYING ABNORMAL 5.043 5.028 232.494
AMOXIL RASH MACULO-PAPULAR 3.196 3.138 202.191
WARFARIN PROTHROMBIN ACTIVITY DECREASED 31.61 31.133 201.098
HEPARIN THROMBOCYTOPENIA 11.833 11.754 198.973
AMPICILLIN RASH MACULO-PAPULAR 3.287 3.225 179.524
STEMETIL DYSTONIA 13.083 12.976 173.908
MAXOLON DYSTONIA 10.175 10.104 164.398
TRIPLE ANTIGEN INJECTION SITE REACTION 4.187 4.16 161.233
CECLOR URTICARIA 4.654 4.632 155.533
FLUCLOXACILLIN JAUNDICE 7.755 7.705 144.382
AMOXIL PRURITUS 2.062 2.022 116.589
AMPICILLIN RASH 2.549 2.474 115.566
FLUCLOXACILLIN PRURITUS 2.287 2.23 113.656
ANGIOGRAFIN URTICARIA 7.426 7.369 113.623
CAPOTEN COUGHING 4.448 4.415 113.425
AMOXIL RASH 2.11 2.066 113.369
NORVASC OEDEMA DEPENDENT 11.074 10.949 105.887
STEMETIL OCULOGYRIC CRISIS 13.787 13.596 102.119
TETANUS VACCINE INJECTION SITE REACTION 23.014 22.519 100.747
ALDOMET FEVER 3.069 2.955 97.154
VANCOMYCIN PRURITUS 3.261 3.151 96.648
FLUCLOXACILLIN RASH 2.132 2.08 96.529
CLOZARIL NEUTROPENIA 16.754 16.46 94.03
AUGMENTIN JAUNDICE 10.893 10.757 93.162
MAXOLON OCULOGYRIC CRISIS 11.068 10.927 92.491
VENTOLIN BRONCHOSPASM 3.667 3.58 89.79
GENTAMICIN RASH 2.161 2.103 89.737
CECLOR ARTHRITIS 10.421 10.288 87.721
DIPHTHERIA AND TETANUS INJECTION SITE
VACCINE REACTION 17.874 17.521 87.455
ZOCOR MYALGIA 4.503 4.462 87.414
UROGRAFIN URTICARIA 5.996 5.945 85.866
IMIGRAN CHEST PAIN 9.261 9.15 84.781
PENICILLIN RASH 2.748 2.633 83.972
TEGRETOL FEVER 2.739 2.625 83.779
VANCOMYCIN RASH ERYTHEMATOUS 4.816 4.775 82.674
GENTAMICIN RASH MACULO-PAPULAR 2.562 2.461 81.398
AMOXIL RASH ERYTHEMATOUS 2.253 2.18 79.227
MODURETIC HYPONATRAEMIA 6.965 6.892 76.987
FLUCLOXACILLIN RASH MACULO-PAPULAR 2.512 2.41 75.352
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 10.11: MGPS Drug-ReactionClass (ATC-SOC – CS) Ordered by Relative Ratio
Drug ATC Name SOC Class RR* EBGM† EXCS‡
Psoralen neoplasm 238.199 2.153 -0.002
Somatrem neoplasm 130.638 6.943 0.026
Megestrol and oestrogen neoplasm 126.974 6.929 0.027
Somatropin neoplasm 83.724 6.681 0.034
MCT Oil metabolic and nutritional 64.521 3.99 -0.001
Rauwolfia alkaloids neoplasm 342.524 10.372 0.731
Diphenoxylate urinary system disorders 40.913 1.978 -0.014
Enemas, combinations metabolic and nutritional 38.097 1.964 -0.015
Procainamide collagen disorders 37.585 17.964 5.295
Lynoestrenol and Mestranol neoplasm 32.964 3.546 -0.006
Methysergide collagen disorders 32.918 14.237 3.118
Hydralazine collagen disorders 32.021 25.324 39.056
Diethylstilbestrol neoplasm 31.201 5.609 0.048
Tryptophan collagen disorders 31.115 1.921 -0.019
Nortriptyline neonatal and infancy disorders 30.376 1.916 -0.019
Mitotane endocrine disorders 30.203 1.914 -0.019
Electrolytes metabolic and nutritional 29.999 1.913 -0.019
Primidone neonatal and infancy disorders 29.307 3.445 -0.018
Ergotamine, comb. excl. psycholeptics neonatal and infancy disorders 28.188 1.898 -0.021
Tretinoin foetal disorders 27.715 11.451 2.055
Desogestrel and oestrogen neoplasm 26.622 1.884 -0.022
Insulin lispro foetal disorders 25.696 5.293 0.047
Norethisterone reproductive system 25.201 3.306 -0.011
Progesterone and oestrogen foetal disorders 25.065 6.856 0.337
Meclozine foetal disorders 24.674 5.222 0.047
Clidinium and psycholeptics foetal disorders 24.124 1.859 -0.025
Hydralazine neonatal and infancy disorders 23.072 3.22 -0.013
Melphalan neoplasm 23.032 3.218 -0.013
Tetracosactrin endocrine disorders 21.851 7.636 0.738
Hydroxyprogesterone foetal disorders 21.506 1.827 -0.028
Phenol urinary system disorders 21.078 1.822 -0.029
Dicyclomine, combinations foetal disorders 20.487 12.037 4.959
Mephenytoin foetal disorders 20.099 1.808 -0.03
Fluoride foetal disorders 19.662 1.802 -0.031
Dinoprostone foetal disorders 19.275 11.304 4.494
Clomiphene foetal disorders 19.191 10.569 3.425
Dipyrone haemic and lymphatic systems 18.613 1.785 -0.033
Tamoxifen neoplasm 18.183 7.106 0.782
Sulthiame foetal disorders 18.079 8.451 1.603
Iproniazide liver and biliary system disord. 18.065 4.623 0.04
Chlorambucil neoplasm 17.717 1.77 -0.035
Diphenoxylate haemic and lymphatic systems 17.638 1.769 -0.035
Atovaquone liver and biliary system disord. 17.382 1.764 -0.036
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 10.12: MGPS Drug-ReactionClass (ATC-SOC – CS) Ordered by Empirical Bayesian Geo-
metric Mean
Drug ATC Name SOC Class RR* EBGM† EXCS‡
Hydralazine collagen disorders 32.021 25.324 39.056
Procainamide collagen disorders 37.585 17.964 5.295
Methysergide collagen disorders 32.918 14.237 3.118
Dicyclomine, comb. foetal disorders 20.487 12.037 4.959
Tretinoin foetal disorders 27.715 11.451 2.055
Dinoprostone foetal disorders 19.275 11.304 4.494
Clomiphene foetal disorders 19.191 10.569 3.425
Rauwolfia alkaloids neoplasm 42.524 10.372 0.731
Halothane liver/biliary system 11.024 10.247 49.911
Tiaprofenic acid urinary system disorders 10.166 9.842 117.639
Spironolactone endocrine disorders 10.379 9.516 37.083
Amiodarone endocrine disorders 10.17 29.401 40.963
Analgesic urinary system disorders 13.051 9.398 6.818
Coumarin liver/biliary system 11.656 9.356 11.591
Phenformin metabolic/nutritional 16.155 9.27 3.103
Primidone foetal disorders 13.282 9.176 5.562
Dinoprostone reproductive system 11.996 9.095 8.19
Insulin comb. metabolic/nutritional 10.298 8.86 17.336
Cimetidine endocrine disorders 9.192 8.747 62.78
Lithium endocrine disorders 9.699 8.667 23.952
Valproate foetal disorders 9.312 8.514 30.691
Sulthiame foetal disorders 18.079 8.451 1.603
Indinavir metabolic/nutritional 8.455 8.075 61.431
Tetracosactrin endocrine disorders 21.851 7.636 0.738
Royal jelly respiratory system disord. 9.229 7.506 8.979
Stavudine metabolic/nutritional 7.792 7.372 43.789
Clozapine haemic/lymphatic syst. 7.366 7.265 199.248
Tamoxifen neoplasm 18.183 7.106 0.782
Dapsone haemic/lymphatic syst. 7.435 7.019 38.973
Oxymetholone liver/biliary system 9.534 6.995 4.593
Somatrem neoplasm 130.638 6.943 0.026
Megestrol/oestrogen neoplasm 126.974 6.929 0.027
Methyltestosterone liver/biliary system 11.221 6.919 2.327
Progesterone/oestrogen foetal disorders 25.065 6.856 0.337
Lecithin liver/biliary system 7.982 6.771 10.264
Somatropin neoplasm 83.724 6.681 0.034
Mitomycin haemic/lymphatic syst. 7.96 6.601 8.303
Fusidic acid liver/biliary system 7.492 6.593 13.572
Chlorpropamide metabolic/nutritional 8.127 6.581 7.04
Amsacrine haemic/lymphatic syst. 7.31 6.425 12.858
Lamivudine metabolic/nutritional 6.668 6.371 44.255
Propylthiouracil haemic/lymphatic syst. 6.855 6.325 22.456
Mitozantrone haemic/lymphatic syst. 6.949 6.3 17.569
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 10.13: MGPS Drug-ReactionClass (ATC-SOC – CS) Ordered by EXCESS
Drug ATC Name SOC Class RR* EBGM† EXCS‡
Amoxycillin Skin and appendages disord. 1.96 1.955 840.712
Sulfonamides combinations, Skin and appendages
Intermediate-acting disorders 1.812 1.804 463.695
Ampicillin Skin and appendages disorders 1.985 1.975 460.817
Flucloxacillin liver and biliary system 4.747 4.727 384.743
Diphtheria-pertussis-tetanus body as a whole 2.115 2.103 357.101
Warfarin haemic and lymphatic systems 4.743 4.722 351.548
Sulfamethoxazole and trimethoprim Skin and appendages disorders 1.62 1.612 347.785
Cefaclor Skin and appendages disorders 2.558 2.55 338.373
Sertraline psychiatric disorders 2.357 2.346 322.496
Enalapril respiratory system disord. 2.535 2.526 315.477
Flucloxacillin Skin and appendages disorders 1.65 1.64 295.498
Amoxicillin and clavulanate liver and biliary system 5.072 5.041 284.049
Sunscreen body as a whole 2.729 2.72 273.955
Heparin haemic and lymphatic systems 3.859 3.842 263.599
Meglumine diatrizoate Skin and appendages disorders 1.614 1.604 258.22
Salbutamol respiratory system disord. 2.264 2.248 245.022
Specific immunoglobulins, Comb. body as a whole 2.013 1.994 235.4
Simvastatin musculo-skeletal system disord. 2.853 2.843 230.069
Gentamicin Skin and appendages disorders 1.606 1.594 207.917
Paracetamol Skin and appendages disorders 1.354 1.349 204.773
Penicillin Skin and appendages disorders 1.977 1.956 204.592
Vancomycin Skin and appendages disorders 2.071 2.05 200.587
Clozapine haemic and lymphatic systems 7.366 7.265 199.248
Diphtheria-pertussis-tetanus nervous system/special senses 1.923 1.901 194.378
Phenytoin Skin and appendages disorders 1.466 1.458 193.179
Naproxen gastro-intestinal system 1.692 1.676 189.199
Cephalexin Skin and appendages disorders 1.786 1.767 188.952
Metoclopramide nervous system/special senses 1.464 1.456 187.614
Cefaclor musculo-skeletal system disorders 4.647 4.61 185.456
Prochlorperazine nervous system/special senses 1.7356 1.717 181.615
Meglumine diatrizoate respiratory system disord. 2.842 2.829 178.681
Erythromycin gastro-intestinal system 1.662 1.646 174.562
Prochlorperazine musculo-skeletal system disorders 3.97 3.943 173.699
Erythromycin liver and biliary system 3.318 3.301 172.975
Allopurinol Skin and appendages disorders 1.333 1.328 171.222
Felodipine cardiovascular system 2.159 2.134 163.431
Paroxetine psychiatric disorders 2.401 2.381 161.599
Beclomethasone dipropionate respiratory system disord. 12.538 2.52 158.555
Amlodipine cardiovascular system 2.086 2.06 156.634
Piroxicam gastro-intestinal system 1.95 1.923 152.426
Sertraline nervous system/special senses 11.377 1.37 152.095
Carbamazepine liver and biliary system 2.709 2.692 139.418
Paroxetine nervous system/special senses 1.614 1.596 136.55
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
Chapter 11
MGPS – Drug-Event Triples and
Interactions
The higher dimension MGPS analysis (term triples) of these ADRAC data is populated by a large
number of drug and reaction terms that are redundant.
In the case of reactions, pairs of similar or equivalent reaction terms appear in DEE triples.
This is overcome by stratifying the data by SOC, but this aggregation may be too coarse grained
for some purposes. I propose that there is a need for some way of combining equivalent or similar
reaction terms to avoid this problem. Examples of this problem will be discussed below.
In the case of drugs, innocent bystander drugs appear to be very common in DDE triples. This
can be largely overcome by supplying suspect codes to identify suspected drugs and ‘weed out’
innocent bystanders. Also preprocessing the data with tools such as PROFILE [417] or STATFILE
[34]. Examples of this problem will also be discussed below.
11.1 Drug-event Results for triples: DEE, DDE, ordering
by RR, EMBGM and EXCESS
The results for drug-event triples: DEE, DDE, ordering by RR, EMBGM and EXCESS are pre-
sented in Tables 11.2, 11.3, 11.4, 11.5, 11.6, and 11.7.
In Table 11.2 the records are ordered by RR. When the DEE’s are ordered on RR, the other two
estimators’ values with respect to their ranges (see Table 10.4), in the case of EBGM (4.2–188),
which covers approximately 50% of the range and is in the lower half of this range. EXCESS
(0–0.126), which covers approximately 0.1% of the range and is in the third sixteenth of this
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range. It must be noted here that some of the reaction terms are probably redundant. For
example, in the second third and fifth record, there is RENAL FUNCTION as the first second
event term and URINARY CRYSTALS. The first term includes the second, making the second
term redundant. This highlights a problem of SOC as an ontology, because it does not order
event terms enough into a hierarchy of more general terms with more specific ones beneath them.
When we get term redundancy, as with this example, the second event position of DEE analysis
becomes ‘clogged’. I will refer to this as the “term redundancy problem”. More examples are:
record 4 CATARACT and CATARACT SUBCAPSULAR, record 6 SKIN ULCERATION and
INJECTION SITE NECROSIS, and 27 APPLICATION SITE REACTION and SKIN NECROSIS,
could be combined into one term, likewise in record 9, TOOTH DISCOLOURATION and TOOTH
DISORDER, could be combined. In records 16 and 22, INFLAMMATION could be too general.
In Table 11.3 the records are ordered by EBGM. When the DEE’s are ordered on RR, the other
two estimators’ values with respect to their ranges, in the case of RR (143–2643), which covers
19.4% of the range and is in the lower quarter of this range. EXCESS (0.034–14.766), which covers
approximately 10.9% of the range and is in the second eighth of this range. The values of RR
and EBGM are at the top of their range and the records’ values are parallel in each estimator’s
distribution. Similar cases of redundant event terms can be seen here too. Record 1, ABDOMINAL
PAIN and PERITONITIS could be combined into one term. There are other examples here, but
fewer than for RR.
In Table 11.4 the records are ordered by EXCESS. When the DEE’s are ordered on EXCESS,
the other two estimators’ values with respect to their ranges, in the case of RR (2.9–80.9), which
covers 0.6% of the range and is in the lower one hundred and fiftieth part of this range. EBGM
(2.884–77.849), which covers approximately 20.3% of the range and is in the third sixteenth of this
range. It must also be noted that the values in each record in the table are very similar for both
RR and EBGM. More cases of redundant event terms can be seen here. Records 6–9 11 17 24 41
42 have VOMITING as the first term and NAUSEA as the second. The first term renders the
second redundant. There are a large number of records that have PRURITUS as the first term
and some form of RASH as the second, which seems to carry a lot of redundancy.
In Table 11.5 the records are ordered by RR. When the DDE’s are ordered on RR, the other
two estimators’ values with respect to their ranges (see Table 10.4), in the case of EBGM (1.61–
14.666), which covers approximately 18.8% of the range and is in the lower quarter of this range.
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EXCESS (0–0.009), which covers approximately 0.01% of the range and is in the fifth sixteenth
of this range. Many of the drug doubles could have one active and one that is an innocent by-
stander. For example, records 14 20 31 include DIAZEPAM plus some other drug and the reaction
BLEPHARITIS (chronic inflammation of eyelids). Records 23 25 29 39 43 include SANDIMMUN
plus some other drug and the reaction BLINDNESS
In Table 11.6 the records are ordered by EBGM. When the DDE’s are ordered on RR, the
other two estimators’ values with respect to their ranges, in the case of RR (34–886), which covers
1.6% of the range and is in the lowest sixtieth of this range. EXCESS (0.247–3.539), which covers
approximately 4.8% of the range and is in the sixth sixteenth of this range. The values of RR and
EBGM are at the top of their range and many of the records’ values parallel in each estimator’s
distribution. Similar to the previous table, there may be many drugs that could be innocent by-
standers. Records 11–15 18–21 23 25 27 30 31 include SURGAM plus some other drug and the
reaction CYSTITIS. Records 3–6 include SABRIL plus some other drug and the reaction VISUAL
FIELD DEFECT.
In Table 11.7 the records are ordered by EXCESS. When the DDE’s are ordered on EXCESS,
the other two estimators’ values with respect to their ranges, in the case of RR (2.144–31.779),
which covers 0.05% of the range and is in the lower seventeen thousanth part of this range. EBGM
(2.739–30.815), which covers approximately 40.6% of the range and is in the lower half of this
range. It must also be noted that the values in each record in the table are very similar for both RR
and EBGM. Here too there may be many drugs that are possible innocent by-standers. Records
4 5 10 24 26 28 include WARFARIN plus some other drug and the reaction PROTHROMBIN
DECREASED.
11.2 Drug-class Results for triples: CSS, CCS, ordering by
RR, EMBGM and EXCESS
The results for drug-‘class’ triples: CSS, CCS, ordering by RR, EMBGM are presented in Tables
11.8, 11.9, 11.10, 11.11, 11.12, 11.13, and 11.14.
In Table 11.8 the records are ordered by RR. When the CSS’s are ordered on RR, the other two
estimators’ values with respect to their ranges, in the case of EBGM (0.732–43.638), which covers
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approximately 99.9% of the range. EXCESS (0.145–23.277), which covers approximately 4.45% of
the range and is in the twelfth sixteenth part of this range. Here also the use of SOC as the event
class provides triples which are more useful; a drug term with a pair of reaction classes.
In Table 11.9 the records are ordered by EBGM. When the CSS’s are ordered on EBGM, the
other two estimators’ values with respect to their ranges, in the case of RR (6.846–92.764), which
covers approximately 32.4% of the range. Many of the values of RR and EBGM are similar. EX-
CESS (-0.05– +6), which covers approximately 1.15% of the range and is in the eleventh sixteenth
part of this range. Here also the use of SOC as the event class provides triples which are more
useful; a drug term with a pair of reaction classes.
In Table 11.10 the records are ordered by EXCESS. When the CSS’s are ordered on EXCESS,
the other two estimators’ values with respect to their ranges, in the case of RR (1.473–5.225),
which covers approximately 1.4% of the range in the lowest seventieth part. EBGM (1.45–5.18),
which covers approximately 5.4% of the range and is in the first sixteenth part of this range. The
values of RR and EBGM are very similar. It must also be noted that the values in each record in
the table are very similar for both RR and EBGM. Here also the use of SOC as the event class
provides triples which are more useful; a drug term with a pair of reaction classes.
In Table 11.11 the records are ordered by RR. When the CCS’s are ordered on RR, the other
two estimators’ values with respect to their ranges, in the case of EBGM (0.806–21.987), which
covers approximately 95.7% of the range. EXCESS (-0.012–0.719), which covers approximately
0.4% of the range and is in the ninth sixteenth part of this range. In the CCS tables there appears
to be some problem with innocent by-stander drugs. For example, in Table 11.11 Hydrazine +
some other drug is associated with collagen disorders in records 4 6 10 19 45; Procainamide +
some other drug is associated with collagen disorders in records 7 10 11 14 31.
In Table 11.12 and 11.13 the records are ordered by RR. When the CCS’s are ordered on
EBGM, the other two estimators’ values with respect to their ranges, in the case of RR (9.425–
129.282), which covers approximately 11.5% of the range. EXCESS (-0.012–0.831), which covers
approximately 4.9% of the range and is in the ninth sixteenth part of this range. Many of the
values of RR and EBGM are similar. The problem of potential innocent by-stander drugs appears
to be even more pronounced in the EBGM view of CCS. This is why I have extended the records
displayed here to two tables. Hydrazine + some other drug is associated with collagen disorders in
records 1–23; Procainamide + some other drug associated with collagen disorders in records 24–31;
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Halothane + some other drug associated with liver and biliary system disorders in records 36–47
49 80; the NSAID Tiaprofenic acid + some other drug associated with urinary system disorders in
records 48 50–57 59–67 70–72 74–77 81–83 85 86.
In Table 11.14 the records are ordered by EXCESS. When the CCS’s are ordered on EXCESS,
the other two estimators’ values with respect to their ranges, in the case of RR (1.37–27.107),
which covers approximately 2.5% of the range. EBGM (1.351–8.967), which covers approximately
34.4% of the range and is in the first half of this range. The values of RR and EBGM are very
similar. In the view of CCS triples presented by high EXCESS value, it would appear that innocent
by-stander drugs are less of a problem. The only obvious possible cases are: Warfarin + some other
drug associated with haemic and lymphatic systems in records 1 3 16; Digoxin + some other drug
associated with haemic and lymphatic systems in records 1 7. There could also be more innocent
by-stander drugs with antibiotic + some other drug associated with skin and appendages disorders
in records 10 19 23 25 29 30 36 38 43; and two antibiotics associated with skin and appendages
disorders in records 4 14 26 34 42. In the last case, the two antibiotics may both contribute to the
reaction and hence be ‘legitimate’ CCS triples.
11.3 Interaction Results for triples: DEE, DDE, CSS, CCS
The results for interactions from the triples, DEE, DDE, CSS, CCS, are presented in Tables 11.15,
11.16, 11.17, and 11.18.
11.3.1 INTSS Interaction calculation
Interaction in the various drug-event triples is measured using interaction signal score (INTSS)
described in Appendix D.1.3. For a 3D run, the computation explicitly takes combinations into
account:
Drug A and Event E (DE)
Drug B and Event E (DE) (Drug A + Drug B) and Event E (DDE)
INTSS = EB05 / EB95MAX
Where:
EB05 is the conservative estimate score for (Drug A + Drug B) and Event E (the 3D
combination of DDE)
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EB95MAX is the highest EB95 score found for the individual Drugs A and B and the
Event E (the 2D combinations of DE)
If INTSS >1, the combination of the two drugs with the event (DDE) indicates a stronger associ-
ation with the event than is found for either of the two individual drugs (DE).
Remark 11.3.1. Note: Usually, we would not conclude that the potential interaction is interesting
unless the EB05 score for that DDE combination is large (for example, over 1.5 or 2.0).12
11.3.2 INTSS results
The results of interactions, as expressed by INTSS, for DEE are presented in Table 11.15. The
situation is similar to that seen in Table 11.4, where the records are ordered by EXCESS. When
the DEE’s were ordered on EXCESS, cases of redundant event terms were seen. Many records
had VOMITING as the first term and NAUSEA as the second. In Table 11.15 records 2 4 6 7
9 10 12 13 15–19 24 26 34 38 39 43. Another redundant reaction term pair in this table was
HAEMATEMESIS and MELAENA in records 1 3 8 11. As was discussed in Section 10.2 the
analysis becomes ‘clogged’ due to the “term redundancy problem”. It should be also noted that
the values for INTSS in this table are high; ≥ 3.8.
The results of INTSS for DDE are presented in Table 11.16 it should be first noted that the
values for INTSS are low; ≤ 0.8. Another feature of these interactions is that they are only between
one of the drugs and a reaction for all 52397 DDE records. That is no drug-drug interaction
was stronger than any drug-event interaction. Furthermore, as in Table 11.5, many of the drug
doubles could have one active and one that is an innocent by-stander. For example, records 2 28
32 34 include WARFARIN plus some other drug and the reaction PROTHROMBIN ACTIVITY
DECREASED, records 7 19 include PETHIDINE plus some other drug and the reaction NAUSEA.
The results of INTSS for CSS in Table 11.17 it can be seen that the stratification by reaction
gives a reduction in the INTSS value compared to DEE and only the top 12 are > 1.5. Many of
the the pairs of drugs of the CCS triple could contain an innocent by-stander.
1It is assumed that INTSS is meant here in the documentation, since a value of 2.0 is large for INTSS but small
for EB05.
2To clarify this Bill DuMouchel has the following explanation: “I think that statement in the documentation is
getting at the idea that even if
EB05[Drug1*Drug2] > max(EBGM[Drug1], EBGM[Drug2])
You might not want to call it an interaction if EB05[Drug1*Drug2] is small (less than 1.5, say) in the case that
both of EBGM[Drug1] and EBGM[Drug2] are small (maybe even less than 1).
– Bill”
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The results of INTSS for CCS in Table 11.18 it can be seen that the INTSS value is low with the
top 43 close to 0.8 or above. Also interactions were only between one of the drugs and a reaction
class for all 707030 CCS records.
11.3.3 Comparison with examples in Chapter 9
I want to compare the examples used in Chapter 9 in regard to the placement of these DE pairs
in the top 50 when ordering by RR, EBGM, EXCESS, or INTSS. (i) celocoxib and cardiovascular
system produced a warning level signal in November 1999, (ii) heparin and haemic and lymphatic
systems produced a alert level signal in July 1998, (iii) clozapine and cardiovascular system pro-
duced an alert level signal in August 1999, (iv) amoxicillin and clavulanate and liver and biliary
system disorders produced a strong notice signal in February 1999. For these DE pairs, in MGPS
the following was observed (none observed in RR):
EBGM EXCESS INTSS
DE (ii), *,† − −
CS ‡ (ii), (iv), * −
DEE − † ¶
DDE − − §
CSS (iv) − £
CCS − § F, §
* clozapine and haemic and lymphatic systems.
† amoxicillin and clavulanate and skin and appendages disorders.
‡ clozapine and haemic and lymphatic systems.
¶ heparin and gastro-intestinal system disorders.
§ amoxicillin and skin and appendages disorders.
£ amoxicillin with: cardiovascular system, or respiratory system disorders, or body as a whole,
or psychiatric disorders, or gastro-intestinal system disorders; or amoxicillin and clavulanate with:
cardiovascular system, or respiratory system disorders, or body as a whole.
F heparin and skin and appendages disorders.
Of those DEs from Chapter 9 only (i) and (ii) DEs were foung in EBGM or EXCESS. Other
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DE combinations involving heparin, clozapine, and amoxicillin are noted. Other combinations
involving paracetamol were seen, but were not shown because the DEs selected for testing the
signal detection method were expected to give weak signals with any method.
11.4 Conclusion for Chapters 10 and 11
This has been an important development in my work to analyze the ADRAC data using a standard
drug safety tool. I did try to use GPS with ADRAC data, but this does not use multi-item data
as does BoosTexter. The limitation to one run entailed a number of restrictions on the analysis
that was possible. For one thing it was not possible to gain enough experience to adequately tailor
the input to get an output that was easily comparable to the other results reported in this thesis.
However, it was still possible for me to see what would need to be done to prepare for the next
run, which I have described in detail. Now I am more familiar with MGPS from my analysis of the
first output, I am better able to capitalize on the ATC classification. I have stressed why and how
we need to implement drug and reaction ontologies. I have used the output to demonstrate some
of the inadequacies of the SOC classification and why an improved reaction ontology would make
better use of the capabilities of MGPS. Some of the problems regarding SOC and other reaction
ontologies is reviewed in Section 2.2.2.
The drug event counts serve to give a summary of the ADRAC data. this also gives an
opportunity to illustrate some features of these data. I have illustrated how the trade name coding
can split the same ingredient into separate codes and multiple ingredients into one code. ATC
codes were supplied, but in the different levels of the hierarchy were not exploited. With the
experience from the first round of analysis, a better understanding of the requirement means that
the data can be tailored as I have detailed for a more useful second round.
Three different estimators were used to order the data and each gave a different view of these
data. The ranges of the values in samples presented in each table is compared to the complete
range of values for each estimator is summarized in Table 11.1. It can be seen that there is
a large variation in the percentage of the range represented by each estimator over the various
combinations. Thus, some combinations, each estimator covers a very different part of the data.
In the present analysis, this has presented an opportunity to reveal different aspects of the data.
In the future it may be possible to exploit these differences between these estimators in order to
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Table 11.1: MGPS Summary – part of total range represented by the top order of each estimator
(values as percent of range in tables of top ordering, presented here, with respect to the complete
range for each estimator)
2ples/3ples DE CS DEE DDE CSS CCS
Estimator RR EB EX RR EB EX RR EB EX RR EB EX RR EB EX RR EB EX
RR − < 0.01 50 − 93 < 0.01 − 50 0.1 − 18.8 0.01 − 99.9 4.45 − 95.7 0.4
EBGM 39 − 9 50 − 16.6 19.4 − 10.9 1.6 − 4.8 32 − 1.15 11.5 − 4.9
EXCESS 1.4 33 − 5 23 − 0.6 20.3 − 0.05 40.6 − 1.4 5.4 − 2.5 34.4 −
reveal interesting patterns in the data.
To highlight these differences in view I summarize the ordering of events with respect to their
SOC for each estimator. This is best illustrated in the drug-event (DE) doubles, but also apparent
in the triples. When the top 53 events (Table 10.5) are classed into SOC, only 10 classes are
present. These top 10, I call ‘common’ SOCs, and the latter 8 the ‘rare’ SOCs. I use this to
contrast each DE-estimator combination. DE ordered by RR(Table 10.8) had 9 SOC 3 of which
were rare, and one, neoplasm (the second rarest) was first. DE ordered by EBGM (Table 10.9)
had 12 SOC 5 of which were rare. DE ordered by EXCESS (Table 10.10) had 8 SOC all of which
were common. CS ordered by RR (Table 10.11) had 9 SOC, 7 of which were rare. CS ordered by
EBGM (Table 10.12) had 9 SOC, 6 of which were rare. CS ordered by EXCESS (Table 10.13) had
9 SOC all common. Thus, in this comparison of the estimators, EXCESS is more aligned to the
overall ordering.
Another measure of similarity of estimators is between RR and EBGM was in their values. In
many the two estimator values were quite similar or were parallel to each other in their respective
distribution. To summarize, when the DEs are ordered by EBGM or EXCESS:
EBGM EXCESS
DE ' '
DEE Top range and ‖ '
DDE Top EBGM, many ‖ '
CS many ' most '
CSS many ' '
CCS many ' '
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Interactions, measured by INTSS were also examined. For DEE triples the INTSS level were
high, ≥ 3.8, but there are many redundant reaction terms in ADRAC preferred terms that calls
for a better reaction term ontology to eliminate the ‘clogging’ effect of redundant terms. The
value of INTSS for DDE triples is low, ≤ 0.8, and no drug-drug interactions, only drug-event
interactions are seen. Many innocent by-stander drugs appear to also be clogging the DDE triples.
In CSS triples, the INTSS values are only > 1.5, which is considered a significant INTSS value,
in the top 12 records. There were only CSS drug-event interactions. For CCS the highest INTSS
value was 0.873, which is not considered significant, and here too, only Drug-event actions were
seen. Thus the best interactions were seen in DEE triples. Removal of ‘redundant’ events could
reveal more interesting interaction. It should be noted that the reason that redundant reactions
and innocent by-stander drugs appear to be a problem with MGPS is due to the fact that it
uses disproportionality, which makes it more prone to such problems see Section 2.1.1. One use
of ontology to alleviate the reaction redundancy problem would be to categorize reactions on a
severity scale [346] using selection or combining reaction terms based on this scale.
I have compared the DE pairs chosen to demonstrate the signal detection method investigated
in Chapter 9 in Section 11.3.3 regarding their appearance in the top 50 ordering by: RR, EBGM,
EXCESS, and INTSS. Only heparin and haemic and lymphatic systems, and amoxicillin and
clavulanate and liver and biliary system disorders appeared in EBGM and EXCESS.
This chapter has addressed research question 1. This has enabled me to compare the dispro-
portionality methods using the same data set that I have been using for my investigation. It would
have been better to install MGPS locally to facilitate more interactivity with this tool. Having the
ADRAC data run on Lincoln Technologies implementation was definitely the next best option and
is standard implementation of MGPS. This gave an opportunity to see some of the strengths and
weaknesses of this method. Just an examination of further runs on MGPS, as I have suggested
above would make a very interesting project in its own right, particularly the utilization of the
ATC ontology.
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Table 11.2: MGPS Drug Trade Name-Event-Event (DEE) Ordered by Relative Ratio
Drug Trade Name Preferred Term Preferred Term RR* EB† EXS‡
ADIFAX CARDIAC FAILURE HEART VALVE DISORD. 12889.125 77.967 0.006
LAMIVUDINE RENAL FUNCTION § URINARY CRYSTALS 12872.046 8.87 0
STAVUDINE RENAL FUNCTION § URINARY CRYSTALS 11401.842 8.705 0
CHLORPROMAZINE CATARACT CATARACT SUBCAPS, 8194.623 7.688 0
CRIXIVAN RENAL FUNCTION § URINARY CRYSTALS 7905.064 8.47 0
DIAZEPAM SKIN ULCERATION INJECTION SITE NECRO. 6262 5.361 0
HALOPERIDOL TREMOR BRADYKINESIA 5066.188 8.689 0
DUCENE ARTHRALGIA PERINEAL PAIN FEM. 4299.994 8.46 0
HIFLUOR TOOTH DISCOLOUR TOOTH DISORDER 3248.812 9.31 0.001
ZANTAC PLEURAL EFFUSION HEART DISORDER 2949.753 4.391 0
DILANTIN VIT. B12 DEFICIENCY FOLATE SERUM § 2857.689 66.576 0.011
GLIBENCLAMIDE CREATINE P-KIN. ↑ ¶ HYPOKINESIA 2796.515 5.72 0
TETRACYCLINE MONILIASIS GENITAL MONILIASIS GI 2780.743 7.712 0.001
PENICILLAMINE DIPLOPIA MYASTHENIA GRAVIS-
LIKE SYNDROME 2642.521 187.934 0.034
TITRALAC VOMITING BLINDNESS 2613.499 8.149 0.001
CANESTEN BULLOUS ERUPTION INFLAMMATION 2550.682 61.778 0.023
GLIBENCLAMIDE TACHYCARDIA HYPOKINESIA 2511.272 5.719 0
VENTOLIN PLEURISY BRONCHITIS 2417.248 4.846 0
TICARCILLIN ALBUMINURIA CYSTITIS HAEMORRHAG. 2398.368 32.802 0.006
LITHIUM DEHYDRATION DIABETES INSIPIDUS 2393.608 176.017 0.035
STEMETIL MALFORMATIONS OESOPHAGEAL ATRESIA 2361.143 4.656 0
CANESTEN SKIN ULCERATION INFLAMMATION 2320.882 38.735 0.007
POTASSIUM Cl ASTHENIA TESTIS DISORDER 2289.459 4.766 0
NITROFURANTOIN ASTHENIA MUSCLE ATROPHY 2283.099 123.23 0.053
GENTAMICIN HYPOCALCAEMIA HYPOMAGNESAEMIA 2238.793 4.2 0
FOLIC ACID VASCULITIS GLOMERULONEPHRITIS 2234.705 4.523 0
NITROUS OXIDE APPLICN. SITE REACT. SKIN NECROSIS 2210.932 5.342 0
MINOMYCIN RHINITIS SINUSITIS 2200.536 5.007 0
MAXOLON GYNAECOMASTIA LACTATION NP £ 2183.194 5.235 0
SEREPAX GYNAECOMASTIA LACTATION NP £ 2140.134 4.939 0
RENITEC PLEURAL EFFUSION HEART DISORDER 2116.034 28.567 0.012
PARLODEL PLEURAL EFFUSION PLEURAL FIBROSIS 2070.437 92.61 0.021
DIAMOX URINARY INCONTNCE. FAECAL INCONTINENCE 2039.17 5.278 0
XANAX TOLERANCE ↑ DRUG DEPENDENCE 2035.349 7.42 0.001
SALAZOPYRIN HEPATIC FAILURE HEPATIC NECROSIS 2026.025 5.161 0
TOBRAMYCIN ALBUMINURIA CYSTITIS HAEMORRHAG. 1999.109 57.564 0.013
IMMUCYST HAEMATURIA INFECTION TBC 1990.184 63.65 0.015
SANDIMMUN VOMITING BLINDNESS 1970.269 45.918 0.01
DAPSONE CYANOSIS METHAEMOGLOBINAEM. 1919.939 244.037 0.126
CISAPRIDE SYNCOPE TORSADE DE POINTES 1913.783 97.612 0.024
CLOXACILLIN SOMNOLENCE CEREBELLAR SYND. 1912.811 5.194 0
UNIPARIN-CA THROMBOCYTOPENIA THROMBOEMBOLISM 1865.798 12.011 0.002
DIGOXIN TESTIS DISORDER BONE PAIN 1849.297 4.982 0
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
§ ABNORMAL
¶ P-KIN. – PHOSPHOKINASE
£ NP – NONPUERPERAL
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Table 11.3: MGPS Drug Trade Name-Event-Event (DEE) Ordered by Empirical Bayesian Geo-
metric Mean
Drug Trade Name Preferred Term Preferred Term RR* EB† EXS‡
VANCOMYCIN ABDOMINAL PAIN PERITONITIS 1188.696 369.602 1.32
SEREPAX CONVULSIONS DRUG ABUSE 1706.727 359.601 0.895
SEREPAX WITHDRAWAL SYND. DRUG ABUSE 489.642 260.634 3.031
DAPSONE CYANOSIS METHAEMOGLOBINAEM. 1919.939 244.037 0.126
MINOCYCLINE HEADACHE HYPERTENSION IC
∮
344.244 240.81 4.503
MINOCYCLINE HEADACHE PAPILLOEDEMA 387.265 209.329 2.286
PENICILLAMINE DIPLOPIA MYASTHENIA £ 2642.521 187.934 0.034
NaPO4 LAXATIVE HYPERPHOSPHATAEMIA HYPOCALCAEMIA 339.624 181.758 1.167
LITHIUM DEHYDRATION DIABETES INSIPIDUS 2393.608 176.017 0.035
PENICILLAMINE PTOSIS MYASTHENIA £ 1429.36 174.983 0.058
SURGAM URINARY INCONTNCE. MICTURITION DISORD. 260.944 170.454 4.193
MODECATE HYPERTONIA NEUROLEPTIC MS § 495.369 170.385 0.536
DILANTIN ATAXIA NYSTAGMUS 198.489 166.504 14.766
DILANTIN TREMOR NYSTAGMUS 337.363 155.274 1.617
MINOCYCLINE VISION ABNORMAL HYPERTENSION IC
∮
355.824 155.071 0.678
SURGAM URINARY INCONTNCE. DYSURIA 181.371 146.701 6.412
DE-NOL TONGUE DISCOLOUR TOOTH DISCOLOUR 1454.968 143.223 0.047
CISPLATIN HYPOCALCAEMIA HYPOMAGNESAEM. 551.786 138.115 0.389
COGENTIN FEVER NEUROLEPTIC MS § 425.561 137.312 0.701
CISAPRIDE QT PROLONGED TORSADE DE POINTES 867.925 137.16 0.155
DILANTIN DIPLOPIA NYSTAGMUS 236.531 136.805 2.433
HALOPERIDOL FEVER NEUROLEPTIC MS § 160.434 133.329 7.871
VAGINAL GEL BRADYCARDIA FOETAL DISTRESS 332.291 132.506 0.389
HALOPERIDOL CREATINE P-KIN. ↑ NEUROLEPTIC MS § 173.418 130.328 4.246
MINOCYCLINE DIPLOPIA HYPERTENSION IC
∮
253.725 129.917 0.793
VANCOMYCIN NAUSEA PERITONITIS 435.067 126.713 0.284
ELOCON APPLICATION SITE ROSACEA 167.415 124.327 2.093
NITROFURANTOIN ASTHENIA MUSCLE ATROPHY 2283.099 123.23 0.053
HALOPERIDOL SWEATING INCREASED NEUROLEPTIC MS § 198.593 121.268 1.721
HYDRALAZINE ARTHRALGIA LE SYNDROME 199.921 120.201 0.929
DILANTIN GAIT ABNORMAL NYSTAGMUS 296.925 119.426 0.872
HALOPERIDOL TACHYCARDIA NEUROLEPTIC MS § 190.323 117.929 1.745
PROPINE VISION ABNORMAL MYDRIASIS 617.1 116.933 0.185
SURGAM PYURIA CYSTITIS 357.93 116.788 0.153
MINOCYCLINE VISION ABNORMAL PAPILLOEDEMA 438.119 116.422 0.259
AMIODARONE WEIGHT DECREASE HYPERTHYROIDISM 257.895 116.374 0.439
MODECATE FEVER NEUROLEPTIC MS § 304.707 114.032 0.364
METFORMIN RENAL FAILURE ACUTE ACIDOSIS 234.039 114.011 0.753
HYDRALAZINE PLEURISY LE SYNDROME 231.163 113.622 0.477
MINOCYCLINE HYPERTENSION IC
∮
PAPILLOEDEMA 143.054 111.956 3.28
ACTRAPID HM COMA HYPOGLYCAEMIA 459.33 111.861 0.114
DAONIL COMA HYPOGLYCAEMIA 289.825 111.083 0.592
FLUVAX ASTHENIA NEURITIS 323.521 110.963 0.53
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
§ MS – MALIGNANT SYNDROME
£ GRAVIS-LIKE SYNDROME
¶ P-KIN. – PHOSPHOKINASE∮
IC – INTRACRANIAL
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Table 11.4: MGPS Drug Trade Name-Event-Event (DEE) Ordered by EXCESS
Drug Trade Name Preferred Term Preferred Term RR* EB† EXCS‡
TRIPLE ANTIGEN CRYING ABNORMAL FEVER 3.578 3.564 119.201
AMOXIL PRURITUS RASH MACULO-PAPULAR 5.439 5.376 73.927
AMPICILLIN PRURITUS RASH MACULO-PAPULAR 5.243 5.17 55.777
TRIPLE ANTIGEN FEVER INJECTION SITE REACTION 3.211 3.186 55.177
TRIPLE ANTIGEN VOMITING FEVER 4.796 4.736 51.552
DIGOXIN VOMITING NAUSEA 7.838 7.495 48.02
LASIX VOMITING NAUSEA 7.931 7.444 46.352
PETHIDINE VOMITING NAUSEA 6.667 6.441 44.814
SLOW-K VOMITING NAUSEA 8.116 7.663 44.703
LASIX PRURITUS RASH MACULO-PAPULAR 4.207 4.084 43.417
ALDOMET RIGORS FEVER 17.281 16.434 42.428
VENTOLIN VOMITING NAUSEA 8.073 7.549 41.984
AMOXIL PRURITUS RASH ERYTHEMATOUS 4.475 4.386 41.787
LASIX PRURITUS RASH 3.454 3.368 39.699
FLUCLOXACILLIN PRURITUS JAUNDICE 12.002 11.749 39.084
GENTAMICIN PRURITUS RASH MACULO-PAPULAR 5.863 5.712 38.194
VANCOMYCIN PRURITUS RASH ERYTHEMATOUS 8.068 7.891 37.521
LANOXIN VOMITING NAUSEA 9.397 8.79 37.305
AMOXIL PRURITUS RASH 3.046 2.999 35.626
PETHIDINE PRURITUS RASH 4.232 4.103 33.247
AMPICILLIN PRURITUS RASH ERYTHEMATOUS 4.512 4.402 33.139
VENTOLIN PRURITUS RASH 3.766 3.636 33.065
FLUCLOXACILLIN PRURITUS RASH 3.209 3.155 32.749
MAXOLON VOMITING NAUSEA 6.849 6.473 32.675
PANADOL PRURITUS RASH 4.179 4.068 32.621
MAXOLON PRURITUS RASH 4.654 4.45 31.346
TEGRETOL PRURITUS RASH 4.486 4.328 31.275
TRIPLE ANTIGEN CRYING ABNORMAL INJECTION SITE REACTION 2.914 2.884 30.981
BACTRIM PRURITUS RASH 4.325 4.214 30.598
CECLOR ARTHRITIS URTICARIA 5.242 5.173 29.998
TEGRETOL PRURITUS RASH MACULO-PAPULAR 5.728 5.526 29.926
FLUCLOXACILLIN PRURITUS RASH MACULO-PAPULAR 4.261 4.161 29.872
BACTRIM PRURITUS RASH MACULO-PAPULAR 4.546 4.419 29.839
ZYLOPRIM PRURITUS RASH MACULO-PAPULAR 5.866 5.614 29.832
SURGAM DYSURIA MICTURITION FREQUENCY 80.81 77.849 29.801
LASIX PRURITUS RASH ERYTHEMATOUS 3.996 3.846 29.608
SLOW-K PRURITUS RASH 3.618 3.498 29.497
SLOW-K PRURITUS RASH MACULO-PAPULAR 4.144 3.979 29.404
AUGMENTIN PRURITUS JAUNDICE 21.9289 21.19 29.332
TRIPLE ANTIGEN FEVER NERVOUSNESS 4.409 4.326 29.218
PREDNISOLONE VOMITING NAUSEA 7.282 6.766 28.348
PANADEINE FORTE VOMITING NAUSEA 8.496 7.972 27.513
TEGRETOL FEVER HEPATIC FUNCTION ABNL. 10.911 10.39 26.942
TRIPLE ANTIGEN FEVER ANOREXIA 3.96 3.887 26.636
DILANTIN PRURITUS RASH MACULO-PAPULAR 5.591 5.383 26.279
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.5: MGPS Drug Trade Name-Drug Trade Name-Event (DDE) Ordered by Relative Ratio
Drug Trade Name Drug Trade Name Preferred Term RR* EB† EXS‡
CHLOROTHIAZIDE LASIX CALCINOSIS 53621.869 8.257 0
DISOPYRAMIDE KINIDIN DURULES CHLOASMA 17232.126 2.733 0
VAGIFEM ZOCOR ANTICHOLINERGIC SYND. 16948.529 2.725 0
DISOPYRAMIDE MEXITIL CHLOASMA 14063.807 2.733 0
αTOCOPHEROL LASIX CALCINOSIS 13233.129 8.257 0.001
KINIDIN DURULES MEXITIL CHLOASMA 10591.726 2.628 0
AURORIX ZOCOR ANTICHOLINERGIC SYND. 8887.484 1.61 0
LASIX SODIUM CHLORIDE CALCINOSIS 8472.944 8.257 0.002
INTAL FORTE TILADE CAPILLARY FRAGILITY ↑ 5755.97 2.754 0.001
MIDAZOLAM VENTOLIN ILEUS 5015.135 2.15 0
CHLORSIG SODIUM VALPROATE BLEPHARITIS 4739.694 14.666 0.005
HYDRALAZINE MINOXIDIL PERICARDIAL EFFUSION 4699.09 2.571 0.001
MYDRIACYL OPHTHETIC KERATITIS 4613.957 2.832 0.001
CHLORSIG DIAZEPAM BLEPHARITIS 4135.425 14.666 0.006
CHLORSIG NYSTATIN BLEPHARITIS 4126.313 14.666 0.006
ESTRADERM PROTHIADEN TENDON RUPTURE 4063.016 2.181 0
INTAL FORTE SEREVENT CAPILLARY FRAGILITY ↑ 4018.769 2.754 0.001
DANAZOL SANDIMMUN BLINDNESS 3853.749 13.731 0.006
NYSTATIN PHENOBARBITONE BLEPHARITIS 3783.383 1.923 0
DIAZEPAM NYSTATIN BLEPHARITIS 3602.196 1.923 0
AURORIX VAGIFEM ANTICHOLINERGIC SYND. 3406.886 2.725 0.001
CHLORSIG PHENYTOIN BLEPHARITIS 3396.087 14.666 0.007
ALLBEE WITH C SANDIMMUN BLINDNESS 3312.621 13.731 0.007
CHLORSIG PHENOBARBITONE BLEPHARITIS 3284.604 14.666 0.007
CLONAZEPAM SANDIMMUN BLINDNESS 3186.447 13.731 0.007
ETHRANE MAXOLON LARYNGITIS 3169.374 2.4 0.001
DANAZOL FERROUS SULPHATE BLINDNESS 3006.052 2.059 0.001
PHENOBARBITONE VALLERGAN FORTE BLEPHARITIS 2939.12 2.336 0.001
SANDIMMUN TITRALAC BLINDNESS 2933.284 13.731 0.008
OGEN VAGIFEM ANTICHOLINERGIC SYND. 2882.813 2.725 0.001
DIAZEPAM VALLERGAN FORTE BLEPHARITIS 2814.727 2.336 0.001
PETHIDINE UROGRAFIN 60% BLINDNESS 2810.981 2.09 0.001
SERZONE BECOTIDE SEXUAL FUNCTION ABN. 2802.761 2.215 0.001
ESTRADERM BRONCOSTAT PLEURISY 2782.307 2.76 0.001
NAPROXEN PROMETHAZINE PNEUMONIA EOSINOPHLC 2755.631 2.121 0.001
AMOXYCILLIN NAPROXEN PNEUMONIA EOSINOPHLC 2726.746 1.781 0
CANESTEN VIBRAMYCIN INFLAMMATION 2643.174 11.487 0.007
LAMIVUDINE STAVUDINE URINARY CRYSTALS 2537.158 2.579 0.001
FERROUS SULPHATE SANDIMMUN BLINDNESS 2491.556 13.731 0.009
AMOXYCILLIN PROMETHAZINE PNEUMONIA EOSINOPHLC 2478.149 2.121 0.001
AUGMENTIN SANDOMIGRAN ASCITES 2390.224 1.905 0.001
ESTRADERM VENTOLIN PLEURISY 2360.949 1.868 0.001
CALCITRIOL SANDIMMUN BLINDNESS 2355.562 13.731 0.01
CLONAZEPAM DANAZOL BLINDNESS 2321.439 2.059 0.001
CRIXIVAN LAMIVUDINE URINARY CRYSTALS 2309.819 2.579 0.001
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.6: MGPS Drug Trade Name-Drug Trade Name-Event (DDE) Ordered by Empirical
Bayesian Geometric Mean
Drug Trade Name Drug Trade Name Preferred Term RR* EB† EXS‡
DAPSONE FERROUS SULPHATE ANAEMIA HAEMOLYTIC 368.943 69.386 0.33
DAPSONE FOLIC ACID ANAEMIA HAEMOLYTIC 157.32 68.913 0.767
EPILIM SABRIL VISUAL FIELD DEFECT 145.751 63.066 1.138
SABRIL TEGRETOL VISUAL FIELD DEFECT 113.608 62.823 1.453
RIVOTRIL SABRIL VISUAL FIELD DEFECT 210.245 62.627 0.521
DILANTIN SABRIL VISUAL FIELD DEFECT 178.497 62.537 0.613
DICLOXACILLIN ASPIRIN THROMBOPHLEBITIS 175.924 61.937 0.616
PENICILLAMINE PREDNISONE MYASTHENIA G-L S § 462.209 59.636 0.226
NAPROSYN PENICILLAMINE MYASTHENIA G-L S § 418.348 59.617 0.249
PENICILLAMINE PREDNISOLONE MYASTHENIA G-L S § 342.269 59.571 0.305
ALLOPURINOL SURGAM CYSTITIS 259.435 56.941 0.576
MINIPRESS SURGAM CYSTITIS 121.156 56.928 1.645
PREMARIN SURGAM CYSTITIS 97.512 56.716 2.036
LIPEX SURGAM CYSTITIS 162.1 56.14 0.605
ADALAT SURGAM CYSTITIS 151.6 56.102 0.646
CHLORPROMAZINE LITHIUM DIABETES INSIPIDUS 475.014 56.051 0.206
SURGAM ZYLOPRIM CYSTITIS 62.996 55.977 3.098
CAPOTEN SURGAM CYSTITIS 107.442 55.846 0.905
RENITEC SURGAM CYSTITIS 62.744 55.616 2.308
CHLOTRIDE SURGAM CYSTITIS 85.012 55.586 1.134
OROXINE SURGAM CYSTITIS 73.18 55.365 1.308
SURGAM ZOCOR CYSTITIS 72.649 55.353 1.318
PROVERA SURGAM CYSTITIS 67.941 55.233 1.402
SURGAM ZANTAC CYSTITIS 47.825 54.73 2.88
PEPCIDINE SURGAM CYSTITIS 50.946 54.525 1.727
ACTRAPID PROTAPHANE HYPOGLYCAEMIA 139.362 54.304 2.39
LASIX SURGAM CYSTITIS 39.655 53.478 1.588
PROTAPHANE VELOSULIN (NORDISK) HYPOGLYCAEMIA 227.337 52.916 0.406
MALOPRIM PRIMAQUINE PO4 METHAEMOGLOBINAEMIA 236.607 52.681 0.779
SURGAM TENORMIN CYSTITIS 34.51 52.59 1.556
MODURETIC SURGAM CYSTITIS 33.96 52.466 1.552
CHLOROQUINE PRIMAQUINE PO4 METHAEMOGLOBINAEMIA 123.759 52.384 1.48
ADRIAMYCIN ENDOXAN-ASTA CYSTITIS HAEMORRHAGIC 393.232 50.559 0.337
ENDOXAN-ASTA METHOTREXATE CYSTITIS HAEMORRHAGIC 885.962 50.101 0.0993
ENDOXAN-ASTA PREDNISOLONE CYSTITIS HAEMORRHAGIC 353.63 50.002 0.247
CHLOTRIDE HYDRALAZINE LE SYNDROME 172.424 47.387 0.959
HYDRALAZINE METOPROLOL LE SYNDROME 87.575 47.015 1.871
ACTRAPID MONOTARD HYPOGLYCAEMIA 81.086 46.963 3.539
ACTRAPID ISOTARD HYPOGLYCAEMIA 324.841 46.697 0.376
DE-NOL FLAGYL TOOTH DISCOLOUR 93.103 46.697 0.87
HYDRALAZINE MODURETIC LE SYNDROME 83.597 46.665 1.457
CIPROXIN PREDNISOLONE TENDINITIS 247.167 46.507 1.643
HYDRALAZINE TENORMIN LE SYNDROME 126.353 46.437 0.639
HYDRALAZINE PRAZOSIN LE SYNDROME 105.823 46.341 0.76
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
§ G-L S – GRAVIS-LIKE SYNDROME
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Table 11.7: MGPS Drug Trade Name-Drug Trade Name-Event (DDE) Ordered by EXCESS
Drug Trade Name Drug Trade Name Preferred Term RR* EB† EXS‡
CRIXIVAN STAVUDINE LIPODYSTROPHY 31.779 30.815 43.939
PETHIDINE STEMETIL DYSTONIA 15.123 12.446 40.749
SABIN VACCINE TRIPLE ANTIGEN FEVER 3.452 3.577 39.512
LASIX WARFARIN PROTHROMBIN ↓ 22.327 27.134 34.928
DIGOXIN WARFARIN PROTHROMBIN ↓ 20.377 25.608 33.542
CRIXIVAN LAMIVUDINE LIPODYSTROPHY 29.778 30.453 32.833
SABIN VACCINE TRIPLE ANTIGEN CRYING ABNORMAL 4.009 4.857 30.302
FLUOROURACIL STREPTOZOTOCIN NAUSEA 7.638 7.391 28.168
ISONIAZID RIFAMPICIN FEVER 5.61 5.243 27.933
FRUSEMIDE WARFARIN PROTHROMBIN ↓ 22.584 27.382 27.811
STAVUDINE LAMIVUDINE LIPODYSTROPHY 19.832 19.381 27.365
MAXOLON STEMETIL DYSTONIA 12.075 11.889 26.511
FLUOROURACIL STREPTOZOTOCIN VOMITING 7.181 8.351 26.104
GENTAMICIN AMPICILLIN RASH MACULO-PAPULAR 2.547 2.877 21.73
PETHIDINE STEMETIL OCULOGYRIC CRISIS 11.645 12.323 20.717
ISONIAZID PYRIDOXINE FEVER 6.002 5.273 20.613
BECOTIDE VENTOLIN BRONCHOSPASM 5.165 3.872 20.279
HIBTITER TRIPLE ANTIGEN FEVER 4.598 3.97 20.182
ETHAMBUTOL ISONIAZID FEVER 5.286 5.186 18.695
HIBTITER SABIN VACCINE FEVER 5.12 4.017 17.907
MAXOLON STEMETIL OCULOGYRIC CRISIS 13.514 12.521 17.434
ALDACTONE LASIX GYNAECOMASTIA 17.568 17.25 17.303
CRIXIVAN TRIMETHOPRIM- LIPODYSTROPHY
SULFAMETHOXAZOLE 32.612 30.729 17.114
SLOW-K WARFARIN PROTHROMBIN ↓ 19.844 26.382 16.176
GENTAMICIN AMPICILLIN RASH 2.264 2.262 16.021
LANOXIN WARFARIN PROTHROMBIN ↓ 31.301 28.664 15.795
HAEMOPHILUS INFLUE- TRIPLE ANTIGEN FEVER
NZAE TYPE B VACCINE 5.099 4.854 14.486
AMIODARONE WARFARIN PROTHROMBIN ↓ 23.593 27.818 14.075
HEPARIN WARFARIN THROMBOCYTOPENIA 9.913 10.64 13.74
SUXAMETHONIUM THIOPENTONE HYPOTENSION 7.986 8.971 13.156
GENTAMICIN VANCOMYCIN RASH ERYTHEMATOUS 4.013 4.32 12.852
DIPHTHERIA-TETANUS- SABIN VACCINE FEVER
PERTUSSIS VACCINE 5.682 4.496 12.842
ATROVENT VENTOLIN BRONCHOSPASM 3.509 3.292 12.823
CRIXIVAN LAMIVUDINE LIPODYSTROPHY 22.11 29.076 12.648
FENTANYL THIOPENTONE HYPOTENSION 13.008 9.373 12.55
ALCURONIUM THIOPENTONE HYPOTENSION 18.043 14.962 12.393
LAMIVUDINE STAVUDINE LIPODYSTROPHY 15.054 18.702 12.301
ATROPINE THIOPENTONE HYPOTENSION 8.702 9.052 12.231
GENTAMICIN VANCOMYCIN PRURITUS 2.144 2.739 12.114
ISONIAZID RIFAMPICIN RIGORS 6.654 6.398 12.093
STAVUDINE TRIMETHOPRIM- LIPODYSTROPHY
SULFAMETHOXAZOLE 28.448 21.278 12.089
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.8: MGPS Drug-ReactionClass-ReactionClass (ATC-SOC-SOC – CSS) Ordered by Rela-
tive Ratio
Drug ATC Name SOC Class SOC Class RR* EBGM† EXCS‡
Ergotamine, comb. foetal disorders neonatal/infancy
excl. psycholeptics disorders 264.798 2.032 -0.001
Insulin isophane reproductive system foetal disorders 205.824 2.96 0.003
Procainamide musculo-skeletal system collagen disorders 92.764 17.963 0.145
Hydralazine musculo-skeletal system collagen disorders 72.035 43.638 5.944
Amiodarone collagen disorders endocrine disorders 54.231 10.856 0.254
Ciprofloxacin endocrine disorders reproductive system 49.664 0.732 -0.027
Colchicine musculo-skeletal system collagen disorders 45.55 1.251 -0.019
Moclobemide musculo-skeletal system collagen disorders 45.103 1.072 -0.023
Domperidone endocrine disorders reproductive system 42.362 4.891 0.11
Diphenoxylate haemic/lymphatic systems urinary system 38.507 2.083 -0.003
Contact laxatives psychiatric disorders metabolic/nutritional 38.026 2.335 0.003
Salmeterol metabolic/nutritional endocrine disorders 37.704 1.693 -0.009
Sertraline foetal disorders neonatal/infancy 37.447 1.571 -0.016
Fluticasone metabolic/nutritional endocrine disorders 37.356 6.363 0.184
Minocycline musculo-skeletal system collagen disorders 36.101 2.02 0.005
Potassium chloride musculo-skeletal system collagen disorders 34.558 1.759 -0.012
Clorazepate urinary system reproductive system 234.544 1.868 -0.009
Danazol nervous system/special senses endocrine disorders 34.53 7.032 0.449
Phenformin gastro-intestinal system metabolic/nutritional 33.356 8.993 0.169
Lamivudine psychiatric disorders endocrine disorders 29.767 2.053 0.008
Indinavir psychiatric disorders endocrine disorders 29.727 1.673 -0.012
Lisinopril musculo-skeletal system collagen disorders 29.226 1.059 -0.036
Norfloxacin metabolic/nutritional endocrine disorders 29.212 1.01 -0.037
Sertraline respiratory system disorders neonatal/infancy 28.669 1.564 -0.021
Progesterone/oestrogen nervous system/special senses foetal disorders 25.038 6.661 0.146
Sodium aurothiomalate metabolic/nutritional urinary system 24.996 1.713 -0.019
Sulphasalazine musculo-skeletal system collagen disorders 24.634 2.942 0.023
Sodium phosphate nervous system/special senses metabolic/nutritional 24.355 6.633 0.443
Risperidone endocrine disorders reproductive system 23.606 8.831 1.521
Sodium phosphate nervous system/special senses urinary system 22.952 4.507 0.266
Ketorolac metabolic/nutritional urinary system 22.871 4.976 0.204
Pentostatin psychiatric disorders urinary system 22.357 2.91 0.024
Cortisone psychiatric disorders endocrine disorders 22.213 4.492 0.084
Zimelidine nervous system/special senses liver/biliary system 21.69 2.917 0.025
Benzyl benzoate gastro-intestinal system reproductive system 21.679 1.446 -0.032
Zimelidine musculo-skeletal system liver/biliary system 21.612 2.916 0.025
Dinoprostone reproductive system foetal disorders 20.388 13.642 2.95
Herbal medicines metabolic/nutritional endocrine disorders 20.175 1.34 -0.04
Streptokinase cardiovascular system foetal disorders 120.044 3.007 0.031
Nitrous oxide musculo-skeletal system metabolic/nutritional 19.958 1.496 -0.032
Muromonab haemic/lymphatic systems urinary system 19.924 1.119 -0.05
Hydralazine Skin/appendages disorders collagen disorders 19.276 19.156 5.405
Lithium metabolic/nutritional endocrine disorders 19.272 11.305 2.547
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.9: MGPS Drug-ReactionClass-ReactionClass (ATC-SOC-SOC – CSS) Ordered by Em-
pirical Bayesian Geometric Mean
Drug ATC Name SOC Class SOC Class RR* EBGM† EXCS‡
Hydralazine musculo-skeletal system collagen disorders 72.035 43.638 5.944
Hydralazine Skin/appendages disorders collagen disorders 19.276 19.156 5.405
Procainamide musculo-skeletal system collagen disorders 92.764 17.963 0.145
Dinoprostone reproductive system foetal disorders 20.388 13.642 2.95
Insulin comb. nervous syst./special senses metabolic/nutritional 17.878 11.453 3.201
Lithium metabolic/nutritional endocrine disorders 19.272 11.305 2.547
Halothane gastro-intestinal syst. liver/biliary system 13.885 11.268 4.5
Amiodarone collagen disorders endocrine disorders 54.231 10.856 0.254
Dinoprostone nervous syst./special senses foetal disorders 16.676 10.427 0.687
Methysergide collagen disorders urinary system 10.684 10.166 1.365
Insulin comb. psychiatric disorders metabolic/nutritional 16.771 9.84 1.364
Coumarin gastro-intestinal syst. liver/biliary system 11.747 9.238 2.164
Phenformin gastro-intestinal syst. metabolic/nutritional 33.356 8.993 0.169
Halothane psychiatric disorders liver/biliary system 10.291 8.856 1.73
Risperidone endocrine disorders reproductive system 23.606 8.831 1.521
Amiodarone musculo-skeletal system endocrine disorders 12.71 8.444 0.673
Coumarin psychiatric disorders liver/biliary system 16.339 8.176 0.279
Amoxicillin psychiatric disorders liver/biliary system
and clavulanate 9.488 8.172 23.277
Flucloxacillin psychiatric disorders liver/biliary system 9.398 7.972 22.136
Indinavir nervous syst./special senses metabolic/nutritional 8.534 7.327 2.133
Analgesic cardiovascular system urinary system 9.617 7.121 0.35
Royal jelly Skin/appendages disorders respiratory system 8.203 7.059 2.627
Danazol nervous syst./special senses endocrine disorders 34.53 7.032 0.449
Coumarin liver/biliary system metabolic/nutritional 7.234 7.007 2.198
Isoniazid gastro-intestinal syst. liver/biliary system 7.688 6.942 12.828
Nomifensine gastro-intestinal syst. foetal disorders 9.904 6.93 3.991
Tiaprofenic acid metabolic/nutritional urinary system 8.224 6.902 0.373
Amiodarone nervous syst./special senses endocrine disorders 6.846 6.87 5.098
Lithium musculo-skeletal system endocrine disorders 10.062 6.84 0.321
Dinoprostone nervous syst./special senses reproductive system 7.637 6.732 0.725
Lithium gastro-intestinal syst. endocrine disorders 7.207 6.724 1.634
Royal jelly cardiovascular system respiratory system 8.526 6.663 1.068
Progesterone/oestrogen nervous syst./special senses foetal disorders 25.038 6.661 0.146
Royal jelly nervous syst./special senses respiratory system 8.478 6.646 1.069
Sodium phosphate nervous system/special senses metabolic/nutritional 24.355 6.633 0.443
Rifampicin gastro-intestinal system liver/biliary system 7.158 6.614 18.073
Quinine cardiovascular system haemic/lymphatic syst. 7.194 6.583 46.456
Insulin nervous syst./special senses metabolic/nutritional 7.172 6.573 10.948
Halothane musculo-skeletal system liver/biliary system 6.822 6.459 0.386
Antiinfectives & nervous system and respiratory system
local anesthetics special senses disorders 8.627 6.394 1.864
Fluticasone metabolic/nutritional endocrine disorders 37.356 6.363 0.184
Nomifensine musculo-skeletal system liver/biliary system 9.317 6.35 2.54
Insulin comb. gastro-intestinal syst metabolic/nutritional 6.994 6.349 0.711
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.10: MGPS Drug-ReactionClass-ReactionClass (ATC-SOC-SOC – CSS) Ordered by EX-
CESS
Drug ATC Name SOC Class SOC Class RR* EB† EXCS‡
Cefaclor Skin/appendages disorders musculo-skeletal system 5.225 5.18 153.966
Diphtheria-pertussis-tetanus nervous syst/special senses body as a whole 1.886 1.885 126.654
Sertraline nervous syst/special senses psychiatric disorders 2.311 2.303 104.14
Paroxetine nervous syst/special senses psychiatric disorders 2.982 2.935 95.358
Meglumine diatrizoate cardiovascular system respiratory system 4.233 4.089 80.168
Diphtheria-pertussis-tetanus psychiatric disorders body as a whole 2.232 2.214 73.597
Amoxicillin&clavulanate Skin/appendages disorders liver/biliary system 3.754 3.767 65.588
Erythromycin gastro-intestinal syst body as a whole 1.636 1.63 59.092
Digoxin gastro-intestinal syst body as a whole 1.539 1.516 57.865
Pethidine nervous syst/special senses cardiovascular system 2.069 2.015 56.693
Nifedipine nervous syst/special senses cardiovascular system 2.248 2.192 54.873
Flucloxacillin gastro-intestinal syst liver/biliary system 4.919 4.854 53.802
Flucloxacillin Skin/appendages disorders liver/biliary system 2.282 2.286 52.537
Fluoxetine nervous syst/special senses psychiatric disorders 2.698 2.644 52.148
Paracetamol &no psycholeptics nervous syst/special senses gastro-intestinal syst 1.633 1.608 52.003
Felodipine nervous syst/special senses cardiovascular system 2.492 2.447 50.949
Salbutamol cardiovascular system respiratory syst 2.889 2.807 49.719
Paracetamol &no psycholeptics nervous syst/special senses psychiatric disorders 2.084 1.984 49.17
Amoxicillin and clavulanate gastro-intestinal syst liver/biliary system 3.531 3.548 49.108
Carbamazepine liver/biliary system body as a whole 2.012 2.018 47.666
Quinine cardiovascular system haemic/lymphatic syst 7.194 6.583 46.456
Moclobemide nervous syst/special senses psychiatric disorders 3.132 3.048 46.32
Meglumine diatrizoate nervous syst/special senses cardiovascular system 3.018 2.832 46.056
Immunoglobulins Specif comb Skin/appendages disorders body as a whole 1.721 1.72 46.051
Ranitidine nervous syst/special senses psychiatric disorders 1.994 1.897 45.328
Digoxin nervous syst/special senses psychiatric disorders 2.005 1.897 44.474
Meglumine diatrizoate Skin/appendages disorders respiratory syst 1.978 1.985 44.473
Diphtheria-pertussis-tetanus gastro-intestinal syst body as a whole 2.085 2.07 42.03
Methyldopa nervous syst/special senses body as a whole 1.867 1.811 41.899
Immunoglobulins Specif comb nervous syst/special senses body as a whole 1.753 1.751 40.351
Indomethacin nervous syst/special senses psychiatric disorders 2.251 2.122 39.838
Methyldopa liver/biliary system body as a whole 2.313 2.304 39.449
Acetylsalicylic acid nervous syst/special senses cardiovascular system 1.473 1.45 39.337
Influenza, inactiv nervous syst/special senses body as a whole 2.153 2.136 39.182
Temazepam nervous syst/special senses psychiatric disorders 2.367 2.211 37.476
Glyceryl trinitrate nervous syst/special senses cardiovascular system 1.921 1.865 37.27
Diazepam nervous syst/special senses psychiatric disorders 2.077 1.963 35.638
Amitriptyline nervous syst/special senses psychiatric disorders 2.591 2.449 35.611
Hepatitis B immunoglobulin nervous syst/special senses body as a whole 1.919 1.891 35.517
Oxazepam nervous syst/special senses psychiatric disorders 2.35 2.27 35.077
Simvastatin musculo-skeletal system metabolic/nutritional 4.005 3.783 34.185
Streptokinase nervous syst/special senses cardiovascular system 4.474 4.173 34.02
Diphtheria-pertussis-tetanus nervous syst/special senses psychiatric disorders 1.785 1.777 33.531
Digoxin psychiatric disorders gastro-intestinal syst 1.814 1.736 33.527
Hepatitis B immunoglobulin nervous syst/special senses gastro-intestinal syst 2.449 2.277 32.005
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.11: MGPS Drug-rug-ReactionClass (ATC-ATC-SOC – CCS) Ordered by Relative Ratio
Drug ATC Name Drug ATC Name SOC Class RR* EB† EXS‡
Ferrous sulphate Hydralazine neonatal and infancy 1039.417 2.787 0.003
Morphine Hydroxychloroquine collagen disorders 298.845 3.082 0.012
Spironolactone Diclofenac neoplasm 238.017 2.021 0.007
Hydralazine Flucloxacillin collagen disorders 154.426 21.865 0.236
Calcium Folic acid foetal disorders 135.699 3.847 0.036
Ranitidine Hydralazine collagen disorders 129.572 21.853 0.28
Metoclopramide Procainamide collagen disorders 129.282 15.516 0.196
Rauwolfia alkaloids Diazepam neoplasm 121.091 8.967 0.114
Oxazepam Nortriptyline neoplasm 119.958 1.194 0.001
Potassium chloride Procainamide collagen disorders 114.842 15.512 0.22
Procainamide Chlorothiazide collagen disorders 114.216 15.645 0.344
Streptokinase Glyceryl trinitrate foetal disorders 101.485 1.336 0.004
Cimetidine Tetracycline&Nystatin endocrine disorders 99.519 7.562 0.114
Procainamide Amylobarbitone collagen disorders 99.446 15.506 0.253
Ferrous sulphate Primidone foetal disorders 83.763 7.998 0.222
Hydralazine Oxazepam collagen disorders 81.875 21.987 0.685
Simethicone comb Salbutamol neoplasm 79.962 1.044 -0.002
Tolbutamide Acetylsalicylic acid endocrine disorders 75.507 1.083 -0.001
&no psycholeptics 75.507 1.083 -0.001
Hydralazine Colchicine collagen disorders 74.176 21.798 0.474
Diltiazem Diazepam neoplasm 73.996 1.122 0
Warfarin Lithium endocrine disorders 69.956 7.488 0.16
Paracetamol &no psycholeptics Methysergide collagen disorders 68.214 12.283 0.286
Insulin isophane Insulin lispro foetal disorders 67.658 4.616 0.14
Multivitamins & minerals MCT Oil metabolic/nutritional 67.217 3.482 0.096
MCT Oil Sodium chloride metabolic/nutritional 66.711 3.451 0.062
MCT Oil Chlorothiazide metabolic/nutritional 64.738 3.451 0.064
Tocopherol MCT Oil metabolic/nutritional 64.738 3.451 0.064
MCT Oil Frusemide metabolic/nutritional 63.379 3.481 0.101
Ferrous sulphate Sulthiame foetal disorders 59.811 7.362 0.283
Salt comb Frusemide endocrine disorders 59.711 1.979 0.025
Procainamide Glyceryl trinitrate collagen disorders 56.472 15.469 0.434
Clorazepate Imipramine reproductive system 56.091 1.535 0.013
Levothyroxine Carbimazole foetal disorders 52.184 1.915 0.027
Ketoprofen Perphenazine endocrine disorders 50.84 0.921 -0.007
Phenytoin Alphaxalone urinary system disorders 50.285 1.1 0
Amiodarone Nitrazepam endocrine disorders 49.409 8.113 0.247
Penicillamine Acetylsalicylic acid collagen disorders 49.184 1.798 0.038
Phytomenadione Phenobarbital metabolic/nutritional 49.041 0.806 -0.012
Fluoride Ferrous sulphate foetal disorders 47.577 2.895 0.066
Dexamethasone Theophylline metabolic/nutritional
&no psycholeptics 47.137 1.37 0.009
Suxamethonium Haloperidol metabolic/nutritional 46.998 2.979 0.07
Salt combinations Metoprolol endocrine disorders 46.31 1.978 0.033
Clomiphene Bromocriptine foetal disorders 45.482 9.115 0.306
Risperidone Moclobemide endocrine disorders 45.443 4.791 0.142
Hydralazine Alprenolol collagen disorders 45.08 21.708 0.719
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.12: MGPS Drug-rug-ReactionClass (ATC-ATC-SOC – CCS) Ordered by Empirical
Bayesian Geometric Mean
Drug ATC Name Drug ATC Name SOC Class RR* EBGM† EXCS‡
Hydralazine Metoprolol collagen disorders 34.933 22.331 6.088
Hydralazine Propranolol collagen disorders 28.28 22.222 8.831
Hydralazine Hydrochlorothiazide collagen disorders 39.113 22.116 2.916
Hydralazine Pindolol collagen disorders 32.021 22.071 4.14
Hydralazine Chlorothiazide collagen disorders 29.545 22.066 5.129
Hydralazine Oxazepam collagen disorders 81.875 21.987 0.685
Hydralazine Atenolol collagen disorders 30.834 21.903 3.001
Ranitidine Hydralazine collagen disorders 129.572 21.853 0.28
Hydralazine Colchicine collagen disorders 74.176 21.798 0.474
Hydralazine Bendrofluazide collagen disorders 34.621 21.767 1.494
Hydralazine Cyclopenthiazide collagen disorders 26.873 21.724 2.496
Hydralazine Alprenolol collagen disorders 45.08 21.708 0.719
Hydralazine Naproxen collagen disorders 42.174 21.691 0.76
Potassium chloride Hydralazine collagen disorders 23.809 21.551 1.894
Hydralazine Methyclothiazide collagen disorders 27.512 21.543 1.082
Hydralazine Chlorthalidone collagen disorders 27.107 21.537 1.095
Potassium chloride Hydralazine collagen disorders 24.069 21.476 1.208
Prazosin Hydralazine collagen disorders 17.25 21.238 1.579
Hydralazine Allopurinol collagen disorders 17.035 21.203 2.393
Clonidine Hydralazine collagen disorders 16.065 21.169 1.67
Hydralazine Oxprenolol collagen disorders 12.064 20.787 2.088
Methyldopa Hydralazine collagen disorders 11.509 20.361 3.137
Digoxin Hydralazine collagen disorders 9.425 20.248 2.513
Procainamide Chlorothiazide collagen disorders 114.216 15.645 0.344
Digoxin Procainamide collagen disorders 38.086 15.634 1.373
Metoclopramide Procainamide collagen disorders 129.282 15.516 0.196
Potassium chloride Procainamide collagen disorders 114.842 15.512 0.22
Procainamide Amylobarbitone collagen disorders 99.446 15.506 0.253
Procainamide Glyceryl trinitrate collagen disorders 56.472 15.469 0.434
Procainamide Frusemide collagen disorders 26.949 15.467 1.375
Procainamide Nitrazepam collagen disorders 42.511 15.44 0.555
Paracetamol &no psycholeptics Methysergide collagen disorders 68.214 12.283 0.286
Dicyclomine comb Ferrous sulphate foetal disorders 25.241 10.474 1.336
Clomiphene Bromocriptine foetal disorders 45.482 9.115 0.306
Rauwolfia alkaloids Diazepam neoplasm 121.091 8.967 0.114
Chlorothiazide Halothane liver/biliary system 25.126 8.932 1.123
Methyldopa Halothane liver/biliary system 24.872 8.931 -0.012
Sulfamethoxazole & trimethoprim Halothane liver/biliary system 27.603 8.885 0.754
Halothane Prochlorperazine liver/biliary system 15.735 8.826 1.271
Flucloxacillin Halothane liver/biliary system 15.394 8.823 0.07
Gentamicin Halothane liver/biliary system 23.814 8.806 0.528
Levothyroxine Halothane liver/biliary system 19.875 8.791 0.61
Tubocurarine Halothane liver/biliary system 19.793 8.791 0.613
Halothane Nitrazepam liver/biliary system 12.996 8.743 0.862
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.13: MGPS Drug-rug-ReactionClass (ATC-ATC-SOC – CCS) Ordered by Empirical
Bayesian Geometric Mean – CONTINUED
Drug ATC Name Drug ATC Name SOC Class RR* EBGM† EXCS‡
Pancuronium Halothane liver/biliary system 9.236 8.707 1.756
Halothane Papaveretum liver/biliary system 8.35 8.702 3.268
Halothane Temazepam liver/biliary system 9.334 8.68 1.122
Conjugated oestrogens Tiaprofenic acid urinary system disorders 17.377 8.672 3.171
Halothane Pethidine liver/biliary system 7.531 8.636 4.136
Medroxyprogesterone Tiaprofenic acid urinary system disorders 18.408 8.592 1.838
Frusemide Tiaprofenic acid urinary system disorders 11.715 8.582 4.617
Simvastatin Tiaprofenic acid urinary system disorders 12.535 8.58 3.771
Atenolol Tiaprofenic acid urinary system disorders 11.877 8.565 3.964
Fosinopril Tiaprofenic acid urinary system disorders 16.08 8.533 1.651
Prazosin Tiaprofenic acid urinary system disorders 12.612 8.525 2.625
Chlorothiazide Tiaprofenic acid urinary system disorders 13.535 8.504 1.931
Tiaprofenic acid Allopurinol urinary system disorders 9.13 8.494 6.467
Digoxin Spironolactone endocrine disorders 11.009 8.466 15.307
Methotrexate Tiaprofenic acid urinary system disorders 13.776 8.464 1.342
Tiaprofenic acid CONTRAST MEDIUM urinary system disorders 22.717 8.458 0.526
Ranitidine Tiaprofenic acid urinary system disorders 8.406 8.415 4.759
Tiaprofenic acid Theophylline urinary system disorders 10.411 8.408 1.572
Omeprazole Tiaprofenic acid urinary system disorders 13.402 8.407 0.807
Metformin Tiaprofenic acid urinary system disorders 13.205 8.405 0.817
Timolol Tiaprofenic acid urinary system disorders 13.075 8.404 0.823
Potassium chloride Tiaprofenic acid urinary system disorders 12.914 8.402 0.832
Tiaprofenic acid Carbamazepine urinary system disorders 11.293 8.382 0.926
Amiodarone Frusemide endocrine disorders 10.831 8.38 17.237
Frusemide Spironolactone endocrine disorders 9.013 8.369 24.355
Oestradiol Tiaprofenic acid urinary system disorders 10.359 8.367 0.993
Verapamil Tiaprofenic acid urinary system disorders 10.361 8.367 0.993
Tiaprofenic acid Temazepam urinary system disorders 8.368 8.363 2.485
Procainamide Fentanyl liver/biliary system 5.564 8.362 3.216
Hydrochlorothiazide Tiaprofenic acid urinary system disorders 8.016 8.358 3.244
Enalapril Tiaprofenic acid urinary system disorders 7.995 8.357 3.247
Famotidine Tiaprofenic acid urinary system disorders 8.123 8.35 2.523
Tiaprofenic acid Tiaprofenic acid urinary system disorders 9.339 8.346 1.079
Chlorothiazide Spironolactone endocrine disorders 21.764 8.33 1.503
Clonidine Spironolactone endocrine disorders 36.525 8.324 0.715
Halothane Thiopentone liver/biliary system 6.528 8.307 9.938
Lisinopril Tiaprofenic acid urinary system disorders 7.783 8.302 1.245
Glyceryl trinitrate Tiaprofenic acid urinary system disorders 7.673 8.298 1.259
Tiaprofenic acid Salbutamol urinary system disorders 7.034 8.271 1.346
Amiodarone Enalapril endocrine disorders 15.361 8.27 3.395
Captopril Tiaprofenic acid urinary system disorders 6.662 8.252 1.404
Metoprolol Tiaprofenic acid urinary system disorders 6.659 8.252 1.404
Digoxin Amiodarone endocrine disorders 9.33 8.243 13.254
Spironolactone Diazepam endocrine disorders 22.488 8.242 0.846
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.14: MGPS Drug-rug-ReactionClass (ATC-ATC-SOC – CCS) Ordered by EXCESS
Drug ATC Name Drug ATC Name SOC Class RR* EB† EXCS‡
Warfarin Digoxin haemic/lymphatic syst. 3.719 3.995 92.118
Beclomethasone Salbutamol respiratory system disord. 2.745 2.384 89.218
Warfarin Frusemide haemic/lymphatic syst. 3.845 4.045 86.647
Ampicillin Gentamicin Skin/appendages disorders 1.685 1.715 49.109
Indinavir Lamivudine metabolic/nutritional 7.005 7.048 48.385
Poliomyelitis vaccine Diphtheria-pertussis-tetanus body as a whole 1.804 1.829 47.872
Digoxin Frusemide haemic/lymphatic syst. 1.604 1.406 42.301
Salbutamol Theophylline respiratory system disord. 3.015 2.177 42.015
Indinavir Stavudine metabolic/nutritional 8.701 7.285 40.595
Amoxycillin Metronidazole Skin/appendages disorders 1.534 1.654 40.302
Stavudine Lamivudine metabolic/nutritional 7.437 6.582 39.359
Ipratropium bromide Salbutamol liver/biliary system 7.514 5.482 37.135
Hemophilus influenzae B Diphtheria-pertussis-tetanus body as a whole 1.73 1.811 36.205
Ampicillin Amoxycillin Skin/appendages disorders 2.058 1.798 33.351
Pethidine Prochlorperazine musculo-skeletal system 5.505 3.7 31.466
Potassium chloride Warfarin haemic/lymphatic syst. 27.107 4.058 29.884
Simvastatin Acetylsalicylic acid musculo-skeletal system 2.454 2.478 29.546
Alcuronium Thiopentone cardiovascular system 3.878 3.351 28.38
Frusemide Ampicillin Skin/appendages disorders 1.939 1.769 28.27
Frusemide Enalapril respiratory system disord. 1.917 2.137 27.553
Poliomyelitis vaccine Diphtheria-pertussis-tetanus nervous syst./special senses 1.929 1.715 27.447
Suxamethonium Thiopentone cardiovascular system 2.472 2.315 27.338
Gentamicin Metronidazole Skin/appendages disorders 1.847 1.499 27.006
Beclomethasone Theophylline respiratory system disord. 3.348 2.357 26.577
Amoxycillin Salbutamol Skin/appendages disorders 1.686 1.704 26.246
Amoxycillin Gentamicin Skin/appendages disorders 1.706 1.709 26.134
Penicillin Flucloxacillin Skin/appendages disorders 1.825 1.733 26.086
Potassium chloride Frusemide haemic/lymphatic syst. 1.478 1.351 25.945
Ampicillin Metronidazole Skin/appendages disorders 1.833 1.747 25.873
Frusemide Amoxycillin Skin/appendages disorders 1.913 1.747 25.802
Heparin Frusemide haemic/lymphatic syst. 2.992 3.283 25.474
Digoxin Frusemide urinary system disorders 1.37 1.422 25.193
Warfarin Captopril haemic/lymphatic syst. 3.57 4.006 25.03
Benzylpenicillin Flucloxacillin Skin/appendages disorders 2.121 1.754 24.986
Pyridoxine (vit B6) Isoniazid liver/biliary system 6.411 8.967 24.658
Amoxycillin Paracetamol Skin/appendages disorders 1.925 1.748 24.363
Frusemide Spironolactone endocrine disorders 9.013 8.369 24.355
Digoxin Ampicillin Skin/appendages disorders 1.914 1.76 24.287
Rifampicin Ethambutol liver/biliary system 5.939 4.973 23.962
Isoniazid Ethambutol liver/biliary system 6.44 5.296 23.942
Streptozotocin Fluorouracil gastro-intestinal syst. 3.695 3.32 23.77
Metoclopramide Prochlorperazine musculo-skeletal system 5.006 3.602 23.507
Digoxin Amoxycillin Skin/appendages disorders 2.017 1.761 23.418
Gentamicin Vancomycin Skin/appendages disorders 1.806 1.794 23.312
*Relative Ratio – for more details see Appendix D.1.3.
† Empirical Bayesian Geometric Mean.
‡ EXCESS – A conservative estimate of how many extra cases were observed above what was
expected.
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Table 11.15: Interactions (INTSS) for DEE
INTSS* Drug Trade Name Preferred Term Preferred Term
1 7.665 LASIX † HAEMATEMESIS ‡ MELAENA
2 6.538 ASPIRIN † VOMITING NAUSEA ‡
3 5.99 ASPIRIN † HAEMATEMESIS MELAENA ‡
4 5.582 LASIX † VOMITING NAUSEA ‡
5 5.412 ASPIRIN † TONGUE OEDEMA FACE OEDEMA ‡
6 5.345 VENTOLIN † VOMITING NAUSEA ‡
7 5.323 ZYLOPRIM † VOMITING NAUSEA ‡
8 5.215 LANOXIN † HAEMATEMESIS MELAENA ‡
9 5.157 WARFARIN † VOMITING ‡ NAUSEA
10 5.089 GENTAMICIN † VOMITING NAUSEA ‡
11 5.073 SLOW-K † HAEMATEMESIS ‡ MELAENA
12 5.063 ALLOPURINOL † VOMITING ‡ NAUSEA
13 5.03 HEPARIN † VOMITING ‡ NAUSEA
14 5.018 ZYLOPRIM † HAEMATEMESIS MELAENA ‡
15 4.899 ALDOMET † HAEMATEMESIS MELAENA ‡
16 4.692 FRUSEMIDE † VOMITING ‡ NAUSEA
17 4.669 SLOW-K † VOMITING ‡ NAUSEA
18 4.608 BECOTIDE † VOMITING NAUSEA ‡
19 4.607 MODURETIC † VOMITING NAUSEA ‡
20 4.566 ZANTAC † VOMITING NAUSEA ‡
21 4.475 LASIX † TONGUE OEDEMA ‡ ANGIOEDEMA
22 4.466 LASIX † RIGORS FEVER ‡
23 4.436 FLUCLOXACILLIN † FATIGUE ANOREXIA ‡
24 4.351 LANOXIN † VOMITING ‡ NAUSEA
25 4.335 SLOW-K † GASTRIC ULCER MELAENA ‡
26 4.33 RANITIDINE † VOMITING ‡ NAUSEA
27 4.325 TENORMIN † BRONCHOSPASM PERIPHERAL ISCHAEMIA ‡
28 4.275 DIGOXIN † WEIGHT DECREASE ANOREXIA ‡
29 4.275 PETHIDINE † BRADYCARDIA HYPOTENSION ‡
30 4.242 SLOW-K † RIGORS ‡ FEVER
31 4.204 FRUSEMIDE † WEIGHT DECREASE ANOREXIA ‡
32 4.196 PETHIDINE † TACHYCARDIA ‡ HYPERTENSION
33 4.157 ALLOPURINOL † RIGORS FEVER ‡
34 4.128 AMPICILLIN † VOMITING ‡ NAUSEA
35 4.116 PANADOL † CONFUSION ‡ HALLUCINATION
36 4.107 PETHIDINE † SWEATING INCREASED PALLOR ‡
37 4.095 LASIX † GASTRIC ULCER MELAENA ‡
38 4.091 AMOXIL † VOMITING ‡ NAUSEA
39 4.003 ALDOMET † VOMITING NAUSEA ‡
40 3.993 LASIX † ANOREXIA ‡ MALAISE
41 3.953 TEGRETOL † RIGORS FEVER ‡
42 3.901 TEGRETOL † ATAXIA NYSTAGMUS ‡
43 3.899 CAPOTEN † VOMITING NAUSEA ‡
*INTSS = EB05 / EB95MAX – see Appendix D.1.3.
† MAXITEM1 – see Appendix D.1.3.
‡ MAXITEM2 – see Appendix D.1.3.
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Table 11.16: Interactions (INTSS) for DDE
INTSS* Drug Trade Name Drug Trade Name Preferred Term
1 0.783 LASIX SLOW-K † RASH ‡
2 0.78 RULIDE WARFARIN † PROTHROMBIN ACTIVITY DECREASED ‡
3 0.779 PANADOL † TEMAZEPAM PRURITUS ‡
4 0.777 PETHIDINE STEMETIL † DYSTONIA ‡
5 0.777 AMOXIL † AMPICILLIN PRURITUS ‡
6 0.773 DILANTIN AMOXIL † PRURITUS ‡
7 0.767 PETHIDINE † ATROPINE NAUSEA ‡
8 0.766 AMPICILLIN † METRONIDAZOLE RASH MACULO-PAPULAR ‡
9 0.765 LASIX † MOGADON RASH ‡
10 0.765 LASIX † SEREPAX PRURITUS ‡
11 0.765 FLUCLOXACILLIN † TEMAZEPAM PRURITUS ‡
12 0.764 MAXOLON PETHIDINE † PRURITUS ‡
13 0.764 LANOXIN SLOW-K † RASH ‡
14 0.764 AMOXIL † SLOW-K RASH MACULO-PAPULAR ‡
15 0.763 FLUCLOXACILLIN † PENICILLIN PRURITUS ‡
16 0.761 AMOXIL † VENTOLIN RASH MACULO-PAPULAR ‡
17 0.761 FLUCLOXACILLIN † PETHIDINE RASH ‡
18 0.76 FLUCLOXACILLIN † TEMAZEPAM RASH ‡
19 0.759 FENTANYL CITRATE PETHIDINE † NAUSEA ‡
20 0.759 GENTAMICIN † TEMAZEPAM PRURITUS ‡
21 0.758 CAPOTEN † LASIX PRURITUS ‡
22 0.758 LASIX † SLOW-K PRURITUS ‡
23 0.758 HEPARIN † RANITIDINE THROMBOCYTOPENIA ‡
24 0.758 AMPICILLIN † SLOW-K RASH ‡
25 0.757 LASIX † RENITEC PRURITUS ‡
26 0.757 LASIX † NAPROSYN PRURITUS ‡
27 0.757 LASIX † VENTOLIN RASH ‡
28 0.757 PEPCIDINE WARFARIN † PROTHROMBIN ACTIVITY DECREASED ‡
29 0.757 FLUCLOXACILLIN † HEPARIN PRURITUS ‡
30 0.757 GENTAMICIN † SLOW-K RASH ‡
31 0.756 FRUSEMIDE SLOW-K † RASH ‡
32 0.756 ERYTHROMYCIN WARFARIN † PROTHROMBIN ACTIVITY DECREASED ‡
33 0.756 ERYTHROMYCIN AMOXIL † RASH ‡
34 0.755 VENTOLIN WARFARIN † PROTHROMBIN ACTIVITY DECREASED ‡
35 0.755 AMOXIL AMPICILLIN † RASH MACULO-PAPULAR ‡
36 0.755 FLUCLOXACILLIN † GENTAMICIN PRURITUS ‡
37 0.755 FLUCLOXACILLIN † PANADOL PRURITUS ‡
38 0.755 AMOXIL † SLOW-K PRURITUS ‡
39 0.754 INDERAL LASIX † PRURITUS ‡
40 0.754 AMPICILLIN ASPIRIN † RASH MACULO-PAPULAR ‡
41 0.754 HEPARIN AMOXIL † RASH MACULO-PAPULAR ‡
42 0.754 AMOXIL † ORBENIN RASH MACULO-PAPULAR ‡
43 0.754 AMOXIL † MYLANTA RASH MACULO-PAPULAR ‡
*INTSS = EB05 / EB95MAX – see Appendix D.1.3.
† MAXITEM1 – see Appendix D.1.3.
‡ MAXITEM2 – see Appendix D.1.3.
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Table 11.17: Interactions (INTSS) for CSS
INTSS* Drug ATC Name SOC Class SOC Class
1 1.862 Flucloxacillin † psychiatric disorders gastro-intestinal system ‡
2 1.805 Warfarin † nervous syst./special senses psychiatric disorders ‡
3 1.688 Amoxycillin † nervous syst./special senses ‡ psychiatric disorders
4 1.683 Flucloxacillin † psychiatric disorders body as a whole ‡
5 1.612 Sulfonamides¶ † cardiovascular system respiratory system disorders‡
6 1.562 Paracetamol † nervous syst./special senses ‡ psychiatric disorders
7 1.558 Amoxycillin † cardiovascular system ‡ respiratory system disorders
8 1.55 Ampicillin † nervous syst./special senses psychiatric disorders ‡
9 1.537 Digoxin † nervous syst./special senses psychiatric disorders ‡
10 1.515 Frusemide † nervous syst./special senses ‡ psychiatric disorders
11 1.507 Amoxicillin & clavulanate † cardiovascular system respiratory system disorders‡
12 1.505 Sulfamethoxazole & trimethoprim† nervous syst./special senses respiratory system disorders‡
13 1.488 Diphtheria-pertussis-tetanus † cardiovascular system ‡ respiratory system disorders
14 1.435 Sulfamethoxazole & trimethoprim† respiratory system disorders body as a whole‡
15 1.414 Paracetamol † cardiovascular system respiratory system disorders‡
16 1.41 Paracetamol§ † nervous syst./special senses psychiatric disorders ‡
17 1.4 Ranitidine † nervous syst./special senses psychiatric disorders ‡
18 1.399 Carbamazepine † musculo-skeletal system body as a whole ‡
19 1.397 Paracetamol§ † cardiovascular system ‡ respiratory system disorders
20 1.389 Cefaclor † nervous syst./special senses ‡ psychiatric disorders
21 1.377 Metoclopramide † cardiovascular system ‡ respiratory system disorders
22 1.36 Carbamazepine † gastro-intestinal system body as a whole ‡
23 1.352 Amoxycillin † cardiovascular system ‡ body as a whole
24 1.35 Indomethacin † nervous syst./special senses ‡ psychiatric disorders
25 1.342 Phenytoin † respiratory system disorders body as a whole ‡
26 1.341 Phenytoin † nervous syst./special senses ‡ psychiatric disorders
27 1.337 Temazepam † nervous syst./special senses psychiatric disorders ‡
28 1.324 Amoxycillin † nervous syst./special senses cardiovascular system ‡
29 1.322 Benzylpenicillin † cardiovascular system respiratory system disorders‡
30 1.317 Allopurinol † musculo-skeletal system body as a whole ‡
31 1.316 Warfarin † gastro-intestinal system ‡ body as a whole
32 1.312 Ranitidine † gastro-intestinal system ‡ body as a whole
33 1.311 Digoxin † psychiatric disorders ‡ body as a whole
34 1.31 Amoxycillin † musculo-skeletal system body as a whole ‡
35 1.309 Frusemide † psychiatric disorders gastro-intestinal system ‡
36 1.304 Meglumine diatrizoate † nervous syst./special senses cardiovascular system ‡
37 1.294 Amoxycillin † nervous syst./special senses gastro-intestinal system ‡
38 1.29 Enalapril † metabolic/nutritional urinary system disorders ‡
39 1.287 Sulfonamides¶ † musculo-skeletal system body as a whole ‡
40 1.284 Amoxycillin † respiratory system disorders body as a whole ‡
41 1.283 Potassium chloride † nervous syst./special senses psychiatric disorders ‡
42 1.283 Amoxicillin & clavulanate † psychiatric disorders body as a whole ‡
43 1.275 Flucloxacillin † cardiovascular system ‡ respiratory system disorders
*INTSS = EB05 / EB95MAX – see Appendix D.1.3.
† MAXITEM1 – see Appendix D.1.3.
‡ MAXITEM2 – see Appendix D.1.3.
§ , combinations excluding psycholeptics
¶ Combinations, Intermediate-acting
294
Table 11.18: Interactions (INTSS) for CCS
INTSS* Drug ATC Name Drug ATC Name SOC Class
1 0.873 Dexamethasone Phenytoin † Skin/appendages disorders ‡
2 0.842 Potassium chloride Frusemide † Skin/appendages disorders ‡
3 0.836 Frusemide † Captopril Skin/appendages disorders ‡
4 0.832 Salbutamol † Theophylline respiratory system disorders ‡
5 0.83 Paracetamol§ Temazepam † Skin/appendages disorders ‡
6 0.829 Frusemide † Salbutamol Skin/appendages disorders ‡
7 0.822 Digoxin † Frusemide haemic/lymphatic system ‡
8 0.822 Frusemide Allopurinol † Skin/appendages disorders ‡
9 0.821 Metoclopramide Paracetamol§ † Skin/appendages disorders ‡
10 0.817 Gentamicin † Metronidazole Skin/appendages disorders ‡
11 0.815 Digoxin Frusemide † Skin/appendages disorders ‡
12 0.814 Metoprolol Acetylsalicylic acid † Skin/appendages disorders ‡
13 0.814 Paracetamol † Paracetamol§ Skin/appendages disorders ‡
14 0.813 Flucloxacillin † Paracetamol Skin/appendages disorders ‡
15 0.812 Digoxin † Frusemide gastro-intestinal system ‡
16 0.812 Potassium chloride Frusemide † cardiovascular system ‡
17 0.81 Metoclopramide Pethidine † Skin/appendages disorders ‡
18 0.809 Ranitidine Phenytoin † Skin/appendages disorders ‡
19 0.807 Paracetamol † Temazepam Skin/appendages disorders ‡
20 0.807 Paracetamol Phenytoin † Skin/appendages disorders ‡
21 0.805 Frusemide Nitrazepam † Skin/appendages disorders ‡
22 0.804 Potassium chloride † Frusemide body as a whole ‡
23 0.804 Digoxin † Frusemide body as a whole ‡
24 0.803 Potassium chloride Digoxin † body as a whole ‡
25 0.803 Isosorbide dinitrate Frusemide † Skin/appendages disorders ‡
26 0.803 Frusemide † Acetylsalicylic acid Skin/appendages disorders ‡
27 0.803 Digoxin Captopril † Skin/appendages disorders ‡
28 0.803 Flucloxacillin † Gentamicin Skin/appendages disorders ‡
29 0.803 Digoxin Acetylsalicylic acid † nervous syst./special senses ‡
30 0.803 Metoclopramide Paracetamol † Skin/appendages disorders ‡
31 0.803 Heparin Paracetamol † Skin/appendages disorders ‡
32 0.802 Glyceryl trinitrate Frusemide † Skin/appendages disorders ‡
33 0.802 Heparin Flucloxacillin † Skin/appendages disorders ‡
34 0.801 Potassium chloride Digoxin † gastro-intestinal system ‡
35 0.801 Beclomethasone dipropionate † Salbutamol respiratory system disorders ‡
36 0.8 Digoxin Acetylsalicylic acid † gastro-intestinal system ‡
37 0.799 Ampicillin † Amoxycillin Skin/appendages disorders ‡
38 0.799 Digoxin Amoxycillin † Skin/appendages disorders ‡
39 0.798 Potassium chloride Amoxycillin † Skin/appendages disorders ‡
40 0.798 Amoxycillin † Allopurinol Skin/appendages disorders ‡
41 0.797 Paracetamol§ † Salbutamol Skin/appendages disorders ‡
42 0.796 Ranitidine † Acetylsalicylic acid nervous syst./special senses ‡
43 0.796 Digoxin Acetylsalicylic acid † body as a whole ‡
*INTSS = EB05 / EB95MAX – see Appendix D.1.3.
† MAXITEM1 – see Appendix D.1.3.
‡ MAXITEM2 – see Appendix D.1.3.
§ , combinations excluding psycholeptics
Chapter 12
Conclusion
12.1 Overview
This work has demonstrated the following:
Â The Australian drug safety data was used to compare and investigate the development of
alternative methods for pharmacovigilance decision support, which do not rely upon dispro-
portionality to flag events of concern,
Â methods based on covariability can overcome problems faced by disproportionality drug-event
signalling methods.
Â The covariability methods are more robust and offer potential for discovering interactions
from analysis of drug safety data.
Â A text categorization method can use Australian drug safety data and have found some
interesting features of its modus operandi and its potential as an additional drug safety tool.
Â The covariability methods show evidence of being useful to investigate, interactions, syn-
dromes, and suspected drug attribution, because of the way they represent expected and
observed events as multi-dimensional vectors,
Â drug and reaction ontologies enable the useful employment of association rule data mining
methods in the analysis of drug safety data.
Â This has lead to the development of a prototype method for adverse event signalling from
spontaneous ADR report data, which uses association rules and critical reaction term knowl-
edge to sensitize it to more serious reactions.
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Â This prototype method for adverse event signalling from spontaneous ADR report data,
which uses association rules and critical reaction term knowledge to sensitize it to more
serious reactions. Prototype method is flexible in terms of adjusting parameters to tune the
signal sensitivity to meet decision support requirements.
Â I was able to gain access to Lincoln Technology’s implementation of MGPS on which to run
Australian drug safety data. I have used the output from this single run for a preliminary
comparison to the other methods I have worked with and made recommendations for future
runs.
I believe that this thesis makes a significant contribution to the field of pharmacovigilance
decision support by showing the usefulness of drug and reaction ontologies and the way theory and
methods from other areas can vitalize this area.
12.2 The value of Disproportionality Analysis Signal Detec-
tion Methods
The traditional drug safety methods that M. Hauben takes to mean: the qualitative/semiquantitative
heuristic/rules-based approach that use pharmacovigillance domain expertise of the prepared mind
that has historically been the foundation of post-marketing surveillance [203], which I have referred
to as disproportionality analysis signal detection methods, attempt to overcome the poor quality
of this type of spontaneous reporting data (such as, incomplete information, lack of adequate con-
trol data, poor structure, and variable terminology). In general all these methods make a 2 × 2
comparison of drug and reaction pair to the generality of all drugs and reactions in the database
as a control. The opportunity to analyze the Australian drug safety data on Lincoln Technology’s
MGPS suite of methods has addressed research question 1. This uses Relative Ratio as well as
Baysean estimators, which has allowed me to illustrate some of limitations of disproportionality
signal detection methods. One major problem surfaced with the use of ADRAC preferred reaction
terms, which I called term redundancy. By using several similar terms for a condition that could
be represented by one term clogs MGPS with redundant terms. This could also be revealing a
weakness in MGPS itself, that its performance may be affected by the AE dictionary structure,
which is cited as an outstanding issue for automated signal detection and data mining techniques
[202] – see Section 2.2.2. A similar problem appears to occur with drugs with what appears to be
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many innocent by-stander drugs. The later problem could have been alleviated if I had included
the ADRAC suspect codes with the drug data sent to Bill DuMouchel. Nevertheless, I believe
this highlights the problem in general with the disproportionality approach, which is essentially
two-dimensional. The interaction estimator, INTSS, was also examined. The INTSS values were
only significant for drug-event interactions and no drug interactions were seen. This contrasts with
the covariability algorithms, which are well suited finding drug-drug interactions by comparison of
drug-reaction vectors between different report records and different drug combinations.
12.3 The development and testing of Covariability Tech-
niques
I have participated in the development of covariability algorithms specifically designed for Aus-
tralian drug safety data and a text categorization algorithm that could be applied to these data.
This also applies to research question 1. These methods are not restricted to a 2 × 2 comparison
of drug and reaction pair to the generality of all drugs and reactions in the database as a control.
Both approaches are multi-dimensional. This means that vectors can be compared for expected
versus observed. This makes these methods much more robust and flexible as to their mode of
implementation. Both algorithms assign weights to drug-event associations, but each does this
differently. Average Error was the measure applied to evaluate each algorithm’s performance in
predicting events. The covariability method performed better in most cases, but BoosTexter per-
formed better on test sets when new events were highest. This means that further investigation
using both methods is warranted.
BoosTexter was used because it is a high performance algorithm that was able to process drug
safety data in a meaningful way. There is no gold standard for drug safety data, but it was very
important to be able to compare my results with a standard drug safety tool.
The fuzzy set relationship implemented by the covariability algorithms can also be used to
implement notions such as potential reactions and interactions. This is a vector that contains the
expected values based on the data upon which it was trained. This has been used to compare
each record to this standard of expected value. A significant deviation from the expected value is
measured using error distance measures. This was then extended as a way to measure interaction
and suspected drugs. This may also be refined to determine whether a significant deviation of a
record from the expected value is indicative of an ADR signal. Much of the work in this direction
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is focussed on defining an appropriate error distance measure between the multi-vector of expected
values and that of observed values. Results in Chapter 7 have supported that some distance
measures tested are able to detect suspected drug and interaction of drugs. The results reported
in Sections 4.7.4, 7.8 and 7.9.5 have indicated that interactions can be discovered using fuzzy
relations, which relates to research question 5.
12.4 The importance of Ontology
There is a vast and growing amount of medical knowledge. I have have been able to show that
application of knowledge to pharmacovigilance decision support methods in the form of drug and
reaction ontologies is desirable.
The application of the ATC classification to ADRAC data enables the association rule generator
combined with methods of data mining to be usefully employed. This relates to research question
3. The ATC ontology has structured the data so that: (i) the number of drug variables can be
drastically reduced, (ii) so that finer levels of granularity can be accessed via a tree structure. This
has meant that a data mining method that was hitherto not accessible to the analysis of drug safety
data has become very useful. This also lead to our development of a prototype signal detection
method that exploited the tree structure of the ATC ontology to develop an adverse event signalling
method that can ‘drill down’ the ATC tree to find individual drugs that have significantly more
reactions in a given SOC. Then, using the critical term ontology (research question 4), monthly
reaction frequencies are examined to produce warnings when reactions rise to a significant level.
I believe that this application of ontologies to drug safety data enables a significant advance in
adverse event signalling methodology.
The application of the ATC ontology to ADRAC drugs helps grouping of data so optimization
techniques can be applied to existing methods developed for the analysis of drug safety data. The
ATC grouping also makes it possible to apply more traditional, well established methods to drug
safety data that were formerly not useful. However, ontology brings with it its own set of problems.
First, there is the difficulty of convincing the peers at large in a discipline of the importance of
ontology. Then there is the need to set a standard for the “right ontology”. Finally, the need for
ongoing maintenance (curation) to incorporate new knowledge.
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12.5 Future Work
The opportunity to analyze the Australian drug safety data on Lincoln Technology’s MGPS suite
of methods has enabled me to compare the disproportionality methods using the same data set
that was used for my investigation. It would have been better to install MGPS locally to facilitate
more interactivity with this tool. Having the ADRAC data run on Lincoln Technologies imple-
mentation was definitely the next best option and is standard implementation of MGPS. This gave
an opportunity to see some of the strengths and weaknesses of this method. Just an examination
of further runs on MGPS, as I have suggested above would make a very interesting project in its
own right, particularly the utilization of the ATC ontology. Some combinations, each estimator
covers a very different part of the data. In the present analysis, this has presented an opportunity
to reveal different aspects of the data. In the future it may be possible to exploit these differences
between these estimators in order to reveal interesting patterns in the data.
The application of the fuzzy derivative algorithm FDM appears to have value for prediction
of outcomes and may have other applications to this field. The method is particularly useful for
detecting the influence of one parameter upon another.
The fact that BoosTexter performed better in some situations than the covariability method
developed specifically for ADR analysis means that further investigation using both methods is
warranted using BoosTexter and other text categorization methods.
This investigation has concentrated on complete fields in the ADRAC data, particularly drugs
and reactions. Dosage information has not been used in this investigation. This is important
information, which should be utilized in future investigations of this data. In the ATC codes,
defined daily dose (DDD) are also supplied by the Upsala Monitoring Center (UMC) for each ATC
code [560]. The DDD can be utilized as basis for comparing actual dose. The time when the
administration of each drug ceases and the decay function of the drug using the formula (5.2.4)
is a very interesting problem for future investigations. This also needs to take into account many
other factors such as the metabolism and elimination of drugs. Drug exposure time will be another
important factor to take into consideration [82].
Other fields that relate to ADRs, such as, “severity codes”, “hospitalization code”, “first dose
indication” – reaction after first dose, would be useful to rank reactions in some order of severity.
The “reaction suspect code” (to help identify which drugs are likely to cause reactions and help
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to remove “innocent bystander” drugs from the analysis) has been used, see Chapters 6, 7, 10,
11. Some examination of whether the codes are correctly attributed has been done in Chapter
7, however, it would be interesting to extend this to the examination other drugs that may cause
reactions (code ‘S’) or interact (code ‘I’), but which have not been identified in the suspect codes;
that is those of code ‘O’ – ‘other’.
The study more sensible definitions of the function H to define ‘potential reaction’ is an in-
teresting problem for future investigations (see Section 5.2.1). This problem is also related to the
study of Interaction of Drugs (see Sections 4.6.3, 4.7.4). Results in Chapter 7 have supported that
some distance measures tested are able to detect suspected drug and interaction of drugs. The
results reported in Section 4.7.4 have indicated that interactions can be discovered using fuzzy
relations. I am confident that our fuzzy relation approach to this problem will be fruitful for the
exploration of both interactions and syndromes. This is particularly so because fuzzy logic theory
is firmly established – see Section 1.6.
The future development of these algorithms will need to take advantage of the hierarchy of
levels embedded in the ATC codes. Furthermore, it makes these data more accessible to methods
that have difficulty when the number of variables is excessive. It is anticipated that the ATC
classification will lead to enhanced signal detection capabilities of many algorithms.
The ATC ontology, because it is hierarchical, allows the grouping of data to different levels in
the hierarchy. This will make the ADRAC data more amenable to the application of optimization
techniques (Chapter 7, for discussion see [326]), because it is now possible to greatly decrease
the number of variables using higher level drug terms in this classification. Furthermore, some
other methods commonly applied in data mining [417] should become applicable to ADRAC data.
This ATC classification will also facilitate the use drug class information already ‘learnt’ by some
algorithm to apply to drugs belonging to that class that have not been previously encountered in
the data [326]. That is information about a drug class can be used to compare whether a new drug
is behaving typically for the class or if it is not.
This work has shown the usefulness of and it is to be hoped this contributed to the development
of improved reaction and drug ontologies that incorporate more knowledge and that are designed
to better facilitate their integration into data processing methods. In view of the fact that the
automated methods are able to process vast amounts of data and because rare events require large
samples to have sufficient data to provide trend information, a larger source of drug safety data is
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required. Therefore, the methods described here should be modified to use more drug safety data
from different sources. For example, FDA data are available for purchase at http://www.ntis.gov/
as “FDA Quarterly Data Extracts”.
Definitions and Glossary
12.6 Definition of Terms Used
Adverse drug event (ADE) – adverse event that is drug related, whether it is the result of a
consumer being given a wrong drug or dosage, or related to properties of the drug [377].
Adverse event (AE) – In the current context, some adverse medical condition not necessarily
attributable to a particular cause, but in some sense connected to medical management rather
than a disease processes [489, 508].
Adverse drug reaction (ADR) – A response to a drug that is noxious and unintended and
occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for
modification of physiological function [570]. They constitute a subset of ADEs [377]. Aronson and
Ferner devised a three dimensional classification system based on dose relatedness, timing, and
patient susceptibility (DoTS) [20, 142].
Bellman-Harris – branching processes.
Churg-Strauss Syndrome (CSS) – A systemic vasculitis. This disease was first described in
1951 by Dr. Jacob Churg and Dr. Lotte Strauss as a syndrome consisting of ”asthma, eosinophilia
[an excessive number of eosinophils in the blood], fever, and accompanying vasculitis of various
organ systems”. CSS shares many of the clinical and pathological features of polyarteritis nodosa
(”PAN”, another type of vasculitis). Churg and Strauss discovered that the presence of granulomas
as well as the abundance of eosinophils distinguished this disease from PAN. Another name for
Churg- Strauss Syndrome is Allergic granulomatosis. [502, 117]:
Confounding – mixing up [553]:
Confounding by association – is a variable other than the risk factor and outcome under study
that is related independently to both the risk factor and the outcome variable and that may create
an apparent association or mask the real one [431, 495]. Examples of confounding by association:
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(i) where two or more drugs are being used by an individual and it is difficult to determine which
drug is associated with an ADR; (ii) if an individual is taking medication for a medical condition
and a person’s age is also a possible cause for the development of a medical condition [34].
Confounding by indication – patient’s apparent reaction is due to patient’s condition and not the
drug. [556]
Confounding by chance – reaction is unrelated to either the condition being treated or to the drug
therapy.
Contra-indications – a pre-existing condition in a patient that may be aggravated by certain
drugs, For example, paracetamol and liver conditions.
Consumer Error – Failure to understand instructions, failure to follow instructions, drug taken
by someone other than whom the drug was prescribed [569].
Covariability – I have not found a precise definition, but use it to mean something more general
than covariance. It is used in meteorology, for example [307, 444, 462, 516], or in [403] – page
76: “The one option is taking into account also temporal covariability, that means that the (much
larger) covariance matrix and mean vector would be computed taking into account relationships
between variables at different time points also. This way more information would be incorporated
in our estimation and therefore we could expect more accurate estimates. This is described in
[462].”
Critical [reaction] Terms – WHO-ART Critical Terms are defined as: “The word ‘critical’ is
taken to mean ‘relating to a crisis’ or ‘decisive’ or ‘crucial’. Thus the terms which are included
in the new Critical Term List do not necessarily refer to serious conditions in themselves, but are
terms which may be part of or lead to a serious syndrome.” [571, 572]
Drug – Implied, as it pertains to this study, in the definition of ADR.
Eicosanoids – are hormone like autacoids formed by body tissues during self-healing responses to
stimuli. [372]
Defective Product – Error in the manufacture of the drug. [569]
Event – An incident, occurrence, especially an occurrence of some importance. In the doctrine
of chances: any one of the possible (mutually exclusive) occurrences, one of which must happen
under stated conditions, and the relative probability of which may be calculated. The outcome,
issue, of a course of proceedings; that which results from the operation of a cause; a consequence.
[304]
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Frequent sets – sets of attributes, which may appear in many records.
Genotype – This is the “internally coded, inheritable information” carried by all living organisms.
This stored information is used as a ”blueprint” or set of instructions for building and maintaining
a living creature. These instructions are found within almost all cells (the “internal” part), they
are written in a coded language (the genetic code), they are copied at the time of cell division or
reproduction and are passed from one generation to the next (“inheritable”). These instructions
are intimately involved with all aspects of the life of a cell or an organism. They control every-
thing from the formation of protein macromolecules, to the regulation of metabolism and synthesis.
[http://www.brooklyn.cuny.edu/bc/ahp/BioInfo/GP/Definition.html]
in vitro – By derivation means “in glass”. In general, applied to biological processes when they are
experimentally made to occur in isolation from the whole organism (which usually means within
a glass vessel) [1].
Medication Error – Error in prescribing: calculating dosage, correct drug; dispensing: reading
handwriting, understanding verbal medication errors, proper medication [569].
Medical Error – Misdiagnosis, improper choice of treatment, failure to avoid drug interactions,
failure to detect that treatment is not working, failure to detect if the drug is causing further
injury, failure to avoid allergic reaction [569].
Mine Associate – A web-based data mining package for processing rules generated by the Apriori
algorithm. Originally called “Web Associate” in [247].
Nocebo phenomenon – The nocebo phenomenon or effect is when a patient takes a substance
that normally does not cause harm, but believes that they have experienced harmful effects.
Pharmacoepidemiology – The process of evaluating and improving the safety of marketed
medicines [539].
Pharmacovigilance – The science and activities relating to the detection, assessment, under-
standing and prevention of adverse effects or any other drug-related problems. [573]
Phenotype – This is the “outward, physical manifestation” of the organism. These are the phys-
ical parts, the sum of the atoms, molecules, macromolecules, cells, structures, metabolism, energy
utilization, tissues, organs, reflexes and behaviors; anything that is part of the observable structure,
function or behavior of a living organism. [http://www.brooklyn.cuny.edu/bc/ahp/BioInfo/GP/Definition.html]
Pierian – ‘of Pieria’, mountain in North Thessaly, sacred to the Muses, and pertaining to knowl-
edge or with poetry. [553]
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Placebo effect – A patient experiences a positive effect from a substance that normally produces
no such effect.
Poisson process – independent events occurring at a constant underlying rate.
Preferred terms – These are the principal terms used for describing drug adverse reactions. They
are the main terms used at the input side, but may also be used for output purposes. [572]
Prostaglandins – For example, thromboxane, leukotrienes , hydroperoxydes, epoxides, are molecules
of 20 Carbon atoms. They are carboxylic acids. [314]
Serious Reaction – A reaction which results in death, requires inpatient hospitalization or pro-
longation of existing hospitalization, results in persistent or significant disability or incapacity or
is life threatening [560].
SDR – signal of disproportional reporting [210].
Signal – Reported information on a possible causal relationship between an adverse event and
a drug, the relationship being unknown or incompletely documented previously. A signal is an
evaluated association, which is considered important to investigate further. A signal may refer to
new information on an already known association. Usually more than a single report is required to
generate a signal, depending upon the seriousness of the event and the quality of the information
[35, 119, 489]. A departure from independence model and hypothesis about possible drug-event
association that may warrant further investigation [205]. However, there is considerable semantic
ambiguity and imprecision about even basic terminology of what constitutes a signal [210].
Syndrome – a syndrome comprises several clinical abnormalities occurring simultaneously in an
individual patient.
System – ‘a collection of parts that work together to achieve some purpose’. A distinction can be
made between natural and human made systems. Some generalization can be made:
Â a system has a purpose and a function,
Â a system has a context or environment in which is has applicability,
Â a system has a boundary which marks the limits of its environment,
Â the removal of a single component of a system will cause the system to fail,
Â a system usually has inputs and outputs,
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Â complex systems usually consist of subsystems which in turn may have subsystems of their
own,
Â a component may belong to more than one system [47].
See Weber [551] for a rigorous formal treatment of the subject. It must be noted that no system
stands in isolation, since everything is connected to everything else [313].
Torsade de pointes: literally meaning twisting of points, is a distinctive form of polymorphic
ventricular tachycardia (VT) characterized by a gradual change in the amplitude and twisting of
the QRS complexes around the isoelectric line. Torsade de pointes (torsade) is associated with a
prolonged QT interval, which may be congenital or acquired. It usually terminates spontaneously
but frequently recurs and may degenerate into sustained VT and ventricular fibrillation. [103, 370]
Types of ADR:
Type A – Predictable events or reactions, pharmaceutical reactions or expected events or reactions.
They are common and are accounted for by a drug’s known pharmacological properties [260].
Type B – Unpredictable events or reactions: Also referred to as “idiosyncratic” or unexpected
events or reactions. These are considered the most serious and are potentially life threatening
[260]. This group includes hypersensitive reactions. A person may have a slight reaction the first
time they are in contact with the drug, but may react more severely with subsequent contact [377].
Type C – Dose related and time related. Uncommon and related to cumulative dose [121].
Type D – Delayed. Uncommon, usually dose related and usually becomes apparent some time after
the use of the drug [121].
Type E – Withdrawal – commonly occurs soon after the withdrawal of the drug [121].
Type F – Unexpected failure of therapy. Common, dose related and often caused by drug interac-
tions [121]. Subtypes of Type F:
1. ADRs of this type can be due to: shortened shelf life due to breach of storage conditions,
quality control problems in manufacture, and vaccine failures [121].
2. ADEs of this type can be due to: insufficient dose, incorrect diagnosis, inadvertent prescrip-
tion of the wrong medication, and non-compliance by consumer [121].
3. Drug interactions: can be caused by Drug-drug or drug-food interaction [260].
4. Pharmacokinetic: Pharmacokinetic variables determine the relationship between the dose of
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a drug administered and the concentration delivered to the site of action [342]. For example,
absorption, distribution, localization in tissues, biotransformation or excretion of drug [377].
5. Pharmacodynamic: Pharmacodynamic variables determine the relationship between the con-
centration of the drug at the site of action and the intensity of the effect produced [342].
An example is when two drugs are taken for hypertension, hypertension may be the reaction
[377].
Unexpected Reaction – An adverse reaction, the nature and severity of which is not consistent
with domestic labelling or market authorization, or expected from the characteristics of the drug
[560].
12.7 Glossary of Terms and Acronyms
ADE – adverse drug event
ADR – adverse drug reaction
ADRAC – Australian adverse drug reaction advisory committee
AED – anti-epileptic drug
AERS – adverse event reporting system – FDA
AI – Artificial Intelligence
ALL – acute lymphoblastic leukemia
Apoptosis – cell death.
ATC – anatomical-therapeutic-chemical classification of drugs
ATM – asynchronous transfer mode (in high speed data network)
BCPNN – Bayesian confidence propagation neural network
COSTART – Coding Symbols for a Thesaurus of Adverse Reaction Terminology
CTP – computational theory of perception
CYP450 – cytochrome P450
DDD – defined daily dose
DEC – drug-event combination [209]
DPR – direct probability redistribution [195]
DRUG INGREDIENT – a field in the ADRAC data for listing ingredients belonging to ADRAC
drug trade names
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DRUG TRADE NAME – a field in the ADRAC data for drug trade name
DTW – Dynamic Time Warping
EBS – empiric Baysean screening
Ergodic Theory – Ergodic theory can be described as the statistical and qualitative behavior of
measurable group and semigroup actions on measure spaces. The group is most
commonly N,R,R+, and Z. It had its origins in the work of Boltzmann in
statistical mechanics problems where time- and space-distribution averages
are equal. [559]
iid – independent and identically distributed – A sequence or other collection of random
variables is independent and identically distributed (i.i.d.) if each has the same
probability distribution as any of the others as any of the others and all
are mutually independent. From the point of view of the sample space X, this
means that n trials correspond on Xn to the n-fold product of the probability
measure for one trial [237].
FDA – Food and Drug Administration
GO – Gene Ontology
GPS – Gamma Poisson shrinker
HMM – Hidden Markov Model
ICD – International Classification of Diseases
ICD-CM – International Classification of Diseases with Clinical Modification
ICH – International Conference on Harmonization
IP – internet protocol
IR – information retrieval
IS – information system, or importance sampling
J-ART – Japanese Adverse Reaction Terminology
KAN – keyword association network
KDD – knowledge discovery in databases
k-NN – k nearest-neighbor
LC – liquid chromatography
LR – logistic regression
MeDRA – Medical Dictionary for Regulatory Activities
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MFS – Maximum frequent sets
MHRA – UK Medicines and Healthcare products Regulatory Agency
MIPS – Munich information center for protein sequences
MGPS – mulit-item gamma Poisson shrinker
NER – Named entity recognition
NLP – Natural language processing
NNRTI – non-nucleoside reverse transcriptase inhibitor
NSAID – non-steroidal anti-inflammatory drug
OR – odds ratio
PEM – prescription-event monitoring [334]
PI – protease inhibitor
PROFILE – probabiliy filtering [417]
PRR – probability filtering [417]
QCA – quasi-classification algorithm
RES – Reticuloendothelial system
ROR – Reporting Odds Ratio
RR – relative risk
SCFA – short-chain fatty acid
SCOP – structural classification of proteins
SCROL – Semantic Conflict Resolution Ontology
SLE – systemic lupus erythematosus – a rheumatological disease [308]
SNP – Single Nucleotide Polymorphism – SNPs are single base pair positions in genomic DNA
at which different sequence alternatives (alleles) exist in normal individuals in some
population(s), wherein the least frequent allele has an abundance of 1% or greater. [69]
SQL – Structured Query Language for relational databases
SOC – systems organ class classification of adverse drug reactions
somnolence – prolonged drowsiness or a condition resembling trance, which may
continue for a number of days; sleepiness [506]
SSRIs – selective serotonin reuptake inhibitors are a class of antidepressants. [561]
STATFILE – statistical filtering [34]
SVM – support vector machines
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Swiss-Prot – annotated protein sequence database
TC – text categorization
TGA – Therapeutic Goods Administration – Canberra
UDP – Uridine diphosphate – is a nucleotide. It is an ester of pyrophosphoric acid with the
nucleoside uridine. UDP consists of the pyrophosphate group, the pentose sugar ribose,
and the nucleobase uracil. http://en.wikipedia.org/wiki/Uridine diphosphate
UMC – Upsala Monitoring Center
WHO – World Health Organization
WHO-ART – World Health Organization Adverse Reaction Terminology [571, 572]
Appendix A
Literature Review Supplement
A.1 Ontology
A.1.1 International Conference on Formal Ontology in Information Sys-
tems (FOIS-2006)
Since ancient times, ontology, the analysis and categorisation of what exists, has been fundamental
to philosophical enquiry. But, until recently, ontology has been seen as an abstract, purely theoret-
ical discipline, far removed from the practical applications of science. However, with the increasing
use of sophisticated computerised information systems, solving problems of an ontological nature
is now key to the effective use of technologies supporting a wide range of human activities. The
ship of Theseus and the tail of Tibbles the cat are no longer merely amusing puzzles. We em-
ploy databases and software applications to deal with everything from ships and ship building to
anatomy and amputations. When we design a computer to take stock of a ship yard or check that
all goes well at the veterinary hospital, we need to ensure that our system operates in a consistent
and reliable way even when manipulating information that involves subtle issues of semantics and
identity. So, whereas ontologists may once have shied away from practical problems, now the
practicalities of achieving cohesion in an information-based society demand that attention must be
paid to ontology.
Researchers in such areas as artificial intelligence, formal and computational linguistics, biomed-
ical informatics, conceptual modeling, knowledge engineering and information retrieval have come
to realise that a solid foundation for their research calls for serious work in ontology, understood
as a general theory of the types of entities and relations that make up their respective domains of
inquiry. In all these areas, attention is now being focused on the content of information rather than
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on just the formats and languages used to represent information. The clearest example of this de-
velopment is provided by the many initiatives growing up around the project of the Semantic Web.
And, as the need for integrating research in these different fields arises, so does the realization that
strong principles for building well-founded ontologies might provide significant advantages over ad
hoc, case-based solutions. The tools of formal ontology address precisely these needs, but a real
effort is required in order to apply such philosophical tools to the domain of information systems.
Reciprocally, research in the information sciences raises specific ontological questions which call
for further philosophical investigations. [45]
A.2 Treatment of Chronic Inflammatory Disease
I will return to the, so called, Vioxx disaster alluded to in Section 0.2 as a case study of a specific
drug class and some of factors concerning its use, in order to illustrate the complexities confronting
pharmacovigilance and pharmacoepidemiology. Because signal detection methods support phar-
macoepidemiology, they must be able to be designed to incorporate as much relevant information
as possible. Our understanding is limited, but could be enhanced by better data linkage (sharing
of information via appropriate networks) [110, 340]. As mentioned at the beginning of this chapter,
the pharmaceutical industry is global, but the post-marketing systems are national [2], therefore
signalling methods need to have a global scope and I will illustrate some of the relevant information
should take into account through this case study.
As described by Mukherjee et al. [366] aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDS) have analgesic, anti-inflammatory, and anti-thrombotic properties but also have sig-
nificant gastric toxicity. The gastrointestinal toxicity appears to be due to the inhibition of the
enzyme cyclooxegenase 1 (COX-1). The identification of another enzyme COX-2 lead to the search
for a safer analgesic and anti-inflammatory drug via the inhibition of COX-2. This lead to the the
introduction of the COX-2 inhibitor class of drug in 1999 – represented by celocoxib and rofecoxib.
COX-1 predominates in the gastric mucosa and yields protective prostaglandins, whereas COX-
2 is induced in inflammation. Selective COX-2 inhibitors decrease vascular prostacyclin and may
affect the balance between pro-thrombotic and anti-thrombotic eicosanoids, which may lead to
cardiovascular thrombotic events. In view of these effects of COX-2 inhibitors, there had been
variously postulated, neutral, harmful, and beneficial cardiovascular effects resulting from these
changes. In a review of several studies conducted on the effects of rofecoxib, Weir et al. [554]
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concluded that the data were not consistent with increased cardiovascular risk from having taken
this drug.
VIGOR [60] was a study designed to rigorously assess the gastrointestinal safety of rofecoxib,
where supratherapeutic doses of this drug were compared to therapeutic doses of naproxen. The
conclusion drawn from this study was that rofecoxib was associated with significantly fewer upper
gastrointestinal events than naproxin. It was further suggested that naproxin could have a coranary
protective effect, but required further study. In view of the fact that this trial lacked a placebo
comparitor, another study assessed a large placebo-controlled database was undertaken [277]. In
this study the data were still not sufficient to ascertain the cardioprotective benefits of naproxin.
However, recent results suggest that long-term use of NSAIDs can increase the risk of myocardial
infarction in some individuals [430]. In the year 2002 evidence was published raising concern that
rofecoxib, especially in doses higher than 25 milligrams, may be associated with serious coronary
heart disease [229, 422]. In 2003 ADRAC advised on the risk of rofecoxib and celecoxib with regard
to cardiovascular and cerebrovascular disease, particularly cautioning not to exceed the maximum
approved dose of 25 milligrams of rofecoxib per day [25]. This illustrates the importance of including
dose information in signal methods.
Ju˝ni et al. [258] in late 2004 searched bibliographic databases and relevant files of the US FDA
and their analysis of these data led them to the conclusion that rofecoxib should have been with-
drawn several years earlier. They also caution that we can never be sure that we understand all
there is to know about biological mechanisms. They further recommend that drug licensing author-
ities should review their procedures, and identify and remove the obstacles to making continuously
updated summary information available to decision makers.
Despite these setbacks for COX inhibitors, there is still hope that a new generation of cyclooxy-
genase inhibitor may yet emerge and prove useful in the future treatment of chronic inflammatory
disease. Other COX-2 inhibitors that appear to have improved gastro-intestinal safety have been
reported. Martin et al. [337] studied meloxicam and reported a low incidence of gastro-intestinal
disturbance in an English cohort. Dallob et al. [98] found etoricoxib had similar gastro-intestinal
activity and no effect on platelet activity. Willoughby et al. [564] describe an inducible isoform
of the cyclooxygenase enzyme family, COX-3. It has been suggested that the inhibition of COX-3
could represent the primary central mechanism by which the COX inhibitors decrease pain and
possibly fever [80, 550].
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Another interesting facet of this story is that leptomycin B can affect the COX-2 gene expres-
sion, which could possibly be exploited in diseases where COX-2 plays a pathogenic role [249],
such as adenocarcinomas and other tumors [305]. Recently it was reported that COX-2 inhibitors
appear to have chemopreventative effects against breast cancer [196]. To further illustrate the com-
plex role of anti-inflammatory agents a recent review by Karin and Greten [262] link inflammation
to immunity and cancer. For tumor progression, the antitumorigenic effects of tumor-associated
macrophages are affected by the regulation of COX-2 enzyme gene expression. Because of these
new insights into the molecular link between inflammation and tumorogenesis, these authors rec-
ommend the development of novel strategies that target inflammation, for both cancer prevention
and therapy. Kucab et al. [281] provide evidence to suggest celecoxib analogues can disrupt Akt
signalling in primary breast cancer tumours, which may lead to further treatment options. Also the
evidence that at low doses of COX-2 inhibitors (see Section 2.3) may be beneficial to some patients
[340], shows why it is crucial to obtain as much information as possible in pharmacovigilance and
pharmacoepidemiology.
Paracetamol (acetaminophen) differs significantly from aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs), because it is only a weak anti-inflammatory agent and has a low
incidence of gastric side effects. There is little definitive proof that its analgesic and antipyretic
effects are dependent on COX1, COX2, or even COX3, which has been suggested [273]. There is
some evidence that the analgesic and antipyretic effects of paracetamol are mediated by molecular
targets distinct from COX recently suggested by Ho¨gasta¨tt, Zygmunt et al. [225]. Motivated by
the striking relationship between the structures of acetaminophen and the N-acyl phenolamine
(AM404), which is both a potent activator of the ion channel TRPV1 and has effects on cannabi-
noid CB1 receptors. Both TRPV1 and CB1 receptors are involved in pain and thermoregulatory
pathways. These findings show promise for targets for the development of new drugs for the
treatment of pain and inflammation.
It should be further noted that there is more evidence accumulating of the role genetics plays
in the type of ADR experienced by individuals. A study published by the American Gastroentero-
logical Association (AGA) journal, Gastroenterology, found a difference in how people responded
to popular painkillers and that up to 30 percent of this variability can be attributed to an individ-
ual’s genetic make-up. This variation can influence both how useful the drugs are in affording relief
from pain and inflammation, and the number and severity of the adverse effects. This evaluation
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is perhaps the most rigorous look at how people vary in their response to drugs and was designed
as part of a strategy to determine genetic and other markers that might help predict response and
safety of these drugs, including susceptibility to cardiovascular complications. The study looked
at people taking two COX-2 inhibitors, rofecoxib and celecoxib [13]. In a similar study, Ulrich
et al. [524] investigate NSAIDs’ potential for cancer prevention and find that genetic character-
istics might determine success. NSAIDs seem to work early in the cancer process across multiple
pathways, and do so with little evidence of carcinogenic activity: reducing inflammation, inducing
apoptosis (cell death) and decreasing proliferation. However, new strategies need to be tailored to
individual medical history and genetic make-up.
An important development in the quest for new anti-inflammatory drugs is described by Macil-
wain [315] from the study of tick salivary proteins. These proteins have evolved over millions of
years to evade detection by the host’s immune system. One of particular interest, dubbed rEV131,
binds to histamine, which is produced by the body in association with allergies and inflamma-
tion. As has been described in this section of my thesis, anti-inflammatory drugs tend to work by
blocking of one of at least four different histamine binding sites. rEV131’s behavior is much more
efficient because it inactivates histamine from binding to the receptors. rEV131 was shown to be
effective in the treatment of hay fever. Many other of the tick salivary proteins also hold promise
for new drug development.
There is a very recent report in the UK, all six drug trail volunteers who took an anti-
inflammatory drug, which manipulates the immune system, were hospitalized suffering multiple or-
gan failure. Two were in critical condition and the remainder were in a serious condition [192, 398].
The drug, an antibody called TGN1412, is being developed by German company TeGenero with
the aim of directing the immune system to fight cancer cells, or calm joints inflamed by rheumatoid
arthritis. The antibody binds to a receptor called CD28 on the surface of the immune system’s
infection fighting T cells. This trial has illustrated how incredibly potent some immune-altering
agents can be. Drugs like this might find a use in medicine, if researchers learn how to harness and
direct its power. CD28 is a pivotal molecule in the immune system, so the potential for off-target
effects is enormous. Normally, a T cell needs two incoming signals before it fires up: one from
the CD28 and a second from a separate T-cell receptor. This double signal is thought to act as a
safeguard to ensure that T cells react only to real threats such as toxins or invading pathogens.
The drug TGN1412 overrides this basic control mechanism. When it binds to the CD28 receptor,
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the T cell becomes active without the need to signal the second receptor. There are several possible
ways that the drug could have triggered multiple organ failure. It may have stimulated T cells
so much that they released an overwhelming flood of inflammatory molecules called cytokines.
Or perhaps wayward T cells launched an attack on the body’s own tissues, ignoring the safety
mechanisms that normally keep this in check. At least one similar drug has already shown side
effects in human trials. Skin rashes and gut reactions have been seen during tests of a drug called
anti-CTLA4 antibody. [398] This illustrates why limited knowledge is dangerous (see [411] – quote
at head of Chapter 1).
The major lesson from the COX2 difficulties is that a strategy is needed to detect not just
an increase in rare events but, more importantly, an increase in common events. Such a strategy
needs to avoid impeding drug development [110].
Appendix B
The ADRAC Database
B.1 ADRAC data fields
B.1.1 Information about patients
This group is represented by 5 fields of the 49:
i) PATIENT-DATE-OF-BIRTH.
ii) PATIENT-AGE-CODE (Adad) – has 255 different codes.
iii) PATIENT-HEIGHT – in centimeters.
iv) PATIENT-WEIGHT – in kilograms.
v) PATIENT-SEX – values ‘M’ or ‘F’.
The first field was not used by us because, at this stage of our analysis, we used field ii) as a
basis for age. In the case of Patient Age Code, there were 11819 missing values. The age codes
were converted in the following way to assist our analysis: ‘A1’ (adolescent) = 15, ‘A2’ (Twenties)
= 25, ‘A3’ (Thirties) = 35, ‘A4’ (Forties) = 45, ‘A5’ (Fifties) = 55, ‘A6’ (Sixties) = 65, ‘A7’
(Seventies) = 75, ‘A8’ (Eighties) = 85, ‘A9’ (Nineties) = 95, ‘AB’ (Baby) = 1, ‘AC’ (Child) = 5,
‘AD’ (Adult) = 20, ‘AE’ (Elderly Adult) = 70, xY = x, xM = 1 [where x represents a specific
number, e.g., 79 in this field, ‘Y’ represents the unit ‘year’, and ‘M’ represents the unit ‘month’].
This was done in order to represent the ADRAC codes in a consistent way with a numerical value.
In the case of the Patient Height field we considered that this was unlikely to be a useful feature
for our preliminary study. The Patient Weight field was utilized and when the value was missing,
we set the value to zero. The Patient Sex field was converted to a numeric value: if the value was
‘M’ it was assigned a value of 0, if it was ‘F’ a value of 1, and if it was missing a value of 2.
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B.1.2 Information about patient’s reactions
This group is represented by 4 fields of the 49:
Reaction terminology has been developed over more than 30 years by the WHO to serve as a
basis for rational coding of adverse reaction terms.
Because new drugs and new indications produce new terms to be incorporated, the structure of
the terminology is flexible enough to allow new developments to be incorporated whilst maintaining
the structure of the terminology and without losing previous relationships. The basic logic allowing
such flexibility is a hierarchical structure starting with body system/organ level, within which there
are grouping (general or high level) terms which are useful for the broadest view of drug problems.
Within these broad categories the specific, frequently used ‘preferred terms’ provide for precise
identification of drug problems. [572]
i) PREFERRED-TERM – Description of the adverse drug reaction taken from standard prede-
fined included or preferred terms. These are the principal terms used for describing drug adverse
reactions.
ii) INCLUDED-TERM – User defined reaction term taken from the included terms dictionary.
iii) SEVERITY-CODE (Adrsv) – is the severity rating of the adverse reaction, which takes the
values ‘1’ (1498 records), ‘2’ (5803 records), ‘3’ (729 records), ‘4’ (1169 records), missing (271,465
records).
iv) DURATION-CODE (Adrdu) – is the duration of the reported adverse drug reaction, which
consists of 203 different codes for duration, of which 1300 values were assigned and 270364 were
missing.
There were 1392 kinds of reaction recorded, but it should be noted that many patients are
recorded as having more than one reaction and up to a possible maximum of 10 reactions reported.
On the basis of Preferred Term, each patient averages 2.04 reactions out of a total of 280669
reactions for all patients. Of the above listed 4 fields just described, PREFERRED-TERM is
the term used by us to represent reactions. The INCLUDED-TERM was not used by us for this
investigation, because the preferred term is the one used by WHO and is a more reliable field to use
for queries to the database. The SEVERITY-CODE looked like an interesting feature to include
for our analysis, but, because of the large number of missing values, it was decided not to utilize
this field at this stage of our investigation, but it could be useful to combine with an ‘outcome’
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feature in future. Similarly, the DURATION-CODE looked a useful feature, but it also had too
many missing values for us to use it in a preliminary analysis of the data set, but it might be
combined with a dosage feature in future analyses. We want to include as many records as possible
so as not to loose information which could contribute to discovering interesting combinations of
reactions which can direct our focus in subsequent analyses.
B.1.3 Information about drug therapy
This group is represented by 16 fields of the 49:
i) DRUG-TRADE-NAME - takes 7416 values.
ii) REACTION-SUSPECT-CODE (Adrsp) - code determining the degree to which this drug
is suspected of causing the adverse reaction, taking values, ‘I’ – interaction, ‘O’ – other drug
suspected, ‘S’ – suspected.
iii) REASON-FOR-USE (Adicd) – an ICD code used to indicate the sickness for which the
drug was administered.
iv) DRUG-PREV-USED-INDIC – a Yes/No field to indicate whether this drug was previously
administered.
v) DRUG-WITHDRAWAL-CODE – takes 3 values: ‘1’ – suspected drug withdrawn, ‘2’ –
suspected drug continued at previous dose level, ‘3’ – suspected drug continued at reduced dose
level.
vi) DOSE-START-DATE
vii) DOSE-HALT-DATE
viii) DOSE-START-CODE – takes values ‘L TERM’(long term) and ‘S TERM’ (short term).
ix) DOSE-HALT-CODE – has 260 different codes for time intervals.
x) DOSE-ROUTE-CODE (Adrte) – the way the patient took / was given the drug which caused
the adverse reaction.
xi) DOSAGE-FREQUENCY-CODE (Addfy) – the frequency that the drug was taken for this
treatment. There are 23 codes for this field for frequency value.
xii) DOSAGE-AMOUNT – numeric values.
xiii) DOSAGE-UNIT-CODE (Adunt) – code to indicate the unit of measure for the drug dosage
(e.g., MG, GM).
xiv) DOSAGE-FORM-CODE (Addfm) – code to indicate the physical form of the drug (e.g.,
320
TAB, OIN, SOL, CAP).
xv) FIRST-SINGLE-DOSE-NDIC – Yes/blank indicator to identify whether the reaction oc-
curred after the first dose of the drug.
xvi) DOSE-STRENGTH - there are 919 codes for this field (e.g., STANDARD, REDUCING,
VARIABLE)
The Drug Trade Name has been used by us as a field to identify drugs. Reaction Suspect
Code has no missing values, which makes it a useful feature, but it was not used for this part of
the analysis because we want to see if our analysis agrees with this feature independently. The
Reason for use code had 1381 different codes for this field and 113572 missing values. This we
consider to be an important feature for subsequent analysis, but not for our preliminary general
analysis of all data. The Drug Previously used Indication field had 12003 ‘No’, 10200 ‘Yes’, and
274144 missing values. This field could be useful for later use, but its large proportion of missing
is a major limitation to its usefulness. The Drug Withdrawal Code field had values: ‘1’ 52672, ‘2’
1243, ‘3’ 2339, and missing 240093. This is another field that may prove useful when dose rates
are considered. The Dose Start Date and the Dose Halt Date fields could both prove important in
the future when we look at dosage and duration of treatment, however there are missing values for
these fields that will restrict these analyses: 112532 records for Start Date, and 181548 for Halt
Date. The Dose Start Code field contains 13707 - ‘L TERM’, 487 – ‘S TERM’, and 282153 missing
values and the Dose Halt Code field has 258408 missing values and 260 different codes making
these fields possibly of no use for our purposes since a more accurate value for duration of drug
administration can be calculated using the Dose Start Date and the Dose Halt Date, which also
have fewer missing values. The Dosage Route Code has 31 different codes and contains 114433
missing values. This is considered to be an important feature for a later stage of our analysis
when drugs themselves are focused on more specifically. The Dosage Frequency Code had 50026
missing values, but is an important field to use for determining dosage rates in our later analyses.
The Dose Strength field has 919 codes with 288308 missing values, but may be useful for dosage
information when dose is considered if it is combined with other dosage factors.
B.1.4 Outcome information and evaluation
This group is represented by 4 fields of the 49:
i) OUTCOME-DEATH – takes values: ‘0’ and ‘1’.
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ii) REPORT-DEATH – takes values: ‘0’, ‘1’, ‘2’, ‘3’, ‘4’.
iii) REACTION-OUTCOME (Adroc) – takes values: ‘A’ recovered without sequel, ‘B’ recovered
with sequelae, ‘C’ death maybe drug, ‘D’ death as a reaction, ‘E’ recovered without treatment, ‘F’
not yet recovered, ‘N’ unrelated death, ‘U’ unknown. [These were assigned the following numbers:
‘A’=1, ‘B’=2, ‘C’=3, ‘D’=4, ‘E’=5, ‘F’=6, ‘N’=7, ‘U’=8]
iv) CAUSALITY-CODE (Adcsy) – takes values: ‘01’– causality probable, ‘02’ – causality
certain, ‘03’ – causality possible, ‘04’ – causality unclear; based on the WHO Causality Assessment
of Suspected Adverse Reactions [573].
The Outcome Death field has values: ‘0’ – 51485, ‘1’ – 903, and missing – 84891, so because
of the large number of missing values, it was not included, but reserved as a feature to be utilized
in subsequent studies. The Report Death field has values: ‘0’ – 51485, ‘1’ – 856, ‘2’ – 40, ‘3’ –
5, ‘4’ – 2, and missing – 84891, similar comments apply to this field, as for Outcome Death field.
The Reaction Outcome field has values: ‘A’ – 84618, ‘B’ – 1095, ‘C’ – 1182, ‘D’ – 742, ‘E’ – 135,
‘F’ – 27123, ‘N’ – 417, ‘U’ – 21967, which we changed to numeric values for our analysis: ‘A’ =1,
‘B’= 2, . . . , ‘U’=8. The Causality Code field had values: ‘01’ – 37890, ‘02’ – 16627, ‘03’ – 88762.
Both of the latter two fields were considered of sufficient interest to be included in our preliminary
investigation.
B.1.5 Other fields
This group is represented by 20 fields of the 49:
i) RECORD-STATUS – which has no description and takes on values ‘A’ (136943 records) and
‘U’ (336 records) with no missing values.
ii) ADRAC-ID-NBR – ID number to identify Adverse Reaction Report.
iii) ADRAC-SEQ-NBR - a sequential number to identify the number of reports relating to a
particular patient.
iv) OTHER-FACTORS (Adofr) – takes values: ‘01’ – occupation, ‘02’ – industrial, ‘03’ –
household, ‘04’ – diet (non-therapeutic), ‘05’ – smoking, ‘06’ – climate, ‘07’ – positive family
history, ‘08’ – allergy history, ‘09’ – fair complexion, ‘14’ – alcohol, ‘24’ – malnutrition.
v) HOSPITALIZATION-CODE (Adhos) – take values: ‘1’ – hospitalization prolonged, ‘2’ –
admitted to hospital, ‘3’ – treated in outpatient department only.
vi) MEDICATION-INDIC – Yes/No field to indicate if medication was given to the patient to
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treat the adverse drug reaction.
vii) REPORT-DATE – date reported by reporter.
viii) ONSET-DATE – date of onset of first adverse reaction.
ix) ENTRY-DATE – date adverse drug reaction report is entered in the database.
x) ADR-REPORT-STATUS – indicator of the status of the processing of the adverse drug
reaction report.
xi) DRUG-STATUS – GM records the type of drug used in the ADRSADR advisory committee
member for the report.
xii) SECRETARIAT-COMMENT (Adset) – an indicator of status if any determined by an
ADR advisory committee member for the report.
xiii) INCLUDE-EXCLUDE-CODE (Adinx) - determine if report is included in WHO extract
tape. This takes values: ‘E’ report excluded from WHO, ‘G’ – general list report, ie C, ‘I’ –
included, ‘W’ – excluded from statistics.
xiv) POSSIBLE-INTERACTION (Adint) – takes values: ‘1’ - Drug – drug interaction, ‘2’ –
Drug – food interaction, ‘3’ – Drug – alcohol interaction.
xv) INVESTIGATION-CATEGORY (Adldi) – indicates the major medical category of a lab-
oratory test undertaken for the patient in relation to this ADR report.
xvi) INVESTIGATION-TYPE – indicates the particular type of laboratory test for a major
investigation category.
xvii) LAB-NORMAL-RANGE – an indication of testing standards of the particular laboratory
used in the test.
xviii) DATE-TESTED
xix) LAB-RESULT
xx) FILLER
These fields were not used in this study, however, the Other Factors field could be of interest
for the next stage, but it has 136210 missing values. The Hospitalization Code field could be used
or factored into a measure of a reaction severity feature in subsequent analysis. The Medication
Indication field could be a useful feature which could be combined with Reason For Use. The
Report Date and Onset Date fields could have some value to add to other features. The Entry
Date field is an important feature which must be considered in subsequent analyses. The Possible
Interactions field could be an important feature, in its own right, but it has values: ‘1’ – 853,
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‘2’ – 42, ‘3’ – 8, and missing – 136376, which is too many missing. The Investigation Category,
Investigation Type, Lab Normal Range, and Lab Result fields could provide important features
for our later investigation.
B.2 Types of Reaction in each of the Four Classes of Car-
diovascular Reaction in
Chapter 4
B.2.1 Class 1
Hypotension, Bradycardia, Hypertension, Palpitation, Tachycardia, Hypotension Postural, Car-
diac arrest, Cardiac failure, Arrythmia, Tachycardia ventricular, Tachycardia supraventricular,
Aggravated Hypertension , Arrythmia ventricular, Blood pressure fluctuation, T Wave inversion,
Cardiac tamponade, SGOT increased, Arrythmia nodal, Arrythmia atrial.
B.2.2 Class 2
Myocardial infarction, Fibrillation atrial, Extrasystoles, Heart block, Embolism pulmonary, Car-
diomyopathy, Angina pectoris, ECG abnormal, Angina pectoris aggravated, Cardiac failure left,
Fibrillation ventricular, QT prolonged, Digitalis toxicity, Heart disorder, Myocarditis, Pericarditis,
AV block, ECG abnormal specific, Pericardial effusion, Bundle branch block, Myocardial ischaemia,
Cardiomegaly, Claudication intermittent, Mitral insufficiency, Thrombosis coronary, Haemorrhage
ant chamber eye, Hypertension pulmonary, Fibrillation cardiac, Pulmonary infarction, Adams
Stokes Syndrome, Aortic incompetence, Aortic valve incompetence, Cardiac failure right, Coro-
nary artery disorder, Heart valve disorders, Left ventricular failure, Spider naevi.
B.2.3 Class 3
Purpura, Syncope, Flushing, Oedema, Oedema Peripheral, Oedema Periorbital, Oedema gener-
alized, Cyanosis, Pallor, Gingival bleeding, Skin cold clammy, Telanggiectasis, Vasculitis aller-
gic, Melanoma malignant, Rash purpuric, Purpura allergic, Purpura thrombopecnic thrombotic,
Phlebitis superficial, Oedema vulval, Thrombophlebitis leg superficial, Capillary fragility increased,
Thrombophlebitis arm superficial, Thrombophlebitis multiple superficial, Cyanosis neonatal, Non-
thrombocytic Purpura, Non-thrombocytopecnic Purpura.
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B.2.4 Class 4
Hyperaemia, Oedema dependent, Vasculitis, Peripheral Ischaemia, Thrombophlebitis deep, Cere-
brovascular disorder, Haemorrhage NOS, Thrombophlebitis, Cerebral Haemorrhage, Circulatory
failure, Phlebitis, Thrombophlebitis superficial, Haemorrhage intracranial, Torsade de Pointes,
Thrombosis, Gangrene, Vasodilation, Thrombophlebitis leg deep, Thrombophlebitis retinal vein,
Subarachnoid Haemorrhage, Thromboembolism, Vascular disorder, Vein pain, Thrombophlebitis
arm, Vasospasm, Aneurism, Embolism Arterial, Ocular Haemorrhage, Thrombosis Arterial, Throm-
bosis cerebral, Thrombosis mesenteric vessel, Vein distended, Peripheral Gangrene, Thrombophlebitis-
leg, Arteritis, Embolism limb, Encephalopathy hypertensive, Thrombosis Arterial arm, Thrombosis
Arterial leg, Thrombosis cerebral Arterial, Thrombosis retinal artery, Atherosclerosis, Embolism
- blood clot, Haemorrhage ante-partum, Thrombophlebitis arm deep, Thrombophlebitis multiple,
Thrombosis hepatic vein, Vein disorder, Vein Varicose.
Appendix C
Algorithms
C.1 Chapter 4
C.1.1 Fuzzy classification algorithm (QCA)
Consider a training set A, which consists of m classes Ai. Let N i be the number of observations in
the class Ai, i = 1, 2, ...,m. Every observation aik ∈ Ai (k = 1, 2, ..., N i) is a set (combination) of
drugs that were taken by a patient. Denote by K(aik) the number of drugs used by the observation
aik :
aik = (a
i
k,j), j = 1, 2, ...,K(a
i
k).
Note that the numberK(aik) is restricted to 10 in the ADRAC data. Therefore every observation
in the training set A is some combination of drugs. Let the set of all drugs used in the training set
A be denoted by D. So aik ∈ D.
The purpose of the present algorithm QCA is to define a degree – a measure of association with
the class (reaction) for each drug.
Let d ∈ D be a drug. n(d) is denoted by the number of occurrences of the drug d in the set A.
Note that some observation can have just one drug used, that is, it can be K(aik) = 1 for some
observation aik.
nai (d) is denoted by the number of occurrences of the drug d in the class A
i, where this drug was
taken alone, and by nci (d) denotes the number of occurrences of the drug if it is used in combination
with some other drug(s). Set
na(d) =
m∑
i=1
nai (d), n
c(d) =
m∑
i=1
nci (d), n(d) = n
a(d) + nc(d), p(d) = 100.
na(d)
n(d)
.
325
326
The degrees as a prediction of the classes Ai (or association with Ai) will be denoted by ∂i(d),
(i = 1, 2, ...,m) and let ∂(d) = (∂1(d), ∂2(d), ...∂m(d)).
This vector has the following meaning. Assume that every drug can be the cause of some
reactions to different degrees. The number ∂i(d) indicates the degree of the occurrence of the
reaction i (or association with reaction i, in this case, class Ai , which can be a combination
of some reactions). The main problem is to define a vector degree for each drug. Here different
approaches can be used. In particular, degrees of association can be defined as a solution of a global
optimization or linear programming problems. In this study, the following method of calculation
is used.
Using the notation δ(a, d) for a chosen observation a and drug d. If the drug d was taken by
this observation, then set δ(a, d) = 1, if not set δ(a, d) = 0.
The number ∂i(d) is defined by the formula:
∂i(d) =

nai (d)
n(d) if p(d) ≥ p∗;∑Ni
k=1
δ(aik,d)
n(d)K(aik)
if p(d) < p∗
(C.1.1)
The number p∗ is the percentage of use of the drug alone. Regarding the formula (C.1.1), if
this percentage is greater than p∗, then the degrees for this drug are defined using cases where the
drug was used alone. This is a case when a particular reaction and a particular drug are observed
in a pure relationship. If p(d) < p∗, it means that the cases where a single drug was used (for the
drug d) few that it is not informative for the definition of degrees, in which case, cases where the
drug was also used in combination with other drugs were used . So the number p∗ is a boundary
point, regarding maximal information about this drug. To achieve this aim, other approaches could
be used. For example, instead of percentage, the number of cases in which a drug was used alone
could be used.
By the definition of degrees of association ∂i(d) it is clear that
0 ≤ ∂i(d) ≤ 1 and
m∑
i=1
∂i(d) ≤ 1.
Therefore for each drug d the vector ∂(d) can be considered as a fuzzy set defined on the set
{1, 2, ...,m}.
Remark C.1.1. Note that the degree ∂i(d) is not a probability of the occurrence of the reaction i;
that is, the sum
∑m
i=1 ∂i(d) does not need to be equal 1 (see Example 4.6.1 Section 4.6.1).
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C.1.2 Fuzzy derivative
Consider n objects and assume that the states of these objects can be described by scalar variables
xi, i = 1, ..., n The increase and decrease of these variables indicates changes in the objects.
Let x0i be the initial states of the objects.
The events xi increases and decreases will be denoted by xi ↑ and xi ↓, respectively.
Consider an event E related to the parameters x1, ..., xi. For example, this event can be E =
(x1 ↑, x2 ↑, ..., xi ↑), which means that all parameters are increasing. A study the influence of this
event on another parameter xj will be made.
As a result of the event E the parameter xj may either increase or decrease. To determine the
influence the degree of these events must be defined; that is both
1) the degree of the increase of xj , and
2) the degree of the decrease of xj need to be defined.
Of course the degree of these events depends on the initial state (x01, ..., x
0
i , x
0
j ). The degree is
defined as a number in the interval [0,1]. This number will be considered as a value of a membership
function. Taking different initial points fuzzy sets on the (i+1) dimensional space can be defined.
Therefore, the degree of the increase of xj and the degree of the decrease of xj can be defined
as fuzzy sets, which are denoted by d(E, xj ↑) and d(E, xj ↓), respectively.
Assume that if, for example, d(E, x ↑) = 1 then the influence is highest and if d(E, x ↑) = 0
then the influence is lowest.
Clearly at every initial point (x1, ..., xi, xj) we have
0 ≤ d(E, xj ↑) + d(E, xj ↓) ≤ 2.
If d(E, xj ↑) + d(E, xj ↓) = 1, this is a case of probability. But in applications below it can be
seen that as a rule the sum of d(E, xj ↑) + d(E, xj ↓) does not equal 1 and this is the main factor
which creates the “forces” acting on changes in the system (see Proposition 3 [319]).
Therefore the fuzzy sets d(E, xj ↑) and d(E, xj ↓) completely describe the influence of the
event E on xj . Since this influence characterizes the changes of the parameter xj was called a
fuzzy derivative and denote it by ∂xj/∂E;
∂xj/∂E = (d(E, xj ↑), d(E, xj ↓)).
Now consider a data set A = {(an) = (an1 , an2 , ..., anF ), n = 1, ..., N}, where N is the number of all
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observations and F is the number of features (attributes). Assume that the data set A consists of
m classes: Ai = {(ai,n) = (ai,n1 , ai,n2 , ..., ai,nF ), n = 1, ..., N i},
∑
i=1,mN
i = N.
A method for calculating the fuzzy derivatives at a certain point (the centroid) is as follows.
The fuzzy derivatives in these applications describe the influence of a some combination of features
on a chosen single feature.
First calculate the centroid (xj), j = 1, ..., F of the set A. Take any combination of features,
say (j1, j2, ..., jl), and a feature j ∈ {1, 2, ...,K}. Let E be a given event related to the chosen
combination of features.
For each class Ai calculate the influence of the event E on j as the values of fuzzy derivatives
(∂j/∂E)i = (di(E, j ↑), di(E, j ↓)), i = 1, ...,m,
computed at the centroid (xj1 , xj2 , ..., xjl , xj), that is taken as an initial point. In this work the
following formula was used (see [327]):
di(E, j ↑) = Ki,1
K + 1
, di(E, j ↓) = Ki,2
K + 1
, i = 1, ...,m.
Here K =
∑
i=1,nKi and Ki is the number of observations a ∈ Ai satisfying E; Ki,1 is the number
of observations a ∈ Ai satisfying E and an inequality aj ≥ xj ; Ki,2 is the number of observations
a ∈ Ai satisfying E and an inequality aj ≤ xj .
C.1.3 The FDM classification algorithm.
Consider a data (training) set A which consists of 2 classes Ai (i = 1, 2). Let J = {1, 2, ..., F} be
a set of features. N itr is the number of observations in class i.
The algorithm requires two parameters. The number α > 0 is used for the minimal accuracy in
the training phase. The number β is used in the definition of the dominant class. The algorithm
generates sets of classification rules taking different numbers α and β. The FDM algorithm for the
chosen numbers α and β. will be described.
Step 1. Let k = 1 and Aik = A
i, i = 1, 2.
Step 2. If k = 1 for every fixed feature j ∈ J calculate the centroid x′j of the set A1k ∪ A2k (see
Note 2). If k > 1 for every j ∈ J take x′j = xk−1j .
Then for every feature j consider two intervals J1(j) = (−∞, x′j ] and J2(j) = [x′j ,+∞).
329
Take a couple of features (j1, j2) and denote by N(Jp(j1, j2), Aik) the number of all observations
of the set Aik that j
q−the coordinate belongs to the interval Jp(jq), q = 1, 2, p = 1, 2. Let
N0p = N
2
tr ·N(Jp(j1, j2), A1k) +N1tr ·N(Jp(j1, j2), A2k)
and
Np(j1, j2, 1) =
100 ·N2tr ·N(Jp(j1, j2), A1k)
N0p
,
Np(j1, j2, 2) =
100 ·N1tr ·N(Jp(j1, j2), A2k)
N0p
.
Calculate
N∗ = max
(j1,j2)
max
p=1,2
max
i=1,2
N(Jp(j1, j2), Aik)/N
0
p .
Choose features (j1, j2), intervals J1k , J
2
k and class ik, such that the number N
0
p is maximal and
Np(j1, j2, i) ≥ N∗ − β.
Therefore the class ik is the dominant class at this stage. Define the event E(j1k, j
2
k) related
to the intervals J1k , J
2
k .
Step 3. Set s = 3. Denote by Aik(s − 2) the set of all observations in the class Aik for which
E(j1k, ..., j
s−2
k ) is satisfied.
Step 4. For every feature j ∈ J calculate a centroid - xkj of the set A1k(s − 2) ∪ A2k(s − 2).
Denote E = E(j1k, ..., j
s−2
k ).
Take a pair of features j1, j2 and study the influence of j1 on j2 over the classes. First define
the events E+ = E ∩ {j1 ↑} and E− = E ∩ {j1 ↓}.
Then calculate the values of the fuzzy derivatives (∂j2/∂E+)i and (∂j2/∂E−)i at the point
(xj1 , xj2).
Let
(∂j2/∂E+)i = (di1(j
1, j2), di2(j
1, j2)) and (∂j2/∂E−)i = (di3(j
1, j2), di4(j
1, j2)),
i = 1, ...,m. The maximal discrimination of the class ik from another class are being sought. Choose
a pair of features (js−1k , j
s
k) and a number l
s
k ∈ {1, 2, 3, 4} solving the following problem
max
j1,j2∈J
max
l=1,2,3,4
f(ik| d1l (j1, j2), d2l (j1, j2))→ max
(see Note 1). Define E(j1k, ..., j
s
k) corresponding to the solution obtained (j
s−1
k , j
s
k) and l
s
k. Denote
by Aik(s) a set of all observations in the class A
i
k(s − 2) for which E(j1k, ..., jsk) is satisfied. Let
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N i(s) be a number of observations in Aik(s) and
N(s) = 1 +
∑
i=1,m
N i(s), N−(s) = 1 +
∑
i=1,m;i6=ik
N i(s).
Let αs = 100N ik(s)/N(s). If s ≥ F or αs ≥ α or αs ≤ αs−2 then go to Step 5. Otherwise set
s = s+ 2 and go to Step 4.
Step 5. In this step the following classification rule applies: a new example a, for which
E(j1k, ..., j
s
k) is satisfied, belongs to the class ik. The degree of membership in this class is defined
as
Dk =
N i(s)
N−(s)
.
Denote by Aik− all observations in the class A
i
k satisfying this classification rule. Set A
i
k+1 =
Aik \Aik−. The algorithm terminates if Aik = ∅ for some i = 1, 2. Otherwise set k = k + 1 and go
to Step 2.
Note 1. Consider here two classes and, therefore, the function f(ik| c1, c2) in this application
is defined as follows:
f(ik| c1, c2) = cik − ci, i 6= ik.
Note 2. For every feature j ∈ J a centroid xj of the set A1 ∪ A2 is calculated as follows.
For every class i ∈ {1, 2} calculate the maximal and minimal numbers
jimin = min{aj : a ∈ Ai}, jimax = max{aj : a ∈ Ai}.
Let
jmin = max{j1min, j2min} and jmax = min{j1max, j2max}.
If jmin < jmax then the number xj is defined as a midpoint of all points of the set A1∪A2,
which belongs to the interval [jmin, jmax]. If jmin ≥ jmax then set xj = (jmin + jmax)/2.
Appendix D
Supplementary Information on
MGPS
D.1 Mulit-item Gamma Poisson Shrinker (MGPS) Files
D.1.1 Input Files
To Bill DuMouchel:
“I have prepared the files according to your requirements. I hope they work OK. The files have
a .csv extension, but are tab delimited. The covariates.csv has the fields: RecordID, Year – binned
into 10 groups, age – binned into 6 groups, and gender – male, female, unknown. The items.csv
had RecodID and Item – E prefixing event codes and D the drug (trade name) codes. I have two
Itemtype files, one for events and one for drugs. The event itemtype file classifies the events to the
system organ class (SOC) and the drug Itemtype file classifies the trade name codes to my ATC
classification.
File: covariates.csv – 137280 rows
File: items.csv – 9891 rows
File: ItemTypeDrug.csv – 5057 rows
File: ItemTypeEvent.csv – 1411 rows”
D.1.2 Result Files
The files whose names begin with “adrac-mgps” are reduced versions (subsets of rows and columns)
of output files from MGPS. Each row of each file corresponds to a pair or triple of items. For
example, the “-DE.txt” file has one row for each Drug-Event pair, while the “-DDE.txt” file has one
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row for each Drug1-Drug2-Event triple. Pairs or Triples that have fewer than 2 occurrences in the
data are omitted. The files with names that begin with “item-counts” and ”strata-counts” provide
summary counts for each item and each stratum for the D-E analysis and the C-S analysis. A
file named “Hyperparameters.txt” provides the estimates of the gamma mixture prior distribution
parameters that were used in the Bayesian estimation.
File: adrac-mgps-CCS.txt – 70122 rows
File: adrac-mgps-CS.txt – 9891 rows
File: adrac-mgps-CSS.txt – 18627 rows
File: adrac-mgps-DDE.txt – 52397 rows
File: adrac-mgps-DE.txt – 58052 rows
File: adrac-mgps-DEE.txt – 50104 rows
File: Hyperparameters.txt – 12 rows
File: item-counts-CS.txt – 1827 rows
File: item-counts-DE.txt – 6281 rows
File: strata-counts-CS.txt – 179 rows
File: strata-counts-DE.txt – 179 rows
D.1.3 Result file field definitions
The following come from the file “Results Table mgps.doc”:
ID – For an MGPS run, identifies the unique row number assigned as Oracle loads data from the
run’s output files.
N – Observed number of cases with the combination of items.To drill down to a list of the cases
with the combination, click the N (observed count) value. (Drilldown is not available for the results
of simulation runs.)
E – The expected number of cases with the combination. For a 2-dimensional (2D) run, calculated
as:
Observed number cases with ITEM1
Total number cases × Observed number cases with ITEM2Total number cases
× Total number cases
With stratification, calculated as total of expected values for all the strata, where the expected
number of cases for each stratum is calculated as:
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Observed number cases with ITEM1 for stratum
Total number cases for stratum × Observed number cases with ITEM2 for stratumTotal number cases for stratum
× Total number cases for stratum
Overall Expected = Total of Expected values for all strata
When E <.001, displays in scientific notation. For a 3-dimensional (3D) run, the calculations
include ITEM3 as well; for a 4D run, they include ITEM4; and for a 5D run they include ITEM5.
For 3D and higher dimensional runs, the calculation of E depends on the mix of item types in the
set of items. If all items are of the same type (for example, all drugs or all events) then E = E IND.
This is also true if all items in the set are of different type. However, if the set of items includes
at least two different types and also includes at least two items of the same type, then E is the
result of MGPS Interaction Calculations. In this model, E incorporates observed within-item-type
associations, and only the assumption of cross-item-type independence is used in the computation
of E.
E IND – The expected number of cases with the combination, as calculated by the MGPS Inde-
pendence Model. Calculated as:
Observed number cases with ITEM1 for stratum
Total number cases for stratum × Observed number cases with ITEM2 for stratumTotal number cases for stratum
× Total number cases for stratum
With stratification, calculated as total of expected values for all the strata, where the expected
number of cases for each stratum is calculated as:
Observed number cases with ITEM1 for stratum
Total number cases for stratum × Observed number cases with ITEM2 for stratumTotal number cases for stratum
× Total number cases for stratum
Overall Expected = Total of Expected values for all strata
When E IND <.001, displays in scientific notation.For a 3D run, the calculations include ITEM3
as well; for a 4D run, they include ITEM4; and for a 5D run they include ITEM5.
RR – Relative Ratio. (The same as N/E.) Observed number of cases with the combination divided
by the expected number of cases with the combination. This may be viewed as a sampling estimate
of the true Relative Ratio (that would be observed if the database were much larger, but drawn
from the same conceptual population of reports) for the particular combination of drug and event.
RR is calculated as:
Observed number cases with ITEM1−ITEM2 pair
Expected number cases with ITEM1−ITEM2 pair
With stratification, calculated as:
Observed number cases with ITEM1−ITEM2 pair for all strata
Final Expected number cases with ITEM1−ITEM2 pair
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For a 3D run, the calculations include ITEM3; for a 4D run, they include ITEM4; and for a 5D
run they include ITEM5.
EBGM – Empirical Bayesian Geometric Mean. A more stable estimate than RR; the so-called
shrinkage estimate, computed as the geometric mean of the posterior distribution of the true
Relative Ratio.
EB05 – A value such that there is approximately a 5% probability that the true Relative Ratio
lies below it.
EB95 – A value such that there is approximately a 5% probability that the true Relative Ratio
lies above it.The interval from EB05 to EB95 may be considered to be the 90% confidence interval.
EXCESS – A conservative estimate of how many extra cases were observed above what was
expected. Calculated as: (EB05 - 1) * E
EBMAX – Applies to runs with more than 2 dimensions. For each 3D or higher itemset, EBMAX
is the largest 2D EBGM among all included cross-item-type 2D combinations. If the itemset is
homogeneous, so that there are no included cross-item-type combinations, EBMAX is the largest
EBGM among all the included 2D combinations. The 2D combination for which EBGM = EBMAX
is specified by the columns MAXITEM1 and MAXITEM2.
MAXITEM1 – First item determining the 2D combination for which EBGM = EBMAX.
MAXITEM2 – Second item determining the 2D combination for which EBGM = EBMAX.
INTSS – Interaction Signal Score. Applies to runs with more than 2 dimensions. Essentially,
this is a way of measuring of the strength of a higher-order association above and beyond what
would be expected from the largest of the previously-computed component two-factor associations.
Calculated as:EB05 / EB95MAXwhere EB95MAX is the largest 2D EB95 among all included cross-
item-type combinations. For more information, see MGPS Interaction Calculations below D.1.4.
D.1.4 Files for further descriptions
MGPS Interaction Calculations
Contained in file “MGPS interactions calculations.doc”.
For MGPS data mining runs with three or more dimensions, MGPS calculates an interaction
signal score, INTSS, in addition to scores for EBGM, EB05, EB95, et cetera.
Tip: WebVDME also calculates scores using the MGPS independence model. Scores calculated
in this way are labelled with the suffix “ IND” such as EBGM IND, EB05 IND, EB95 IND, et
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cetera.
Interaction Calculations
When you create an MGPS data mining run, you select item variables. Typically, the item
variables represent drugs and events, but in general there can be one or more item types for any
given data mining run. The counting and estimation that the MGPS calculation performs divides
the combinations of the selected item types into separate itemsets, based on the combinations
possible for the number of dimensions in the run. That is, for the two items D and E, in a three
dimensional run MGPS performs calculations on the itemsets DD, DDD, DE, DDE, DEE, EE, and
EEE.
MGPS 3D and higher dimensional calculations focus on measuring and scoring cross-item type
associations, but allow any observed dependence within item types to be fit completely without
generating a score. The only exception to this is during the analysis of a homogeneous itemset,
such as three events (E1,E2,E3) where all items are of the same type and in which case high EBGM
scores do alert reviewers to a potential within-item type association. Thus, for a mixed-type triple
like (D1,D2,E1) the values of EBGM, EB05 and so forth measure how many times more frequently
the pair (D1,D2) occurs with E1 than would be expected if the pair (D1,D2) were independent
of E1, without making any statement about whether the drugs D1 and D2 appear in the same
reports more frequently than independence would predict.
Tip: In other contexts, the term “interaction” applies to DDE itemsets only. However, We-
bVDME does calculate interaction scores for all multiple-item associations, including syndrome
(DEE) and homogeneous (DDD or EEE) itemsets.
Interaction Signal Score (INTSS)
For a 3D run, the computation explicitly takes combinations into account:
Drug A and Event E (DE)
Drug B and Event E (DE) (Drug A + Drug B) and Event E (DDE)
INTSS = EB05 / EB95MAX
Where:
EB05 is the conservative estimate score for (Drug A + Drug B) and Event E (the 3D
combination of DDE)
EB95MAX is the highest EB95 score found for the individual Drugs A and B and the
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Event E (the 2D combinations of DE)
If INTSS >1, the combination of the two drugs with the event (DDE) indicates a stronger asso-
ciation with the event than is found for either of the two individual drugs (DE). Note: Usually,
we would not conclude that the potential interaction is interesting unless the EB05 score for that
DDE combination is large (for example, over 1.5 or 2.0).
Technical Summary of MGPS
For a Technical Summary of MGPS see file “tech summ mgps.pdf”.1
For an arbitrary itemset, it is desired to estimate the expectation λ = E[N/E], where N is the
observed frequency of the itemset, and E is a baseline (null hypothesis) count; for example, a count
predicted from the assumption that items are independent. An itemset is defined by its members
i, j, k, . . . , which occur as subscripts to N, E, and other variables, so that, for example, Nij is the
number of reports involving both items i and j, Eijk is the baseline prediction for the number of
reports including the itemset triple ( i, j, k ), et cetera.
A common model for computing baseline counts is the assumption of within-stratum independence;
when E is computed under this assumption we shall often denote it by E0. Assume that all reports
are assigned to strata denoted by s = 1, 2, ..., S. Let:
P si = proportion of reports in stratum s that contain item i
ns = total number of reports in stratum s
Baseline frequencies for pairs and triples are defined under independence as:
E0ij =
∑
s ns Pi
sPjs E0ijk =
∑
s ns P
s
i P
s
j P
s
k
For itemsets of size 3 or more, an “all-2-factor” loglinear model can be defined as the frequencies
E2 for the itemsets that match all the estimated pairwise two-way marginal frequencies but contain
no higher-order dependencies. For triples, E2ijk agree with the estimates for the three pairs:
λijE0ij λik E0ikλjkE0jk
For “four-tuples,” E2ijkl agrees with 6 such pairs, et cetera. WebVDME version 4 and earlier
analyzed associations among itemsets of size 3 or more by comparing the estimated frequency to
the all-2-factor prediction by simple subtraction. For example, in case of triples:
Excess02ijk = λijk E0ijk − E2ijk
1CONFIDENTIAL Copyright c© 2005 by Lincoln Technologies, Inc. All rights reserved.
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The parameters λ above are estimated by their geometric means, denoted EBGM, of their empirical
Bayes posterior distributions, using E = E0 in the formulas below. See the next section for a
description of how WebVDME version 5 analyzes higher-dimensional associations.
For simplicity, the formulas below use just two subscripts, for itemsets of size 2, such as the
occurrence of drug i and symptom j in a medical report. Estimates for other itemset sizes are
computed analogously. Let:
Nij = the observed counts
Eij = the expected (baseline) counts
RRij = Nij/Eij = ratio of observed to baseline
We wish to estimate λij = µij/Eij , where Nij ∼ Poisson(µij). Assume a superpopulation model for
µij (prior distribution) based on a mixture of two gamma distributions (a convenient 5-parameter
family of distributions that can fit almost any empirical distribution):
pi(λ;α1, β1, α2, β2, P ) = P g(λ;α1, β1) + (1− P ) g(λ;α2, β2)
g(λ;α, β) = βαλα−1e−βλ/Γ(α)
Estimate the prior distribution from all the (Nij , Eij) pairs. Estimate the 5 hyperparameters:
θ = (α1, β1, α2, β2, P )
by maximizing the likelihood function L(θ) in 5 dimensions:
L(θ) = Πij{Pf(Nij ;α1, β1, Eij) + (1P )f(Nij ;α2, β2, Eij)}
f(n;α, β, E) = (1 + β/E)−n (1 + E/β)−α Γ(α+ n)/Γ(α)n!
In WebVDME, MGPS requires the specification of a threshold (n∗ = minimum count > 1) for
the observed counts of all combinations that are analyzed. In accord with this specification, the
formula for f(n;α, β, E) is modified to incorporate the condition Nij ≥ n∗ :
If n∗ = 1, f(n;α, β,E, n∗ = 1) = f(n;α, β,E)/[1(1 + E/β).α]
For other n∗, the denominator above is [1
∑
f(n′;α, β,E)], where the sum extends over n′ =
0, 1, , n∗ − 1. For simplicity, the formulas below omit the reference to n∗.
Given θ , the posterior distributions of each λij are also a mixture of gamma distributions used to
create “shrinkage” estimates. Assuming that θ and E are known, then the distribution of N is:
Prob(N = n) = Pf(n;α1, β1, E) + (1− P ) f(n;α2, β2, E)
Let Qn be the posterior probability that λ came from the first component of the mixture, given N
= n. From Bayes rule, the formula for Qn is:
Qn = Pf(n;α1, β1, E)/[P f(n;α1.β1, E) + (1− P ) f(n;α2, β2, E)]
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Then, the posterior distribution of λ
¨
after observing N = n can be represented as:
λ|N = n ∼ pi(λ;α1 + n, α1 + E, α2 + n, β2 + E, Qn)
where (as above):
pi(λ;α1, β1, α2, β2, P ) = P g(λ;α1, β1) + (1− P ) g(λ;α2, β2)
Because the posterior distribution of λ is often very skewed, we focus on the logarithmic expected
value,
E[log(λij)|Nij , θ]
while defining our preferred point estimate of λij .
To obtain a quantity on the same scale as RR, we define the Empirical Bayes Geometric Mean
(EBGM):
EBGMij = eE[log(λij)|Nij ,θ], where:
E[λ|N = n, θ] = Qn(α1 + n)/(β1 + E) + (1−Qn)(α2 + n)/(β2 + E)
E[log(λ)|N = n, α] = Qn [ψ(α1 + n)log(β1 + E)] + (1−Qn) [ψ(α2 + n)log(β2 + E)]
where ψ(x) = d(log Γ(x))/dx. In the same way, the cumulative gamma distribution function can
be used to obtain percentiles of the posterior distribution of λ. The 5th percentile of λ is denoted:
EB05ij = Solution to : Prob(λ < EB05|Nij , θ) = 0.05
and is interpreted as a lower 1-sided 95% confidence limit. The upper limit EB95ij is defined
analogously.
Analysis of higher-dimensional associations in WebVDME version 5
Introduction
WebVDME version 5 uses new definitions of baseline frequencies for more than two dimensions, and
new definitions of some other output columns. The purpose of this change is to allow the analysis to
focus more naturally on combinations in which, for example, there is a strong association between
the occurrence of a pair of drugs in a report and some event, irrespective of whether the two drugs
are taken together more frequently than chance or not. The change is also intended to simplify
the analysis and, in particular, not require the use of the all-two-factor log-linear model, which did
not seem to contribute much, if at all, to substantive understanding in analyses of spontaneous
adverse event databases.
WebVDME allows all items to be partitioned into item types. The prototypical division is into two
types, drugs and events, but in general there can be one or more types for a particular data mining
run. We conceptually divide the counting and estimation that MGPS does into separate itemset
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types. That is, if there are two types of items, labelled D and E, we similarly define itemset types
such as DD, DE, DDE, DDEE and so forth. This last four dimensional example (DDEE) will be
used here to make it plain how the new calculations go in general and the corresponding definitions
for the other itemset types should be obvious. The individual items will be named D1, D2, E1, E2.
The calculation of counts, baseline frequencies, and hyperparameter estimates is separate for every
different itemset type. The calculations for a given dimension will sometimes depend on the results
from previous calculations for a lower dimension.
Review of Two-Dimensional Calculations
For every pair of items, say j and k, Pjs and Pks are the respective proportions of the ns reports
in stratum s that contain items j and k. There are n reports total and Njk of the reports contain
both items j and k. The 2-dimensional baseline frequencies are:
Ejk =
∑
s nsPjsPks
The values of RRjk = Njk/Ejk are smoothed using the MGPS model (separate estimates for each
type of pair) to get corresponding values of EBGMjk, EB05jk and EB95jk.
Handling Homogeneous Itemset Types in Three or More Dimensions
In the descriptions that follow, it will be assumed that the itemset has at least two different item
types. Homogeneous itemset types such as DDD or EEEE require the following special convention:
Use the methods described below as if every item being considered were of a different type. That is,
treat homogeneous itemsets like (D1, D2, D3) as if they were (D1, E1, F1), one item from each of
three item types, rather than three items of the same type. This is just for the purpose of following
the formulas below. We do not actually pool the data of type DDD with other combinations.
Handling Heterogeneous Itemset Types in Three or More Dimensions
Notation for the four dimensional example
As mentioned above, we will assume for presentation purposes that we are calculating the MGPS
model for the itemset type of form DDEE. As a shorthand, we use the abbreviations D1 = 1, D2
= 2, E1 = 3, E2 = 4, especially when using subscripts. Thus, for example, the number of reports
overall that contain both E1 and E2 will be denoted N34, and the number of reports that contain
the triple (D1, D2, E1) is denoted N123. The proportion of reports in stratum s that contain item
E2 is P4s, and so forth.
Defining baseline frequencies
Let E0 be the expected frequency when all four items are independent, namely:
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E0 =
∑
s nsP1s P2s P3s P4s
However, E0 is modified by multiplying by terms corresponding to each item type with more than
one item, in this case both the D and E items.
E = E0× [N12/M12]× [N34/M34] (D.1.1)
Where M12 =
∑
s ns P1s P2s and M34 =
∑
s ns P3s P4s
E represents the baseline frequency under the assumption that each of the item types is independent
from other item types, but within an item type complete dependence is assumed. It is as if the
pair (D1, D2) was thought of as a compound drug whose count in the database is N12, and that
is why E1 is multiplied by the correction factor N12/M12. An analogous argument applies to the
pair (E1, E2), which could be thought of as a syndrome treated as a single event.
If the itemset being considered has no duplicate item types, then E = E0, as would happen if
the original itemset was completely homogeneous and we were following the prescription in the
previous section to treat such itemsets as if every item were a different type.
Technically, N = N1234andE = E1234, but we will just define N,ERR = N/E,EBGM, et cetera
for the 4-tuple without subscripts.
Defining the interaction signal score
Let EB95max be the highest two-factor EB95 for pairs that are NOT of the same type. In this four-
dimensional example, there are six possible pairs, but only four of the pairs are of heterogeneous
type, and EBmax is the largest of those. That is,
EB95max = maxEB9513, EB9523, EB9514, EB9524
The EB95 values above would come from the previously performed pair-wise analyses of DE itemset
types. The value EB95max represents the largest estimated upper 95% confidence limit association
found among the heterogeneous PAIRS of items being considered. Remember that if the itemset
was originally all of one type, then we pretend they are all different and so EB95max would be the
largest of all the included 2 dimensional EB95s.
We declare an “interaction alert” if the smoothed value of RR = N/E for the sextuple, is signifi-
cantly greater than EB95max. Namely,
INTSS(interaction signal score) = EB05/EB95max
INTSS > 1 is the threshold for an alert for a 3D or higher-way association that cannot be
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explained by any single pairwise association. When INTSS > 1, the confidence interval around
EBGM for the 4-tuple does not overlap any of the confidence intervals for the heterogeneous
pairwise EBGMs that are part of the 4-tuple.
How the EB model is set up
Based on the two-factor analyses, we do not expect the baseline expected counts E to fit the
observed counts N well for 3D or higher dimensions if many pairwise EBGMs are large, since
the baseline E is the prediction one might make if it were known that all pairwise EBGMs = 1.
Therefore, we prefer to shrink N towards the product E × EBmax rather than just toward E,
where EBmax is the largest of the pairwise EBGMs for included heterogeneous pairs of items.
Analogous to the definition of EB95max, we define EBmax (for our D1−D2−E1−E2 example)
as
EBmax = maxEBGM13, EBGM23, EBGM14, EBGM24
Note that the pair of items that define EBmax might not be the same pair that define EB95max
as defined above. The shrinkage model is set up as follows:
LetE∗ = E × EBmax
Note that E* is the product of terms for absolute independence (E0) times terms for within item
type dependence, as in equation D.1.1, times a measure of heterogeneous item type dependence,
EBmax.
Now use the pairs (N,E∗) to estimate hyperparameters and get smoothed values of N/E∗, which
would be summarized by the estimates and confidence limits EBGM∗, EB05∗ and EB95∗. These
computations are performed just as in the previous section with the substitution of E∗ for E.
Finally, we convert back to smoothed estimates of N/E by defining:
EBGM = EBGM∗ × EBmax;
EB05 = EB05∗ × EBmax;
EB95 = EB95∗ × EBmax
Thus EBGM as a measure of deviation from independence of item types, which is more directly
comparable to EBGMs of lower dimensional heterogeneous item types.
The value of INTSS = EB05/EB95max is a multiplicative relative measure of how much excess
association is present in the four-tuple that cannot be explained by any single DE association.
INTSS > 1 will identify those 3D and higher-way combinations in which there are large cross-item
associations that cannot be explained by any single 2D cross-item association. Because INTSS
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is defined as the ratio of a lower confidence limit divided by an upper confidence limit it will tend
to be conservative alerting threshold when the relevant counts are small and the corresponding
confidence intervals are wide.
The value INTSS is a relative measure and does not provide information as to the absolute number
of reports in the database that are in excess of the number that might be explained by a single
cross-item association. The quantity Excess2 focuses on the absolute number of such reports,
defined as
Excess2 = E × EB95max× (INTSS − 1)
= E × (EB05− EB95max)
It is a conservative estimate of the number of reports of that itemset in the database that cannot
be explained by any single cross-type association.
Table D.1: Correspondence between notation here and variable labels in WebVDME
Mathematical Notation WebVDME and Help
E0 E IND
λ True Relative Ratio
E E
E2 E2 IND
Excess02 EXCESS2 IND
Excess2 EXCESS2
EB95max EB05/INTSS
EBmax EBMAX
Pair where EBGM = EBmax MAXITEM1, MAXITEM2
E* E * EBMAX
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